US20120245155A1 - Fused heterocyclic compound having amino group - Google Patents
Fused heterocyclic compound having amino group Download PDFInfo
- Publication number
- US20120245155A1 US20120245155A1 US13/514,907 US201013514907A US2012245155A1 US 20120245155 A1 US20120245155 A1 US 20120245155A1 US 201013514907 A US201013514907 A US 201013514907A US 2012245155 A1 US2012245155 A1 US 2012245155A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- compound
- ring
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003277 amino group Chemical group 0.000 title description 10
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 362
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 239000012453 solvate Substances 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 18
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 230000008021 deposition Effects 0.000 claims abstract description 12
- 230000028327 secretion Effects 0.000 claims abstract description 12
- -1 cyano, carboxy Chemical group 0.000 claims description 175
- 229910052739 hydrogen Inorganic materials 0.000 claims description 103
- 239000001257 hydrogen Substances 0.000 claims description 103
- 125000000217 alkyl group Chemical group 0.000 claims description 102
- 125000000623 heterocyclic group Chemical group 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 71
- 150000002431 hydrogen Chemical group 0.000 claims description 70
- 229910052799 carbon Inorganic materials 0.000 claims description 64
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 54
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical group 0.000 claims description 51
- 125000002252 acyl group Chemical group 0.000 claims description 45
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 44
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 125000003342 alkenyl group Chemical group 0.000 claims description 43
- 125000000304 alkynyl group Chemical group 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 39
- 125000002837 carbocyclic group Chemical group 0.000 claims description 37
- 125000002947 alkylene group Chemical group 0.000 claims description 34
- 150000001721 carbon Chemical group 0.000 claims description 34
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 33
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 26
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 25
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 24
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims description 24
- 125000004423 acyloxy group Chemical group 0.000 claims description 22
- 125000004450 alkenylene group Chemical group 0.000 claims description 22
- 125000004468 heterocyclylthio group Chemical group 0.000 claims description 22
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000005136 alkenylsulfinyl group Chemical group 0.000 claims description 19
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims description 19
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 19
- 125000004414 alkyl thio group Chemical group 0.000 claims description 18
- 125000005134 alkynylsulfinyl group Chemical group 0.000 claims description 18
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 125000005108 alkenylthio group Chemical group 0.000 claims description 16
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 125000005109 alkynylthio group Chemical group 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims description 12
- 102100021257 Beta-secretase 1 Human genes 0.000 claims description 11
- 125000004419 alkynylene group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- 150000003216 pyrazines Chemical class 0.000 claims description 8
- 150000003222 pyridines Chemical class 0.000 claims description 8
- 150000003230 pyrimidines Chemical class 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 description 168
- 239000000243 solution Substances 0.000 description 127
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 239000000203 mixture Substances 0.000 description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 84
- 238000006243 chemical reaction Methods 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 239000002904 solvent Substances 0.000 description 72
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 71
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 238000012360 testing method Methods 0.000 description 54
- 230000002829 reductive effect Effects 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 49
- 125000006239 protecting group Chemical group 0.000 description 46
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 239000012044 organic layer Substances 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 37
- 239000000706 filtrate Substances 0.000 description 37
- 0 *.*.*C1(*)C[Y]C(*)(*)C(*)(C(=C(C)C)C(C)C)C1(C)C(C)C.*C1(*)C[Y]c(*)(C)c([4*])(c([3*])C(C)C)C1(C)C(C)C Chemical compound *.*.*C1(*)C[Y]C(*)(*)C(*)(C(=C(C)C)C(C)C)C1(C)C(C)C.*C1(*)C[Y]c(*)(C)c([4*])(c([3*])C(C)C)C1(C)C(C)C 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- 125000001153 fluoro group Chemical group F* 0.000 description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 33
- 239000012267 brine Substances 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 28
- 125000001188 haloalkyl group Chemical group 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 150000001540 azides Chemical class 0.000 description 27
- 125000001309 chloro group Chemical group Cl* 0.000 description 26
- 238000001816 cooling Methods 0.000 description 25
- 238000001914 filtration Methods 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000002198 insoluble material Substances 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 18
- 230000003647 oxidation Effects 0.000 description 18
- 238000007254 oxidation reaction Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- 239000000470 constituent Substances 0.000 description 16
- 238000010511 deprotection reaction Methods 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 12
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 239000012046 mixed solvent Substances 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KGFNLTQUICUPOS-UHFFFAOYSA-N B.C.CC(C)C.C[W]C Chemical compound B.C.CC(C)C.C[W]C KGFNLTQUICUPOS-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 150000001555 benzenes Chemical class 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 239000007818 Grignard reagent Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000004795 grignard reagents Chemical class 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000011812 mixed powder Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000011533 pre-incubation Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 4
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 4
- 229920003114 HPC-L Polymers 0.000 description 4
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 4
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 4
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 3
- 125000000676 alkoxyimino group Chemical group 0.000 description 3
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 3
- 125000005530 alkylenedioxy group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 3
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 3
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000002902 organometallic compounds Chemical class 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960000351 terfenadine Drugs 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- GAZRNXIMWKZADY-UHFFFAOYSA-N 3,5-dimethylpyrazole-1-carboximidamide Chemical compound CC=1C=C(C)N(C(N)=N)N=1 GAZRNXIMWKZADY-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FKDBWYONNWPUEM-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid;hydrate Chemical compound O.OC(=O)C1=CC=C(C#N)C=N1 FKDBWYONNWPUEM-UHFFFAOYSA-N 0.000 description 2
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- LJXUAAPRGDYTMB-UHFFFAOYSA-N C=C1SC(N)=NC2(C3=CC=CC=C3F)COCC12 Chemical compound C=C1SC(N)=NC2(C3=CC=CC=C3F)COCC12 LJXUAAPRGDYTMB-UHFFFAOYSA-N 0.000 description 2
- FZWQYJRCJVSWFC-UHFFFAOYSA-N CNC(=O)C1=CC=C(C2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 Chemical compound CNC(=O)C1=CC=C(C2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 FZWQYJRCJVSWFC-UHFFFAOYSA-N 0.000 description 2
- WLXOBDRJXVRWNV-UHFFFAOYSA-N COC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 Chemical compound COC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 WLXOBDRJXVRWNV-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 238000005675 Corey-Kim oxidation reaction Methods 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CQCSUQRTKQBHCV-AWEZNQCLSA-N NC1=CC=C(F)C([C@]23CCCCC2=CSC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23CCCCC2=CSC(N)=N3)=C1 CQCSUQRTKQBHCV-AWEZNQCLSA-N 0.000 description 2
- IZKHIMGINYHRHK-RJSPSEDBSA-N NC1=CC=C(F)C([C@]23CCCCC2COC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23CCCCC2COC(N)=N3)=C1 IZKHIMGINYHRHK-RJSPSEDBSA-N 0.000 description 2
- NLTIAMTZUYHGKF-UHFFFAOYSA-N NC1=NC2(C3=CC(NC(=O)C4=NC=C(Cl)C=C4)=CC=C3F)COCC2CO1 Chemical compound NC1=NC2(C3=CC(NC(=O)C4=NC=C(Cl)C=C4)=CC=C3F)COCC2CO1 NLTIAMTZUYHGKF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000006323 alkenyl amino group Chemical group 0.000 description 2
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000000002 alkyl sulfinylimino group Chemical group 0.000 description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 2
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 2
- PAGNOIFWRGQSNM-UHFFFAOYSA-N anthracen-2-amine;methylsulfinylmethane Chemical compound CS(C)=O.C1=CC=CC2=CC3=CC(N)=CC=C3C=C21 PAGNOIFWRGQSNM-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 description 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 208000015756 familial Alzheimer disease Diseases 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 102000044297 human BACE1 Human genes 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- HFWWEMPLBCKNNM-UHFFFAOYSA-N n-[bis(hydroxyamino)methyl]hydroxylamine Chemical compound ONC(NO)NO HFWWEMPLBCKNNM-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- HJNXBCYVGDGGTF-UHFFFAOYSA-N *.*.*.*.*.*.*.*.C=C1OC(N)=NC2(C)COCC12.CC12CCCC1COC(N)=N2.CC12CCCC=C1CSC(N)=N2.CC12CCCCC1=COC(N)=N2.CC12COCC1COC(N)=N2.CC12COCC=C1CSC(N)=N2.CC12COCCC1=COC(N)=N2.CC1=C2CCCCC2(C)N=C(N)O1 Chemical compound *.*.*.*.*.*.*.*.C=C1OC(N)=NC2(C)COCC12.CC12CCCC1COC(N)=N2.CC12CCCC=C1CSC(N)=N2.CC12CCCCC1=COC(N)=N2.CC12COCC1COC(N)=N2.CC12COCC=C1CSC(N)=N2.CC12COCCC1=COC(N)=N2.CC1=C2CCCCC2(C)N=C(N)O1 HJNXBCYVGDGGTF-UHFFFAOYSA-N 0.000 description 1
- AQFFYQPOEKTDIT-UHFFFAOYSA-N *.CC12CCCC=C1COC(N)=N2 Chemical compound *.CC12CCCC=C1COC(N)=N2 AQFFYQPOEKTDIT-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical compound FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZNBNBTIDJSKEAM-UHFFFAOYSA-N 4-[7-hydroxy-2-[5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic acid Chemical compound C1C(O)C(C)C(C(C)C(OC(=O)CC)C(C)C(O)=O)OC11OC(C)(C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CC1 ZNBNBTIDJSKEAM-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 description 1
- YVGVOPNUEFTVQO-UHFFFAOYSA-N 5-methoxypyrazine-2-carboxylic acid Chemical compound COC1=CN=C(C(O)=O)C=N1 YVGVOPNUEFTVQO-UHFFFAOYSA-N 0.000 description 1
- DHMYULZVFHHEHE-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(sulfanylidenemethylidene)carbamate Chemical compound C1=CC=C2C(COC(=O)N=C=S)C3=CC=CC=C3C2=C1 DHMYULZVFHHEHE-UHFFFAOYSA-N 0.000 description 1
- 208000018282 ACys amyloidosis Diseases 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- NNIBUKOUNYZXDY-UHFFFAOYSA-N B.B.B.B.CC(=O)CC1=CC=C(F)C(C(C)C)=C1.CC(=O)CC1=CC=CC(C(C)C)=C1.CC(=O)CC1=CN=CC(C(C)C)=C1.CC1=CC=C(F)C(C(C)C)=C1 Chemical compound B.B.B.B.CC(=O)CC1=CC=C(F)C(C(C)C)=C1.CC(=O)CC1=CC=CC(C(C)C)=C1.CC(=O)CC1=CN=CC(C(C)C)=C1.CC1=CC=C(F)C(C(C)C)=C1 NNIBUKOUNYZXDY-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- CSMCMGWUHKOATJ-BUOYSTTRSA-N C.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(C)SC2=C.[H][C@]12COCC1(C1=CC(CC(=O)C3=NC=C(C#N)C=C3)=CC=C1F)N=C(N)SC2=C.[H][C@]12COCC1(C1=CC(N)=CC=C1F)N=C(N)SC2=C.[I-3].[IH-2] Chemical compound C.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(C)SC2=C.[H][C@]12COCC1(C1=CC(CC(=O)C3=NC=C(C#N)C=C3)=CC=C1F)N=C(N)SC2=C.[H][C@]12COCC1(C1=CC(N)=CC=C1F)N=C(N)SC2=C.[I-3].[IH-2] CSMCMGWUHKOATJ-BUOYSTTRSA-N 0.000 description 1
- WFPWUFWWQNBJSK-UHFFFAOYSA-N C=C1SC(N)=NC2(C3=CC(NC(=O)C4=CC=C(C#N)C=N4)=CC=C3F)COCC12 Chemical compound C=C1SC(N)=NC2(C3=CC(NC(=O)C4=CC=C(C#N)C=N4)=CC=C3F)COCC12 WFPWUFWWQNBJSK-UHFFFAOYSA-N 0.000 description 1
- HNUZKSIOSQKCAY-UHFFFAOYSA-N C=C1SC(N)=NC2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)COCC12 Chemical compound C=C1SC(N)=NC2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)COCC12 HNUZKSIOSQKCAY-UHFFFAOYSA-N 0.000 description 1
- JYUHBSRHKNGRMW-UHFFFAOYSA-N CC#CCOC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 Chemical compound CC#CCOC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 JYUHBSRHKNGRMW-UHFFFAOYSA-N 0.000 description 1
- MFNZJFVPNZPSCN-UHFFFAOYSA-N CC(C)=C(C(C)C)C(C)C.CC(C)C(=C1C=CC=C1)C(C)C.CC(C)C(=C1C=CC=CC1)C(C)C.CC(C)C(=C1C=CCC1)C(C)C.CC(C)C(=C1C=CCC=C1)C(C)C.CC(C)C(=C1C=CCCC1)C(C)C.CC(C)C(=C1CC=CC1)C(C)C.CC(C)C(=C1CC=CCC1)C(C)C.CC(C)C(=C1CC=CCC1)C(C)C.CC(C)C(=C1CCCC1)C(C)C.CC(C)C(=C1CCCCC1)C(C)C.CC(C)C(=C1CCNC1)C(C)C.CC(C)C(=C1CCOC1)C(C)C.CC(C)C(=C1CCOCC1)C(C)C.CC(C)C(=C1CCSC1)C(C)C.CC(C)C(=C1COCCN1)C(C)C.CC(C)C(=C1COCOC1)C(C)C.CC(C)C(=C1NCCN1)C(C)C.CC(C)C(=C1OCCCO1)C(C)C.CC(C)C(=C1OCCO1)C(C)C Chemical compound CC(C)=C(C(C)C)C(C)C.CC(C)C(=C1C=CC=C1)C(C)C.CC(C)C(=C1C=CC=CC1)C(C)C.CC(C)C(=C1C=CCC1)C(C)C.CC(C)C(=C1C=CCC=C1)C(C)C.CC(C)C(=C1C=CCCC1)C(C)C.CC(C)C(=C1CC=CC1)C(C)C.CC(C)C(=C1CC=CCC1)C(C)C.CC(C)C(=C1CC=CCC1)C(C)C.CC(C)C(=C1CCCC1)C(C)C.CC(C)C(=C1CCCCC1)C(C)C.CC(C)C(=C1CCNC1)C(C)C.CC(C)C(=C1CCOC1)C(C)C.CC(C)C(=C1CCOCC1)C(C)C.CC(C)C(=C1CCSC1)C(C)C.CC(C)C(=C1COCCN1)C(C)C.CC(C)C(=C1COCOC1)C(C)C.CC(C)C(=C1NCCN1)C(C)C.CC(C)C(=C1OCCCO1)C(C)C.CC(C)C(=C1OCCO1)C(C)C MFNZJFVPNZPSCN-UHFFFAOYSA-N 0.000 description 1
- NFVPUCYDHVEFED-UHFFFAOYSA-N CC(C)C(=C1C=NC=NC1)C(C)C.CC(C)C(=C1CC=NCC1)C(C)C.CC(C)C(=C1CCCNC1)C(C)C.CC(C)C(=C1CCNCC1)C(C)C.CC(C)C(=C1CCSCC1)C(C)C.CC(C)C(=C1N=CC=CN1)C(C)C.CC(C)C(=C1NCCCN1)C(C)C.CC(C)C(=C1SCCCS1)C(C)C Chemical compound CC(C)C(=C1C=NC=NC1)C(C)C.CC(C)C(=C1CC=NCC1)C(C)C.CC(C)C(=C1CCCNC1)C(C)C.CC(C)C(=C1CCNCC1)C(C)C.CC(C)C(=C1CCSCC1)C(C)C.CC(C)C(=C1N=CC=CN1)C(C)C.CC(C)C(=C1NCCCN1)C(C)C.CC(C)C(=C1SCCCS1)C(C)C NFVPUCYDHVEFED-UHFFFAOYSA-N 0.000 description 1
- HZFSPLBGCRKLIM-UHFFFAOYSA-N CC(C)C1(C(C)C)C=NC=NC1.CC(C)C1(C(C)C)CC=CC=N1.CC(C)C1(C(C)C)CC=NCC1.CC(C)C1(C(C)C)CCCCN1.CC(C)C1(C(C)C)CNCNC1 Chemical compound CC(C)C1(C(C)C)C=NC=NC1.CC(C)C1(C(C)C)CC=CC=N1.CC(C)C1(C(C)C)CC=NCC1.CC(C)C1(C(C)C)CCCCN1.CC(C)C1(C(C)C)CNCNC1 HZFSPLBGCRKLIM-UHFFFAOYSA-N 0.000 description 1
- CMFCXKWPSULZPP-UHFFFAOYSA-N CC1=C(C(C)C)C=CC=C1.CC1=CC(C)=C(C(C)C)N=C1.CC1=CN=C(C(C)C)N=C1.CC1=NC(C)=C(C(C)C)N=C1 Chemical compound CC1=C(C(C)C)C=CC=C1.CC1=CC(C)=C(C(C)C)N=C1.CC1=CN=C(C(C)C)N=C1.CC1=NC(C)=C(C(C)C)N=C1 CMFCXKWPSULZPP-UHFFFAOYSA-N 0.000 description 1
- NTBQFXSLFIFCIB-UHFFFAOYSA-N CC1=CC=C(F)C(C2(C)CCCCC2CO)=C1.CC1=CC=C(F)C(C23CCCC/C2=C/S/C(N)=N\3)=C1.COC(OC)C1CCCCC1(N)C1=CC(C)=CC=C1F.COC(OC)C1CCCCC1(NC(C)=S)C1=CC(C)=CC=C1F.NC1=CC=C(F)C(C23CCCC/C2=C/S/C(N)=N\3)=C1.[C-]#[N+]C1=CN=C(C(=O)CC2=CC=C(F)C(C34CCCC/C3=C/S/C(N)=N\4)=C2)C=C1.[I-17] Chemical compound CC1=CC=C(F)C(C2(C)CCCCC2CO)=C1.CC1=CC=C(F)C(C23CCCC/C2=C/S/C(N)=N\3)=C1.COC(OC)C1CCCCC1(N)C1=CC(C)=CC=C1F.COC(OC)C1CCCCC1(NC(C)=S)C1=CC(C)=CC=C1F.NC1=CC=C(F)C(C23CCCC/C2=C/S/C(N)=N\3)=C1.[C-]#[N+]C1=CN=C(C(=O)CC2=CC=C(F)C(C34CCCC/C3=C/S/C(N)=N\4)=C2)C=C1.[I-17] NTBQFXSLFIFCIB-UHFFFAOYSA-N 0.000 description 1
- WTJORISAYYARRR-UHFFFAOYSA-N CC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 Chemical compound CC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1 WTJORISAYYARRR-UHFFFAOYSA-N 0.000 description 1
- FTEHDSHZFYQJQF-UHFFFAOYSA-N COC1=CN=C(C(=O)CC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1.[H]C12COCC1(C1=CC(N)=CC=C1F)N=C(N)SC2.[H]C12COCC1(C1=CC(NC(=O)C(F)(F)F)=CC=C1F)N=C(N)SC2.[H]C12COCC1(C1=CC(NC(=O)C(F)(F)F)=CC=C1F)N=C(NC(=O)C1=CC=CC=C1)SC2.[I-35] Chemical compound COC1=CN=C(C(=O)CC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=N1.[H]C12COCC1(C1=CC(N)=CC=C1F)N=C(N)SC2.[H]C12COCC1(C1=CC(NC(=O)C(F)(F)F)=CC=C1F)N=C(N)SC2.[H]C12COCC1(C1=CC(NC(=O)C(F)(F)F)=CC=C1F)N=C(NC(=O)C1=CC=CC=C1)SC2.[I-35] FTEHDSHZFYQJQF-UHFFFAOYSA-N 0.000 description 1
- KRADVCXMSVWQON-UHFFFAOYSA-N COC1=CN=CC(C2=CC=C(F)C(C34CCCC3COC(N)=N4)=C2)=C1 Chemical compound COC1=CN=CC(C2=CC=C(F)C(C34CCCC3COC(N)=N4)=C2)=C1 KRADVCXMSVWQON-UHFFFAOYSA-N 0.000 description 1
- VBVXJOQLQDAINY-UHFFFAOYSA-N COC1=CN=CC(C2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)=C1 Chemical compound COC1=CN=CC(C2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)=C1 VBVXJOQLQDAINY-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000012848 Dextrorphan Substances 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- JMIBUXFNFBTUBD-NRFANRHFSA-N N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCC=C3COC(N)=N4)=C2)N=C1 Chemical compound N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCC=C3COC(N)=N4)=C2)N=C1 JMIBUXFNFBTUBD-NRFANRHFSA-N 0.000 description 1
- HDCAXWDEHXSLPZ-NRFANRHFSA-N N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCC=C3CSC(N)=N4)=C2)N=C1 Chemical compound N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCC=C3CSC(N)=N4)=C2)N=C1 HDCAXWDEHXSLPZ-NRFANRHFSA-N 0.000 description 1
- FOGBGNQSRXGEME-NRFANRHFSA-N N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCCC3=COC(N)=N4)=C2)N=C1 Chemical compound N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCCC3=COC(N)=N4)=C2)N=C1 FOGBGNQSRXGEME-NRFANRHFSA-N 0.000 description 1
- SPLJFPLFOQUIQM-NRFANRHFSA-N N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCCC3=CSC(N)=N4)=C2)N=C1 Chemical compound N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCCC3=CSC(N)=N4)=C2)N=C1 SPLJFPLFOQUIQM-NRFANRHFSA-N 0.000 description 1
- PBZCFAHCFSNALU-YNNZGITBSA-N N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCCC3COC(N)=N4)=C2)N=C1 Chemical compound N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34CCCCC3COC(N)=N4)=C2)N=C1 PBZCFAHCFSNALU-YNNZGITBSA-N 0.000 description 1
- VUYSJBDRVJENRG-FQEVSTJZSA-N N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34COCCC3=CSC(N)=N4)=C2)N=C1 Chemical compound N#CC1=CC=C(C(=O)NC2=CC=C(F)C([C@]34COCCC3=CSC(N)=N4)=C2)N=C1 VUYSJBDRVJENRG-FQEVSTJZSA-N 0.000 description 1
- ZOGMPKZANIPPDK-UHFFFAOYSA-N N#CC1=CN=C(C(=O)NC2=CC=C(F)C(C34CCCC3COC(N)=N4)=C2)C=C1 Chemical compound N#CC1=CN=C(C(=O)NC2=CC=C(F)C(C34CCCC3COC(N)=N4)=C2)C=C1 ZOGMPKZANIPPDK-UHFFFAOYSA-N 0.000 description 1
- WDHJMACPRAKXPV-UHFFFAOYSA-N N#CC1=CN=C(C(=O)NC2=CC=C(F)C(C34CCCCC3CSC(N)=N4)=C2)C=C1 Chemical compound N#CC1=CN=C(C(=O)NC2=CC=C(F)C(C34CCCCC3CSC(N)=N4)=C2)C=C1 WDHJMACPRAKXPV-UHFFFAOYSA-N 0.000 description 1
- KULLKLYWPZVJNH-UHFFFAOYSA-N N#CC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=C1 Chemical compound N#CC1=CN=C(C(=O)NC2=CC=C(F)C(C34COCC3COC(N)=N4)=C2)C=C1 KULLKLYWPZVJNH-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- CEAYRCYYRLRHDZ-AWEZNQCLSA-N NC1=CC=C(F)C([C@]23CCCC=C2COC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23CCCC=C2COC(N)=N3)=C1 CEAYRCYYRLRHDZ-AWEZNQCLSA-N 0.000 description 1
- GMGBPKSPUBQTLI-AWEZNQCLSA-N NC1=CC=C(F)C([C@]23CCCC=C2CSC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23CCCC=C2CSC(N)=N3)=C1 GMGBPKSPUBQTLI-AWEZNQCLSA-N 0.000 description 1
- YOWJWSIPCGGPEC-AWEZNQCLSA-N NC1=CC=C(F)C([C@]23CCCCC2=COC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23CCCCC2=COC(N)=N3)=C1 YOWJWSIPCGGPEC-AWEZNQCLSA-N 0.000 description 1
- WGQDTIYZHUAZQH-ZDUSSCGKSA-N NC1=CC=C(F)C([C@]23COCC=C2CSC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23COCC=C2CSC(N)=N3)=C1 WGQDTIYZHUAZQH-ZDUSSCGKSA-N 0.000 description 1
- VZXJLYCFMQQNHW-ZDUSSCGKSA-N NC1=CC=C(F)C([C@]23COCCC2=CSC(N)=N3)=C1 Chemical compound NC1=CC=C(F)C([C@]23COCCC2=CSC(N)=N3)=C1 VZXJLYCFMQQNHW-ZDUSSCGKSA-N 0.000 description 1
- WLBJOWWDARISLZ-UHFFFAOYSA-N NC1=NC2(C3=CC(C4=CC(Cl)=CN=C4)=CC=C3F)COCC2CO1 Chemical compound NC1=NC2(C3=CC(C4=CC(Cl)=CN=C4)=CC=C3F)COCC2CO1 WLBJOWWDARISLZ-UHFFFAOYSA-N 0.000 description 1
- LEPYPBZHXGYKMA-UHFFFAOYSA-N NC1=NC2(C3=CC(C4=CC=CN=C4F)=CC=C3F)CCCC2CO1 Chemical compound NC1=NC2(C3=CC(C4=CC=CN=C4F)=CC=C3F)CCCC2CO1 LEPYPBZHXGYKMA-UHFFFAOYSA-N 0.000 description 1
- SAALBFNPVFZJTG-UHFFFAOYSA-N NC1=NC2(C3=CC(C4=CC=CN=C4F)=CC=C3F)COCC2CO1 Chemical compound NC1=NC2(C3=CC(C4=CC=CN=C4F)=CC=C3F)COCC2CO1 SAALBFNPVFZJTG-UHFFFAOYSA-N 0.000 description 1
- UPHYCIFCZJOYJC-UHFFFAOYSA-N NC1=NC2(C3=CC(C4=CN=CN=C4)=CC=C3F)CCCC2CO1 Chemical compound NC1=NC2(C3=CC(C4=CN=CN=C4)=CC=C3F)CCCC2CO1 UPHYCIFCZJOYJC-UHFFFAOYSA-N 0.000 description 1
- FTCAYDYDTMHAIW-UHFFFAOYSA-N NC1=NC2(C3=CC(NC(=O)C4=NC=C(OC(F)F)C=C4)=CC=C3F)CCCC2CO1 Chemical compound NC1=NC2(C3=CC(NC(=O)C4=NC=C(OC(F)F)C=C4)=CC=C3F)CCCC2CO1 FTCAYDYDTMHAIW-UHFFFAOYSA-N 0.000 description 1
- FFKCOPXKENJSEF-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCC=C2CO1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCC=C2CO1 FFKCOPXKENJSEF-FQEVSTJZSA-N 0.000 description 1
- WSNXLNKVJXLSRH-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCC=C2CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCC=C2CS1 WSNXLNKVJXLSRH-FQEVSTJZSA-N 0.000 description 1
- MDWKTBZBHATNEJ-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCCC2=CO1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCCC2=CO1 MDWKTBZBHATNEJ-FQEVSTJZSA-N 0.000 description 1
- MHTCFWJXGXYBNP-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCCC2=CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCCC2=CS1 MHTCFWJXGXYBNP-FQEVSTJZSA-N 0.000 description 1
- AORMZPRKXMXFJZ-XRDRKEPISA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCCC2CO1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)CCCCC2CO1 AORMZPRKXMXFJZ-XRDRKEPISA-N 0.000 description 1
- UZFYIHKRHZIECW-IBGZPJMESA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)COCC=C2CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)COCC=C2CS1 UZFYIHKRHZIECW-IBGZPJMESA-N 0.000 description 1
- POOOAQFCAVMULX-IBGZPJMESA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)COCCC2=CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=C(F)C=C(F)C=N4)=CC=C3F)COCCC2=CS1 POOOAQFCAVMULX-IBGZPJMESA-N 0.000 description 1
- RJQWSPMNZKHTEP-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCC=C2CO1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCC=C2CO1 RJQWSPMNZKHTEP-FQEVSTJZSA-N 0.000 description 1
- AYZDJODTQNXKLO-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCC=C2CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCC=C2CS1 AYZDJODTQNXKLO-FQEVSTJZSA-N 0.000 description 1
- HBWFUOASCQXFEE-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCCC2=CO1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCCC2=CO1 HBWFUOASCQXFEE-FQEVSTJZSA-N 0.000 description 1
- YHTWQECGOLLSJR-FQEVSTJZSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCCC2=CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCCC2=CS1 YHTWQECGOLLSJR-FQEVSTJZSA-N 0.000 description 1
- CQHHZTPYTGGWKK-UDRWWJRQSA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCCC2CO1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)CCCCC2CO1 CQHHZTPYTGGWKK-UDRWWJRQSA-N 0.000 description 1
- VULKZXUBNGLZBR-IBGZPJMESA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)COCC=C2CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)COCC=C2CS1 VULKZXUBNGLZBR-IBGZPJMESA-N 0.000 description 1
- SLIITAUHYYWFJT-IBGZPJMESA-N NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)COCCC2=CS1 Chemical compound NC1=N[C@@]2(C3=CC(NC(=O)C4=CC=C(Cl)C=N4)=CC=C3F)COCCC2=CS1 SLIITAUHYYWFJT-IBGZPJMESA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- HWFHWIYWOIPGGG-UHFFFAOYSA-N OB(O)C1=CC=CN=C1F.[H]C12COCC1(C1=CC(C3=CC=CN=C3F)=CC=C1F)N=C(N)OC2.[H]C12COCC1(C1=CC(I)=CC=C1F)N=C(NC(=O)OC(C)(C)C)OC2.[I-40] Chemical compound OB(O)C1=CC=CN=C1F.[H]C12COCC1(C1=CC(C3=CC=CN=C3F)=CC=C1F)N=C(N)OC2.[H]C12COCC1(C1=CC(I)=CC=C1F)N=C(NC(=O)OC(C)(C)C)OC2.[I-40] HWFHWIYWOIPGGG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JXIRCSAMTPZGMV-FQEVSTJZSA-N [C-]#[N+]C1=CC=C(C(=O)NC2=CC=C(F)C([C@]34COCC=C3CSC(N)=N4)=C2)N=C1 Chemical compound [C-]#[N+]C1=CC=C(C(=O)NC2=CC=C(F)C([C@]34COCC=C3CSC(N)=N4)=C2)N=C1 JXIRCSAMTPZGMV-FQEVSTJZSA-N 0.000 description 1
- GSXXDMRPLIHYDX-UHFFFAOYSA-N [H]C1(CO)COCC1(CC(=S)CC(=O)C1=CC=CC=C1)C1=CC(NC(=O)C(F)(F)F)=CC=C1F.[H]C1(CO)COCC1(N)C1=CC(NC(=O)C(F)(F)F)=CC=C1F.[H]C12COCC1(C1=CC(I)=CC=C1F)N=C(CC(=O)C1=CC=CC=C1)OC2.[H]C12COCC1(C1=CC(I)=CC=C1F)N=C(N(C(=O)OC(C)(C)C)C(=O)C1=CC=CC=C1)OC2.[H]C12COCC1(C1=CC(N)=CC=C1F)N=C(CC(=O)C1=CC=CC=C1)OC2.[H]C12COCC1(C1=CC(NC(=O)C(F)(F)F)=CC=C1F)N=C(CC(=O)C1=CC=CC=C1)OC2 Chemical compound [H]C1(CO)COCC1(CC(=S)CC(=O)C1=CC=CC=C1)C1=CC(NC(=O)C(F)(F)F)=CC=C1F.[H]C1(CO)COCC1(N)C1=CC(NC(=O)C(F)(F)F)=CC=C1F.[H]C12COCC1(C1=CC(I)=CC=C1F)N=C(CC(=O)C1=CC=CC=C1)OC2.[H]C12COCC1(C1=CC(I)=CC=C1F)N=C(N(C(=O)OC(C)(C)C)C(=O)C1=CC=CC=C1)OC2.[H]C12COCC1(C1=CC(N)=CC=C1F)N=C(CC(=O)C1=CC=CC=C1)OC2.[H]C12COCC1(C1=CC(NC(=O)C(F)(F)F)=CC=C1F)N=C(CC(=O)C1=CC=CC=C1)OC2 GSXXDMRPLIHYDX-UHFFFAOYSA-N 0.000 description 1
- FYDAOBCSAZLCJU-VHNYESJRSA-N [H][C@]1(C=C)COCC1(C)C1=CC(C)=CC=C1F.[H][C@]1(C=C)COCC1(N)C1=CC(C)=CC=C1F.[H][C@]1(C=C)COCC1(NC(C)=S)C1=CC(C)=CC=C1F.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(C)SC2=C.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(C)SC2CI.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(N(C(=O)OC(C)(C)C)C(=O)C1=CC=CC=C1)SC2=C Chemical compound [H][C@]1(C=C)COCC1(C)C1=CC(C)=CC=C1F.[H][C@]1(C=C)COCC1(N)C1=CC(C)=CC=C1F.[H][C@]1(C=C)COCC1(NC(C)=S)C1=CC(C)=CC=C1F.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(C)SC2=C.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(C)SC2CI.[H][C@]12COCC1(C1=CC(C)=CC=C1F)N=C(N(C(=O)OC(C)(C)C)C(=O)C1=CC=CC=C1)SC2=C FYDAOBCSAZLCJU-VHNYESJRSA-N 0.000 description 1
- KTRAOQRFLQNVAC-VNSBZIOLSA-N [H][C@]1(C=C)COC[C@]1(C)C1=CC=CC=C1F.[H][C@]1(C=C)COC[C@]1(N)C1=CC=CC=C1F.[H][C@]1(C=C)COC[C@]1(NC(C)=S)C1=CC=CC=C1F.[H][C@]1(CO)COC[C@]1(C)C1=CC=CC=C1F.[H][C@]1(CO)COC[C@]1(N)C1=CC=CC=C1F.[H][C@]1(OC)COC[C@]1(C)C1=CC=CC=C1F.[H][C@]12COC[C@@]1(C1=CC=CC=C1F)NOC2 Chemical compound [H][C@]1(C=C)COC[C@]1(C)C1=CC=CC=C1F.[H][C@]1(C=C)COC[C@]1(N)C1=CC=CC=C1F.[H][C@]1(C=C)COC[C@]1(NC(C)=S)C1=CC=CC=C1F.[H][C@]1(CO)COC[C@]1(C)C1=CC=CC=C1F.[H][C@]1(CO)COC[C@]1(N)C1=CC=CC=C1F.[H][C@]1(OC)COC[C@]1(C)C1=CC=CC=C1F.[H][C@]12COC[C@@]1(C1=CC=CC=C1F)NOC2 KTRAOQRFLQNVAC-VNSBZIOLSA-N 0.000 description 1
- IMBXPACJCOWGOL-ZSZIIVAOSA-N [H][C@]1(C=O)COCC1(C)C1=CC(C)=CC=C1F.[H][C@]1(CO)COCC1(C)C1=CC(C)=CC=C1F.[H][C@]1(CO)COCC1(N)C1=CC(C)=CC=C1F.[H][C@]12COCC1(C1=CC(C)=CC=C1F)NOC2.[H][C@]12COCC1(C1=CC(N)=CC=C1F)NOC2.[H][C@]12COCC1(C1=CC([N+](=O)[O-])=CC=C1F)NOC2.[H][C@]12COCC1(C1=CC=CC=C1F)NOC2 Chemical compound [H][C@]1(C=O)COCC1(C)C1=CC(C)=CC=C1F.[H][C@]1(CO)COCC1(C)C1=CC(C)=CC=C1F.[H][C@]1(CO)COCC1(N)C1=CC(C)=CC=C1F.[H][C@]12COCC1(C1=CC(C)=CC=C1F)NOC2.[H][C@]12COCC1(C1=CC(N)=CC=C1F)NOC2.[H][C@]12COCC1(C1=CC([N+](=O)[O-])=CC=C1F)NOC2.[H][C@]12COCC1(C1=CC=CC=C1F)NOC2 IMBXPACJCOWGOL-ZSZIIVAOSA-N 0.000 description 1
- JFMXGJKILLEBDW-MFKMUULPSA-N [H][C@]12COC[C@@]1(C1=CC(N)=CC=C1F)N=C(N)SC2=C Chemical compound [H][C@]12COC[C@@]1(C1=CC(N)=CC=C1F)N=C(N)SC2=C JFMXGJKILLEBDW-MFKMUULPSA-N 0.000 description 1
- PZUPUMODBOSJDZ-BOAUOJDGSA-N [H][C@]12COC[C@@]1(C1=CC=CC=C1F)N=C(C)SC2CI.[H][C@]12COC[C@@]1(C1=CC=CC=C1F)N=C(N)SC2=C.[I-] Chemical compound [H][C@]12COC[C@@]1(C1=CC=CC=C1F)N=C(C)SC2CI.[H][C@]12COC[C@@]1(C1=CC=CC=C1F)N=C(N)SC2=C.[I-] PZUPUMODBOSJDZ-BOAUOJDGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- QALAKUHQOSUJEU-UHFFFAOYSA-N calcium;magnesium Chemical compound [Mg+2].[Ca+2] QALAKUHQOSUJEU-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 dextrorphan Drugs 0.000 description 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- WHFKIZXBVFEJGA-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 WHFKIZXBVFEJGA-UHFFFAOYSA-L 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003135 donepezil hydrochloride Drugs 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JISVIRFOSOKJIU-UHFFFAOYSA-N hexylidene Chemical group [CH2+]CCCC[CH-] JISVIRFOSOKJIU-UHFFFAOYSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 229910000378 hydroxylammonium sulfate Inorganic materials 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229920003113 low viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000005889 octahydrochromenyl group Chemical group 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 239000006833 oxoid nutrient broth Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZGNPLWZYVAFUNZ-UHFFFAOYSA-N tert-butylphosphane Chemical compound CC(C)(C)P ZGNPLWZYVAFUNZ-UHFFFAOYSA-N 0.000 description 1
- NZBUCABTIWJWAN-UHFFFAOYSA-N tetrabromomethane;triphenylphosphane Chemical compound BrC(Br)(Br)Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NZBUCABTIWJWAN-UHFFFAOYSA-N 0.000 description 1
- VSWLXYAZJZQIKA-UHFFFAOYSA-N tetrachloromethane;triphenylphosphane Chemical compound ClC(Cl)(Cl)Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VSWLXYAZJZQIKA-UHFFFAOYSA-N 0.000 description 1
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000005040 tridecenyl group Chemical group C(=CCCCCCCCCCCC)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- PMBLXLOXUGVTGB-UHFFFAOYSA-N zanapezil Chemical compound C=1C=C2CCCCNC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 PMBLXLOXUGVTGB-UHFFFAOYSA-N 0.000 description 1
- 229950010696 zanapezil Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to a compound which has amyloid ⁇ production inhibitory activity, and is useful as an agent for treating or preventing disease induced by production, secretion and/or deposition of amyloid ⁇ protein.
- amyloid ⁇ protein the peptide composed of about 40 amino acids residue as is called amyloid ⁇ protein, that accumulates to form insoluble specks (senile specks) outside nerve cells is widely observed. It is concerned that this senile specks kill nerve cells to cause Alzheimer's disease, so the therapeutic agents for Alzheimer's disease, such as decomposition agents of amyloid ⁇ protein and amyloid vaccine, are under investigation.
- Secretase is an enzyme which cleaves a protein called amyloid ⁇ precursor protein (APP) in cell and produces amyloid ⁇ protein.
- the enzyme which controls the production of N terminus of amyloid ⁇ protein is called as ⁇ -secretase (beta-site APP-cleaving enzyme 1, BACE1). It is thought that inhibition of this enzyme leads to reduction of producing amyloid ⁇ protein and that the therapeutic agent for Alzheimer's disease will be created due to the inhibition.
- Patent Literature 1 to 15 are known as ⁇ secretase inhibitor, however, all compounds in these literatures have different structures from the present invention.
- the present invention provides compounds which have reducing effects to produce amyloid ⁇ protein, especially BACE1 inhibitory activity, and are useful as an agent for treating or preventing diseases induced by production, secretion and/or deposition of amyloid ⁇ protein.
- the present invention provides the following items:
- —X— is —O—, —S— or —N(R 1 )—
- R 1 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoy
- —Y— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R 7 )—, —O—, —S—, —SO— or —SO 2 —
- —Z— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R 7 )Ak—, —OAk—, —SAk—, —SOAk- or —SO 2 Ak—, Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene, provided that when —Y— is —N(R 7 )—, —O—, —S—, —SO— or —SO 2 —, then Ak is not a bond, R 7 is
- —X— is —O—, —S— or —N(R 1 )—
- R 1 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoy
- —Y— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R 7 )—, —O—, —S—, —SO— or —SO 2 —
- —Z— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R 7 )Ak—, —OAk—, —SAk—, —SOAk- or —SO 2 Ak—, Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene, provided that when —Y— is —N(R 7 )—, —O—, —S—, —SO— or —SO 2 —, then Ak is not a bond, R 7 is
- R za and R zb are each independently hydrogen, halogen or substituted or unsubstituted alkyl
- R 4a , R 5a , R 5b , R 6a and R 6b are each independently hydrogen or substituted or unsubstituted alkyl, its pharmaceutically acceptable salt or a solvate thereof, (4) the compound according to any one of the item (1), (1-1), (2) and (3) wherein —Y— is substituted or unsubstituted C1-C3 alkylene or —O—, and —Z— is a bond, its pharmaceutically acceptable salt or a solvate thereof, (5) the compound according to any one of the item (1), (1-1) and (2) to (4) wherein ring A is
- ring A′ and ring B are each independently a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle
- —W— is a bond, -L 1 -C( ⁇ O)N(R 8 )-L 2 -L 1 -N(R 8 )C( ⁇ O)-L 2 - or -L 1 -N(R 8 )-L 2 -
- L 1 and L 2 are each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene
- R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl, its pharmaceutically acceptable salt or a solvate thereof, (6) the compound according to item (5) wherein —W
- the compounds of the present invention are useful as an agent for treating or preventing diseases induced by production, secretion or deposition of amyloid 13 protein such as Alzheimer's disease.
- halogen includes fluorine, chlorine, bromine, and iodine.
- alkyl includes linear or branched alkyl of a carbon number of 1 to 15, for example, a carbon number of 1 to 10, a carbon number of 1 to 6, or a carbon number of 1 to 3.
- Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl.
- the “substituted or unsubstituted alkyl” may be substituted with one or more substituents selected from a substituent group ⁇ .
- the substituent group ⁇ is a group consisting of halogen, hydroxy, alkoxy, halogenoalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, acylamino, alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfamoyl, alkylsulfinyl, alkylsulfonylamino, alkylsulfonylalkylamino, alkylsulfonylimino, alkylsulfinylamino, alkylsulfinylalkylamino, alkylsulfinylimino, cyano, nitro
- substituent of the “substituted or unsubstituted alkoxy”, the “substituted or unsubstituted alkoxycarbonyl”, “substituted or unsubstituted alkylthio”, “substituted or unsubstituted alkylsulfinyl”, and the “substituted or unsubstituted alkylsulfonyl” include one or more groups selected from the above substituent group ⁇ .
- halogenoalkyl examples include trifluoromethyl, fluoromethyl, and trichloromethyl.
- halogenoalkoxy examples include trifluoromethoxy, fluoromethoxy, and trichloromethoxy.
- alkylidene includes a divalent group of the above “alkyl”, and examples include methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and hexylidene.
- alkenyl includes linear or branched alkenyl of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, a carbon number of 2 to 6, or a carbon number of 2 to 4, having one or more double bonds at any available position.
- Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl and pentadecenyl.
- alkenyl part of the “alkenyloxy”, the “alkenyloxycarbonyl”, the “alkenylcarbonyl”, the “alkoxyalkenyloxy”, the “alkenylthio”, the “alkenylamino”, the “alkenylsulfonyl”, and the “alkenylsulfinyl” is the same as the above “alkenyl”.
- alkynyl includes linear or branched alkynyl of a carbon number of 2 to 10, for example, a carbon number of 2 to 8, or a carbon number of 3 to 6, having one or more triple bonds at any available position. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl. These may further a double bond at any available position.
- alkynyl part of the “alkoxyalkynyl”, the “alkynyloxy”, the “alkynyloxycarbonyl”, “alkynylcarbonyl”, the “alkoxyalkynyloxy”, the “alkynylthio”, the “alkynylsulfinyl”, the “alkynylsulfonyl” and the “alkynylamino” is the same as the above “alkynyl”.
- substituents of the “substituted or unsubstituted amino”, “substituted or unsubstituted carbamoyl”, “substituted or unsubstituted thiocarbamoyl” and the “substituted or unsubstituted sulfamoyl” include 1 to 2 substituents selected from alkyl, acyl, hydroxy, alkoxy, alkoxycarbonyl, a carbocyclic group and a heterocyclic group.
- acyl includes formyl, alkylcarbonyl of a carbon number of 1 to 10, alkenylcarbonyl of a carbon number of 2 to 10, alkynylcarbonyl of a carbon number of 2 to 10, carbocyclylcarbonyl and heterocyclylcarbonyl.
- Examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, benzoyl, cyclohexanecarbonyl, pyridinecarbonyl, furancarbonyl, thiophenecarbonyl, benzothiazolecarbonyl, pyrazinecarbonyl, piperidinecarbonyl, and thiomorpholino.
- substituent of the “substituted or unsubstituted acyl” and “substituted or unsubstituted acyloxy” include one or more substituents selected from the substituent group ⁇ .
- a ring part of the carbocyclylcarbonyl and the heterocyclylcarbonyl may be substituted with one or more substituents selected from alkyl, the substituent group ⁇ , and alkyl substituted with one or more groups selected from the substituent group ⁇ .
- the “carbocyclic group” includes cycloalkyl, cycloalkenyl, aryl and a non-aromatic fused carbocyclic group.
- cycloalkyl is a carbocyclic group of a carbon number of 3 to 10, for example, a carbon number of 3 to 8, or a carbon number of 4 to 8, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
- cycloalkenyl includes the cycloalkyl having one or more double bonds at any available position in the ring, and examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptynyl, cyclooctynyl and cyclohexadienyl.
- aryl includes phenyl, naphthyl, anthryl and phenanthryl, and specific example is phenyl.
- non-aromatic fused carbocyclic group includes non-aromatic groups in which two or more cyclic groups selected from the above “cycloalkyl”, the above “cycloalkenyl” and the above “aryl” are fused, and examples include indanyl, indenyl, tetrahydronaphthyl and fluorenyl.
- a carbocyclyl part of the “non-aromatic carbocyclic group” is the same as the “cycloalkyl”, “cycloalkenyl” and “non-aromatic fused carbocyclic group”.
- Examples are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene and cyclooctene.
- a carbocyclyl part of the “carbocyclic”, the “carbocyclyloxy”, the “carbocyclylalkyl”, the “carbocyclylalkoxy”, the “carbocyclylalkoxycarbonyl”, the “carbocyclylthio”, the “carbocyclylamino”, the “carbocyclylalkylamino”, the “carbocyclylcarbonyl”, the “carbocyclylsulfamoyl”, “carbocyclylsulfinyl”, the “carbocyclylsulfonyl”, the “carbocyclylcarbamoyl”, the “carbocyclylalkylcarbamoyl”, the “carbocyclyloxycarbonyl” and the “carbocyclylsulfonyl” is the same as the “carbocyclic group”.
- aryl part of the “arylalkyl”, the “aryloxy”, the “aryloxycarbonyl”, the “aryl alkoxycarbonyl”, the “arylthio”, the “arylamino”, the “arylalkoxy”, the “arylalkylamino”, the “arylsulfonyl”, the “arylsulfamoyl”, the “arylcarbamoyl”, and the “arylalkylcarbamoyl” is the same as the “aryl”.
- heterocyclic group includes a heterocyclic group having one or more hetero atoms optionally selected from O, S and N in a ring, and examples include 5- to 6-membered heteroaryl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, and thiadiazolyl; non-aromatic heterocyclic groups such as dioxanyl, thiiranyl, oxyranyl, oxetanyl, oxathioranyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl
- a heterocycle portion of “non-aromatic heterocycle” is the same as the heterocycle portion of the above “non-aromatic heterocyclyl.”
- Specific examples are dioxane, thiirane, oxirane, oxetane, oxathiolane, azetidine, thiane, thiazolidine, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dihydropyridine, tetrahydropyridine, tetrahydrofuran, tetrahydropyran, dihydrothiazole, tetrahydrothiazole, tetrahydroisothiazole, dihydrooxazine, hexahydroazepine, tetrahydrodiazepine and tetrahydropyridazine.
- a bond of the “heterocyclic group” may be situated on any ring.
- heteroaryl includes an aromatic cyclic group among the “heterocyclic group”.
- ring A′ and ring B are each independently substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle
- L 1 , L 2 , and L 3 are each independently a bond, substituted or unsubstituted alkynylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene,
- ⁇ W 1 is ⁇ O, ⁇ S, or ⁇ NR 9 ,
- W 2 is O, S, or N MO
- R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl
- R 9 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl, when ring A is (i), then the constituent carbon atom of L 1 and the constituent carbon atom of L 2 , or the constituent carbon atom of L 1 and the nitrogen atom of W 2 may be connected with substituted or unsubstituted alkylene to form a ring, when ring A is (ii), then the constituent carbon atom of L 1 and the constituent carbon atom of L 2 , or the nitrogen atom of W 2 and the constituent atom of L 2 may be connected with substituted or unsubstituted alkylene to
- L is each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene
- ring T is a carbocycle optionally substituted with a group(s) selected from the substituent group ⁇ , or a heterocycle optionally substituted with a group(s) selected from the group ⁇ , and that and other symbols are the same as defined above.
- substituents of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle” and “substituted or unsubstituted benzene” in ring A, ring A′, and ring B include:
- substituent group a such as halogen, hydroxy, alkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, carbamoyl, amino, cyano, alkylamino and/or alkylthio; alkyl substituted with one or more groups selected from the substituent group ⁇ , hydroxyimino and alkoxyimino, wherein the substituent is, for example, halogen, hydroxy, alkoxy and/or alkoxycarbonyl, or unsubstituted alkyl; aminoalkyl substituted with one or more groups selected from the substituent group a; wherein the substituent is, for example, acyl, alkyl and/or alkoxy; alkenyl substituted with one or more substituents selected from the substituent group ⁇ , wherein the substituent is, for example, alkoxycarbonyl, halogen, and/or halogenoalkoxycarbonyl, or unsubstituted alkenyl;
- Substituted or unsubstituted carbocycle “substituted or unsubstituted heterocycle”, “substituted or unsubstituted benzene”, “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine” and “substituted or unsubstituted pyrazine” may be substituted with one or more substituents selected from them.
- examples of the substituent of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle” and “substituted or unsubstituted benzene” in ring A′ and ring B, and “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine” and “substituted or unsubstituted pyrazine” in ring B include halogen, cyano, hydroxy, nitro, carboxy, alkyl substituted with one or more substituents selected from the substituent group ⁇ , unsubstituted alkyl, alkenyl substituted with one or more substituents selected from the substituent group ⁇ , unsubstituted alkenyl, alkynyl substituted with one or more substituents selected from the substituent group ⁇ , unsubstituted alkynyl, alkoxy substituted with
- substituent other than “—W-ring B” of “substituted or unsubstituted carbocycle” or “substituted or unsubstituted heterocycle” in ring A include halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, or cyano.
- substituents of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle” or “substituted or unsubstituted benzene” in ring A′ include halogen.
- substituents of “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine”, or “substituted or unsubstituted pyrazine” in ring B include halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, or cyano.
- alkylene include a linear or branched divalent carbon chain of a carbon number of 1 to 10, for example, a carbon number of 1 to 6, or a carbon number of 1 to 3. Examples include methylene, dimethylene, trimethylene, tetramethylene, and methyltrimethylene.
- alkylene portion in “alkylenedioxy” is the same as the above “alkylene.”
- alkenylene includes a linear or branched divalent carbon chain of a carbon number of 2 to 10, for example, a carbon number of 2 to 6, or a carbon number of 2 to 4, having a double bond at any available position. Examples include vinylene, propenylene, butenylene, butadienylene, methylpropenylene, pentenylene and hexenylene.
- alkynylene includes a linear or branched divalent carbon chain of a carbon number of 2 to 10, for example, a carbon number of 2 to 6, or, a carbon number of 2 to 4, having a triple bond at any available position and, further, optionally having a double bond. Examples include ethynylene, propynylene, butynylene, pentynylene and hexynylene.
- substituents of “substituted or unsubstituted alkylene”, “substituted or unsubstituted C1-C3 alkylene”, “substituted or unsubstituted alkenylene”, “substituted or unsubstituted C2-C3 alkenylene”, and “substituted or unsubstituted alkynylene” include the groups selected from the substituent group ⁇ , and specific examples are halogen and hydroxy.
- R za and R zb together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle” include the following examples.
- These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group ⁇ , unsubstituted alkyl and the substituent group ⁇ at any available position.
- R 3a and R 3b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle
- R 5a and R 5b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle
- These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group ⁇ , unsubstituted alkyl and the substituent group ⁇ at any available position.
- solvate includes, for example, solvates with organic solvents and hydrates. It can be prepared in accordance with the known methods. Examples of solvate include a solvate with acetone, 2-butanol, 2-propanol, ethanol, ethyl acetate, tetrahydrofuran or diethyl ether. For example, it includes a non-toxic and water-soluble hydrate or solvate such as a solvate with ethanol. In the case that a hydrate or solvate is formed, the compound or salt may be coordinated with any number of solvate molecules or water molecules.
- the compound of the formula (I) includes a pharmaceutically acceptable salt.
- examples include salts with alkali metals such as lithium, sodium or potassium; alkaline earth metals such as calcium; magnesium; transition metals such as zinc or iron; ammonium; organic bases; and amino acids; or salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid or hydroiodic acid; and organic acids such as acetic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid or ethanesulfonic acid. Specific examples are hydrochloric acid, phosphoric acid, tartaric acid and methanesulfonic acid. These salt
- the compound of the formula (I) is not limited to a specific isomer, but includes all possible isomers, such as keto-enol isomers, imine-enamine isomers, diastereoisomers, optical isomers and rotation isomers; and racemate.
- the compound of the formula (I) wherein R 2a is hydrogen includes the following tautomers.
- one or more hydrogen, carbon or other atoms of the compound of the formula (I) can be replaced by an isotope of the hydrogen, carbon or other atoms.
- Compounds of the formula (I) include all radiolabeled forms of compounds of the formula (I).
- the “radiolabeled,” “radiolabeled form” and the like of the compound of the formula (I) are encompassed by the present invention and useful as a research and/or diagnostic tool in metabolism pharmacokinetic studies and in binding assays. It is also useful for a medicament.
- isotopes that can be incorporated into the compound of the formula (I) of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, iodine and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 15 F, 123 I and 36 Cl, respectively.
- Radiolabeled compounds of the invention can be prepared by methods known in the art.
- tritiated compounds of formula (I) can be prepared by introducing tritium into the particular compound of formula (I), for example, by catalytic dehalogenation with tritium.
- This method may include reacting a suitably halogen-substituted precursor of a compound of formula (I) with tritium gas in the presence of a suitable catalyst such as Pd/C, in the presence or absence of a base.
- a suitable catalyst such as Pd/C
- Other suitable methods for preparing tritiated compounds can be found in Isotopes in the Physical and Biomedical Sciences, Vol. 1 , Labeled Compounds (Part Chapter 6, (1987). 14 C-labeled compounds can be prepared by employing starting materials having a 14 C carbon.
- the present compound of the formula (I-a1) to (I-a3), (I-b1) to (I-136), (I-c1) and (I-c2) can be prepared, for example, according to the method described in Patent Literature 4, or by the following method.
- the present compound of the formula (I) can be prepared by the following method. In the following all steps, when a substituent which interferes with the reaction, e.g. hydroxy, mercapto, amino, formyl, carbonyl, carboxy, is possessed, the substituent is protected by the method such as those described in Protective Groups in organic Synthesis, and Theodora W Greene (John Wiley & Sons) in advance, and the protective group may be removed at a desirable stage.
- a substituent which interferes with the reaction e.g. hydroxy, mercapto, amino, formyl, carbonyl, carboxy
- a crossed bond means that the compound is either E isomer or Z isomer, or a mixture thereof with respect to double bond.
- PG represents an amino protective group such as acyl, alkoxycarbonyl, trialkylsilyl, and alkylsulfonyl, and the other symbols represent the same as defined above.
- Compound (a-1) can be prepared by the Preparing Method D described below from a commercially available compound. It can be also prepared by the known methods from a commercially available compound, and can be also prepared by methods described in Examples.
- Compound (a-2) can be prepared by reacting Compound (a-1) with hydroxylamine or a hydroxylamine salt such as hydroxylamine hydrochloride or hydroxylamine sulfate in the presence or absence of a base, in an organic solvent such as ethanol, methanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and dichloromethane, and a mixed solvent of them and water.
- a base include sodium acetate, pyridine, sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide and 2,6-lutidine.
- the reaction time is not particularly limited and is usually between 5 minutes and 30 hours, and preferably between 5 minutes and 12 hours.
- the reaction temperature is usually between ⁇ 20° C. and solvent reflux temperature, and preferably between 0° C. and solvent reflux temperature.
- the reaction in this step can be performed under the usual conditions for an oximation reaction of a carbonyl compound such as the conditions described in Org. Lett., 9 (2007) 5, 753-6, Tetrahedron 54 (1998) 22, 5868-82, and Tetrahedron: Asymmetry 5 (1994) 6, 1018-28.
- Compound (a-3) can be prepared by reacting Oxime Compound (a-2) with N-chlorosuccinimide or sodium hypochlorite in a solvent such as dichloromethane, chloroform, benzene, toluene, xylene, N,N-dimethylformamide, tetrahydrofuran and 1,4-dioxane at the temperature between ice-cooling to solvent reflux temperature for 30 minutes to 48 hours, preferably 0.5 to 24 hours to convert a nitrile oxide, followed by a 1,3-dipolar cycloaddition reaction.
- a solvent such as dichloromethane, chloroform, benzene, toluene, xylene, N,N-dimethylformamide, tetrahydrofuran and 1,4-dioxane
- More preferable results such as suppression of side reactions and improved yield may be achieved by carrying out this reaction in the presence of a base such as sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, an aqueous solution thereof, triethylamine and pyridine.
- a base such as sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, an aqueous solution thereof, triethylamine and pyridine.
- This step is for preparing Compound (a-3) by converting Compound (a-2) to a nitrile oxide derivative and subjecting to a 1,3-dipolar cycloaddition reaction with the olefin moiety in the same molecule.
- the reaction in this step can be performed under the usual conditions for a 1,3-dipolar cycloaddition reaction, for example, the conditions described in Org. Lett., 9 (2007) 5, 753-6, Tetrahedron 54 (1998) 22, 5868-82 and Tetrahedron: Asymmetry 5 (1994) 6, 1018-28.
- Compound (a-4) can be prepared by reacting Compound (a-3) with an organic metal reagent such as an aryl lithium reagent (wherein aryl includes heterocyclyl), a Grignard reagent (wherein the substituent includes heterocyclyl), an aryl magnesium reagent (wherein aryl includes heterocyclyl), which can be prepared by methods known to a person skilled in the art in a solvent which does not interfere with the preparation of a reagent and this reaction such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene and toluene, and a mixed solvent thereof.
- an organic metal reagent such as an aryl lithium reagent (wherein aryl includes heterocyclyl), a Grignard reagent (wherein the substituent includes heterocyclyl), an aryl magnesium reagent (wherein aryl includes heterocyclyl), which can be prepared by methods
- the reaction time is usually between 5 minutes and 48 hours, and preferably between 5 minutes and 12 hours.
- the reaction temperature varies according to a starting material, a reagent, solubility and the like, and in general, is preferably maintained to be the temperature for minimizing the formation of a by-product, for example, ⁇ 78° C.
- Favorable results such as an improved yield and a reduced reaction time may be achieved by addition of an additive such as tetramethylethylene diamine, hexamethylphosphoramide or a Lewis acid such as a boron trifluoride-diethyl ether complex.
- reaction in this step can be performed under similar conditions to those described in SYNLETT, 2004, 8, 1408-13, J. Am. Chem. Soc., 2005, 127, 5376-83 and Bull. Chem. Soc. Jpn., 1993, 66, 2730-7.
- Compound (a-5) can be prepared by subjecting Compound (a-4) to a cleavage reaction of the N—O bond by using a zinc-acid, a hydrogen-metal catalyst, a hydride reductant and the like in a solvent which does not interfere with the reaction such as methanol, ethanol, 1,4-dioxane, THF, ether and water.
- the acid examples include acetic acid, formic acid and hydrochloric acid.
- the solvent used in the reaction can be selected from the above solvent, and the above acid can be also used as a solvent.
- the reaction temperature is usually between ⁇ 20° C. and solvent reflux temperature, and preferably between 0° C. and solvent reflux temperature.
- the reaction time is usually between 5 minutes and 48 hours, and preferably between 5 minutes and 24 hours. The reaction can be performed under similar conditions to those described in Org. Lett. 7 (2005) 25, 5741-5742 and J. Org. Chem. 200, 68, 1207-1215.
- the reaction can be performed using a metal catalyst such as platinum oxide under similar conditions to those described in Tetrahedron: Asymmetry 5 (1994) 6, 1019-1028 and Tetrahedron, Vol. 53, No. 16, pp 5752-5746, 1997.
- Compound (a-5) can be prepared by hydrogenating Compound (a-4) using platinum oxide as a catalyst in a solvent such as methanol under hydrogen atmosphere.
- reaction using a hydride reductant such as a lithium aluminum hydride can be performed under similar conditions to those described in Bull. Chem. Soc. Jpn., 66, 2730-2737 (1993).
- compound (a-5) can be prepared by reducing Compound (a-4) using lithium aluminum hydride in a solvent such as ether.
- Compound (a-6) can be prepared by subjecting Compound (a-5) to a functional group protection reaction which is known to a person skilled in the art.
- a protective group is a t-butoxycarbonyl group (hereafter referred to as a Boc group) or a 9-fluorenemethyloxycarbonyl group (hereafter referred to as a Fmoc group)
- a target compound can be prepared under the usual conditions for protection of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-7) can be prepared by adding an oxidant such as 2-iodoxybenzoic acid to a solution of Compound (a-6) in a solvent such as dimethyl sulfoxide and dichloromethane, and reacting at 0° C. to 80° C., preferably 10° C. to 40° C. for 0.5 hours to 48 hours, preferably 1 hour to 12 hours.
- an oxidant such as 2-iodoxybenzoic acid
- a solvent such as dimethyl sulfoxide and dichloromethane
- oxidation conditions used in the reaction include Swern oxidation, Corey-Kim oxidation, Moffatt oxidation, pyridinium chlorochromate oxidation (PCC oxidation), pyridinium dichromate oxidation (PDC oxidation), Dess-Martin oxidation, 503-pyridine oxidation, and 2,2,6,6-tetramethyl-1-piperidinyloxy free radical oxidation (TEMPO oxidation), which are known to a person skilled in the art, and the conditions described in “Comprehensive Organic Transformations, Richard C. Larock; VCH”.
- R 3a R 3b CHPPh 3 such as methyltriphenylphosphonium iodide which is commercially available or can be prepared by methods known to a person skilled in the art is added a strong base such as an alkyl metal reagent such as n-butyllithium in a solvent such as ether, tetrahydrofuran, dioxane, and a mixed solvent thereof to prepare a Wittig reagent which corresponds to a target compound.
- Compound (a-8) can be prepared by adding a solution of Compound (a-7) in a solvent such as ether, tetrahydrofuran, and dioxane to the Wittig reagent at ⁇ 40° C. to 60° C., preferably ⁇ 20° C. to 30° C. and reacting them for 0.1 hours to 24 hours, preferably 0.3 hours to 6 hours.
- An amine free compound can be prepared by deprotecting Compound (a-8) under conditions known to a person skilled in the art such as the usual conditions for deprotecting of a protective group of an amine compound, for example, when a protective group is a Boc group or a Fmoc group, the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-9) can be prepared by adding isocyanate or isothiocyanate such as benzoyl isocyanate and benzoyl isothiocyanate having a protective group, which is commercially available or can be prepared by the known methods to the obtained amine-free compound in a solvent such as dichloromethane, tetrahydrofuran and toluene and a mixed solvent thereof at ⁇ 30° C. to 50° C., preferably ⁇ 10° C. to 25° C. for 0.5 hours to 24 hours, preferably 0.5 hours to 12 hours.
- a solvent such as dichloromethane, tetrahydrofuran and toluene and a mixed solvent thereof at ⁇ 30° C. to 50° C., preferably ⁇ 10° C. to 25° C. for 0.5 hours to 24 hours, preferably 0.5 hours to 12 hours.
- Compound (a-10) can be prepared by adding a halogenium cation source such as iodine, bromine, N-bromosuccinimide (hereafter referred to as NBS), and N-chloro succinimide (hereafter referred to as NCS) to a solution of Compound (a-9) in a solvent such as dichloromethane, and reacting at ⁇ 20° C. to 40° C., preferably 0° C. to 20° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 6 hours.
- a halogenium cation source such as iodine, bromine, N-bromosuccinimide (hereafter referred to as NBS), and N-chloro succinimide (hereafter referred to as NCS)
- NBS N-bromosuccinimide
- NCS N-chloro succinimide
- Compound (a-11) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and 1,8-diazabicyclo[5.4.0] undeca-7-en (hereafter referred to as DBU) to a solution of Compound (a-10) in a solvent such as dioxane, tetrahydrofuran and toluene, and the mixture thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- a base such as pyrrolidine, piperidine, piperazine, morpholine and 1,8-diazabicyclo[5.4.0] undeca-7-en (hereafter referred to as DBU)
- a base such as pyrrolidine, piperidine, piperazine, morpholine and 1,8-diazabicyclo[5.4.0] undeca-7-en (hereafter referred to as DBU
- Compound (a-11) can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (I-a1) can be prepared under the usual conditions for deprotecting a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- R′ represents a group which does not interfere with the reaction such as an amino group
- LG represents a leaving group such as halogen and alkylsulfonyloxy, and the other symbols represent the same as defined above.
- An amine free compound can be prepared by deprotecting Compound (a-8) under conditions known to a person skilled in the art such as the usual conditions for deprotecting a protective group of an amine compound, for example, when a protective group is a Boc group or a Fmoc group, the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-12) can be prepared by reacting the obtained amine-free compound with 3,5-dimethylpyrazole-1-carboxyamidine, S-methylthiourea or the like in a solvent such as acetonitrile, tetrahydrofuran and dimethylformamide at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 hours to 120 hours, preferably 1 hour to 24 hours.
- Compound (a-13) can be prepared by adding a halogenium cation source such as iodine, bromine, NBS, and NCS to a solution of Compound (a-12) in a solvent such as dichloromethane, and reacting at ⁇ 20° C. to 40° C., preferably 0° C. to 20° C. for 0.1 hour to 12 hours, preferably 0.1 hour to 6 hours.
- a halogenium cation source such as iodine, bromine, NBS, and NCS
- Compound (a-14) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU to a solution of Compound (a-13) in a solvent such as dioxane, tetrahydrofuran and toluene, and the mixture thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU
- Step 4 (the Case Wherein R′ is a Protective Group)
- An amine group of Compound (a-14) can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (I-a2) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- R′ and R′′ represent groups which do not interfere with the reaction such as an amino protective group and the other symbols are the same as defined above.
- An amine free compound can be prepared by deprotecting Compound (a-8) under conditions known to a person skilled in the art such as the usual conditions for deprotection of a protective group of an amine compound, for example, when a protective group is a Boc group or a Fmoc group, the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-15) can be prepared by adding isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods, to the obtained amine-free compound in a solvent such as dichloromethane, dioxane, tetrahydrofuran, toluene and acetone, and a mixed solvent thereof at ⁇ 30° C. to 50° C., preferably ⁇ 10° C. to 25° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 3 hours.
- a solvent such as dichloromethane, dioxane, tetrahydrofuran, toluene and acetone
- Compound (a-16) can be prepared by adding a halogenium cation source such as iodine, bromine, NBS, and NCS to a solution of Compound (a-15) in a solvent such as dichloromethane, and reacting at ⁇ 20° C. to 40° C., preferably 0° C. to 20° C. for 1 hour to 12 hours, preferably 0.1 hours to 6 hours.
- a halogenium cation source such as iodine, bromine, NBS, and NCS
- Compound (a-17) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU to a solution of Compound (a-16) in a solvent such as dioxane, tetrahydrofuran and toluene, and a mixed solvent thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU
- Compound (a-17) can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (I-a3) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-7) which can be prepared by the method mentioned above can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (b-8) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (b-8) To a solution of Compound (b-8) in a solvent such as dichloromethane, dioxane, tetrahydrofuran, toluene and acetone, and a mixed solvent thereof is added isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods, and the mixture is reacted at ⁇ 30° C. to 70° C., preferably ⁇ 20° C. to 50° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 6 hours.
- Compound (b-9) can be prepared by evaporating the solvent, adding concentrated sulfuric acid, concentrated nitric acid or the like to the mixture, and reacting at ⁇ 30° C. to 70° C., preferably ⁇ 20° C. to 50° C. for 1 hour to 12 hours, preferably 1 hour to 6 hours.
- an amino group of Compound (b-9) can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (I-b1) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (b-10) can be prepared by reacting Compound (b-8) with 3,5-dimethylpyrazole-1-carboxyamidine, S-methylthiourea or the like in a solvent such as acetonitrile, tetrahydrofuran and dimethylformamide at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 hours to 120 hours, preferably 1 hour to 24 hours.
- a solvent such as acetonitrile, tetrahydrofuran and dimethylformamide
- Compound (b-11) can be prepared by adding concentrated sulfuric acid, concentrated nitric acid or the like to Compound (b-10), and reacting at ⁇ 30° C. to 70° C., preferably ⁇ 20° C. to 50° C. for 1 hour to 12 hours, preferably 1 hour to 6 hours.
- Step 3 (the Case Wherein R′ is a Protective Group)
- Compound (a-14) can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (I-b2) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (b-12) can be prepared by adding isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods, to a solution of Compound (b-8) in a solvent such as dioxane, tetrahydrofuran, toluene and acetone, and a mixed solvent thereof, and reacting at ⁇ 30° C. to 50° C., preferably ⁇ 10° C. to 25° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 3 hours.
- isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods
- Compound (b-13) can be prepared by adding concentrated sulfuric acid, concentrated nitric acid or the like to Compound (b-12), and reacting at 0° C. to 100° C., preferably 0° C. to 60° C. for 0.5 hours to 24 hours, preferably 1 hour to 12 hours.
- Compound (b-13) can be deprotected under conditions for deprotection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (I-b3) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in a document such as T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-1′) can be prepared from a commercially available compound by methods in a similar manner to Method D described below. It can also be prepared by methods known to a person skilled in the art from a commercially available compound or by methods described in Examples.
- Compound (I-b4) can be prepared by subjecting Compound (a-7′) which is prepared by Step 1 to Step 6 of Preparation Method A-I to a reaction of Step 1 to Step 3 of Preparation Method B-I using Compound (a-1′) as a starting material.
- compounds wherein X is NR 1 or O can be prepared according to the scheme described below.
- Compound (a-7′) can be prepared by reacting Compound (a-7) with a Grignard reagent according to usual methods known to a person skilled in the art, and oxidizing the obtained alcohol.
- Compound (a-7′) can be prepared by oxidizing Compound (a-7) to a carboxylic acid according to the usual methods, converting into a Weinreb amide, reacting with a Grignard reagent, and oxidizing the obtained alcohol.
- the conditions described in “Comprehensive Organic Transformations, Richard C. Larock; VCH” can be also used for conversion of these functional groups.
- LG is a leaving group such as halogen or alkylsulfonyloxy
- R′ represents alkyl, arylalkyl or the like
- Tf represents trifluoromethanesulfonyl, either one of dotted lines represent the presence of a bond, and the other symbols are the same as defined above.
- Compound (c-1) can be a commercially available compound. It can be also prepared by methods known to a person skilled in the art from a commercially available compound or by methods described in Examples.
- Compound (c-2) can be prepared by reacting a base such as sodium hydride, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, diisopropylethylamine, pyridine and 2,6-lutidine with Compound (c-1), and reacting N-phenyltrifluoromethanesulfonimide or trifluoromethanesulfonic anhydride.
- a base such as sodium hydride, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, diisopropylethylamine, pyridine and 2,6-lutidine
- the solvent include ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, benzene and toluene.
- the reaction time is usually between 5 minutes and 24 hours, and preferably between 5 minutes and 12 hours.
- the reaction temperature is usually between
- the reaction in this step can be performed under the usual conditions for a trifluoromethanesulfonylation reaction of a carbonyl compound such as the conditions described in J. Org. Chem., 57, 6972-6975 (1992), Tetrahedron., 61, 4129-4140 (2005) and Tetrahedron Letters., 40, 8133-8136 (1999).
- Compound (c-3) can be prepared by a coupling reaction of Compound (c-2) using a transition metal.
- This coupling reaction can be performed under the usual conditions for coupling reaction such as Suzuki-Miyaura coupling reaction or Stille coupling reaction.
- Suzuki-Miyaura coupling reaction or Stille coupling reaction.
- the reaction conditions described in Chem. Rev., 2007, 107, 133-73 and Tetrahedron, 58 (2002), 9633-35 can be applied.
- the organometallic catalyst used in this reaction is not particularly limited.
- examples of the organometallic catalyst include tetrakis(triphenylphosphine)palladium (0), dichlorobis(triphenylphosphine)palladium(II),
- the amount of the organometallic catalyst is about 0.001 to 0.1 equivalent with respect to the raw material.
- the organometallic compound is not particularly limited.
- Preferable examples of the organometallic compound include organotin reagents such as aryl tri-n-butyltin, and organoboron reagents such as aryl boronic acid.
- the amount of the organometallic compound is 1 equivalent to an excess amount with respect to the raw material.
- the solvent is not particularly limited insofar as it does not interfere with the reaction. Examples of the solvent include benzene, toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone, 1,4-dioxane and propionitrile.
- the reaction temperature is usually between ice-cold temperature and solvent reflux temperature, and preferably between room temperature and solvent reflux temperature.
- the reaction time is usually between 10 minutes and 48 hours, and preferably between 30 minutes and 24 hours.
- a more preferable result such as a suppression of side reactions and an improved yield may be achieved by carrying out this reaction in the presence of a base such as sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, an aqueous solution thereof, and triethylamine.
- a base such as sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, an aqueous solution thereof, and triethylamine.
- Compound (c-4) can be prepared by subjecting Compound (c-3) to a reduction reaction by using diisobutylaluminum hydride, lithium aluminum hydride, lithium borohydride or the like in a solvent such as dioxane, tetrahydrofuran or toluene, or a mixed solvent thereof and reacting at ⁇ 80° C. to 0° C., preferably ⁇ 80° C. to ⁇ 20° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 3 hours.
- Compound (c-5) can be prepared by reacting Compound (c-4) with a halogenating agent such as thionyl chloride, phosphorous oxychloride, carbon tetrabromide-triphenylphosphine, and carbon tetrachloride-triphenylphosphine in the presence or absence of a solvent such as toluene or dichloromethane at ⁇ 80° C. to 50° C., preferably ⁇ 20° C. to 20° C. for 0.1 hours to 24 hours, preferably 0.5 hours to 12 hours.
- a halogenating agent such as thionyl chloride, phosphorous oxychloride, carbon tetrabromide-triphenylphosphine, and carbon tetrachloride-triphenylphosphine
- Compound (c-5) can be also prepared by reacting Compound (c-4) with a sulfonylation agent such as methanesulfonyl chloride and p-toluenesulfonyl chloride in the presence of a base such as triethylamine in a solvent such as toluene or dichloromethane at ⁇ 80° C. to 50° C., preferably ⁇ 20° C. to 20° C. for 0.1 hours to 24 hours, preferably 0.5 hours to 12 hours.
- a sulfonylation agent such as methanesulfonyl chloride and p-toluenesulfonyl chloride
- a base such as triethylamine
- solvent such as toluene or dichloromethane
- Compound (c-6) can be prepared from Compound (c-5) by methods known to a person skilled in the art. Specifically, for example, Compound (c-6) can be prepared by reacting Compound (c-5) with thiourea or the like in an organic solvent such as ethanol, 1-propanol, 2-propanol, 1-buthanol, tetrahydrofuran, 1,4-dioxane, and N,N-dimethylformamide. The reaction time is usually between 5 minutes and 24 hours, and preferably between 5 minutes and 12 hours. The reaction temperature is usually between 0° C. and 150° C., and preferably between room temperature and 100° C.
- organic solvent such as ethanol, 1-propanol, 2-propanol, 1-buthanol, tetrahydrofuran, 1,4-dioxane, and N,N-dimethylformamide.
- the reaction time is usually between 5 minutes and 24 hours, and preferably between 5 minutes and 12 hours.
- the reaction temperature
- Compound (I-c1) can be prepared by adding a halogenium cation source such as iodine, bromine, NBS and NCS to a solution of Compound (c-6) in a solvent such as dichloromethane, and reacting the mixture at ⁇ 20° C. to 40° C., preferably 0° C. to 20° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 6 hours.
- a halogenium cation source such as iodine, bromine, NBS and NCS
- a solvent such as dichloromethane
- the objective substituent Rob can be introduced to thus-obtained compounds by methods known to a person skilled in the art.
- Compound (I-c2) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU to a solution of Compound (I-c1) in a solvent such as dioxane, tetrahydrofuran and toluene, and a mixed solvent thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU
- Compound (I-c1′) and Compound (I-c2′) can be prepared by the subsequent steps according to Preparation Method C-I.
- R 4 into Compound (I-c1) or (I-c1′) can be performed under the suitably applied conditions according to methods described in the following documents which are known to a person skilled in the art.
- Compounds (d-1), (d-2) and (d-4) can be a commercially available compound. They can also be prepared by methods known to a person skilled in the art from a commercially available compound, or by methods described in Examples.
- Compound (d-3) can be prepared by adding a base such as sodium hydride, potassium hydride and potassium t-butoxide to a solution of Compound (d-1) in a solvent such as THF, DMF and dimethyl sulfoxide to give an alkoxide, and reacting with Compound (d-2).
- the amounts of the base and Compound (d-2) are each 1 equivalent to an excess amount with respect to Compound (d-1).
- the reaction time is usually between 5 minutes and 90 hours, and preferably between 30 minutes and 24 hours.
- the reaction temperature is usually between ⁇ 20° C. and 80° C.
- a more preferable result such as an improved yield may be achieved by performing the reaction in the presence of a salt such as tetrabutylammonium iodide.
- This reaction can be performed under the usual conditions for O-alkylation of alcohol such as the conditions described in Tetrahedron Lett., 46 (2005) 45, 7751-5.
- Compound (a-1; Y ⁇ O) can be prepared by adding an oxidant such as 2-iodoxy benzoic acid to a solution of Compound (d-3) in a solvent such as dimethyl sulfoxide and dichloromethane, and reacting at 0° C. to 80° C., preferably 10° C. to 40° C. for 0.5 hours to 48 hours, preferably 1 hour to 12 hours.
- an oxidant such as 2-iodoxy benzoic acid
- a solvent such as dimethyl sulfoxide and dichloromethane
- oxidation conditions include Swern oxidation, Corey-Kim oxidation, Moffatt oxidation, pyridinium chlorochromate oxidation (PCC oxidation), pyridinium chromate oxidation (PDC oxidation), Dess-Martin oxidation, SO 3 -pyridine oxidation, and 2,2,6,6-tetramethyl-1-piperizinyloxy free radical oxidation (TEMPO oxidation).
- Compound (d-5) can be prepared from Compound (d-4) in a similar manner to the above preparation of the above Compound (d-3).
- Compound (a-1; Y ⁇ O) can be prepared by deprotecting an acetal group of Compound (d-5) under similar conditions to those described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (d-6) can be a commercially available compound. It can be also prepared by methods known to a person skilled in the art from a commercially available compound or by methods described in Examples.
- Compound (d-7) can be prepared by subjecting Compound (d-6) to a reaction under the conditions for functional group protection known to a person skilled in the art.
- a protective group is a Boc group or a Fmoc group
- Compound (d-7) can be prepared under the usual conditions for protection of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (d-8) can be prepared by adding powder of sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride or potassium t-butoxide to a solution of Compound (d-7) in a solvent such as toluene, THF, DMF and dimethyl sulfoxide, and reacting with Compound (d-2) at ⁇ 20° C. to 100° C. for 5 minutes to 72 hours, preferably 30 minutes to 24 hours.
- the amounts of the base and Compound (d-2) are each 1 equivalent to an excess amount with respect to Compound (d-7).
- a more preferable result such as an improved yield may be achieved by performing the reaction in the presence of a salt such as tetrabutylammonium iodide.
- This reaction can be performed under the usual conditions for N-alkylation of Compound (d-7) such as the conditions described in J. Med. Chem., 2007, 50, 5493-508.
- Compound (a-1) wherein Y ⁇ NH can be prepared by deprotecting a PG group of Compound (d-8) under similar conditions to those described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (I-a1) wherein Y is N(R′) can be prepared by subjecting thus-obtained compounds to each reaction in Preparation Method A and introducing the substituent R 1 by methods known to a person skilled in the art at an appropriate stage.
- the objective compound can be prepared by deprotecting Compound (a-1), introducing R 1 using methods known to a person skilled in the art, and subjecting to each reaction in Preparation Method A
- the optically active isomer of the compound (I) can be prepared by using an optically active compound as a starting material, performing an asymmetric synthesis in the suitable step to prepare an optically active intermediate, or optical resolution of the racemate of the intermediate or the objective compound in the appropriate step.
- the method of optical resolution include the separation of optical isomer using an optically active column, the kinetics optical resolution using enzyme reactions or the like, the crystallization and separation of diastereomers by the salt formation using chiral acids or chiral bases, the preferential crystallization or the like.
- —X— is, for example, —O—, —S— or —N(R 1 )—.
- —X— is, for example, —O— or —S—.
- —X— is, for example, —O—.
- —X— is, for example, —S—.
- R 1 is, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted
- R 1 is, for example, hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group.
- R 2a and R 2b are, for example, each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl or substituted or unsubstituted carbamoyl.
- R 2a and R 2b are, for example, both hydrogen.
- Ring A includes substituted carbocycle or substituted or unsubstituted heterocycle.
- Ring A includes
- Ring N and ring B are each independently substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle
- L 1 , L 2 , and L 3 are each independently a bond, substituted or unsubstituted alkynylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene,
- ⁇ W 1 is ⁇ O, ⁇ S, or ⁇ NR 9 ,
- W 2 is O, S, or N(R 8 ),
- R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl
- R 8 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl, when ring A is (i), then the constituent carbon atom of L 1 and the constituent carbon atom of L 2 , or the constituent carbon atom of L 1 and the nitrogen atom of W 2 may be connected with substituted or unsubstituted alkylene to form a ring, when ring A is (ii), then the constituent carbon atom of L 1 and the constituent carbon atom of L 2 , or the nitrogen atom of W 2 and the constituent carbon atom of L 2 may be connected with substituted or unsubstituted alkylene
- Ring A includes
- L is each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene
- ring T is a carbocycle which may be substituted with a group(s) selected from the substituent group ⁇ or a heterocycle which may be substituted with a group(s) selected from the substituent group ⁇ , and other each symbol is the same as defined above.
- Ring A includes
- Ring A includes
- L 1 and L 2 include each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, and
- R 8 includes hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl.
- Ring A includes
- Ring A′ includes each independently a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle.
- Ring A′ is, for example, substituted or unsubstituted benzene, wherein the substituent is halogen and the like.
- Ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine, wherein the substituent is, for example, halogen, alkyl, alkoxy, halogenoalkoxy, alkynyloxy, alkylcarbamoyl, or cyano.
- R 8 includes hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl.
- R 8 includes hydrogen
- —Y— is, for example, a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R 7 )—, —O—, —S—, —SO— or —SO 2 —.
- —Y— is, for example, substituted or unsubstituted C1-C3 alkylene or —O—.
- —Z— is, for example, a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R 7 )Ak—, —OAk—, —SAk—, —SOAk- or —SO 2 Ak—.
- —Z— is, for example, a bond.
- Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene.
- —Y— is —N(R 7 )—, —O—, —S—, —SO— or —SO 2 —, then Ak is not a bond.
- —Z—Y— is, for example, substituted or unsubstituted C1-C3 alkylene, —O— or —O— (substituted or unsubstituted C1-C3 alkylene)-.
- R 7 is, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted substituted al
- R 7 is, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, or substituted or unsubstituted carbamoyl.
- R za and R zb are, for example, each independently hydrogen, halogen, substituted or unsubstituted alkyl, or R za and R zb together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle.
- R za and R zb are, for example, each independently hydrogen, halogen, substituted or unsubstituted alkyl.
- R 3a and R 3b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfam
- R 3a and R 3b are, for example, both hydrogen.
- R 4a and R 4b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, a substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heterocyclyloxy.
- R 4a and R 4b are, for example, each independently hydrogen or substituted or unsubstituted alkyl.
- R 4b is not hydrogen.
- R 5a , R 5b , R 6a and R 6b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbon
- R 5a , R 5b , R 6a and R 6b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbon
- R 5a R 5b , R 6a and R 6b are, for example, each independently hydrogen, or substituted or unsubstituted alkyl.
- R 5a , R 5b , R 6a and R 6b are, for example, both hydrogen.
- ring A′ is a substituted or unsubstituted carbocycle wherein the substituent is, for example, halogen
- ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine wherein the substituent is, for example, halogen, alkyl, alkoxy, halogenoalkoxy, alkynyloxy, alkylcarbamoyl or cyano
- R 8 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted acyl, more specifically hydrogen
- R za and R zb are each independently hydrogen, halogen or substituted or unsubstituted alkyl
- R 3a is hydrogen, or substituted or unsubstituted alkyl.
- R b1 and R b2 are each independently hydrogen, chloro, fluoro, methoxy, butynyloxy, cyano, amino or carbamoyl, the compound wherein a combination of ring B, R b1 and R b2 (B, R b1 , R b2 ) is as follows: (B1, hydrogen, hydrogen) (hereinafter, referred to as ring B is b1), (B1, hydrogen, chloro) (hereinafter, referred to as ring B is b2), (B1, hydrogen, fluoro) (hereinafter, referred to as ring B is b3), (B1, hydrogen, methoxy) (hereinafter, referred to as ring B is b4), (B1, hydrogen, butynyloxy) (hereinafter, referred to as ring B is b5), (B1, hydrogen, cyano) (hereinafter, referred to as ring B is b6), (B1, hydrogen, amino) (hereinafter, referred
- ring A and ring B (r,A,b) is as follows. (r1,A1,b1), (r1,A1,b2), (r1,A1,b3), (r1,A1,b4), (r1,A1,b5), (r1,A1,b6), (r1,A1,b7), (r1,A1,b8), (r1,A1,b9), (r1,A1,b10), (r1,A1,b11), (r1,A1,b12), (r1,A1,b13), (r1,A1,b14), (r1,A1,b15), (r1,A1,b16), (r1,A1,b17), (r1, A1,b18), (r1,A1,b19), (r1,A1,b20), (r1,A1,b21), (r1,A1,b22), (r1,A1,b23), (r1,A1,b24), (r1,A1,b25), (r1,A 1,b26), (r1,A1,b27), (r1,A1,b28), (r1,A1,b29), (r1,A
- the present compounds are useful in disease induced by the production, secretion or deposition of amyloid 6 protein, and are effective in treatment and/or prevention, and symptom improvement of such as dementia of the Alzheimer's type (Alzheimer's disease, senile dementia of Alzheimer type), Down's syndrome, memory impairment, prion disease (Creutzfeldt-Jakob disease), mild cognitive impairment (MCI), Dutch type of hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, other type of degenerative dementia, mixed dementia with Alzheimer's and vascular type, dementia with Parkinson's Disease, dementia with progressive supranuclear palsy, dementia with Cortico-basal degeneration, Alzheimer's disease with diffuse Lewy body disease, age-related macular degeneration, Parkinson's Disease, amyloid angiopathy and so on.
- dementia of the Alzheimer's type Alzheimer's type
- senile dementia of Alzheimer type Down's syndrome
- memory impairment prion disease (Creutzfeld
- treating Alzheimer's disease includes prevention of advancing in severity of MCI and prevention of onset of familial Alzheimer's disease.
- a pharmaceutical composition for treating Alzheimer's disease includes a pharmaceutical composition for prevention of advancing in severity of MCI and prevention of onset of familial Alzheimer's disease.
- the present compound Since the present compound has high inhibitory activity on BACE1, and/or has high selectivity on other enzymes, it can be a medicament with reduced side effect. Further, since the compound has high effect of reducing amyloid p production in a cell system, particularly, has high effect of reducing amyloid 6 production in brain, it can be an excellent medicament. In addition, by converting the compound into an optically active compound having suitable stereochemistry, the compound can be a medicament having a larger safety margin on the side effect.
- the present compound also has advantages that metabolism stability is high, solubility is high, oral absorbability is high, good bioavailability is exhibited, clearance is good, brain transference is high, a half life is high, non-protein binding rate is high, hERG channel inhibition is low, CYP inhibition is low, CYP MBI (irreversible inhibition (mechanism-based inhibition)) is low and/or an Ames test is negative.
- the present compounds can be administrated in combination with other pharmaceutical agents such as other therapeutic drugs for Alzheimer's disease, e.g., acetylcholinesterase and the like.
- the present compounds can be treated with concomitantly with the anti-dementia agents such as Donepezil Hydrochloride, Tacrine, Galantamine, Rivastigmine, Zanapezil, Memantine, and Vinpocetine.
- the present compound When the present compound is administered to a human, it can be administered orally as powders, granules, tablets, capsules, pills, solutions, or the like, or parenterally as injectables, suppositories, transdermal absorbable agents, inhalations, or the like.
- the present compound can be formulated into pharmaceutical preparations by adding pharmaceutical additives such as excipients, binders, wetting agents, disintegrating agents, lubricants and the like, which are suitable for formulations and an effective amount of the present compound.
- a dose is different depending on state of disease, an administration route, and an age and a weight of a patient, and is usually 0.1 ⁇ g to 1 g/day, preferably 0.01 to 200 mg/day when orally administered to an adult, and is usually 1 ⁇ g to 10 g/day, preferably 0.1 to 2 g/day when parenterally administered.
- a mixed solution of a known compound (1) (3.13 g) which can be prepared according to the method described in Patent Literature 4 and 5% Rh/C (924 mg) in ethanol (40 ml) was stirred under hydrogen atmosphere at room temperature for 22 hours.
- the insoluble material was removed by filtration and the filtrate was concentrated.
- the residue was dissolved in THF (50 mL) and di-tert-butyldicarbonate (3.92 g) was added.
- the mixed solution was stirred at 55° C. for 15 hours.
- the reaction solution was evaporated under reduced pressure.
- the crude product was purified by silica gel chromatography to give Compound (3)(4.08 g).
- RT represents a retention time (minutes).
- the substrate peptide was synthesized by reacting Cryptate TBPCOOH mono SMP (CIS bio international) with Biotin-XSEVNLDAEFRHDSGC (Peptide Institute, Inc.). The final concentrations of the substrate peptide and Recombinant human BACE1 were adjusted to 18 nmol/L and 7.4 nmol/L, respectively, and the reaction was performed in sodium acetate buffer (50 mmol/L sodium acetate, pH 5.0, 0.008% Triton X-100).
- Neuroblastoma SH—SY5Y cells (SH/APPwt) with human wild-type p-APP excessively expressed therein were prepared at 8 ⁇ 105 cells/mL, and 150 ⁇ l portions thereof were inoculated into each well of a 96-well culture plate (Falcon). The cells were cultured for 2 hours at 37° C. in a 5% gaseous carbon dioxide incubator. Then, a solution which had been preliminarily prepared by adding and suspending the test compound (DMSO (dimethyl sulfoxide) solution) so as to be 2 ⁇ l/50 ⁇ l medium was added to the cell sap. Namely, the final DMSO concentration was 1%, and the amount of the cell culture was 200 ⁇ l. After the incubation was performed for 24 hours from the addition of the test compound, 100 ⁇ l of the culture supernatant was collected from each fraction. The amount of the A ⁇ in each fraction was measured.
- DMSO dimethyl sulfoxide
- the A ⁇ amount was measured as follows. 10 ⁇ l of a homogeneous time resolved fluorescence (HTRF) measurement reagent (Amyloid ⁇ 1-40 peptide; IBA Molecular Holding, S. A.) and 10 ⁇ l of the culture supernatant were put into a 384-well half area microplate (black microplate, Costar) and mixed with each other, and then left standing overnight at 4° C. while the light was shielded. Then, the fluorescence intensity (excitation wavelength: 337 nm, measurement wavelength: 620 nm and 665 nm) was measured with a Wallac 1420 multilabel counter (Perkin Elmer life sciences). The A ⁇ amount was determined from the count rate at each measurement wavelength (10000 ⁇ Count 665/Count 620), and the amount needed to inhibit A ⁇ production by 50% (IC 50 ) was calculated from at least six different dosages.
- HTRF time resolved fluorescence
- a test compound is suspended in 0.5% methylcellulose, the final concentration is adjusted to 2 mg/mL, and this is orally administered to male Crj: SD rat (7 to 9 weeks old) at 10 mg/kg.
- male Crj: SD rat (7 to 9 weeks old) at 10 mg/kg.
- vehicle control group only 0.5% methylcellulose is administered, and an administration test is performed at 3 to 8 animals per group.
- a brain is isolated 3 hours after administration, a cerebral hemisphere is isolated, a weight thereof is measured, the hemisphere is rapidly frozen in liquid nitrogen, and stored at ⁇ 80° C. until extraction date.
- the frozen cerebral hemisphere is transferred to a homogenizer manufactured by Teflon (registered trade name) under ice cooling, a 5-fold volume of a weight of an extraction buffer (containing 1% CHAPS ( ⁇ 3-[(3-chloroamidopropyl)dimethylammonio]-1-propanesulfonate ⁇ ), 20 mmol/L M Tris-HCl (pH 8.0), 150 mmol/L NaCl, Complete (Roche) protease inhibitor) is added, up and down movement is repeated, and this is homogenized to solubilize for 2 minutes.
- Teflon registered trade name
- the suspension is transferred to a centrifugation tube, allowed to stand on an ice for 3 hours or more and, thereafter centrifuged at 100,000 ⁇ g, 4° C. for 20 minutes. After centrifugation, the supernatant is transferred to an ELISA plate (product No. 294-62501, Wako Junyaku Kogyo) for measuring ⁇ amyloid 40. ELISA measurement is performed according to the attached instruction. The lowering effect is calculated as a ratio compared to the brain ⁇ amyloid 40 level of vehicle control group of each test.
- the CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction, and the test was performed using, as CYP3A4 enzyme expressed in Escherichia coli and employing, as an index, a reaction in which 7-benzyloxytrifluoromethylchmarin (7-BFC) is debenzylated by the CYP3A4 enzyme to produce a metabolite, 7-hydroxytrifluoromethylchmarin (HFC) emitting fluorescent light.
- 7-BFC 7-benzyloxytrifluoromethylchmarin
- reaction conditions were as follows: substrate, 5.6 ⁇ mol/L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25° C. (room temperature); CYP3A4 content (expressed in Escherichia coli ), at pre-reaction 62.5 ⁇ mol/mL, at reaction 6.25 ⁇ mol/mL (at 10-fold dilution); test drug concentration, 0.625, 1.25, 2.5, 5, 10, 20 ⁇ mol/L (six points).
- NADPH was added to a remaining preincubation solution to initiate a preincubation (with preincubation) and, after a predetermined time of a preincubation, a part was transferred to another plate so that it was 1/10 diluted with a substrate and a K-Pi buffer to initiate a reaction as an index.
- acetonitrile/0.5 mol/L Tris(trishydroxyaminomethane) 4/1 was added to stop the reaction.
- CYP1A2 7-ethoxyresorufin O-deethylation
- CYP2C9 mephenyloin 4′-hydroxylation
- CYP2D6 dextromethorphan O-demethylation
- CYP3A4 terfenadine hydroxylation
- reaction conditions were as follows: substrate, 0.5 ⁇ mol/L ethoxyresorufin (CYP1A2), 100 ⁇ mol/L tolbutamide (CYP2C9), 50 ⁇ mol/L S-mephenyloin (CYP2C19), 5 ⁇ mol/L dextromethorphan (CYP2D6), 1 ⁇ mol/L terfenadine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37° C.; enzyme, pooled human hepatic microsome 0.2 mg protein/mL; test drug concentration, 1, 5, 10, 20 ⁇ mol/L (four points).
- resorufin CYP1A2 metabolite
- CYP1A2 metabolite resorufin in the supernatant was quantified by a fluorescent multilabel counter and tolbutamide hydroxide (CYP2C9 metabolite), mephenyloin 4′ hydroxide (CYP2C19 metabolite), dextrorphan (CYP2D6 metabolite), and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC/MS/MS.
- Each 20 ⁇ L of freeze-stored Salmonella typhimurium (TA98 and TA100 strain) is inoculated in 10 mL of liquid nutrient medium (2.5% Oxoid nutrient broth No. 2), and the cultures are incubated at 37° C. under shaking for 10 hours.
- 9 mL of TA98 culture is centrifuged (2000 ⁇ g, 10 minutes) to remove medium, and the bacteria is suspended in 9 mL of Micro F buffer (K 2 HPO 4 : 3.5 g/L, KH2PO 4 : 1 g/L, (NH 4 ) 2 SO 4 : 1 g/L, trisodium citrate dihydrate: 0.25 g/L, MgSO 4 .7H 2 O: 0.1 g/L), and the suspension is added to 110 mL of Exposure medium (Micro F buffer containing Biotin: 8 ⁇ g/mL, histidine 0.2 ⁇ g/mL, glucose: 8 mg/mL) 3.16 mL of TA100 culture is added to 120 mL of Exposure medium to prepare the test bacterial solution.
- Micro F buffer K 2 HPO 4 : 3.5 g/L, KH2PO 4 : 1 g/L, (NH 4 ) 2 SO 4 : 1 g/L, trisodium cit
- DMSO solution of the test substance (eight dose levels from maximum dose 50 mg/mL at 2-fold ratio); DMSO as negative control; 50 ⁇ g/mL of 4-nitroquinoline-1-oxide DMSO solution as positive control for TA98 without metabolic activation system; 0.25 ⁇ g/mL of 2-(2-furyl)-3-(5-nitro-2-furypacrylamide DMSO solution as positive control for TA100 without metabolic activation system; 40 ⁇ g/mL of 2-aminoanthracene DMSO solution as positive control for TA98 with metabolic activation system; or 20 ⁇ g/mL of 2-aminoanthracene DMSO solution as positive control for TA100 with metabolic activation system.
- test bacterial solution a mixed solution of 498 ⁇ l of the test bacterial solution and 90 ⁇ L of S9 mix with metabolic activation condition
- 460 ⁇ L of the bacterial solution exposed to the test substance is mixed with 2300 ⁇ L of Indicator medium (Micro F buffer containing biotin: 8 ⁇ g/mL, histidine: 0.2 ⁇ g/mL, glucose: 8 mg/mL, Bromo Cresol Purple: 37.5 ⁇ g/mL)
- Indicator medium Micro F buffer containing biotin: 8 ⁇ g/mL, histidine: 0.2 ⁇ g/mL, glucose: 8 mg/mL, Bromo Cresol Purple: 37.5 ⁇ g/mL
- a well containing the bacteria which has obtained the ability of proliferation by mutation in the gene coding amino acid (histidine) synthetase, turns the color from purple to yellow due to pH change.
- the mutagenicity is evaluated by counting the number of the yellow wells among the 48 total wells per dose and comparing with the negative control group. ( ⁇ ) means that mutagenicity is negative and (+) means positive.
- a test compound is reacted for a constant time, a remaining rate is calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver is assessed.
- a reaction is performed (oxidative reaction) at 37° C. for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes.
- the test compound in the supernatant is quantified by LC/MS/MS, and a remaining amount of the test compound after the reaction is calculated, letting a compound amount at 0 minute reaction time to be 100%.
- test substances are put into appropriate containers.
- 200 ⁇ L of JP-1 fluid sodium chloride 2.0 g, hydrochloric acid 7.0 mL and water to reach 1000 mL
- 200 ⁇ L of JP-2 fluid phosphate buffer (pH 6.8) 500 mL and water 500 mL
- 2004 of 20 mmol/L TCA (sodium taurocholate)/JP-2 fluid TCA 1.08 g and water to reach 100 mL.
- TCA sodium taurocholate
- the mixtures are filtered, and 100 ⁇ L of methanol is added to each of the filtrate (100 ⁇ L) so that the filtrates are two-fold diluted.
- the dilution ratio may be changed if necessary.
- the dilutions are observed for bubbles and precipitates, and then the containers are sealed and shaken. Quantification is performed by HPLC with an absolute calibration method.
- mice or rats are allowed to freely take solid feed and sterilized tap water
- Dose and grouping orally or intravenously administered at a predetermined dose; grouping is as follows (Dose depends on the compound)
- Administration method in oral administration, forcedly administer into ventriculus with oral probe; in intravenous administration, administer from caudal vein with a needle-equipped syringe
- AUC area under the plasma concentration-time curve
- BA bioavailability
- Intravenous administration is carried out to a rat by 0.5 mg/mL/kg dosage of the compound. 30 minutes later, all blood is drawn from vena cava inferior under isoflurane anesthesia for death from exsanguination. Then, the brain is extracted and 20-25% of homogenate thereof is prepared with distilled water. On the other hand, the obtained blood is used as plasma after centrifuging. Then, to the brain sample is added the control plasma at 1:1. To the plasma samples is added the control brains at 1:1. Each sample is measured using LC/MS/MS. The obtained area ratio (a brain/plasma) is used for the brain Kp value.
- a granule containing the following ingredients is produced.
- the compound of the formula (I), and lactose are passed through a 60 mesh sieve.
- Corn starch is passed through a 120 mesh sieve.
- These are mixed with a V-type mixer.
- a HPC-L (low viscosity hydroxypropyl cellulose) aqueous solution is kneaded, granulated (extrusion granulation, pore diameter 0.5 to 1 mm), and dried.
- the resulting dry granule is passed through a vibration sieve (12/60 mesh) to give a granule.
- a granule for filling a capsule containing the following ingredients is produced.
- the compound of the formula (I), and lactose are passed through a 60 mesh sieve.
- Corn starch is passed through a 120 mesh sieve.
- These are mixed, a HPC-L solution is added to the mixed powder, this is kneaded, granulated, and dried.
- the resulting dry granule is adjusted in a size, and 150 mg of it is filled into a No. 4 hard gelatin capsule.
- a tablet containing the following ingredients is produced.
- the compound of the formula (I), lactose, microcrystalline cellulose, and CMC-Na (carboxymethyl cellulose sodium salt) are passed through a 60 mesh sieve, and mixed. Magnesium stearate is mixed into the mixed powder to give a mixed powder for tabletting. The present mixed powder is directly compressed to give a 150 mg of a tablet.
- the following ingredients are warmed, mixed, and sterilized to give an injectable.
- the present compound can be a medicament useful as an agent for treating or preventing diseases induced by production, secretion and/or deposition of amyloid ⁇ protein.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-βproteins.
A compound of the formula (I):
wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6a, R6b, X, Y, Z, ring A and the dashed lines are defined in the specification,
its pharmaceutically acceptable salt or a solvate thereof.
its pharmaceutically acceptable salt or a solvate thereof.
Description
- The present invention relates to a compound which has amyloid β production inhibitory activity, and is useful as an agent for treating or preventing disease induced by production, secretion and/or deposition of amyloid β protein.
- In the brain of Alzheimer's patient, the peptide composed of about 40 amino acids residue as is called amyloid β protein, that accumulates to form insoluble specks (senile specks) outside nerve cells is widely observed. It is concerned that this senile specks kill nerve cells to cause Alzheimer's disease, so the therapeutic agents for Alzheimer's disease, such as decomposition agents of amyloid β protein and amyloid vaccine, are under investigation.
- Secretase is an enzyme which cleaves a protein called amyloid β precursor protein (APP) in cell and produces amyloid β protein. The enzyme which controls the production of N terminus of amyloid β protein is called as β-secretase (beta-site APP-cleaving enzyme 1, BACE1). It is thought that inhibition of this enzyme leads to reduction of producing amyloid β protein and that the therapeutic agent for Alzheimer's disease will be created due to the inhibition.
- Patent Literature 1 to 15 are known as β secretase inhibitor, however, all compounds in these literatures have different structures from the present invention.
-
- [Patent Literature 1] International Patent Application Publication WO 2007/049532
- [Patent Literature 2] International Patent Application Publication WO 2008/133274
- [Patent Literature 3] International Patent Application Publication WO 2008/133273
- [Patent Literature 4] International Patent Application Publication WO 2009/091016
- [Patent Literature 5] International Patent Application Publication WO 2006/138264
- [Patent Literature 6] International Patent Application Publication WO 2005/058311
- [Patent Literature 7] International Patent Application Publication WO 2009/131974
- [Patent Literature 8] International Patent Application Publication WO 2009/131975
- [Patent Literature 9] International Patent Application Publication WO 2009/151098
- [Patent Literature 10] International Patent Application Publication WO 2010/038686
- [Patent Literature 11] International Patent Application Publication WO 2010/013794
- [Patent Literature 12] International Patent Application Publication WO 2010/013302
- [Patent Literature 13] International Patent Application Publication WO 2008/073365
- [Patent Literature 14] International Patent Application Publication WO 2008/073370
- The present invention provides compounds which have reducing effects to produce amyloid β protein, especially BACE1 inhibitory activity, and are useful as an agent for treating or preventing diseases induced by production, secretion and/or deposition of amyloid β protein.
- For example, the present invention provides the following items:
- (1) a compound of formula (I):
- wherein —X— is —O—, —S— or —N(R1)—, R1 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, R2a and R2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl or substituted or unsubstituted carbamoyl,
ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, - wherein —Y— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)—, —O—, —S—, —SO— or —SO2—,
—Z— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)Ak—, —OAk—, —SAk—, —SOAk- or —SO2 Ak—, Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene,
provided that when —Y— is —N(R7)—, —O—, —S—, —SO— or —SO2—, then Ak is not a bond,
R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, Rza and Rzb are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy or substituted or unsubstituted heterocyclyloxycarbonyl, or Rza and Rzb together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle, R3a and R3b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfonyl or substituted or unsubstituted heterocyclylsulfonyl, or R3a and R3b together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle,
R4a and R4b are each independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy or substituted or unsubstituted heterocyclyloxycarbonyl,
provided that when —X— is —S—, then R4b is not hydrogen, and
R5a, R5b, R6a and R6b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, or
R5a and R5b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle,
R6a and R6b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, its pharmaceutically acceptable salt or a solvate thereof,
(1-1) a compound of formula (I′): - wherein —X— is —O—, —S— or —N(R1)—,
R1 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl,
R2a and R2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl or substituted or unsubstituted carbamoyl,
ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, - wherein —Y— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)—, —O—, —S—, —SO— or —SO2—,
—Z— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)Ak—, —OAk—, —SAk—, —SOAk- or —SO2 Ak—,
Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene,
provided that when —Y— is —N(R7)—, —O—, —S—, —SO— or —SO2—, then Ak is not a bond,
R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyl oxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl,
Rza and Rzb are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, or substituted or unsubstituted heterocyclyloxycarbonyl, or Rza and Rzb together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle,
R3a and R3b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, or R3a and R3b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle,
R4a and R4b are each independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy,
provided that when —X— is —S—, then R4b is not hydrogen, and
R5a, R5b, R6a and R6b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, or
R5a and R5b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle,
R6a and R6b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, its pharmaceutically acceptable salt or a solvate thereof,
(2) the compound according to the item (1) or (1-1) wherein —X— is —O— or —S—, its pharmaceutically acceptable salt or a solvate thereof,
(3) the compound according to the item (1), (1-1) or (2) wherein - Rza and Rzb are each independently hydrogen, halogen or substituted or unsubstituted alkyl, and
- R4a, R5a, R5b, R6a and R6b are each independently hydrogen or substituted or unsubstituted alkyl, its pharmaceutically acceptable salt or a solvate thereof,
(4) the compound according to any one of the item (1), (1-1), (2) and (3) wherein —Y— is substituted or unsubstituted C1-C3 alkylene or —O—, and —Z— is a bond, its pharmaceutically acceptable salt or a solvate thereof,
(5) the compound according to any one of the item (1), (1-1) and (2) to (4) wherein ring A is - wherein ring A′ and ring B are each independently a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, —W— is a bond, -L1-C(═O)N(R8)-L2-L1-N(R8)C(═O)-L2- or -L1-N(R8)-L2-,
L1 and L2 are each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene,
R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl, its pharmaceutically acceptable salt or a solvate thereof,
(6) the compound according to item (5) wherein —W— is —C(═O)N(R8)—, its pharmaceutically acceptable salt or a solvate thereof,
(7) the compound according to the item (5) or (6) wherein ring A′ is substituted or unsubstituted benzene, ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine, its pharmaceutically acceptable salt or a solvate thereof,
(8) a pharmaceutical composition comprising the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof as an active ingredient,
(9) a pharmaceutical composition having BACE1 inhibitory activity comprising the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof as an active ingredient,
(10) the pharmaceutical composition according to the item (8) or (9), which is a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid (3 proteins,
(11) the pharmaceutical composition according to the item (8) or (9), which is a medicament for treating or preventing Alzheimer's disease,
(12) a method for inhibiting BACE1 activity comprising administering the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof,
(13) the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof for use in a method for inhibiting BACE1 activity,
(14) a method for treating or preventing diseases induced by production, secretion or deposition of amyloid β proteins comprising administering the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof,
(15) the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof for use in a method for treating or preventing diseases induced by production, secretion or deposition of amyloid β proteins,
(16) a method for treating or preventing Alzheimer's disease comprising administering the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof,
(17) the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof for use in a method for treating or preventing Alzheimer's disease,
(18) a method, a system, an apparatus, a kit or the like for preparing the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof,
(19) a method, a system, an apparatus, a kit or the like for preparing the pharmaceutical composition comprising the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof,
(20) a method, a system, an apparatus, a kit or the like for use the compound according to any one of the item (1), (1-1) and (2) to (7), its pharmaceutically acceptable salt or a solvate thereof, - The compounds of the present invention are useful as an agent for treating or preventing diseases induced by production, secretion or deposition of amyloid 13 protein such as Alzheimer's disease.
- As used herein, the “halogen” includes fluorine, chlorine, bromine, and iodine.
- As used herein, the “alkyl” includes linear or branched alkyl of a carbon number of 1 to 15, for example, a carbon number of 1 to 10, a carbon number of 1 to 6, or a carbon number of 1 to 3. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl.
- An alkyl part of the “alkoxy”, the “halogenoalkyl”, the “hydroxyalkyl”, the “halogenoalkoxy”, the “hydroxyalkoxy”, the “alkoxycarbonyl”, the “halogenoalkoxycarbonyl”, the “alkylamino”, the “aminoalkyl”, the “alkoxyalkoxy”, the “alkoxyalkenyloxy”, the “alkoxyalkynyl”, the “alkoxyalkynyloxy”, the “alkylcarbamoyl”, the “hydroxyalkylcarbamoyl”, the “alkoxyimino”, the “alkylcarbonyl”, the “alkylthio”, the “alkylsulfonyl”, the “alkylsulfonyloxy”, the “alkylsulfonylamino”, the “alkylsulfonyl alkylamino”, the “alkylsulfonylimino”, the “alkylsulfinylamino”, the “alkylsulfinylalkylamino”, the “alkylsulfinylimino”, the “alkylsulfamoyl”, the “alkylsulfinyl”, the “carbocyclylalkyl”, the “carbocyclylalkoxy”, the “carbocyclylalkoxycarbonyl”, the “carbocyclylalkylamino”, the “carbocyclylalkylcarbamoyl”, the “cycloalkylalkyl”, the “cycloalkylalkoxy”, the “cycloalkylalkylamino”, the “cycloalkylalkoxycarbonyl”, the “cycloalkylalkylcarbamoyl”, the “arylalkyl”, the “arylalkoxy”, the “arylalkylamino”, the “arylalkoxycarbonyl”, the “arylalkylcarbamoyl”, the “heterocyclylalkyl”, the “heterocyclylalkoxy”, the “heterocyclylalkylamino”, the “heterocyclylalkoxycarbonyl”, and the “heterocyclylalkylcarbamoyl” is the same as the above “alkyl”.
- The “substituted or unsubstituted alkyl” may be substituted with one or more substituents selected from a substituent group α.
- As used herein, the substituent group α is a group consisting of halogen, hydroxy, alkoxy, halogenoalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, acylamino, alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfinyl, alkylsulfonylamino, alkylsulfonylalkylamino, alkylsulfonylimino, alkylsulfinylamino, alkylsulfinylalkylamino, alkylsulfinylimino, cyano, nitro, a carbocyclic group and a heterocyclic group wherein the carbocycle and the heterocycle may be each substituted with one or more substituents selected from halogen, alkyl, hydroxyl and alkoxy.
- Examples of the substituent of the “substituted or unsubstituted alkoxy”, the “substituted or unsubstituted alkoxycarbonyl”, “substituted or unsubstituted alkylthio”, “substituted or unsubstituted alkylsulfinyl”, and the “substituted or unsubstituted alkylsulfonyl” include one or more groups selected from the above substituent group α.
- Examples of the “halogenoalkyl” include trifluoromethyl, fluoromethyl, and trichloromethyl.
- Examples of the “halogenoalkoxy” include trifluoromethoxy, fluoromethoxy, and trichloromethoxy.
- The “alkylidene” includes a divalent group of the above “alkyl”, and examples include methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and hexylidene.
- The “alkenyl” includes linear or branched alkenyl of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, a carbon number of 2 to 6, or a carbon number of 2 to 4, having one or more double bonds at any available position. Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl and pentadecenyl.
- An alkenyl part of the “alkenyloxy”, the “alkenyloxycarbonyl”, the “alkenylcarbonyl”, the “alkoxyalkenyloxy”, the “alkenylthio”, the “alkenylamino”, the “alkenylsulfonyl”, and the “alkenylsulfinyl” is the same as the above “alkenyl”.
- The “alkynyl” includes linear or branched alkynyl of a carbon number of 2 to 10, for example, a carbon number of 2 to 8, or a carbon number of 3 to 6, having one or more triple bonds at any available position. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl. These may further a double bond at any available position.
- An alkynyl part of the “alkoxyalkynyl”, the “alkynyloxy”, the “alkynyloxycarbonyl”, “alkynylcarbonyl”, the “alkoxyalkynyloxy”, the “alkynylthio”, the “alkynylsulfinyl”, the “alkynylsulfonyl” and the “alkynylamino” is the same as the above “alkynyl”.
- Examples of the substituent of the “substituted or unsubstituted alkenyl”, “substituted or unsubstituted alkenyloxy”, the “substituted or unsubstituted alkenyloxycarbonyl”, the “substituted or unsubstituted alkenylthio”, the “substituted or unsubstituted alkenylsulfinyl”, the “substituted or unsubstituted alkenylsulfonyl”, the “substituted or unsubstituted alkynyl”, the “substituted or unsubstituted alkynyloxy”, the “substituted or unsubstituted alkynylthio”, the “substituted or unsubstituted alkynyloxycarbonyl”, the “substituted or unsubstituted alkynylsulfinyl” and the “substituted or unsubstituted alkynylsulfonyl” include one or more substituents selected from the above substituent group α.
- Examples of the substituent of the “substituted or unsubstituted amino”, “substituted or unsubstituted carbamoyl”, “substituted or unsubstituted thiocarbamoyl” and the “substituted or unsubstituted sulfamoyl” include 1 to 2 substituents selected from alkyl, acyl, hydroxy, alkoxy, alkoxycarbonyl, a carbocyclic group and a heterocyclic group.
- The “acyl” includes formyl, alkylcarbonyl of a carbon number of 1 to 10, alkenylcarbonyl of a carbon number of 2 to 10, alkynylcarbonyl of a carbon number of 2 to 10, carbocyclylcarbonyl and heterocyclylcarbonyl. Examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, benzoyl, cyclohexanecarbonyl, pyridinecarbonyl, furancarbonyl, thiophenecarbonyl, benzothiazolecarbonyl, pyrazinecarbonyl, piperidinecarbonyl, and thiomorpholino.
- An acyl part of the “acyloxy” and the “acylamino” is as described above “acyl”.
- Examples of the substituent of the “substituted or unsubstituted acyl” and “substituted or unsubstituted acyloxy” include one or more substituents selected from the substituent group α. In addition, a ring part of the carbocyclylcarbonyl and the heterocyclylcarbonyl may be substituted with one or more substituents selected from alkyl, the substituent group α, and alkyl substituted with one or more groups selected from the substituent group α.
- The “carbocyclic group” includes cycloalkyl, cycloalkenyl, aryl and a non-aromatic fused carbocyclic group.
- The “cycloalkyl” is a carbocyclic group of a carbon number of 3 to 10, for example, a carbon number of 3 to 8, or a carbon number of 4 to 8, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
- A cycloalkyl part of the “cycloalkylalkyl”, the “cycloalkoxy”, the “cycloalkylalkoxy”, the “cycloalkylthio”, the “cycloalkylamino”, the “cycloalkylalkylamino”, the “cycloalkylsulfamoyl”, the “cycloalkylsulfonyl”, the “cycloalkylcarbamoyl”, the “cycloalkylalkylcarbamoyl”, the “cycloalkylalkoxycarbonyl”, and the “cycloalkoxycarbonyl” is the same as the above “cycloalkyl”.
- The “cycloalkenyl” includes the cycloalkyl having one or more double bonds at any available position in the ring, and examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptynyl, cyclooctynyl and cyclohexadienyl.
- The “aryl” includes phenyl, naphthyl, anthryl and phenanthryl, and specific example is phenyl.
- The “non-aromatic fused carbocyclic group” includes non-aromatic groups in which two or more cyclic groups selected from the above “cycloalkyl”, the above “cycloalkenyl” and the above “aryl” are fused, and examples include indanyl, indenyl, tetrahydronaphthyl and fluorenyl.
- A carbocyclyl part of the “non-aromatic carbocyclic group” is the same as the “cycloalkyl”, “cycloalkenyl” and “non-aromatic fused carbocyclic group”. Examples are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene and cyclooctene.
- A carbocyclyl part of the “carbocyclic”, the “carbocyclyloxy”, the “carbocyclylalkyl”, the “carbocyclylalkoxy”, the “carbocyclylalkoxycarbonyl”, the “carbocyclylthio”, the “carbocyclylamino”, the “carbocyclylalkylamino”, the “carbocyclylcarbonyl”, the “carbocyclylsulfamoyl”, “carbocyclylsulfinyl”, the “carbocyclylsulfonyl”, the “carbocyclylcarbamoyl”, the “carbocyclylalkylcarbamoyl”, the “carbocyclyloxycarbonyl” and the “carbocyclylsulfonyl” is the same as the “carbocyclic group”.
- An aryl part of the “arylalkyl”, the “aryloxy”, the “aryloxycarbonyl”, the “aryl alkoxycarbonyl”, the “arylthio”, the “arylamino”, the “arylalkoxy”, the “arylalkylamino”, the “arylsulfonyl”, the “arylsulfamoyl”, the “arylcarbamoyl”, and the “arylalkylcarbamoyl” is the same as the “aryl”.
- The “heterocyclic group” includes a heterocyclic group having one or more hetero atoms optionally selected from O, S and N in a ring, and examples include 5- to 6-membered heteroaryl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, and thiadiazolyl; non-aromatic heterocyclic groups such as dioxanyl, thiiranyl, oxyranyl, oxetanyl, oxathioranyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydrofuryl, tetrahydropyranyl, dihydrothiazolyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydrooxazinyl, hexahydroazepinyl, tetrahydrodiazepinyl, and tetrahydropyridazinyl; fused bicyclic heterocyclic groups such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, thienopyridyl, thienopyrrolyl, thienopyrazolyl, thienopyrazinyl, furopyrrolyl, thienothienyl, imidazopyridyl, imidazopyrazolyl, pyrazolopyridyl, pyrazolopyrazinyl, thiazolopyridyl, pyrazolopyrimidinyl, pyrazolotrianidyl, pyridazolopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, dihydrothiazolopyrimidinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzofuryl, dihydrobenzoxazinyl, dihydrobenzimidazolyl, tetrahydrobenzothienyl, tetrahydrobenzofuryl, benzodioxolyl, benzodioxonyl, chromanyl, chromenyl, octahydrochromenyl, dihydrobenzodioxinyl, dihydrobenzoxazinyl, dihydrobenzodioxepinyl, and dihydrothienodioxinyl; tricyclic fused heterocyclic groups such as carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl, imidazoquinolyl, and tetrahydrocarbazolyl. Example is a 5- to 6-membered heteroaryl or a non-aromatic heterocyclic group.
- A heterocyclyl part of the “heterocyclylalkyl”, the “heterocyclyloxy”, the “heterocyclylthio”, the “heterocyclycarbonyl”, the “heterocyclylalkoxy”, the “heterocyclylamino”, the “heterocyclylsulfamoyl”, the “heterocyclylsulfonyl”, the “heterocyclylsulfinyl”, the “heterocyclylcarbamoyl”, the “heterocyclyloxycarbonyl”, the “heterocyclylalkylamino”, the “heterocyclylalkoxycarbonyl” and the “heterocyclylalkylcarbamoyl” is the same as the “heterocyclic group”.
- A heterocycle portion of “non-aromatic heterocycle” is the same as the heterocycle portion of the above “non-aromatic heterocyclyl.” Specific examples are dioxane, thiirane, oxirane, oxetane, oxathiolane, azetidine, thiane, thiazolidine, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dihydropyridine, tetrahydropyridine, tetrahydrofuran, tetrahydropyran, dihydrothiazole, tetrahydrothiazole, tetrahydroisothiazole, dihydrooxazine, hexahydroazepine, tetrahydrodiazepine and tetrahydropyridazine.
- A bond of the “heterocyclic group” may be situated on any ring.
- The “heteroaryl” includes an aromatic cyclic group among the “heterocyclic group”.
- In the specification, examples of ring A are as follows:
- wherein ring A′ and ring B are each independently substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle,
L1, L2, and L3 are each independently a bond, substituted or unsubstituted alkynylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, - R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl,
R9 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl,
when ring A is (i), then the constituent carbon atom of L1 and the constituent carbon atom of L2, or the constituent carbon atom of L1 and the nitrogen atom of W2 may be connected with substituted or unsubstituted alkylene to form a ring,
when ring A is (ii), then the constituent carbon atom of L1 and the constituent carbon atom of L2, or the nitrogen atom of W2 and the constituent atom of L2 may be connected with substituted or unsubstituted alkylene to form a ring,
when ring A is (iii), then two nitrogen atoms of W2 may be connected with substituted or unsubstituted alkylene to form a ring,
when ring A is (vi), then the constituent carbon atom of L1 and the constituent carbon atom of L2 may be connected with substituted or unsubstituted alkylene to form a ring,
p is 1 or 2, and
when multiple L3, multiple W2, or multiple R9 are present, each of them may be independently different. - Specific examples are as follows:
- wherein each symbol is the same as defined above.
- wherein L is each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, ring T is a carbocycle optionally substituted with a group(s) selected from the substituent group α, or a heterocycle optionally substituted with a group(s) selected from the group α, and that and other symbols are the same as defined above.
- More specific examples are as follows:
- wherein each symbol is the same as defined above.
- wherein each symbol is the same as defined above.
- Other examples of the substituent of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle” and “substituted or unsubstituted benzene” in ring A, ring A′, and ring B, and “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine” and “substituted or unsubstituted pyrazine” in ring B include:
- a group selected from the substituent group a such as halogen, hydroxy, alkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, carbamoyl, amino, cyano, alkylamino and/or alkylthio; alkyl substituted with one or more groups selected from the substituent group α, hydroxyimino and alkoxyimino, wherein the substituent is, for example, halogen, hydroxy, alkoxy and/or alkoxycarbonyl, or unsubstituted alkyl; aminoalkyl substituted with one or more groups selected from the substituent group a; wherein the substituent is, for example, acyl, alkyl and/or alkoxy; alkenyl substituted with one or more substituents selected from the substituent group α,
wherein the substituent is, for example, alkoxycarbonyl, halogen, and/or halogenoalkoxycarbonyl, or unsubstituted alkenyl;
alkynyl substituted with one or more substituents selected from the substituent group α,
wherein the substituent is, for example, alkoxycarbonyl, or unsubstituted alkynyl; alkoxy substituted with one or more substituents selected from the substituent group α, wherein the substituent is, for example, halogen, carbamoyl, alkylcarbamoyl and/or hydroxyalkylcarbamoyl;
alkoxyalkoxy substituted with one or more substituents selected from the substituent group α; alkenyloxy substituted with one or more substituents selected from the substituent group α,
wherein the substituent is, for example, halogen, hydroxy, amino and/or alkylamino, or unsubstituted alkenyloxy;
alkoxyalkenyloxy substituted with one or more substituents selected from the substituent group a; alkynyloxy substituted with one or more substituents selected from the substituent group α,
wherein the substituent is, for example, halogen and/or hydroxy, or unsubstituted alkynyloxy; alkoxyalkynyloxy substituted with one or more groups selected from the substituent group α;
alkylthio substituted with one or more substituents selected from the substituent group α, or unsubstituted alkylthio;
alkenylthio substituted with one or more substituents selected from the substituent group α, or unsubstituted alkenylthio;
alkynylthio substituted with one or more substituents selected from the substituent group α, or unsubstituted alkynylthio;
alkylamino substituted with one or more substituents selected from the substituent group α; alkenylamino substituted with one or more substituents selected from the substituent group α;
alkynylamino substituted with one or more substituents selected from the substituent group α; aminooxy substituted with one or more substituents selected from the substituent group α and alkylidene, or unsubstituted aminooxy;
acyl substituted with one or more substituents selected from the substituent group α;
alkylsulfonyl substituted with one or more substituents selected from the substituent group α, or unsubstituted alkylsulfonyl;
alkylsulfinyl substituted with one or more substituents selected from the substituent group α, or unsubstituted alkylsulfinyl;
alkylsulfamoyl substituted with one or more substituents selected from the substituent group α;
a carbocyclic group such as cycloalkyl and aryl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl;
a heterocyclic group substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl;
carbocyclylalkyl such as cycloalkylalkyl and arylalkyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylalkyl;
heterocyclylalkyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylalkyl; carbocyclyloxy such as cycloalkyloxy and aryloxy, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclyloxy;
heterocyclyloxy substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclyloxy;
carbocyclylalkoxy such as cycloalkylalkoxy and arylalkoxy, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylalkoxy;
heterocyclylalkoxy substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylalkoxy;
carbocyclylalkoxycarbonyl such as cycloalkylalkoxycarbonyl and arylalkoxycarbonyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylalkoxycarbonyl such as cycloalkylalkoxycarbonyl and arylalkoxycarbonyl;
heterocyclylalkoxycarbonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylalkoxycarbonyl;
carbocyclylthio such as cycloalkylthio and arylthio, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylthio such as cycloalkylthio and arylthio;
heterocyclylthio substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylthio;
carbocyclylamino such as cycloalkylamino and arylamino, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylamino such as cycloalkylamino and arylamino;
heterocyclylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylamino;
carbocyclylalkylamino such as cycloalkylalkylamino and arylalkylamino, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl or unsubstituted carbocyclylalkylamino such as cycloalkylalkylamino and arylalkylamino;
heterocyclylalkylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylalkylamino;
carbocyclylsulfamoyl such as cycloalkylsulfamoyl and arylsulfamoyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylsulfamoyl;
heterocyclylsulfamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylsulfamoyl;
carbocyclylsulfonyl such as cycloalkylsulfonyl and arylsulfonyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylsulfonyl such as cycloalkylsulfonyl and arylsulfonyl;
heterocyclylsulfonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylsulfonyl; carbocyclylcarbamoyl such as cycloalkylcarbamoyl and arylcarbamoyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylcarbamoyl such as cycloalkylcarbamoyl and arylcarbamoyl;
heterocyclylcarbamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylcarbamoyl;
carbocyclylalkylcarbamoyl such as cycloalkylalkylcarbamoyl and arylalkylcarbamoyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclylalkylcarbamoyl such as cycloalkylalkylcarbamoyl and arylalkylcarbamoyl;
heterocyclylalkylcarbamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclylalkylcarbamoyl;
carbocyclyloxycarbonyl such as cycloalkyloxycarbonyl and aryloxycarbonyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted carbocyclyloxycarbonyl such as cycloalkyloxycarbonyl and aryloxycarbonyl;
heterocyclyloxycarbonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and halogenoalkyl, or unsubstituted heterocyclyloxycarbonyl;
alkylenedioxy substituted with halogen, or unsubstituted alkylenedioxy; oxo; and
azide. - “Substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle”, “substituted or unsubstituted benzene”, “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine” and “substituted or unsubstituted pyrazine” may be substituted with one or more substituents selected from them.
- In the specification, examples of the substituent of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle” and “substituted or unsubstituted benzene” in ring A′ and ring B, and “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine” and “substituted or unsubstituted pyrazine” in ring B include halogen, cyano, hydroxy, nitro, carboxy, alkyl substituted with one or more substituents selected from the substituent group α, unsubstituted alkyl, alkenyl substituted with one or more substituents selected from the substituent group α, unsubstituted alkenyl, alkynyl substituted with one or more substituents selected from the substituent group α, unsubstituted alkynyl, alkoxy substituted with one or more substituents selected from the substituent group α, unsubstituted alkoxy, alkenyloxy substituted with one or more substituents selected from the substituent group α, unsubstituted alkenyloxy, alkynyloxy substituted with one or more substituents selected from the substituent group α, unsubstituted alkynyloxy, amino substituted with one or more substituents selected from the substituent group α, unsubstituted amino, carbamoyl substituted with one or more substituents selected from the substituent group α, unsubstituted carbamoyl, alkylcarbamoyl substituted with one or more substituents selected from the substituent group α, unsubstituted alkylcarbamoyl, alkoxycarbonyl substituted with one or more substituents selected from the substituent group α, and unsubstituted alkoxycarbonyl.
- Examples of the substituent other than “—W-ring B” of “substituted or unsubstituted carbocycle” or “substituted or unsubstituted heterocycle” in ring A include halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, or cyano.
- Examples of the substituents of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle” or “substituted or unsubstituted benzene” in ring A′ include halogen.
- Examples of the substituents of “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine”, or “substituted or unsubstituted pyrazine” in ring B include halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, or cyano.
- Examples of the substituents of “substituted or unsubstituted carbocyclic group”, “substituted or unsubstituted heterocyclic group”, “substituted or unsubstituted arylalkyl”, “substituted or unsubstituted arylalkoxy”, “substituted or unsubstituted carbocyclyloxy”, “substituted or unsubstituted carbocyclylsulfonyl”, “substituted or unsubstituted carbocyclylsulfinyl”, “substituted or unsubstituted carbocyclyloxycarbonyl”, “substituted or unsubstituted heterocyclyloxy”, “substituted or unsubstituted heterocyclylthio”, “substituted or unsubstituted heterocycylsulfonyl”, “substituted or unsubstituted heterocyclylsulfinyl”, “substituted or unsubstituted heterocyclyloxycarbonyl”, “substituted or unsubstituted carbocycle” and “substituted or unsubstituted heterocycle” in other than the above ring A, ring A′ and ring B include alkyl substituted with one or more substituents selected from the substituent group α, unsubstituted alkyl, and the substituent group α.
- The term “alkylene” include a linear or branched divalent carbon chain of a carbon number of 1 to 10, for example, a carbon number of 1 to 6, or a carbon number of 1 to 3. Examples include methylene, dimethylene, trimethylene, tetramethylene, and methyltrimethylene.
- The alkylene portion in “alkylenedioxy” is the same as the above “alkylene.”
- The term “alkenylene” includes a linear or branched divalent carbon chain of a carbon number of 2 to 10, for example, a carbon number of 2 to 6, or a carbon number of 2 to 4, having a double bond at any available position. Examples include vinylene, propenylene, butenylene, butadienylene, methylpropenylene, pentenylene and hexenylene.
- The term “alkynylene”, includes a linear or branched divalent carbon chain of a carbon number of 2 to 10, for example, a carbon number of 2 to 6, or, a carbon number of 2 to 4, having a triple bond at any available position and, further, optionally having a double bond. Examples include ethynylene, propynylene, butynylene, pentynylene and hexynylene.
- Examples of the substituents of “substituted or unsubstituted alkylene”, “substituted or unsubstituted C1-C3 alkylene”, “substituted or unsubstituted alkenylene”, “substituted or unsubstituted C2-C3 alkenylene”, and “substituted or unsubstituted alkynylene” include the groups selected from the substituent group α, and specific examples are halogen and hydroxy.
- The phrase “Rza and Rzb together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle” include the following examples.
- These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group α, unsubstituted alkyl and the substituent group α at any available position.
- The phrases “R3a and R3b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle”, “R5a and R5b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle” and “R6a and R6b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle” include the following examples.
- These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group α, unsubstituted alkyl and the substituent group α at any available position.
- In the specification, the term “solvate” includes, for example, solvates with organic solvents and hydrates. It can be prepared in accordance with the known methods. Examples of solvate include a solvate with acetone, 2-butanol, 2-propanol, ethanol, ethyl acetate, tetrahydrofuran or diethyl ether. For example, it includes a non-toxic and water-soluble hydrate or solvate such as a solvate with ethanol. In the case that a hydrate or solvate is formed, the compound or salt may be coordinated with any number of solvate molecules or water molecules.
- The compound of the formula (I) includes a pharmaceutically acceptable salt. Examples include salts with alkali metals such as lithium, sodium or potassium; alkaline earth metals such as calcium; magnesium; transition metals such as zinc or iron; ammonium; organic bases; and amino acids; or salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid or hydroiodic acid; and organic acids such as acetic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid or ethanesulfonic acid. Specific examples are hydrochloric acid, phosphoric acid, tartaric acid and methanesulfonic acid. These salts can be formed by ordinary methods.
- In addition, the compound of the formula (I) is not limited to a specific isomer, but includes all possible isomers, such as keto-enol isomers, imine-enamine isomers, diastereoisomers, optical isomers and rotation isomers; and racemate. For example, the compound of the formula (I) wherein R2a is hydrogen includes the following tautomers.
- Compounds of the formulas (I-a1) to (I-a3), (I-b1) to (I-b6), (I-c1) and (I-c2) include the similar tautomers.
- In addition, one or more hydrogen, carbon or other atoms of the compound of the formula (I) can be replaced by an isotope of the hydrogen, carbon or other atoms. Compounds of the formula (I) include all radiolabeled forms of compounds of the formula (I). The “radiolabeled,” “radiolabeled form” and the like of the compound of the formula (I) are encompassed by the present invention and useful as a research and/or diagnostic tool in metabolism pharmacokinetic studies and in binding assays. It is also useful for a medicament.
- Examples of isotopes that can be incorporated into the compound of the formula (I) of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, iodine and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 15F, 123I and 36Cl, respectively. Radiolabeled compounds of the invention can be prepared by methods known in the art. For example, tritiated compounds of formula (I) can be prepared by introducing tritium into the particular compound of formula (I), for example, by catalytic dehalogenation with tritium. This method may include reacting a suitably halogen-substituted precursor of a compound of formula (I) with tritium gas in the presence of a suitable catalyst such as Pd/C, in the presence or absence of a base. Other suitable methods for preparing tritiated compounds can be found in Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part Chapter 6, (1987). 14C-labeled compounds can be prepared by employing starting materials having a 14C carbon.
- The present compound of the formula (I-a1) to (I-a3), (I-b1) to (I-136), (I-c1) and (I-c2) can be prepared, for example, according to the method described in Patent Literature 4, or by the following method.
- The present compound of the formula (I) can be prepared by the following method. In the following all steps, when a substituent which interferes with the reaction, e.g. hydroxy, mercapto, amino, formyl, carbonyl, carboxy, is possessed, the substituent is protected by the method such as those described in Protective Groups in organic Synthesis, and Theodora W Greene (John Wiley & Sons) in advance, and the protective group may be removed at a desirable stage.
- In the following formulas, a crossed bond means that the compound is either E isomer or Z isomer, or a mixture thereof with respect to double bond.
-
- wherein PG represents an amino protective group such as acyl, alkoxycarbonyl, trialkylsilyl, and alkylsulfonyl, and the other symbols represent the same as defined above.
- Compound (a-1) can be prepared by the Preparing Method D described below from a commercially available compound. It can be also prepared by the known methods from a commercially available compound, and can be also prepared by methods described in Examples.
- Compound (a-2) can be prepared by reacting Compound (a-1) with hydroxylamine or a hydroxylamine salt such as hydroxylamine hydrochloride or hydroxylamine sulfate in the presence or absence of a base, in an organic solvent such as ethanol, methanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and dichloromethane, and a mixed solvent of them and water. Examples of a base include sodium acetate, pyridine, sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide and 2,6-lutidine. The reaction time is not particularly limited and is usually between 5 minutes and 30 hours, and preferably between 5 minutes and 12 hours. The reaction temperature is usually between −20° C. and solvent reflux temperature, and preferably between 0° C. and solvent reflux temperature.
- The reaction in this step can be performed under the usual conditions for an oximation reaction of a carbonyl compound such as the conditions described in Org. Lett., 9 (2007) 5, 753-6, Tetrahedron 54 (1998) 22, 5868-82, and Tetrahedron: Asymmetry 5 (1994) 6, 1018-28.
- Compound (a-3) can be prepared by reacting Oxime Compound (a-2) with N-chlorosuccinimide or sodium hypochlorite in a solvent such as dichloromethane, chloroform, benzene, toluene, xylene, N,N-dimethylformamide, tetrahydrofuran and 1,4-dioxane at the temperature between ice-cooling to solvent reflux temperature for 30 minutes to 48 hours, preferably 0.5 to 24 hours to convert a nitrile oxide, followed by a 1,3-dipolar cycloaddition reaction. More preferable results such as suppression of side reactions and improved yield may be achieved by carrying out this reaction in the presence of a base such as sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, an aqueous solution thereof, triethylamine and pyridine.
- This step is for preparing Compound (a-3) by converting Compound (a-2) to a nitrile oxide derivative and subjecting to a 1,3-dipolar cycloaddition reaction with the olefin moiety in the same molecule. The reaction in this step can be performed under the usual conditions for a 1,3-dipolar cycloaddition reaction, for example, the conditions described in Org. Lett., 9 (2007) 5, 753-6, Tetrahedron 54 (1998) 22, 5868-82 and Tetrahedron: Asymmetry 5 (1994) 6, 1018-28.
- Compound (a-4) can be prepared by reacting Compound (a-3) with an organic metal reagent such as an aryl lithium reagent (wherein aryl includes heterocyclyl), a Grignard reagent (wherein the substituent includes heterocyclyl), an aryl magnesium reagent (wherein aryl includes heterocyclyl), which can be prepared by methods known to a person skilled in the art in a solvent which does not interfere with the preparation of a reagent and this reaction such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene and toluene, and a mixed solvent thereof. The reaction time is usually between 5 minutes and 48 hours, and preferably between 5 minutes and 12 hours. The reaction temperature varies according to a starting material, a reagent, solubility and the like, and in general, is preferably maintained to be the temperature for minimizing the formation of a by-product, for example, −78° C. Favorable results such as an improved yield and a reduced reaction time may be achieved by addition of an additive such as tetramethylethylene diamine, hexamethylphosphoramide or a Lewis acid such as a boron trifluoride-diethyl ether complex.
- The reaction in this step can be performed under similar conditions to those described in SYNLETT, 2004, 8, 1408-13, J. Am. Chem. Soc., 2005, 127, 5376-83 and Bull. Chem. Soc. Jpn., 1993, 66, 2730-7.
- Compound (a-5) can be prepared by subjecting Compound (a-4) to a cleavage reaction of the N—O bond by using a zinc-acid, a hydrogen-metal catalyst, a hydride reductant and the like in a solvent which does not interfere with the reaction such as methanol, ethanol, 1,4-dioxane, THF, ether and water.
- Examples of the acid include acetic acid, formic acid and hydrochloric acid. The solvent used in the reaction can be selected from the above solvent, and the above acid can be also used as a solvent. The reaction temperature is usually between −20° C. and solvent reflux temperature, and preferably between 0° C. and solvent reflux temperature. The reaction time is usually between 5 minutes and 48 hours, and preferably between 5 minutes and 24 hours. The reaction can be performed under similar conditions to those described in Org. Lett. 7 (2005) 25, 5741-5742 and J. Org. Chem. 200, 68, 1207-1215.
- The reaction can be performed using a metal catalyst such as platinum oxide under similar conditions to those described in Tetrahedron: Asymmetry 5 (1994) 6, 1019-1028 and Tetrahedron, Vol. 53, No. 16, pp 5752-5746, 1997. Compound (a-5) can be prepared by hydrogenating Compound (a-4) using platinum oxide as a catalyst in a solvent such as methanol under hydrogen atmosphere.
- The reaction using a hydride reductant such as a lithium aluminum hydride can be performed under similar conditions to those described in Bull. Chem. Soc. Jpn., 66, 2730-2737 (1993). Specifically, compound (a-5) can be prepared by reducing Compound (a-4) using lithium aluminum hydride in a solvent such as ether.
- Compound (a-6) can be prepared by subjecting Compound (a-5) to a functional group protection reaction which is known to a person skilled in the art. For example, when a protective group is a t-butoxycarbonyl group (hereafter referred to as a Boc group) or a 9-fluorenemethyloxycarbonyl group (hereafter referred to as a Fmoc group), a target compound can be prepared under the usual conditions for protection of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (a-7) can be prepared by adding an oxidant such as 2-iodoxybenzoic acid to a solution of Compound (a-6) in a solvent such as dimethyl sulfoxide and dichloromethane, and reacting at 0° C. to 80° C., preferably 10° C. to 40° C. for 0.5 hours to 48 hours, preferably 1 hour to 12 hours.
- Examples of oxidation conditions used in the reaction include Swern oxidation, Corey-Kim oxidation, Moffatt oxidation, pyridinium chlorochromate oxidation (PCC oxidation), pyridinium dichromate oxidation (PDC oxidation), Dess-Martin oxidation, 503-pyridine oxidation, and 2,2,6,6-tetramethyl-1-piperidinyloxy free radical oxidation (TEMPO oxidation), which are known to a person skilled in the art, and the conditions described in “Comprehensive Organic Transformations, Richard C. Larock; VCH”.
- To R3aR3bCHPPh3 such as methyltriphenylphosphonium iodide which is commercially available or can be prepared by methods known to a person skilled in the art is added a strong base such as an alkyl metal reagent such as n-butyllithium in a solvent such as ether, tetrahydrofuran, dioxane, and a mixed solvent thereof to prepare a Wittig reagent which corresponds to a target compound. Compound (a-8) can be prepared by adding a solution of Compound (a-7) in a solvent such as ether, tetrahydrofuran, and dioxane to the Wittig reagent at −40° C. to 60° C., preferably −20° C. to 30° C. and reacting them for 0.1 hours to 24 hours, preferably 0.3 hours to 6 hours.
- An amine free compound can be prepared by deprotecting Compound (a-8) under conditions known to a person skilled in the art such as the usual conditions for deprotecting of a protective group of an amine compound, for example, when a protective group is a Boc group or a Fmoc group, the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons. Compound (a-9) can be prepared by adding isocyanate or isothiocyanate such as benzoyl isocyanate and benzoyl isothiocyanate having a protective group, which is commercially available or can be prepared by the known methods to the obtained amine-free compound in a solvent such as dichloromethane, tetrahydrofuran and toluene and a mixed solvent thereof at −30° C. to 50° C., preferably −10° C. to 25° C. for 0.5 hours to 24 hours, preferably 0.5 hours to 12 hours.
- Compound (a-10) can be prepared by adding a halogenium cation source such as iodine, bromine, N-bromosuccinimide (hereafter referred to as NBS), and N-chloro succinimide (hereafter referred to as NCS) to a solution of Compound (a-9) in a solvent such as dichloromethane, and reacting at −20° C. to 40° C., preferably 0° C. to 20° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 6 hours.
- Compound (a-11) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and 1,8-diazabicyclo[5.4.0] undeca-7-en (hereafter referred to as DBU) to a solution of Compound (a-10) in a solvent such as dioxane, tetrahydrofuran and toluene, and the mixture thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- An amino group of Compound (a-11) can be deprotected under conditions for deprotection known to a person skilled in the art. For example, when a protective group is a Boc group or a Fmoc group, Compound (I-a1) can be prepared under the usual conditions for deprotecting a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein R′ represents a group which does not interfere with the reaction such as an amino group, LG represents a leaving group such as halogen and alkylsulfonyloxy, and the other symbols represent the same as defined above.
- An amine free compound can be prepared by deprotecting Compound (a-8) under conditions known to a person skilled in the art such as the usual conditions for deprotecting a protective group of an amine compound, for example, when a protective group is a Boc group or a Fmoc group, the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons. Compound (a-12) can be prepared by reacting the obtained amine-free compound with 3,5-dimethylpyrazole-1-carboxyamidine, S-methylthiourea or the like in a solvent such as acetonitrile, tetrahydrofuran and dimethylformamide at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 hours to 120 hours, preferably 1 hour to 24 hours.
- Compound (a-13) can be prepared by adding a halogenium cation source such as iodine, bromine, NBS, and NCS to a solution of Compound (a-12) in a solvent such as dichloromethane, and reacting at −20° C. to 40° C., preferably 0° C. to 20° C. for 0.1 hour to 12 hours, preferably 0.1 hour to 6 hours.
- Compound (a-14) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU to a solution of Compound (a-13) in a solvent such as dioxane, tetrahydrofuran and toluene, and the mixture thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- An amine group of Compound (a-14) can be deprotected under conditions for deprotection known to a person skilled in the art. When a protective group is a Boc group or a Fmoc group, Compound (I-a2) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein R′ and R″ represent groups which do not interfere with the reaction such as an amino protective group and the other symbols are the same as defined above.
- An amine free compound can be prepared by deprotecting Compound (a-8) under conditions known to a person skilled in the art such as the usual conditions for deprotection of a protective group of an amine compound, for example, when a protective group is a Boc group or a Fmoc group, the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons. Compound (a-15) can be prepared by adding isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods, to the obtained amine-free compound in a solvent such as dichloromethane, dioxane, tetrahydrofuran, toluene and acetone, and a mixed solvent thereof at −30° C. to 50° C., preferably −10° C. to 25° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 3 hours.
- Compound (a-16) can be prepared by adding a halogenium cation source such as iodine, bromine, NBS, and NCS to a solution of Compound (a-15) in a solvent such as dichloromethane, and reacting at −20° C. to 40° C., preferably 0° C. to 20° C. for 1 hour to 12 hours, preferably 0.1 hours to 6 hours.
- Compound (a-17) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU to a solution of Compound (a-16) in a solvent such as dioxane, tetrahydrofuran and toluene, and a mixed solvent thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
- Step 4 (the Case Wherein the Deprotection of R′ and/or R″ is Necessary)
- An amino group of Compound (a-17) can be deprotected under conditions for deprotection known to a person skilled in the art. When a protective group is a Boc group or a Fmoc group, Compound (I-a3) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein the symbols are the same as defined above.
- An amino group of Compound (a-7) which can be prepared by the method mentioned above can be deprotected under conditions for deprotection known to a person skilled in the art. When a protective group is a Boc group or a Fmoc group, Compound (b-8) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- To a solution of Compound (b-8) in a solvent such as dichloromethane, dioxane, tetrahydrofuran, toluene and acetone, and a mixed solvent thereof is added isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods, and the mixture is reacted at −30° C. to 70° C., preferably −20° C. to 50° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 6 hours. Compound (b-9) can be prepared by evaporating the solvent, adding concentrated sulfuric acid, concentrated nitric acid or the like to the mixture, and reacting at −30° C. to 70° C., preferably −20° C. to 50° C. for 1 hour to 12 hours, preferably 1 hour to 6 hours.
- If necessary, an amino group of Compound (b-9) can be deprotected under conditions for deprotection known to a person skilled in the art. For example, when a protective group is a Boc group or a Fmoc group, Compound (I-b1) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein the symbols are the same as defined above.
- Compound (b-10) can be prepared by reacting Compound (b-8) with 3,5-dimethylpyrazole-1-carboxyamidine, S-methylthiourea or the like in a solvent such as acetonitrile, tetrahydrofuran and dimethylformamide at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 hours to 120 hours, preferably 1 hour to 24 hours.
- Compound (b-11) can be prepared by adding concentrated sulfuric acid, concentrated nitric acid or the like to Compound (b-10), and reacting at −30° C. to 70° C., preferably −20° C. to 50° C. for 1 hour to 12 hours, preferably 1 hour to 6 hours.
- An amino group of Compound (a-14) can be deprotected under conditions for deprotection known to a person skilled in the art. For example, when a protective group is a Boc group or a Fmoc group, Compound (I-b2) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein the symbols are the same as defined above.
- Compound (b-12) can be prepared by adding isocyanate such as benzoyl isocyanate having a protective group, which is commercially available or can be prepared by the known methods, to a solution of Compound (b-8) in a solvent such as dioxane, tetrahydrofuran, toluene and acetone, and a mixed solvent thereof, and reacting at −30° C. to 50° C., preferably −10° C. to 25° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 3 hours.
- Compound (b-13) can be prepared by adding concentrated sulfuric acid, concentrated nitric acid or the like to Compound (b-12), and reacting at 0° C. to 100° C., preferably 0° C. to 60° C. for 0.5 hours to 24 hours, preferably 1 hour to 12 hours.
- An amino group of Compound (b-13) can be deprotected under conditions for deprotection known to a person skilled in the art. For example, when a protective group is a Boc group or a Fmoc group, Compound (I-b3) can be prepared under the usual conditions for deprotection of a protective group of an amine compound such as the conditions described in a document such as T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein the symbols are the same as defined above.
- Compound (a-1′) can be prepared from a commercially available compound by methods in a similar manner to Method D described below. It can also be prepared by methods known to a person skilled in the art from a commercially available compound or by methods described in Examples.
- Compound (I-b4) can be prepared by subjecting Compound (a-7′) which is prepared by Step 1 to Step 6 of Preparation Method A-I to a reaction of Step 1 to Step 3 of Preparation Method B-I using Compound (a-1′) as a starting material. Similarly, compounds wherein X is NR1 or O can be prepared according to the scheme described below.
- wherein the symbols are the same as defined above.
-
- wherein the symbols are the same as defined above.
- Compound (a-7′) can be prepared by reacting Compound (a-7) with a Grignard reagent according to usual methods known to a person skilled in the art, and oxidizing the obtained alcohol. Alternatively, Compound (a-7′) can be prepared by oxidizing Compound (a-7) to a carboxylic acid according to the usual methods, converting into a Weinreb amide, reacting with a Grignard reagent, and oxidizing the obtained alcohol. The conditions described in “Comprehensive Organic Transformations, Richard C. Larock; VCH” can be also used for conversion of these functional groups.
-
- wherein LG is a leaving group such as halogen or alkylsulfonyloxy, R′ represents alkyl, arylalkyl or the like, Tf represents trifluoromethanesulfonyl, either one of dotted lines represent the presence of a bond, and the other symbols are the same as defined above.
- Compound (c-1) can be a commercially available compound. It can be also prepared by methods known to a person skilled in the art from a commercially available compound or by methods described in Examples.
- Compound (c-2) can be prepared by reacting a base such as sodium hydride, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, diisopropylethylamine, pyridine and 2,6-lutidine with Compound (c-1), and reacting N-phenyltrifluoromethanesulfonimide or trifluoromethanesulfonic anhydride. Examples of the solvent include ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, benzene and toluene. The reaction time is usually between 5 minutes and 24 hours, and preferably between 5 minutes and 12 hours. The reaction temperature is usually between −100° C. and 40° C., and preferably between −78° C. and room temperature.
- The reaction in this step can be performed under the usual conditions for a trifluoromethanesulfonylation reaction of a carbonyl compound such as the conditions described in J. Org. Chem., 57, 6972-6975 (1992), Tetrahedron., 61, 4129-4140 (2005) and Tetrahedron Letters., 40, 8133-8136 (1999).
- Compound (c-3) can be prepared by a coupling reaction of Compound (c-2) using a transition metal. This coupling reaction can be performed under the usual conditions for coupling reaction such as Suzuki-Miyaura coupling reaction or Stille coupling reaction. For example, the reaction conditions described in Chem. Rev., 2007, 107, 133-73 and Tetrahedron, 58 (2002), 9633-35 can be applied.
- The organometallic catalyst used in this reaction is not particularly limited. Examples of the organometallic catalyst include tetrakis(triphenylphosphine)palladium (0), dichlorobis(triphenylphosphine)palladium(II),
- [1,1′-bis(diphenylphosphino)ferrocene]palladium(II)dichloride, bis(tert-butylphosphine)palladium(0), palladium(II) acetate and [1,3-bis(diphenylphosphino)propane]nickel(II). The amount of the organometallic catalyst is about 0.001 to 0.1 equivalent with respect to the raw material. The organometallic compound is not particularly limited. Preferable examples of the organometallic compound include organotin reagents such as aryl tri-n-butyltin, and organoboron reagents such as aryl boronic acid. The amount of the organometallic compound is 1 equivalent to an excess amount with respect to the raw material. The solvent is not particularly limited insofar as it does not interfere with the reaction. Examples of the solvent include benzene, toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone, 1,4-dioxane and propionitrile. The reaction temperature is usually between ice-cold temperature and solvent reflux temperature, and preferably between room temperature and solvent reflux temperature. The reaction time is usually between 10 minutes and 48 hours, and preferably between 30 minutes and 24 hours.
- A more preferable result such as a suppression of side reactions and an improved yield may be achieved by carrying out this reaction in the presence of a base such as sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, an aqueous solution thereof, and triethylamine.
- Compound (c-4) can be prepared by subjecting Compound (c-3) to a reduction reaction by using diisobutylaluminum hydride, lithium aluminum hydride, lithium borohydride or the like in a solvent such as dioxane, tetrahydrofuran or toluene, or a mixed solvent thereof and reacting at −80° C. to 0° C., preferably −80° C. to −20° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 3 hours.
- Compound (c-5) can be prepared by reacting Compound (c-4) with a halogenating agent such as thionyl chloride, phosphorous oxychloride, carbon tetrabromide-triphenylphosphine, and carbon tetrachloride-triphenylphosphine in the presence or absence of a solvent such as toluene or dichloromethane at −80° C. to 50° C., preferably −20° C. to 20° C. for 0.1 hours to 24 hours, preferably 0.5 hours to 12 hours. Compound (c-5) can be also prepared by reacting Compound (c-4) with a sulfonylation agent such as methanesulfonyl chloride and p-toluenesulfonyl chloride in the presence of a base such as triethylamine in a solvent such as toluene or dichloromethane at −80° C. to 50° C., preferably −20° C. to 20° C. for 0.1 hours to 24 hours, preferably 0.5 hours to 12 hours.
- Compound (c-6) can be prepared from Compound (c-5) by methods known to a person skilled in the art. Specifically, for example, Compound (c-6) can be prepared by reacting Compound (c-5) with thiourea or the like in an organic solvent such as ethanol, 1-propanol, 2-propanol, 1-buthanol, tetrahydrofuran, 1,4-dioxane, and N,N-dimethylformamide. The reaction time is usually between 5 minutes and 24 hours, and preferably between 5 minutes and 12 hours. The reaction temperature is usually between 0° C. and 150° C., and preferably between room temperature and 100° C.
- Compound (I-c1) can be prepared by adding a halogenium cation source such as iodine, bromine, NBS and NCS to a solution of Compound (c-6) in a solvent such as dichloromethane, and reacting the mixture at −20° C. to 40° C., preferably 0° C. to 20° C. for 0.1 hours to 12 hours, preferably 0.1 hours to 6 hours.
- The objective substituent Rob can be introduced to thus-obtained compounds by methods known to a person skilled in the art.
- Compound (I-c2) can be prepared by adding a base such as pyrrolidine, piperidine, piperazine, morpholine and DBU to a solution of Compound (I-c1) in a solvent such as dioxane, tetrahydrofuran and toluene, and a mixed solvent thereof, and reacting at 20° C. to 100° C., preferably 40° C. to 80° C. for 0.1 hours to 24 hours, preferably 1 hour to 12 hours.
-
- wherein the symbols are the same as defined above.
- To a solution of Compound (c-3) in a solvent such as ether or tetrahydrofuran, or a mixed solvent such as ether-tetrahydrofuran is added a Grignard reagent having a substituent corresponding to the objective compounds such as methylmagnesiumchloride and ethylmagnesiumbromide at −100° C. to 50° C., preferably −80° C. to 30° C. Alternatively, Compound (c-3) is hydrolyzed, followed by being converted into a Weinreb Amide, and reacted with a Grignard reagent having a substituent corresponding to the objective compounds such as R3aMgBr and R3bMgBr. Thus obtained compound is reacted for 0.2 hours to 24 hours, preferably 0.2 hours to 5 hours to give Compound (c-4′).
- Compound (I-c1′) and Compound (I-c2′) can be prepared by the subsequent steps according to Preparation Method C-I.
-
- wherein the symbols are the same as defined above.
- Conversion of a Leaving Group
- Introduction of R4 into Compound (I-c1) or (I-c1′) can be performed under the suitably applied conditions according to methods described in the following documents which are known to a person skilled in the art.
- MAHAMMED, K. A.; MURTHY, P. S. K.; RAJU, K. M.; Indian J. Chem. Sect. B: Org. Chem. Incl. Med. Chem., 2008, 47 (4), 575-578.,
- KISS, L.; MANGELINCKX, S.; FUELOEP, F.; DE KIMPE, N.; Org. Lett., 2007, 9 (21), 4399-4402.,
- CAO, Y-Q.; WU, G.-Q.; LI, Y. B.; DAI, Z.; CHEN, B.-H.; Synth. Commun., 2006, 36 (22),3353-3358.,
- VACHAL, P.; FLETCHER, J. M.; HAGMANN, W. K.; Tetrahedron Lett., 2007, 48 (33), 5761-5765 and the like.
-
- wherein the symbols are the same as defined above.
- Compounds (d-1), (d-2) and (d-4) can be a commercially available compound. They can also be prepared by methods known to a person skilled in the art from a commercially available compound, or by methods described in Examples.
- Compound (d-3) can be prepared by adding a base such as sodium hydride, potassium hydride and potassium t-butoxide to a solution of Compound (d-1) in a solvent such as THF, DMF and dimethyl sulfoxide to give an alkoxide, and reacting with Compound (d-2). The amounts of the base and Compound (d-2) are each 1 equivalent to an excess amount with respect to Compound (d-1). The reaction time is usually between 5 minutes and 90 hours, and preferably between 30 minutes and 24 hours. The reaction temperature is usually between −20° C. and 80° C. A more preferable result such as an improved yield may be achieved by performing the reaction in the presence of a salt such as tetrabutylammonium iodide.
- This reaction can be performed under the usual conditions for O-alkylation of alcohol such as the conditions described in Tetrahedron Lett., 46 (2005) 45, 7751-5.
- Compound (a-1; Y═O) can be prepared by adding an oxidant such as 2-iodoxy benzoic acid to a solution of Compound (d-3) in a solvent such as dimethyl sulfoxide and dichloromethane, and reacting at 0° C. to 80° C., preferably 10° C. to 40° C. for 0.5 hours to 48 hours, preferably 1 hour to 12 hours.
- Examples of the oxidation conditions include Swern oxidation, Corey-Kim oxidation, Moffatt oxidation, pyridinium chlorochromate oxidation (PCC oxidation), pyridinium chromate oxidation (PDC oxidation), Dess-Martin oxidation, SO3-pyridine oxidation, and 2,2,6,6-tetramethyl-1-piperizinyloxy free radical oxidation (TEMPO oxidation).
- Compound (d-5) can be prepared from Compound (d-4) in a similar manner to the above preparation of the above Compound (d-3).
- Compound (a-1; Y═O) can be prepared by deprotecting an acetal group of Compound (d-5) under similar conditions to those described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
-
- wherein the symbols are the same as defined above.
- Compound (d-6) can be a commercially available compound. It can be also prepared by methods known to a person skilled in the art from a commercially available compound or by methods described in Examples.
- Compound (d-7) can be prepared by subjecting Compound (d-6) to a reaction under the conditions for functional group protection known to a person skilled in the art. For example, when a protective group is a Boc group or a Fmoc group, Compound (d-7) can be prepared under the usual conditions for protection of an amine compound such as the conditions described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (d-8) can be prepared by adding powder of sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride or potassium t-butoxide to a solution of Compound (d-7) in a solvent such as toluene, THF, DMF and dimethyl sulfoxide, and reacting with Compound (d-2) at −20° C. to 100° C. for 5 minutes to 72 hours, preferably 30 minutes to 24 hours. The amounts of the base and Compound (d-2) are each 1 equivalent to an excess amount with respect to Compound (d-7). A more preferable result such as an improved yield may be achieved by performing the reaction in the presence of a salt such as tetrabutylammonium iodide.
- This reaction can be performed under the usual conditions for N-alkylation of Compound (d-7) such as the conditions described in J. Med. Chem., 2007, 50, 5493-508.
- Compound (a-1) wherein Y═NH can be prepared by deprotecting a PG group of Compound (d-8) under similar conditions to those described in T. W Green and P. G M. Wuts, “Protective Groups in Organic Chemistry, Third Edition”, John Wiley & Sons.
- Compound (I-a1) wherein Y is N(R′) can be prepared by subjecting thus-obtained compounds to each reaction in Preparation Method A and introducing the substituent R1 by methods known to a person skilled in the art at an appropriate stage. Alternatively, the objective compound can be prepared by deprotecting Compound (a-1), introducing R1 using methods known to a person skilled in the art, and subjecting to each reaction in Preparation Method A
- In the all steps, an order of steps to be implemented may be appropriately changed, and each intermediate may be isolated, and used in a next step.
- Above-mentioned Compounds (I-a1) to (I-a3), (1-b1) to (I-b6), (I-c1), (I-c2) and these compounds wherein each ring A is substituted with various substituents such as ring B—W-group can be prepared according to the method mentioned above or the known methods such as those described in Patent Literature 1, Patent Literature 2, Patent Literature 3 and the like.
- Moreover, the optically active isomer of the compound (I) can be prepared by using an optically active compound as a starting material, performing an asymmetric synthesis in the suitable step to prepare an optically active intermediate, or optical resolution of the racemate of the intermediate or the objective compound in the appropriate step. The method of optical resolution include the separation of optical isomer using an optically active column, the kinetics optical resolution using enzyme reactions or the like, the crystallization and separation of diastereomers by the salt formation using chiral acids or chiral bases, the preferential crystallization or the like.
- Preferable embodiments of the present invention are illustrated below. Each symbol represents the same as described above.
- (A) In the formula (I), the followings are exemplified.
- —X— is, for example, —O—, —S— or —N(R1)—.
- —X— is, for example, —O— or —S—.
- —X— is, for example, —O—.
- —X— is, for example, —S—.
- R1 is, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfonyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl.
- R1 is, for example, hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group.
- R2a and R2b are, for example, each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl or substituted or unsubstituted carbamoyl.
- R2a and R2b are, for example, both hydrogen.
- Ring A includes substituted carbocycle or substituted or unsubstituted heterocycle.
- Ring A includes
- wherein
- Ring N and ring B are each independently substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle,
L1, L2, and L3 are each independently a bond, substituted or unsubstituted alkynylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, - R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl,
R8 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl,
when ring A is (i), then the constituent carbon atom of L1 and the constituent carbon atom of L2, or the constituent carbon atom of L1 and the nitrogen atom of W2 may be connected with substituted or unsubstituted alkylene to form a ring,
when ring A is (ii), then the constituent carbon atom of L1 and the constituent carbon atom of L2, or the nitrogen atom of W2 and the constituent carbon atom of L2 may be connected with substituted or unsubstituted alkylene to form a ring
when ring A is then two nitrogen atoms of W2 may be connected with substituted or unsubstituted alkylene to form a ring,
when ring A is (vi), then the constituent carbon atom of L1 and the constituent carbon atom of L2 may be connected with substituted or unsubstituted alkylene to form a ring,
p is 1 or 2, and
when multiple L3, multiple W2, or multiple R9 are present, each of them may be independently different. - Ring A includes
- wherein
- wherein L is each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, ring T is a carbocycle which may be substituted with a group(s) selected from the substituent group α or a heterocycle which may be substituted with a group(s) selected from the substituent group α, and other each symbol is the same as defined above.
- Ring A includes
- wherein
- wherein each symbol is the same as defined above.
- Ring A includes
- wherein
- L1 and L2 include each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, and
- R8 includes hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl.
- Ring A includes
- Ring A′ includes each independently a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle.
- Ring A′ is, for example, substituted or unsubstituted benzene, wherein the substituent is halogen and the like.
- Ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine, wherein the substituent is, for example, halogen, alkyl, alkoxy, halogenoalkoxy, alkynyloxy, alkylcarbamoyl, or cyano.
- R8 includes hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl.
- R8 includes hydrogen.
- As used herein, —Y— is, for example, a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)—, —O—, —S—, —SO— or —SO2—.
- —Y— is, for example, substituted or unsubstituted C1-C3 alkylene or —O—.
- —Z— is, for example, a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)Ak—, —OAk—, —SAk—, —SOAk- or —SO2Ak—.
- —Z— is, for example, a bond.
- Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene.
- Provided that when —Y— is —N(R7)—, —O—, —S—, —SO— or —SO2—, then Ak is not a bond. —Z—Y— is, for example, substituted or unsubstituted C1-C3 alkylene, —O— or —O— (substituted or unsubstituted C1-C3 alkylene)-.
- As used herein, R7 is, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl.
- R7 is, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, or substituted or unsubstituted carbamoyl.
- Rza and Rzb are, for example, each independently hydrogen, halogen, substituted or unsubstituted alkyl, or Rza and Rzb together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle.
- Rza and Rzb are, for example, each independently hydrogen, halogen, substituted or unsubstituted alkyl.
- R3a and R3b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfonyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl.
- R3a and R3b are, for example, both hydrogen.
- R4a and R4b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, a substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heterocyclyloxy.
- R4a and R4b are, for example, each independently hydrogen or substituted or unsubstituted alkyl.
- However provided that when —X— is —S—, then R4b is not hydrogen.
- R5a, R5b, R6a and R6b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, or R5a and R5b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R6a and R6b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle.
- R5a, R5b, R6a and R6b are, for example, each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl.
- R5aR5b, R6a and R6b are, for example, each independently hydrogen, or substituted or unsubstituted alkyl.
- R5a, R5b, R6a and R6b are, for example, both hydrogen.
- As specific aspect of compound (I), the followings are exemplified.
- wherein ring A′ is a substituted or unsubstituted carbocycle wherein the substituent is, for example, halogen,
ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine wherein the substituent is, for example, halogen, alkyl, alkoxy, halogenoalkoxy, alkynyloxy, alkylcarbamoyl or cyano,
R8 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted acyl, more specifically hydrogen,
Rza and Rzb are each independently hydrogen, halogen or substituted or unsubstituted alkyl, and
R3a is hydrogen, or substituted or unsubstituted alkyl. - As another aspect, the following compounds are exemplified.
- A comopund of the formula (I) wherein
- the compound wherein ring A is
- the compound wherein ring B is
- wherein Rb1 and Rb2 are each independently hydrogen, chloro, fluoro, methoxy, butynyloxy, cyano, amino or carbamoyl,
the compound wherein a combination of ring B, Rb1 and Rb2 (B, Rb1, Rb2) is as follows:
(B1, hydrogen, hydrogen) (hereinafter, referred to as ring B is b1),
(B1, hydrogen, chloro) (hereinafter, referred to as ring B is b2),
(B1, hydrogen, fluoro) (hereinafter, referred to as ring B is b3),
(B1, hydrogen, methoxy) (hereinafter, referred to as ring B is b4),
(B1, hydrogen, butynyloxy) (hereinafter, referred to as ring B is b5),
(B1, hydrogen, cyano) (hereinafter, referred to as ring B is b6),
(B1, hydrogen, amino) (hereinafter, referred to as ring B is b7),
(B1, hydrogen, carbamoyl) (hereinafter, referred to as ring B is b8),
(B1, chloro, hydrogen) (hereinafter, referred to as ring B is b9),
(B1, chloro, chloro) (hereinafter, referred to as ring B is b10),
(B1, chloro, fluoro) (hereinafter, referred to as ring B is b11),
(B1, chloro, methoxy) (hereinafter, referred to as ring B is b12),
(B1, chloro, butynyloxy) (hereinafter, referred to as ring B is b13),
(B1, chloro, cyano) (hereinafter, referred to as ring B is b14),
(B1, chloro, amino) (hereinafter, referred to as ring B is b15),
(B1, chloro, carbamoyl) (hereinafter, referred to as ring B is b16),
(B1, fluoro, hydrogen) (hereinafter, referred to as ring B is b17),
(B1, fluoro, chloro) (hereinafter, referred to as ring B is b18),
(B1, fluoro, fluoro) (hereinafter, referred to as ring B is b19),
(B1, fluoro, methoxy) (hereinafter, referred to as ring B is b20),
(B1, fluoro, butynyloxy) (hereinafter, referred to as ring B is b21),
(B1, fluoro, cyano) (hereinafter, referred to as ring B is b22),
(B1, fluoro, amino) (hereinafter, referred to as ring B is b23),
(B1, fluoro, carbamoyl) (hereinafter, referred to as ring B is b24),
(B1, methoxy, hydrogen) (hereinafter, referred to as ring B is b25),
(B1, methoxy, chloro) (hereinafter, referred to as ring B is b26),
(B1, methoxy, fluoro) (hereinafter, referred to as ring B is b27),
(B1, methoxy, methoxy) (hereinafter, referred to as ring B is b28),
(B1, methoxy, butynyloxy) (hereinafter, referred to as ring B is b29),
(B1, methoxy, cyano) (hereinafter, referred to as ring B is b30),
(B1, methoxy, amino) (hereinafter, referred to as ring B is b31),
(B1, methoxy, carbamoyl) (hereinafter, referred to as ring B is b32),
(B1, butynyloxy, hydrogen) (hereinafter, referred to as ring B is b33),
(B1, butynyloxy, chloro) (hereinafter, referred to as ring B is b34),
(B1, butynyloxy, fluoro) (hereinafter, referred to as ring B is b35),
(B1, butynyloxy, methoxy) (hereinafter, referred to as ring B is b36),
(B1, butynyloxy, cyano) (hereinafter, referred to as ring B is b37),
(B1, butynyloxy, amino) (hereinafter, referred to as ring B is b38),
(B1, butynyloxy, carbamoyl) (hereinafter, referred to as ring B is b39),
(B1, cyano, hydrogen) (hereinafter, referred to as ring B is b40),
(B1, cyano, chloro) (hereinafter, referred to as ring B is b41),
(B1, cyano, fluoro) (hereinafter, referred to as ring B is b42),
(B1, cyano, methoxy) (hereinafter, referred to as ring B is b43),
(B1, cyano, butynyloxy) (hereinafter, referred to as ring B is b44),
(B1, cyano, cyano) (hereinafter, referred to as ring B is b45),
(B1, cyano, amino) (hereinafter, referred to as ring B is b46),
(B1, cyano, carbamoyl) (hereinafter, referred to as ring B is b47),
(B1, amino, hydrogen) (hereinafter, referred to as ring B is b48),
(B1, amino, chloro) (hereinafter, referred to as ring B is b49),
(B1, amino, fluoro) (hereinafter, referred to as ring B is b50),
(B1, amino, methoxy) (hereinafter, referred to as ring B is b51),
(B1, amino, butynyloxy) (hereinafter, referred to as ring B is b52),
(B1, amino, cyano) (hereinafter, referred to as ring B is b53),
(B1, carbamoyl, hydrogen) (hereinafter, referred to as ring B is b54),
(B1, carbamoyl, chloro) (hereinafter, referred to as ring B is b55),
(B1, carbamoyl, fluoro) (hereinafter, referred to as ring B is b56),
(B1, carbamoyl, methoxy) (hereinafter, referred to as ring B is b57),
(B1, carbamoyl, butynyloxy) (hereinafter, referred to as ring B is b58),
(B1, carbamoyl, cyano) (hereinafter, referred to as ring B is b59),
(B3, hydrogen, hydrogen) (hereinafter, referred to as ring B is b60),
(B3, hydrogen, chloro) (hereinafter, referred to as ring B is b61),
(B3, hydrogen, fluoro) (hereinafter, referred to as ring B is b62),
(B3, hydrogen, methoxy) (hereinafter, referred to as ring B is b63),
(B3, hydrogen, butynyloxy) (hereinafter, referred to as ring B is b64),
(B3, hydrogen, cyano) (hereinafter, referred to as ring B is b65),
(B3, hydrogen, amino) (hereinafter, referred to as ring B is b66),
(B3, hydrogen, carbamoyl) (hereinafter, referred to as ring B is b67),
(B3, chloro, hydrogen) (hereinafter, referred to as ring B is b68),
(B3, chloro, chloro) (hereinafter, referred to as ring B is b69),
(B3, chloro, fluoro) (hereinafter, referred to as ring B is b70),
(B3, chloro, methoxy) (hereinafter, referred to as ring B is b71),
(B3, chloro, butynyloxy) (hereinafter, referred to as ring B is b72),
(B3, chloro, cyano) (hereinafter, referred to as ring B is b73),
(B3, chloro, amino) (hereinafter, referred to as ring B is b74),
(B3, chloro, carbamoyl) (hereinafter, referred to as ring B is b75),
(B3, fluoro, hydrogen) (hereinafter, referred to as ring B is b76),
(B3, fluoro, chloro) (hereinafter, referred to as ring B is b77),
(B3, fluoro, fluoro) (hereinafter, referred to as ring B is b78),
(B3, fluoro, methoxy) (hereinafter, referred to as ring B is b79),
(B3, fluoro, butynyloxy) (hereinafter, referred to as ring B is b80),
(B3, fluoro, cyano) (hereinafter, referred to as ring B is b81),
(B3, fluoro, amino) (hereinafter, referred to as ring B is b82),
(B3, fluoro, carbamoyl) (hereinafter, referred to as ring B is b83),
(B3, methoxy, hydrogen) (hereinafter, referred to as ring B is b84),
(B3, methoxy, chloro) (hereinafter, referred to as ring B is b85),
(B3, methoxy, fluoro) (hereinafter, referred to as ring B is b86),
(B3, methoxy, methoxy) (hereinafter, referred to as ring B is b87),
(B3, methoxy, butynyloxy) (hereinafter, referred to as ring B is b88),
(B3, methoxy, cyano) (hereinafter, referred to as ring B is b89),
(B3, methoxy, amino) (hereinafter, referred to as ring B is b90),
(B3, methoxy, carbamoyl) (hereinafter, referred to as ring B is b91),
(B3, butynyloxy, hydrogen) (hereinafter, referred to as ring B is b92),
(B3, butynyloxy, chloro) (hereinafter, referred to as ring B is b93),
(B3, butynyloxy, fluoro) (hereinafter, referred to as ring B is b94),
(B3, butynyloxy, methoxy) (hereinafter, referred to as ring B is b95),
(B3, butynyloxy, cyano) (hereinafter, referred to as ring B is b96),
(B3, butynyloxy, amino) (hereinafter, referred to as ring B is b97),
(B3, butynyloxy, carbamoyl) (hereinafter, referred to as ring B is b98),
(B3, cyano, hydrogen) (hereinafter, referred to as ring B is b99),
(B3, cyano, chloro) (hereinafter, referred to as ring B is b100),
(B3, cyano, fluoro) (hereinafter, referred to as ring B is b101),
(B3, cyano, methoxy) (hereinafter, referred to as ring B is b102),
(B3, cyano, butynyloxy) (hereinafter, referred to as ring B is b103),
(B3, cyano, cyano) (hereinafter, referred to as ring B is b104),
(B3, cyano, amino) (hereinafter, referred to as ring B is b105),
(B3, cyano, carbamoyl) (hereinafter, referred to as ring B is b106),
(B3, amino, hydrogen) (hereinafter, referred to as ring B is b107),
(B3, amino, chloro) (hereinafter, referred to as ring B is b108),
(B3, amino, fluoro) (hereinafter, referred to as ring B is b109),
(B3, amino, methoxy) (hereinafter, referred to as ring B is b110),
(B3, amino, butynyloxy) (hereinafter, referred to as ring B is bill),
(B3, amino, cyano) (hereinafter, referred to as ring B is b112),
(B3, carbamoyl, hydrogen) (hereinafter, referred to as ring B is b113),
(B3, carbamoyl, chloro) (hereinafter, referred to as ring B is b114),
(B3, carbamoyl, fluoro) (hereinafter, referred to as ring B is b115),
(B3, carbamoyl, methoxy) (hereinafter, referred to as ring B is b116),
(B3, carbamoyl, butynyloxy) (hereinafter, referred to as ring B is b117),
(B3, carbamoyl, cyano) (hereinafter, referred to as ring B is b118),
compounds wherein a combination of ring B and Rb1 is as follows.
(B2, hydrogen) (hereinafter, referred to as ring B is b119),
(B2, chloro) (hereinafter, referred to as ring B is b120),
(B2, fluoro) (hereinafter, referred to as ring B is b121),
(B2, methoxy) (hereinafter, referred to as ring B is b122),
(B2, butynyloxy) (hereinafter, referred to as ring B is b123),
(B2, cyano) (hereinafter, referred to as ring B is b124),
(B2, amino) (hereinafter, referred to as ring B is b125),
(B2, carbamoyl) (hereinafter, referred to as ring B is b126),
(B4, hydrogen) (hereinafter, referred to as ring B is b127),
(B4, chloro) (hereinafter, referred to as ring B is b128),
(B4, fluoro) (hereinafter, referred to as ring B is b129),
(B4, methoxy) (hereinafter, referred to as ring B is b130),
(B4, butynyloxy) (hereinafter, referred to as ring B is b131),
(B4, cyano) (hereinafter, referred to as ring B is b132),
(B4, amino) (hereinafter, referred to as ring B is b133), or
(B4, carbamoyl) (hereinafter, referred to as ring B is b134). - Compounds of the formula (I) wherein a combination of
- ring A and ring B (r,A,b) is as follows.
(r1,A1,b1), (r1,A1,b2), (r1,A1,b3), (r1,A1,b4), (r1,A1,b5), (r1,A1,b6), (r1,A1,b7), (r1,A1,b8), (r1,A1,b9), (r1,A1,b10), (r1,A1,b11), (r1,A1,b12), (r1,A1,b13), (r1,A1,b14), (r1,A1,b15), (r1,A1,b16), (r1,A1,b17), (r1, A1,b18), (r1,A1,b19), (r1,A1,b20), (r1,A1,b21), (r1,A1,b22), (r1,A1,b23), (r1,A1,b24), (r1,A1,b25), (r1,A 1,b26), (r1,A1,b27), (r1,A1,b28), (r1,A1,b29), (r1,A1,b30), (r1,A1,b31), (r1,A1,b32), (r1,A1,b33), (r1,A1, b34), (r1,A1,b35), (r1,A1,b36), (r1,A1,b37), (r1,A1,b38), (r1,A1,b39), (r1,A1,b40), (r1,A1,b41), (r1,A1,b 42), (r1,A1,b43), (r1,A1,b44), (r1,A1,b45), (r1,A1,b46), (r1,A1,b47), (r1,A1,b48), (r1,A1,b49), (r1,A1,b5 0), (r1,A1,b51), (r1,A1,b52), (r1,A1,b53), (r1,A1,b54), (r1,A1,b55), (r1,A1,b56), (r1,A1,b57), (r1,A1,b58), (r1,A1,b59), (r1,A1,b60), (r1,A1,b61), (r1,A1,b62), (r1,A1,b63), (r1,A1,b64), (r1,A1,b65), (r1,A1,b66), (r1,A1,b67), (r1,A1,b68), (r1,A1,b69), (r1,A1,b70), (r1,A1,b71), (r1,A1,b72), (r1,A1,b73), (r1,A1,b74), (r1, A1,b75), (r1,A1,b76), (r1,A1,b77), (r1,A1,b78), (r1,A1,b79), (r1,A1,b80), (r1,A1,b81), (r1,A1,b82), (r1,A 1,b83), (r1,A1,b84), (r1,A1,b85), (r1,A1,b86), (r1,A1,b87), (r1,A1,b88), (r1,A1,b89), (r1,A1,b90), (r1,A1, b91), (r1,A1,b92), (r1,A1,b93), (r1,A1,b94), (r1,A1,b95), (r1,A1,b96), (r1,A1,b97), (r1,A1,b98), (r1,A1,b99), (r1,A1,b100), (r1,A1,b101), (r1,A1,b102), (r1,A1,b103), (r1,A1,b104), (r1,A1,b105), (r1,A1,b106), (r1,A1,b107), (r1,A1,b108), (r1,A1,b109), (r1,A1,b110), (r1,A1,b111), (r1,A1,b112), (r1,A1,b113), (r1,A1, b114), (r1,A1,b115), (r1,A1,b116), (r1,A1,b117), (r1,A1,b118), (r1,A1,b119), (r1,A1,b120), (r1,A1,b121), (r1,A1,b122), (r1,A1,b123), (r1,A1,b124), (r1,A1,b125), (r1,A1,b126), (r1,A1,b127), (r1,A1,b128), (r1,A 1,b129), (r1,A1,b130), (r1,A1,b131), (r1,A1,b132), (r1,A1,b133), (r1,A1,b134), (r1,A2,b1), (r1,A2,b2), (r1,A2,b3), (r1,A2,b 4), (r1,A2,b 5), (r1,A2,b6), (r1,A2,b7), (r1,A2,b8), (r1,A2,b9), (r1,A2,b10), (r1,A2,b11), (r1,A2,b12), (r1,A2,b13), (r1,A2,b14), (r1,A2,b15), (r1,A2,b16), (r1,A2,b17), (r1,A2,b18), (r1,A2,b19), (r1,A2,b20), (r1,A2,b21), (r1,A2,b22), (r1,A2,b23), (r1,A2,b24), (r1,A2,b25), (r1,A2,b26), (r1,A2,b27), (r1, A2,b28), (r1,A2,b29), (r1,A2,b30), (r1,A2,b31), (r1,A2,b 32), (r1,A2,b33), (r1,A2,b 34), (r1,A2,b 35), (r1,A 2,b36), (r1,A2,b 37), (r1,A2,b 38), (r1,A2,b39), (r1,A2,b40), (r1,A2,b41), (r1,A2,b42), (r1,A2,b43), (r1,A2, b44), (r1,A2,b 45), (r1,A2,b 46), (r1,A2,b 47), (r1,A2,b 48), (r1,A2,b 49), (r1,A2,b50), (r1,A2,b 51), (r1,A2,b 52), (r1,A2,b 53), (r1,A2,b 54), (r1,A2,b 55), (r1,A2,b56), (r1,A2,b 57), (r1,A2,b 58), (r1,A2,b 59), (r1,A2,b6 0), (r1,A2,b61), (r1,A2,b62), (r1,A2,b 63), (r1,A2,b64), (r1,A2,b65), (r1,A2,b66), (r1,A2,b67), (r1,A2,b68), (r1,A2,b 69), (r1,A2,b70), (r1,A2,b71), (r1,A2,b 72), (r1,A2,b73), (r1,A2,b 74), (r1,A2,b75), (r1,A2,b 76), (r1,A2,b77), (r1,A2,b78), (r1,A2,b79), (r1,A2,b80), (r1,A2,b81), (r1,A2,b82), (r1,A2,b83), (r1,A2,b84), (r1, A2,b85), (r1,A2,b86), (r1,A2,b87), (r1,A2,b88), (r1,A2,b89), (r1,A2,b90), (r1,A2,b91), (r1,A2,b92), (r1,A 2,b93), (r1,A2,b94), (r1,A2,b95), (r1,A2,b96), (r1,A2,b97), (r1,A2,b98), (r1,A2,b99), (r1,A2,b100), (r1,A 2,b101), (r1,A2,b102), (r1,A2,b103), (r1,A2,b104), (r1,A2,b105), (r1,A2,b106), (r1,A2,b107), (r1,A2,b10 8), (r1,A2,b109), (r1,A2,b110), (r1,A2,b111), (r1,A2,b112), (r1,A2,b113), (r1,A2,b114), (r1,A2,b115), (r1, A2,b116), (r1,A2,b117), (r1,A2,b118), (r1,A2,b119), (r1,A2,b120), (r1,A2,b121), (r1,A2,b122), (r1,A2,b1 23), (r1,A2,b124), (r1,A2,b125), (r1,A2,b126), (r1,A2,b127), (r1,A2,b128), (r1,A2,b129), (r1,A2,b130), (r1,A2,b131), (r1,A2,b132), (r1,A2,b133), (r1,A2,b134), (r1,A3,b1), (r1,A3,b2), (r1,A3,b3), (r1,A3,b4), (r1, A3,b5), (r1,A3,b6), (r1,A3,b7), (r1,A3,b8), (r1,A3,b9), (r1,A3,b10), (r1,A3,b11), (r1,A3,b12), (r1,A3,b13), (r1,A3,b14), (r1,A3,b15), (r1,A3,b16), (r1,A3,b17), (r1,A3,b18), (r1,A3,b19), (r1,A3,b20), (r1,A3,b21), (r1,A3,b22), (r1,A3,b23), (r1,A3,b24), (r1,A3,b25), (r1,A3,b26), (r1,A3,b27), (r1,A3,b28), (r1,A3,b29), (r1, A3,b 30), (r1,A3,b31), (r1,A3,b32), (r1,A3,b33), (r1,A3,b34), (r1,A3,b35), (r1,A3,b36), (r1,A3,b37), (r1,A 3,b38), (r1,A3,b39), (r1,A3,b40), (r1,A3,b41), (r1,A3,b42), (r1,A3,b43), (r1,A3,b44), 1,A3,b45), (r1,A3, b46), (r1,A3,b47), (r1,A3,b48), (r1,A3,b49), (r1,A3,b50), (r1,A3,b51), (r1,A3,b52), (r1,A3,b53), (r1,A3,b54), (r1,A3,b55), (r1,A3,b56), (r1,A3,b57), (r1,A3,b58), (r1,A3,b59), (r1,A3,b60), 1,A3,b61), (r1,A3,b6 2), (r1,A3,b63), (r1,A3,b64), (r1,A3,b65), 1,A3,b66), (r1,A3,b67), (r1,A3,b68), (r1,A3,b69), 1,A3,b70), (r1,A3,b71), (r1,A3,b72), (r1,A3,b73), (r1,A3,b74), (r1,A3,b75), (r1,A3,b76), (r1,A3,b77), (r1,A3,b78), (r1,A3,b79), (r1,A3,b80), (r1,A3,b81), (r1,A3,b82), (r1,A3,b83), (r1,A3,b84), (r1,A3,b85), (r1,A3,b86), (r1, A3,b87), (r1,A3,b88), (r1,A3,b89), (r1,A3,b90), (r1,A3,b91), (r1,A3,b92), (r1,A3,b93), (r1,A3,b94), (r1,A 3,b95), (r1,A3,b96), (r1,A3,b97), (r1,A3,b98), (r1,A3,b99), (r1,A3,b100), (r1,A3,b101), (r1,A3,b102), (r1, A3,b103), (r1,A3,b104), (r1,A3,b105), (r1,A3,b106), (r1,A3,b107), (r1,A3,b108), (r1,A3,b109), (r1,A3,b110), (r1,A3,b111), (r1,A3,b112), (r1,A3,b113), (r1,A3,b114), (r1,A3,b115), (r1,A3,b116), (r1,A3,b117), (r1,A3,b118), (r1,A3,b119), (r1,A3,b120), (r1,A3,b121), (r1,A3,b122), (r1,A3,b123), (r1,A3,b124), (r1,A3, b125), (r1,A3,b126), (r1,A3,b127), (r1,A3,b128), (r1,A3,b129), (r1,A3,b130), (r1,A3,b131), (r1,A3,b132), (r1,A3,b133), (r1,A3,b134), (r1,A4,b1), (r1,A4,b2), (r1,A4,b3), (r1,A4,b 4), (r1,A4,b 5), (r1,A4,b 6), (r1,A 4,b7), (r1,A4,b8), (r1,A4,b9), (r1,A4,b10), (r1,A4,b11), (r1,A4,b12), (r1,A4,b13), (r1,A4,b14), (r1,A4,b15), (r1,A4,b16), (r1,A4,b17), (r1,A4,b18), (r1,A4,b19), (r1,A4,b20), (r1,A4,b21), 1,A4,b22), (r1,A4,b23), (r1,A4,b24), (r1,A4,b25), (r1,A4,b26), (r1,A4,b27), (r1,A4,b28), (r1,A4,b29), (r1,A4,b30), (r1,A4,b31), (r1, A4,b 32), (r1,A4,b 33), (r1,A4,b 34), (r1,A4,b 35), (r1,A4,b36), (r1,A4,b 37), (r1,A4,b 38), (r1,A4,b 39), (r1,A 4,b40), (r1,A4,b 41), (r1,A4,b 42), (r1,A4,b 43), (r1,A4,b 44), (r1,A4,b 45), (r1,A4,b46), (r1,A4,b 47), (r1,A4, b48), (r1,A4,b49), (r1,A4,b 50), (r1,A4,b51), (r1,A4,b52), (r1,A4,b53), 1,A4,b54), (r1,A4,b55), 1,A4,b 56), (r1,A4,b57), (r1,A4,b 58), (r1,A4,b 59), (r1,A4,b60), (r1,A4,b61), (r1,A4,b 62), (r1,A4,b63), (r1,A4,b6 4), (r1,A4,b 65), (r1,A4,b66), (r1,A4,b67), (r1,A4,b68), (r1,A4,b69), (r1,A4,b 70), (r1,A4,b 71), (r1,A4,b72), (r1,A4,b 73), (r1,A4,b 74), (r1,A4,b75), (r1,A4,b76), (r1,A4,b77), (r1,A4,b 78), (r1,A4,b 79), (r1,A4,b80), (r1,A4,b81), (r1,A4,b82), (r1,A4,b83), (r1,A4,b84), (r1,A4,b85), (r1,A4,b86), (r1,A4,b87), (r1,A4,b88), (r1, A4,b89), (r1,A4,b90), (r1,A4,b91), (r1,A4,b92), (r1,A4,b93), (r1,A4,b94), (r1,A4,b95), (r1,A4,b96), (r1,A 4,b97), (r1,A4,b98), (r1,A4,b99), (r1,A4,b100), (r1,A4,b101), (r1,A4,b102), (r1,A4,b103), (r1,A4,b104), (r1,A4,b105), (r1,A4,b106), (r1,A4,b107), (r1,A4,b108), (r1,A4,b109), (r1,A4,b110), (r1,A4,b111), (r1,A4, b112), (r1,A4,b113), (r1,A4,b114), (r1,A4,b115), (r1,A4,b116), (r1,A4,b117), (r1,A4,b118), (r1,A4,b119), (r1,A4,b120), (r1,A4,b121), (r1,A4,b122), (r1,A4,b123), (r1,A4,b124), (r1,A4,b125), (r1,A4,b126), (r1, A4,b127), (r1,A4,b128), (r1,A4,b129), (r1,A4,b130), (r1,A4,b131), (r1,A4,b132), (r1,A4,b133), (r1,A4,b134),
(r2,A1,b1), (r2,A1,b2), (r2,A1,b 3), (r2,A1,b 4), (r2,A1,b 5), (r2,A1,b6), (r2,A1,b7), (r2,A1,b8), (r2,A1,b9), r2,A1,b10), (r2,A1,b11), (r2,A1,b12), (r2,A1,b13), (r2,A1,b14), (r2,A1,b15), (r2,A1,b16), (r2,A1,b17), (r2, A1,b18), (r2,A1,b19), (r2,A1,b20), (r2,A1,b21), (r2,A1,b22), (r2,A1,b23), (r2,A1,b24), (r2,A1,b25), (r2,A 1,b26), (r2,A1,b27), (r2,A1,b28), (r2,A1,b29), (r2,A1,b 30), (r2,A1,b31), (r2,A1,b32), (r2,A1,b33), (r2,A1, b34), (r2,A1,b35), (r2,A1,b36), (r2,A1,b37), (r2,A1,b 38), (r2,A1,b39), (r2,A1,b40), (r2,A1,b41), (r2,A1,b 42), (r2,A1,b43), (r2,A1,b 44), (r2,A1,b 45), (r2,A1,b 46), (r2,A1,b 47), (r2,A1,b 48), (r2,A1,b 49), (r2,A1,b 5 0), (r2,A1,b51), (r2,A1,b52), (r2,A1,b53), (r2,A1,b54), (r2,A1,b55), (r2,A1,b56), (r2,A1,b57), (r2,A1,b58), (r2,A1,b 59), (r2,A1,b60), (r2,A1,b61), (r2,A1,b62), (r2,A1,b63), (r2,A1,b64), (r2,A1,b 65), (r2,A1,b66), (r2,A1,b67), (r2,A1,b68), (r2,A1,b69), (r2,A1,b 70), (r2,A1,b 71), (r2,A1,b72), (r2,A1,b 73), (r2,A1,b 74), (r2, A1,b75), (r2,A1,b76), (r2,A1,b77), (r2,A1,b78), (r2,A1,b79), (r2,A1,b80), (r2,A1,b81), (r2,A1,b82), (r2,A 1,b83), (r2,A1,b84), (r2,A1,b85), (r2,A1,b86), (r2,A1,b87), (r2,A1,b88), (r2,A1,b89), (r2,A1,b90), (r2,A1, b91), (r2,A1,b 92), (r2,A 1,b93), (r2,A1,b94), (r2,A1,b95), (r2,A1,b 96), (r2,A 1,b97), (r2,A 1,b98), (r2,A1,b 99), (r2,A1,b100), (r2,A1,b101), (r2,A1,b102), (r2,A1,b103), (r2,A1,b104), (r2,A1,b105), (r2,A1,b106), (r 2,A1,b107), (r2,A1,b108), (r2,A1,b109), (r2,A1,b110), (r2,A1,b111), (r2,A1,b112), (r2,A1,b113), (r2,A 1, b114), (r2,A1,b115), (r2,A1,b116), (r2,A1,b117), (r2,A1,b118), (r2,A1,b119), (r2,A1,b120), (r2,A1,b121), (r2,A1,b122), (r2,A1,b123), (r2,A1,b124), (r2,A1,b125), (r2,A1,b126), (r2,A1,b127), (r2,A1,b128), (r2,A 1,b129), (r2,A1,b130), (r2,A1,b131), (r2,A1,b132), (r2,A1,b133), (r2,A1,b134), (r2,A2,b1), (r2,A2,b2), 2,A2,b 3), (r2,A2,b4), (r2,A2,b 5), (r2,A2,b6), (r2,A2,b7), (r2,A2,b 8), (r2,A2,b9), (r2,A2,b10), (r2,A2,b11), (r2,A2,b12), (r2,A2,b13), (r2,A2,b14), (r2,A2,b15), (r2,A2,b16), (r2,A2,b17), (r2,A2,b18), (r2,A2,b19), (r 2,A2,b20), (r2,A2,b21), (r2,A2,b22), (r2,A2,b23), (r2,A2,b24), (r2,A2,b25), (r2,A2,b26), (r2,A2,b27), (r2, A2,b28), (r2,A2,b29), (r2,A2,b 30), (r2,A2,b 31), (r2,A2,b 32), (r2,A2,b33), (r2,A2,b 34), (r2,A2,b35), (r2,A 2,b 36), (r2,A2,b 37), (r2,A2,b 38), (r2,A2,b39), (r2,A2,b 40), (r2,A2,b 41), (r2,A2,b 42), (r2,A2,b 43), (r2,A2, 1,b44), (r2,A2,b 45), (r2,A2,b 46), (r2,A2,b 47), (r2,A2,b 48), (r2,A2,b49), (r2,A2,b 50), (r2,A2,b 51), (r2,A2,b 52), (r2,A2,b 53), (r2,A2,b 54), (r2,A2,b 55), (r2,A2,b56), (r2,A2,b 57), (r2,A2,b 58), (r2,A2,b 59), (r2,A2,b6 0), (r2,A2,b61), (r2,A2,b62), (r2,A2,b 63), (r2,A2,b64), (r2,A2,b65), (r2,A2,b66), (r2,A2,b67), (r2,A2,b68), (r2,A2,b69), (r2,A2,b70), (r2,A2,b71), (r2,A2,b 72), (r2,A2,b 73), (r2,A2,b 74), (r2,A2,b 75), (r2,A2,b76), (r2,A2,b77), (r2,A2,b78), (r2,A2,b 79), (r2,A2,b80), (r2,A2,b81), (r2,A2,b82), (r2,A2,b83), (r2,A2,b84), (r2, A2,b85), (r2,A2,b86), (r2,A2,b87), (r2,A2,b88), (r2,A2,b89), (r2,A2,b90), (r2,A2,b91), (r2,A2,b92), (r2,A 2,b93), (r2,A2,b94), (r2,A2,b95), (r2,A2,b96), (r2,A2,b97), (r2,A2,b98), (r2,A2,b99), (r2,A2,b100), (r2,A 2,b101), (r2,A2,b102), (r2,A2,b103), (r2,A2,b104), (r2,A2,b105), (r2,A2,b106), (r2,A2,b107), (r2,A2,b10 8), (r2,A2,b109), (r2,A2,b110), (r2,A2,b111), (r2,A2,b112), (r2,A2,b113), (r2,A2,b114), (r2,A2,b115), (r2, A2,b116), (r2,A2,b117), (r2,A2,b118), (r2,A2,b119), (r2,A2,b120), (r2,A2,b121), (r2,A2,b122), (r2,A2,b1 23), (r2,A2,b124), (r2,A2,b125), (r2,A2,b126), (r2,A2,b127), (r2,A2,b128), (r2,A2,b129), (r2,A2,b130), (r 2,A2,b131), (r2,A2,b132), (r2,A2,b133), (r2,A2,b134), (r2,A3,b1), (r2,A3,b2), (r2,A3,b 3), (r2,A3,b4), (r2, A3,b 5), (r2,A3,b6), (r2,A3,b7), (r2,A3,b8), (r2,A3,b9), (r2,A3,b10), (r2,A3,b11), (r2,A3,b12), (r2,A3,b13), (r2,A3,b14), (r2,A3,b15), (r2,A3,b16), (r2,A3,b17), (r2,A3,b18), (r2,A3,b19), (r2,A3,b20), (r2,A3,b21), (r 2,A3,b22), (r2,A3,b23), (r2,A3,b24), (r2,A3,b25), (r2,A3,b26), (r2,A3,b27), (r2,A3,b28), (r2,A3,b29), (r2, A3,b 30), (r2,A3,b31), (r2,A3,b 32), (r2,A3,b 33), (r2,A3,b34), (r2,A3,b35), (r2,A3,b 36), (r2,A3,b 37), (r2,A 3,b38), (r2,A3,b 39), (r2,A3,b 40), (r2,A3,b41), (r2,A3,b42), (r2,A3,b 43), (r2,A3,b44), (r2,A3,b 45), (r2,A3, b46), (r2,A3,b 47), (r2,A3,b 48), (r2,A3,b49), (r2,A3,b 50), (r2,A3,b 51), (r2,A3,b52), (r2,A3,b 53), (r2,A3,b 54), (r2,A3,b 55), (r2,A3,b56), (r2,A3,b 57), (r2,A3,b 58), (r2,A3,b 59), (r2,A3,b60), (r2,A3,b61), (r2,A3,b 6 2), (r2,A3,b63), (r2,A3,b64), (r2,A3,b65), (r2,A3,b 66), (r2,A3,b67), (r2,A3,b68), (r2,A3,b69), (r2,A3,b 70), (r2,A3,b 71), (r2,A3,b 72), (r2,A3,b 73), (r2,A3,b74), (r2,A3,b75), (r2,A3,b 76), (r2,A3,b 77), (r2,A3,b78), (r2,A3,b 79), (r2,A3,b80), (r2,A3,b81), (r2,A3,b82), (r2,A3,b83), (r2,A3,b84), (r2,A3,b85), (r2,A3,b86), (r2, A3,b87), (r2,A3,b88), (r2,A3,b89), (r2,A3,b90), (r2,A3,b91), (r2,A3,b 92), (r2,A3,b93), (r2,A3,b94), (r2,A 3,b95), (r2,A3,b96), (r2,A3,b 97), (r2,A3,b98), (r2,A3,b99), (r2,A3,b100), (r2,A3,b101), (r2,A3,b102), (r2, A3,b103), (r2,A3,b104), (r2,A3,b105), (r2,A3,b106), (r2,A3,b107), (r2,A3,b108), (r2,A3,b109), (r2,A3,b110), (r2,A3,b111), (r2,A3,b112), (r2,A3,b113), (r2,A3,b114), (r2,A3,b115), (r2,A3,b116), (r2,A3,b117), (r2,A3,b118), (r2,A3,b119), (r2,A3,b120), (r2,A3,b121), (r2,A3,b122), (r2,A3,b123), (r2,A3,b124), (r2,A3, b125), (r2,A3,b126), (r2,A3,b127), (r2,A3,b128), (r2,A3,b129), (r2,A3,b130), (r2,A3,b131), (r2,A3,b132), (r2,A3,b133), (r2,A3,b134), (r2,A4,b1), (r2,A4,b2), (r2,A4,b3), (r2,A4,b 4), (r2,A4,b 5), (r2,A4,b6), (r2,A 4,b 7), (r2,A4,b8), (r2,A4,b9), (r2,A4,b10), (r2,A4,b11), (r2,A4,b12), (r2,A4,b13), (r2,A4,b14), (r2,A4,b15), (r2,A4,b16), (r2,A4,b17), (r2,A4,b18), (r2,A4,b19), (r2,A4,b20), (r2,A4,b21), (r2,A4,b22), (r2,A4,b23), (r2,A4,b24), (r2,A4,b25), (r2,A4,b26), (r2,A4,b27), (r2,A4,b28), (r2,A4,b29), (r2,A4,b 30), (r2,A4,b31), (r2, A4,b32), (r2,A4,b33), (r2,A4,b 34), (r2,A4,b 35), (r2,A4,b 36), (r2,A4,b 37), (r2,A4,b38), (r2,A4,b 39), (r2,A 4,b40), (r2,A4,b 41), (r2,A4,b 42), (r2,A4,b 43), (r2,A4,b 44), (r2,A4,b 45), (r2,A4,b 46), (r2,A4,b 47), (r2,A4, b48), (r2,A4,b 49), (r2,A4,b50), (r2,A4,b 51), (r2,A4,b 52), (r2,A4,b 53), (r2,A4,b54), (r2,A4,b 55), (r2,A4,b 56), (r2,A4,b57), (r2,A4,b 58), (r2,A4,b59), (r2,A4,b60), (r2,A4,b61), (r2,A4,b62), (r2,A4,b63), (r2,A4,b6 4), (r2,A4,b65), (r2,A4,b66), (r2,A4,b67), (r2,A4,b68), (r2,A4,b69), (r2,A4,b 70), (r2,A4,b71), (r2,A4,b 72), (r2,A4,b 73), (r2,A4,b74), (r2,A4,b 75), (r2,A4,b 76), (r2,A4,b77), (r2,A4,b 78), (r2,A4,b 79), (r2,A4,b 80), (r2,A4,b81), (r2,A4,b82), (r2,A4,b83), (r2,A4,b84), (r2,A4,b 85), (r2,A4,b86), (r2,A4,b87), (r2,A4,b88), (r2, A4,b89), (r2,A4,b90), (r2,A4,b91), (r2,A4,b92), (r2,A4,b 93), (r2,A4,b94), (r2,A4,b95), (r2,A4,b96), (r2,A 4,b97), (r2,A4,b98), (r2,A4,b99), (r2,A4,b100), (r2,A4,b101), (r2,A4,b102), (r2,A4,b103), (r2,A4,b104), (r2,A4,b105), (r2,A4,b106), (r2,A4,b107), (r2,A4,b108), (r2,A4,b109), (r2,A4,b110), (r2,A4,b111), (r2,A4, b112), (r2,A4,b113), (r2,A4,b114), (r2,A4,b115), (r2,A4,b116), (r2,A4,b117), (r2,A4,b118), (r2,A4,b119), (r2,A4,b120), (r2,A4,b121), (r2,A4,b122), (r2,A4,b123), (r2,A4,b124), (r2,A4,b125), (r2,A4,b126), (r2, A4,b127), (r2,A4,b128), (r2,A4,b129), (r2,A4,b130), (r2,A4,b131), (r2,A4,b132), (r2,A4,b133), (r2,A4,b134),
(r3,A1,b1), (r3,A1,b2), (r3,A1,b3), (r3,A1,b4), (r3,A1,b5), (r3,A1,b6), (r3,A1,b7), (r3,A1,b8), (r3,A1,b9), (r3,A1,b10), (r3,A1,b11), (r3,A1,b12), (r3,A1,b13), (r3,A1,b14), (r3,A1,b15), (r3,A1,b16), (r3,A1,b17), (r3, A1,b18), (r3,A1,b19), (r3,A1,b20), (r3,A1,b21), (r3,A1,b22), (r3,A1,b23), (r3,A1,b24), (r3,A1,b25), (r3,A 1,b26), (r3,A1,b27), (r3,A1,b28), (r3,A1,b29), (r3,A1,b30), (r3,A1,b31), (r3,A1,b32), (r3,A1,b33), (r3,A1, b34), (r3,A1,b35), (r3,A1,b36), (r3,A1,b37), (r3,A1,b38), (r3,A1,b39), (r3,A1,b40), (r3,A1,b41), (r3,A1,b42), (r3,A1,b43), (r3,A1,b44), (r3,A 1,b45), (r3,A1,b46), (r3,A1,b47), (r3,A1,b48), (r3,A1,b49), (r3,A1,b5 0), (r3,A1,b51), (r3,A1,b52), (r3,A1,b53), (r3,A1,b54), (r3,A1,b55), (r3,A1,b56), (r3,A1,b57), (r3,A1,b58), (r3,A1,b59), (r3,A1,b60), (r3,A1,b61), (r3,A1,b62), (r3,A1,b63), (r3,A1,b64), (r3,A1,b65), (r3,A1,b66), (r3,A1,b67), (r3,A1,b68), (r3,A1,b69), (r3,A1,b70), (r3,A1,b71), (r3,A1,b72), (r3,A1,b73), (r3,A1,b74), (r3, A1,b75), (r3,A1,b76), (r3,A1,b77), (r3,A1,b78), (r3,A1,b79), (r3,A1,b80), (r3,A1,b81), (r3,A1,b82), (r3,A 1,b83), (r3,A1,b84), (r3,A1,b85), (r3,A1,b86), (r3,A1,b87), (r3,A1,b88), (r3,A1,b89), (r3,A1,b90), (r3,A1, b91), (r3,A1,b92), (r3,A1,b93), (r3,A1,b94), (r3,A1,b95), (r3,A1,b96), (r3,A1,b97), (r3,A1,b98), (r3,A1,b99), (r3,A1,b100), (r3,A1,b101), (r3,A1,b102), (r3,A1,b103), (r3,A1,b104), (r3,A1,b105), (r3,A1,b106), (r 3,A1,b107), (r3,A1,b108), (r3,A1,b109), (r3,A1,b110), (r3,A1,b111), (r3,A1,b112), (r3,A1,b113), (r3,A1, b114), (r3,A1,b115), (r3,A1,b116), (r3,A1,b117), (r3,A1,b118), (r3,A1,b119), (r3,A1,b120), (r3,A1,b121), (r3,A1,b122), (r3,A1,b123), (r3,A1,b124), (r3,A1,b125), (r3,A1,b126), (r3,A1,b127), (r3,A1,b128), (r3,A 1,b129), (r3,A1,b130), (r3,A1,b131), (r3,A1,b132), (r3,A1,b133), (r3,A1,b134), (r3,A2,b1), (r3,A2,b2), (r 3,A2,b3), (r3,A2,b4), (r3,A2,b 5), (r3,A2,b6), (r3,A2,b 7), (r3,A2,b8), (r3,A2,b9), (r3,A2,b10), (r3,A2,b11), (r3,A2,b12), (r3,A2,b13), (r3,A2,b14), (r3,A2,b15), (r3,A2,b16), (r3,A2,b17), (r3,A2,b18), (r3,A2,b19), (r 3,A2,b20), (r3,A2,b21), (r3,A2,b22), (r3,A2,b23), (r3,A2,b24), (r3,A2,b25), (r3,A2,b26), (r3,A2,b27), (r3, A2,b28), (r3,A2,b29), (r3,A2,b30), (r3,A2,b 31), (r3,A2,b32), (r3,A2,b33), (r3,A2,b 34), (r3,A2,b35), (r3,A 2,b36), (r3,A2,b 37), (r3,A2,b 38), (r3,A2,b39), (r3,A2,b 40), (r3,A2,b 41), (r3,A2,b42), (r3,A2,b 43), (r3,A2, b44), (r3,A2,b 45), (r3,A2,b46), (r3,A2,b47), (r3,A2,b48), (r3,A2,b 49), (r3,A2,b 50), (r3,A2,b 51), (r3,A2,b 52), (r3,A2,b53), (r3,A2,b 54), (r3,A2,b 55), (r3,A2,b 56), (r3,A2,b 57), (r3,A2,b 58), (r3,A2,b 59), (r3,A2,b6 0), (r3,A2,b61), (r3,A2,b62), (r3,A2,b63), (r3,A2,b64), (r3,A2,b65), (r3,A2,b66), (r3,A2,b67), (r3,A2,b68), (r3,A2,b 69), (r3,A2,b70), (r3,A2,b71), (r3,A2,b72), (r3,A2,b73), (r3,A2,b 74), (r3,A2,b 75), (r3,A2,b76), (r3,A2,b77), (r3,A2,b 78), (r3,A2,b79), (r3,A2,b80), (r3,A2,b81), (r3,A2,b82), (r3,A2,b83), (r3,A2,b84), (r3, A2,b85), (r3,A2,b86), (r3,A2,b87), (r3,A2,b88), (r3,A2,b89), (r3,A2,b 90), (r3,A2,b91), (r3,A2,b92), (r3,A 2,b93), (r3,A2,b94), (r3,A2,b95), (r3,A2,b96), (r3,A2,b97), (r3,A2,b98), (r3,A2,b99), (r3,A2,b100), (r3,A2,b101), (r3,A2,b102), (r3,A2,b103), (r3,A2,b104), (r3,A2,b105), (r3,A2,b106), (r3,A2,b107), (r3,A2,b10 8), (r3,A2,b109), (r3,A2,b110), (r3,A2,b111), (r3,A2,b112), (r3,A2,b113), (r3,A2,b114), (r3,A2,b115), (r3, A2,b116), (r3,A2,b117), (r3,A2,b118), (r3,A2,b119), (r3,A2,b120), (r3,A2,b121), (r3,A2,b122), (r3,A2,b1 23), (r3,A2,b124), (r3,A2,b125), (r3,A2,b126), (r3,A2,b127), (r3,A2,b128), (r3,A2,b129), (r3,A2,b130), (r 3,A2,b131), (r3,A2,b132), (r3,A2,b133), (r3,A2,b134), (r3,A3,b1), (r3,A3,b2), (r3,A3,b 3), (r3,A3,b 4), (r3, A3,b 5), (r3,A3,b6), (r3,A3,b 7), (r3,A3,b8), (r3,A3,b9), (r3,A3,b10), (r3,A3,b11), (r3,A3,b12), (r3,A3,b13), (r3,A3,b14), (r3,A3,b15), (r3,A3,b16), (r3,A3,b17), (r3,A3,b18), (r3,A3,b19), (r3,A3,b20), (r3,A3,b21), (r 3,A3,b22), (r3,A3,b23), (r3,A3,b24), (r3,A3,b25), (r3,A3,b26), (r3,A3,b27), (r3,A3,b28), (r3,A3,b29), (r3, A3,b30), (r3,A3,b31), (r3,A3,b32), (r3,A3,b33), (r3,A3,b34), (r3,A3,b35), (r3,A3,b36), (r3,A3,b37), (r3,A 3,b38), (r3,A3,b39), (r3,A3,b40), (r3,A3,b41), (r3,A3,b42), (r3,A3,b43), (r3,A3,b44), (r3,A3,b45), (r3,A3, b46), (r3,A3,b47), (r3,A3,b48), (r3,A3,b49), (r3,A3,b50), (r3,A3,b51), (r3,A3,b52), (r3,A3,b53), (r3,A3,b54), (r3,A3,b 55), (r3,A3,b 56), (r3,A3,b 57), (r3,A3,b 58), (r3,A3,b 59), (r3,A3,b60), (r3,A3,b61), (r3,A3,b6 2), (r3,A3,b63), (r3,A3,b64), (r3,A3,b65), (r3,A3,b66), (r3,A3,b67), (r3,A3,b68), (r3,A3,b69), (r3,A3,b 70), (r3,A3,b71), (r3,A3,b72), (r3,A3,b73), (r3,A3,b74), (r3,A3,b75), (r3,A3,b76), (r3,A3,b77), (r3,A3,b78), (r3,A3,b79), (r3,A3,b80), (r3,A3,b81), (r3,A3,b82), (r3,A3,b83), (r3,A3,b84), (r3,A3,b85), (r3,A3,b86), (r3, A3,b87), (r3,A3,b88), (r3,A3,b89), (r3,A3,b90), (r3,A3,b 91), (r3,A3,b92), (r3,A3,b 93), (r3,A3,b94), (r3,A 3,b95), (r3,A3,b96), (r3,A3,b97), (r3,A3,b98), (r3,A3,b99), (r3,A3,b100), (r3,A3,b101), (r3,A3,b102), (r3, A3,b103), (r3,A3,b104), (r3,A3,b105), (r3,A3,b106), (r3,A3,b107), (r3,A3,b108), (r3,A3,b109), (r3,A3,b110), (r3,A3,b111), (r3,A3,b112), (r3,A3,b113), (r3,A3,b114), (r3,A3,b115), (r3,A3,b116), (r3,A3,b117), (r3,A3,b118), (r3,A3,b119), (r3,A3,b120), (r3,A3,b121), (r3,A3,b122), (r3,A3,b123), (r3,A3,b124), (r3,A3, b125), (r3,A3,b126), (r3,A3,b127), (r3,A3,b128), (r3,A3,b129), (r3,A3,b130), (r3,A3,b131), (r3,A3,b132), (r3,A3,b133), (r3,A3,b134), (r3,A4,b1), (r3,A4,b2), (r3,A4,b 3), (r3,A4, b 4), (r3,A4,b 5), (r3,A4,b6), (r3,A 4,b7), (r3,A4,b8), (r3,A4,b9), (r3,A4,b10), (r3,A4,b11), (r3,A4,b12), (r3,A4,b13), (r3,A4,b14), (r3,A4,b15), (r3,A4,b16), (r3,A4,b17), (r3,A4,b18), (r3,A4,b19), (r3,A4,b20), (r3,A4,b21), (r3,A4,b22), (r3,A4,b23), (r3,A4,b24), (r3,A4,b25), (r3,A4,b26), (r3,A4,b27), (r3,A4,b28), (r3,A4,b29), (r3,A4,b30), (r3,A4,b31), (r3, A4,b32), (r3,A4,b33), (r3,A4,b 34), (r3,A4,b 35), (r3,A4,b 36), (r3,A4,b 37), (r3,A4,b 38), (r3,A4,b 39), (r3,A 4,b40), (r3,A4,b 41), (r3,A4,b 42), (r3,A4,b 43), (r3,A4,b 44), (r3,A4,b 45), (r3,A4,b 46), (r3,A4,b47), (r3,A4, b48), (r3,A4,b49), (r3,A4,b50), (r3,A4,b 51), (r3,A4,b 52), (r3,A4,b 53), (r3,A4,b54), (r3,A4,b 55), (r3,A4,b 56), (r3,A4,b57), (r3,A4,b 58), (r3,A4,b 59), (r3,A4,b60), (r3,A4,b 61), (r3,A4,b62), (r3,A4,b63), (r3,A4,b6 4), (r3,A4,b 65), (r3,A4,b66), (r3,A4,b67), (r3,A4,b68), (r3,A4,b69), (r3,A4,b70), (r3,A4,b 71), (r3,A4,b 72), (r3,A4,b73), (r3,A4,b 74), (r3,A4,b75), (r3,A4,b76), (r3,A4,b77), (r3,A4,b 78), (r3,A4,b 79), (r3,A4,b80), (r3,A4,b81), (r3,A4,b82), (r3,A4,b83), (r3,A4,b84), (r3,A4,b85), (r3,A4,b86), (r3,A4,b87), (r3,A4,b88), (r3, A4,b89), (r3,A4,b90), (r3,A4,b91), (r3,A4,b92), (r3,A4,b93), (r3,A4,b94), (r3,A4,b95), (r3,A4,b96), (r3,A 4,b97), (r3,A4,b98), (r3,A4,b99), (r3,A4,b100), (r3,A4,b101), (r3,A4,b102), (r3,A4,b103), (r3,A4,b104), (r3,A4,b105), (r3,A4,b106), (r3,A4,b107), (r3,A4,b108), (r3,A4,b109), (r3,A4,b110), (r3,A4,b111), (r3,A4, b112), (r3,A4,b113), (r3,A4,b114), (r3,A4,b115), (r3,A4,b116), (r3,A4,b117), (r3,A4,b118), (r3,A4,b119), (r3,A4,b120), (r3,A4,b121), (r3,A4,b122), (r3,A4,b123), (r3,A4,b124), (r3,A4,b125), (r3,A4,b126), (r3, A4,b127), (r3,A4,b128), (r3,A4,b129), (r3,A4,b130), (r3,A4,b131), (r3,A4,b132), (r3,A4,b133), (r3,A4,b134),
(r4,A1,b1), (r4,A1,b2), (r4,A1,b 3), (r4,A1,b4), (r4,A1,b 5), (r4,A1,b6), (r4,A1,b7), (r4,A1,b8), (r4,A1,b9), (r4,A1,b10), (r4,A1,b11), (r4,A1,b12), (r4,A1,b13), (r4,A1,b14), (r4,A1,b15), (r4,A1,b16), (r4,A1,b17), (r4, A1,b18), (r4,A1,b19), (r4,A1,b20), (r4,A1,b21), (r4,A1,b22), (r4,A1,b23), (r4,A1,b24), (r4,A1,b25), (r4,A 1,b26), (r4,A1,b27), (r4,A1,b28), (r4,A1,b29), (r4,A1,b30), (r4,A1,b31), (r4,A1,b32), (r4,A1,b33), (r4,A1, b34), (r4,A1,b 35), (r4,A1,b 36), (r4,A1,b37), (r4,A1,b 38), (r4,A1,b 39), (r4,A1,b40), (r4,A1,b41), (r4,A1,b 42), (r4,A1,b43), (r4,A1,b 44), (r4,A1,b 45), (r4,A1,b46), (r4,A1,b47), (r4,A1,b48), (r4,A1,b 49), (r4,A1,b 5 0), (r4,A1,b 51), (r4,A1,b52), (r4,A1,b53), (r4,A1,b 54), (r4,A1,b 55), (r4,A1,b 56), (r4,A1,b57), (r4,A1,b 58), (r4,A1,b 59), (r4,A1,b60), (r4,A1,b61), (r4,A1,b62), (r4,A1,b63), (r4,A1,b 64), (r4,A1,b65), (r4,A1,b66), (r4,A1,b67), (r4,A1,b68), (r4,A1,b69), (r4,A1,b70), (r4,A1,b71), (r4,A1,b72), (r4,A1,b73), (r4,A1,b74), (r4, A1,b75), (r4,A1,b76), (r4,A1,b77), (r4,A1,b78), (r4,A1,b79), (r4,A1,b80), (r4,A1,b81), (r4,A1,b82), (r4,A 1,b83), (r4,A1,b84), (r4,A1,b85), (r4,A1,b86), (r4,A1,b87), (r4,A1,b88), (r4,A1,b89), (r4,A1,b90), (r4,A1, b91), (r4,A1,b92), (r4,A1,b93), (r4,A1,b94), (r4,A1,b95), (r4,A1,b96), (r4,A1,b97), (r4,A1,b98), (r4,A1,b99), (r4,A1,b100), (r4,A1,b101), (r4,A1,b102), (r4,A1,b103), (r4,A1,b104), (r4,A1,b105), (r4,A1,b106), 4,A1,b107), (r4,A1,b108), (r4,A1,b109), (r4,A1,b110), (r4,A1,b111), (r4,A1,b112), (r4,A1,b113), (r4,A1, b114), (r4,A1,b115), (r4,A1,b116), (r4,A1,b117), (r4,A1,b118), (r4,A1,b119), (r4,A1,b120), (r4,A1,b121), (r4,A1,b122), (r4,A1,b123), (r4,A1,b124), (r4,A1,b125), (r4,A1,b126), (r4,A1,b127), (r4,A1,b128), (r4,A 1,b129), (r4,A1,b130), (r4,A1,b131), (r4,A1,b132), (r4,A1,b133), (r4,A1,b134), (r4,A2,b1), (r4,A2,b2), 4,A2,b 3), (r4,A2,b4), (r4,A2,b 5), (r4,A2,b6), (r4,A2,b 7), (r4,A2,b8), (r4,A2,b9), (r4,A2,b10), (r4,A2,b11), (r4,A2,b12), (r4,A2,b13), (r4,A2,b14), (r4,A2,b15), (r4,A2,b16), (r4,A2,b17), (r4,A2,b18), (r4,A2,b19), (r 4,A2,b20), (r4,A2,b21), (r4,A2,b22), (r4,A2,b23), (r4,A2,b24), (r4,A2,b 25), (r4,A2,b26), (r4,A2,b 27), (r4, A2,b28), (r4,A2,b29), (r4,A2,b 30), (r4,A2,b 31), (r4,A2,b 32), (r4,A2,b 33), (r4,A2,b 34), (r4,A2,b 35), (r4,A 2,b36), (r4,A2,b 37), (r4,A2,b38), (r4,A2,b39), (r4,A2,b40), (r4,A2,b 41), (r4,A2,b42), (r4,A2,b 43), (r4,A2, b44), (r4,A2,b45), (r4,A2,b46), (r4,A2,b47), (r4,A2,b 48), (r4,A2,b 49), (r4,A2,b50), (r4,A2,b 51), (r4,A2,b 52), (r4,A2,b 53), (r4,A2,b 54), (r4,A2,b 55), (r4,A2,b56), (r4,A2,b 57), (r4,A2,b 58), (r4,A2,b 59), (r4,A2,b6 0), (r4,A2,b61), (r4,A2,b62), (r4,A2,b63), (r4,A2,b 64), (r4,A2,b65), (r4,A2,b66), (r4,A2,b67), (r4,A2,b68), (r4,A2,b69), (r4,A2,b70), (r4,A2,b71), (r4,A2,b 72), (r4,A2,b73), (r4,A2,b 74), (r4,A2,b 75), (r4,A2,b 76), (r4,A2,b 77), (r4,A2,b 78), (r4,A2,b79), (r4,A2,b80), (r4,A2,b81), (r4,A2,b82), (r4,A2,b83), (r4,A2,b84), (r4, A2,b85), (r4,A2,b86), (r4,A2,b87), (r4,A2,b88), (r4,A2,b89), (r4,A2,b90), (r4,A2,b91), (r4,A2,b92), (r4,A 2,b93), (r4,A2,b94), (r4,A2,b 95), (r4,A2,b96), (r4,A2,b97), (r4,A2,b98), (r4,A2,b99), (r4,A2,b100), (r4,A 2,b101), (r4,A2,b102), (r4,A2,b103), (r4,A2,b104), (r4,A2,b105), (r4,A2,b106), (r4,A2,b107), (r4,A2,b10 8), (r4,A2,b109), (r4,A2,b110), (r4,A2,b111), (r4,A2,b112), (r4,A2,b113), (r4,A2,b114), (r4,A2,b115), (r4, A2,b116), (r4,A2,b117), (r4,A2,b118), (r4,A2,b119), (r4,A2,b120), (r4,A2,b121), (r4,A2,b122), (r4,A2,b1 23), (r4,A2,b124), (r4,A2,b125), (r4,A2,b126), (r4,A2,b127), (r4,A2,b128), (r4,A2,b129), (r4,A2,b130), (r 4,A2,b131), (r4,A2,b132), (r4,A2,b133), (r4,A2,b134), (r4,A3,b1), (r4,A3,b2), (r4,A3,b3), (r4,A3,b 4), (r4, A3,b 5), (r4,A3,b6), (r4,A3,b7), (r4,A3,b8), (r4,A3,b9), (r4,A3,b10), (r4,A3,b11), (r4,A3,b12), (r4,A3,b13), (r4,A3,b14), (r4,A3,b15), (r4,A3,b16), (r4,A3,b17), (r4,A3,b18), (r4,A3,b19), (r4,A3,b20), (r4,A3,b21), (r 4,A3,b22), (r4,A3,b23), (r4,A3,b24), (r4,A3,b25), (r4,A3,b 26), (r4,A3,b27), (r4,A3,b28), (r4,A3,b29), (r4, A3,b 30), (r4,A3,b 31), (r4,A3,b 32), (r4,A3,b 33), (r4,A3,b 34), (r4,A3,b35), (r4,A3,b 36), (r4,A3,b 37), (r4,A 3,b38), (r4,A3,b39), (r4,A3,b40), (r4,A3,b41), (r4,A3,b 42), (r4,A3,b 43), (r4,A3,b 44), (r4,A3,b45), (r4,A3, b46), (r4,A3,b 47), (r4,A3,b 48), (r4,A3,b 49), (r4,A3,b 50), (r4,A3,b51), (r4,A3,b52), (r4,A3,b 53), (r4,A3,b 54), (r4,A3,b 55), (r4,A3,b 56), (r4,A3,b 57), (r4,A3,b 58), (r4,A3,b 59), (r4,A3,b60), (r4,A3,b61), (r4,A3,b6 2), (r4,A3,b 63), (r4,A3,b64), (r4,A3,b65), (r4,A3,b66), (r4,A3,b67), (r4,A3,b68), (r4,A3,b69), (r4,A3,b70), (r4,A3,b 71), (r4,A3,b 72), (r4,A3,b73), (r4,A3,b 74), (r4,A3,b75), (r4,A3,b 76), (r4,A3,b 77), (r4,A3,b 78), (r4,A3,b 79), (r4,A3,b80), (r4,A3,b81), (r4,A3,b82), (r4,A3,b83), (r4,A3,b84), (r4,A3,b85), (r4,A3,b86), (r4, A3,b87), (r4,A3,b88), (r4,A3,b89), (r4,A3,b90), (r4,A3,b 91), (r4,A3,b92), (r4,A3,b 93), (r4,A3,b94), (r4,A 3,b 95), (r4,A3,b96), (r4,A3,b97), (r4,A3,b98), (r4,A3,b99), (r4,A3,b100), (r4,A3,b101), (r4,A3,b102), (r4, A3,b103), (r4,A3,b104), (r4,A3,b105), (r4,A3,b106), (r4,A3,b107), (r4,A3,b108), (r4,A3,b109), (r4,A3,b110), (r4,A3,b111), (r4,A3,b112), (r4,A3,b113), (r4,A3,b114), (r4,A3,b115), (r4,A3,b116), (r4,A3,b117), (r4,A3,b118), (r4,A3,b119), (r4,A3,b120), (r4,A3,b121), (r4,A3,b122), (r4,A3,b123), (r4,A3,b124), (r4,A3, b125), (r4,A3,b126), (r4,A3,b127), (r4,A3,b128), (r4,A3,b129), (r4,A3,b130), (r4,A3,b131), (r4,A3,b132), (r4,A3,b133), (r4,A3,b134), (r4,A4,b1), (r4,A4,b2), (r4,A4,b3), (r4,A4,b 4), (r4,A4,b 5), (r4,A4,b 6), (r4,A 4,b7), (r4,A4,b8), (r4,A4,b 9), (r4,A4,b10), (r4,A4,b11), (r4,A4,b12), (r4,A4,b13), (r4,A4,b14), (r4,A4,b15), (r4,A4,b16), (r4,A4,b17), (r4,A4,b18), (r4,A4,b19), (r4,A4,b20), (r4,A4,b21), (r4,A4,b22), (r4,A4,b23), (r4,A4,b24), (r4,A4,b25), (r4,A4,b26), (r4,A4,b27), (r4,A4,b28), (r4,A4,b29), (r4,A4,b 30), (r4,A4,b 31), (r4, A4,b 32), (r4,A4,b 33), (r4,A4,b 34), (r4,A4,b 35), (r4,A4,b 36), (r4,A4,b 37), (r4,A4,b 38), (r4,A4,b39), (r4,A 4,b40), (r4,A4,b 41), (r4,A4,b 42), (r4,A4,b43), (r4,A4,b 44), (r4,A4,b 45), (r4,A4,b46), (r4,A4,b 47), (r4,A4, b48), (r4,A4,b49), (r4,A4,b 50), (r4,A4,b51), (r4,A4,b 52), (r4,A4,b 53), (r4,A4,b54), (r4,A4,b 55), (r4,A4,b 56), (r4,A4,b 57), (r4,A4,b 58), (r4,A4,b 59), (r4,A4,b60), (r4,A4,b61), (r4,A4,b62), (r4,A4,b63), (r4,A4,b 6 4), (r4,A4,b65), (r4,A4,b66), (r4,A4,b67), (r4,A4,b68), (r4,A4,b69), (r4,A4,b 70), (r4,A4,b71), (r4,A4,b 72), (r4,A4,b 73), (r4,A4,b74), (r4,A4,b 75), (r4,A4,b76), (r4,A4,b 77), (r4,A4,b 78), (r4,A4,b 79), (r4,A4,b80), (r4,A4,b81), (r4,A4,b82), (r4,A4,b83), (r4,A4,b84), (r4,A4,b85), (r4,A4,b86), (r4,A4,b 87), (r4,A4,b88), (r4, A4,b89), (r4,A4,b90), (r4,A4,b91), (r4,A4,b92), (r4,A4,b93), (r4,A4,b94), (r4,A4,b95), (r4,A4,b96), (r4,A 4,b97), (r4,A4,b98), (r4,A4,b99), (r4,A4,b100), (r4,A4,b101), (r4,A4,b102), (r4,A4,b103), (r4,A4,b104), (r4,A4,b105), (r4,A4,b106), (r4,A4,b107), (r4,A4,b108), (r4,A4,b109), (r4,A4,b110), (r4,A4,b111), (r4,A4, b112), (r4,A4,b113), (r4,A4,b114), (r4,A4,b115), (r4,A4,b116), (r4,A4,b117), (r4,A4,b118), (r4,A4,b119), (r4,A4,b120), (r4,A4,b121), (r4,A4,b122), (r4,A4,b123), (r4,A4,b124), (r4,A4,b125), (r4,A4,b126), (r4, A4,b127), (r4,A4,b128), (r4,A4,b129), (r4,A4,b130), (r4,A4,b131), (r4,A4,b132), (r4,A4,b133), (r4,A4,b134),
(r5,A1,b1), (r5,A1,b2), (r5,A1,b3), (r5,A1,b4), (r5,A1,b5), (r5,A1,b6), (r5,A1,b7), (r5,A1,b8), (r5,A1,b9), (r5,A1,b10), (r5,A1,b11), (r5,A1,b12), (r5,A1,b13), (r5,A1,b14), (r5,A1,b15), (r5,A1,b16), (r5,A1,b17), (r5, A1,b18), (r5,A1,b19), (r5,A1,b20), (r5,A1,b21), (r5,A1,b22), (r5,A1,b23), (r5,A1,b24), (r5,A1,b25), (r5,A 1,b26), (r5,A1,b27), (r5,A1,b28), (r5,A1,b29), (r5,A1,b30), (r5,A1,b31), (r5,A1,b32), (r5,A1,b33), (r5,A1, b34), (r5,A1,b 35), (r5,A1,b36), (r5,A1,b37), (r5,A1,b 38), (r5,A1,b39), (r5,A1,b40), (r5,A1,b41), (r5,A1,b 42), (r5,A1,b43), (r5,A1,b44), (r5,A1,b45), (r5,A1,b46), (r5,A1,b47), (r5,A1,b48), (r5,A1,b49), (r5,A1,b 5 0), (r5,A1,b51), (r5,A1,b52), (r5,A1,b53), (r5,A1,b54), (r5,A1,b55), (r5,A1,b56), (r5,A1,b57), (r5,A1,b58), (r5,A1,b 59), (r5,A1,b60), (r5,A1,b61), (r5,A1,b62), (r5,A1,b63), (r5,A1,b64), (r5,A1,b65), (r5,A1,b66), (r5,A1,b67), (r5,A1,b68), (r5,A1,b69), (r5,A1,b70), (r5,A1,b71), (r5,A1,b72), (r5,A1,b73), (r5,A1,b74), (r5, A1,b75), (r5,A1,b76), (r5,A1,b77), (r5,A1,b78), (r5,A1,b79), (r5,A1,b80), (r5,A1,b81), (r5,A1,b82), (r5,A 1,b83), (r5,A1,b84), (r5,A1,b85), (r5,A1,b86), (r5,A1,b87), (r5,A1,b88), (r5,A1,b89), (r5,A1,b90), (r5,A1, b91), (r5,A1,b92), (r5,A1,b93), (r5,A1,b94), (r5,A1,b95), (r5,A1,b96), (r5,A1,b97), (r5,A1,b98), (r5,A1,b99), (r5,A1,b100), (r5,A1,b101), (r5,A1,b102), (r5,A1,b103), (r5,A1,b104), (r5,A1,b105), (r5,A1,b106), (r 5,A1,b107), (r5,A1,b108), (r5,A1,b109), (r5,A1,b110), (r5,A1,b111), (r5,A1,b112), (r5,A1,b113), (r5,A1, b114), (r5,A1,b115), (r5,A1,b116), (r5,A1,b117), (r5,A1,b118), (r5,A1,b119), (r5,A1,b120), (r5,A1,b121), (r5,A1,b122), (r5,A1,b123), (r5,A1,b124), (r5,A1,b125), (r5,A1,b126), (r5,A1,b127), (r5,A1,b128), (r5,A 1,b129), (r5,A1,b130), (r5,A1,b131), (r5,A1,b132), (r5,A1,b133), (r5,A1,b134), (r5,A2,b1), (r5,A2,b2), (r 5,A2,b3), (r5,A2,b 4), (r5,A2,b 5), (r5,A2,b6), (r5,A2,b 7), (r5,A2,b8), (r5,A2,b9), (r5,A2,b10), (r5,A2,b11), (r5,A2,b12), (r5,A2,b13), (r5,A2,b14), (r5,A2,b15), (r5,A2,b16), (r5,A2,b17), (r5,A2,b18), (r5,A2,b19), (r 5,A2,b20), (r5,A2,b21), (r5,A2,b22), (r5,A2,b23), (r5,A2,b24), (r5,A2,b25), (r5,A2,b26), (r5,A2,b27), (r5, A2,b28), (r5,A2,b 29), (r5,A2,b 30), (r5,A2,b31), (r5,A2,b 32), (r5,A2,b33), (r5,A2,b 34), (r5,A2,b35), (r5,A 2,b36), (r5,A2,b 37), (r5,A2,b 38), (r5,A2,b39), (r5,A2,b 40), (r5,A2,b 41), (r5,A2,b 42), (r5,A2,b43), (r5,A2, b44), (r5,A2,b45), (r5,A2,b 46), (r5,A2,b 47), (r5,A2,b48), (r5,A2,b 49), (r5,A2, b50), (r5,A2,b 51), (r5,A2,b 52), (r5,A2,b 53), (r5,A2,b54), (r5,A2,b 55), (r5,A2,b56), (r5,A2,b57), (r5,A2,b 58), (r5,A2,b 59), (r5,A2,b6 0), (r5,A2,b61), (r5,A2,b62), (r5,A2,b63), (r5,A2,b64), (r5,A2,b65), (r5,A2,b66), (r5,A2,b67), (r5,A2,b68), (r5,A2,b69), (r5,A2,b70), (r5,A2,b 71), (r5,A2,b 72), (r5,A2,b 73), (r5,A2,b 74), (r5,A2,b 75), (r5,A2,b 76), (r5,A2,b77), (r5,A2,b 78), (r5,A2,b79), (r5,A2,b80), (r5,A2,b81), (r5,A2,b82), (r5,A2,b83), (r5,A2,b 84), (r5, A2,b85), (r5,A2,b86), (r5,A2,b87), (r5,A2,b88), (r5,A2,b89), (r5,A2,b90), (r5,A2,b91), (r5,A2,b92), (r5,A 2,b93), (r5,A2,b94), (r5,A2,b95), (r5,A2,b96), (r5,A2,b97), (r5,A2,b98), (r5,A2,b99), (r5,A2,b100), (r5,A 2,b101), (r5,A2,b102), (r5,A2,b103), (r5,A2,b104), (r5,A2,b105), (r5,A2,b106), (r5,A2,b107), (r5,A2,b10 8), (r5,A2,b109), (r5,A2,b110), (r5,A2,b111), (r5,A2,b112), (r5,A2,b113), (r5,A2,b114), (r5,A2,b115), (r5, A2,b116), (r5,A2,b117), (r5,A2,b118), (r5,A2,b119), (r5,A2,b120), (r5,A2,b121), (r5,A2,b122), (r5,A2,b1 23), (r5,A2,b124), (r5,A2,b125), (r5,A2,b126), (r5,A2,b127), (r5,A2,b128), (r5,A2,b129), (r5,A2,b130), (r 5,A2,b131), (r5,A2,b132), (r5,A2,b133), (r5,A2,b134), (r5,A3,b1), (r5,A3,b2), (r5,A3,b3), (r5,A3,b4), (r5, A3,b5), (r5,A3,b6), (r5,A3,b7), (r5,A3,b8), (r5,A3,b9), (r5,A3,b10), (r5,A3,b11), (r5,A3,b12), (r5,A3,b13), (r5,A3,b14), (r5,A3,b15), (r5,A3,b16), (r5,A3,b17), (r5,A3,b18), (r5,A3,b19), (r5,A3,b20), (r5,A3,b21), (r 5,A3,b22), (r5,A3,b23), (r5,A3,b24), (r5,A3,b25), (r5,A3,b26), (r5,A3,b27), (r5,A3,b28), (r5,A3,b29), (r5, A3,b 30), (r5,A3,b 31), (r5,A3,b 32), (r5,A3,b 33), (r5,A3,b 34), (r5,A3,b35), (r5,A3,b 36), (r5,A3,b 37), (r5,A 3,b38), (r5,A3,b 39), (r5,A3,b40), (r5,A3,b41), (r5,A3,b42), (r5,A3,b43), (r5,A3,b44), (r5,A3,b45), (r5,A3, b46), (r5,A3,b47), (r5,A3,b48), (r5,A3,b49), (r5,A3,b 50), (r5,A3,b 51), (r5,A3,b52), (r5,A3,b 53), (r5,A3,b 54), (r5,A3,b55), (r5,A3,b 56), (r5,A3,b 57), (r5,A3,b58), (r5,A3,b 59), (r5,A3,b60), (r5,A3,b61), (r5,A3,b6 2), (r5,A3,b63), (r5,A3,b64), (r5,A3,b65), (r5,A3,b66), (r5,A3,b67), (r5,A3,b68), (r5,A3,b69), (r5,A3,b 70), (r5,A3,b71), (r5,A3,b72), (r5,A3,b73), (r5,A3,b74), (r5,A3,b75), (r5,A3,b76), (r5,A3,b77), (r5,A3,b78), (r5,A3,b 79), (r5,A3,b80), (r5,A3,b81), (r5,A3,b82), (r5,A3,b83), (r5,A3,b84), (r5,A3,b85), (r5,A3,b86), (r5, A3,b87), (r5,A3,b88), (r5,A3,b89), (r5,A3,b90), (r5,A3,b91), (r5,A3,b92), (r5,A3,b93), (r5,A3,b94), (r5,A 3,b95), (r5,A3,b96), (r5,A3,b97), (r5,A3,b98), (r5,A3,b99), (r5,A3,b100), (r5,A3,b101), (r5,A3,b102), (r5, A3,b103), (r5,A3,b104), (r5,A3,b105), (r5,A3,b106), (r5,A3,b107), (r5,A3,b108), (r5,A3,b109), (r5,A3,b110), (r5,A3,b111), (r5,A3,b112), (r5,A3,b113), (r5,A3,b114), (r5,A3,b115), (r5,A3,b116), (r5,A3,b117), (r5,A3,b118), (r5,A3,b119), (r5,A3,b120), (r5,A3,b121), (r5,A3,b122), (r5,A3,b123), (r5,A3,b124), (r5,A3, b125), (r5,A3,b126), (r5,A3,b127), (r5,A3,b128), (r5,A3,b129), (r5,A3,b130), (r5,A3,b131), (r5,A3,b132), (r5,A3,b133), (r5,A3,b134), (r5,A4,b1), (r5,A4,b2), (r5,A4,b3), (r5,A4,b4), (r5,A4,b5), (r5,A4,b6), (r5,A 4,b7), (r5,A4,b8), (r5,A4,b 9), (r5,A4,b10), (r5,A4,b11), (r5,A4,b12), (r5,A4,b13), (r5,A4,b14), (r5,A4,b15), (r5,A4,b16), (r5,A4,b17), (r5,A4,b18), (r5,A4,b19), (r5,A4,b20), (r5,A4,b21), (r5,A4,b22), (r5,A4,b23), (r5,A4,b24), (r5,A4,b25), (r5,A4,b26), (r5,A4,b27), (r5,A4,b28), (r5,A4,b29), (r5,A4,b30), (r5,A4,b31), (r5, A4,b 32), (r5,A4,b33), (r5,A4,b 34), (r5,A4,b 35), (r5,A4,b 36), (r5,A4,b 37), (r5,A4,b 38), (r5,A4,b39), (r5,A 4,b40), (r5,A4,b 41), (r5,A4,b 42), (r5,A4,b43), (r5,A4,b 44), (r5,A4,b 45), (r5,A4,b 46), (r5,A4,b47), (r5,A4, b48), (r5,A4,b 49), (r5,A4,b 50), (r5,A4,b 51), (r5,A4,b 52), (r5,A4,b 53), (r5,A4,b54), (r5,A4,b 55), (r5,A4,b 56), (r5,A4,b57), (r5,A4,b58), (r5,A4,b59), (r5,A4,b60), (r5,A4,b61), (r5,A4,b62), (r5,A4,b63), (r5,A4,b6 4), (r5,A4,b65), (r5,A4,b66), (r5,A4,b67), (r5,A4,b68), (r5,A4,b69), (r5,A4,b 70), (r5,A4,b71), (r5,A4,b72), (r5,A4,b 73), (r5,A4,b74), (r5,A4,b75), (r5,A4,b 76), (r5,A4,b77), (r5,A4,b 78), (r5,A4,b 79), (r5,A4,b80), (r5,A4,b81), (r5,A4,b82), (r5,A4,b83), (r5,A4,b84), (r5,A4,b85), (r5,A4,b86), (r5,A4,b87), (r5,A4,b88), (r5, A4,b89), (r5,A4,b90), (r5,A4,b91), (r5,A4,b 92), (r5,A4,b93), (r5,A4,b94), (r5,A4,b95), (r5,A4,b96), (r5,A 4,b97), (r5,A4,b98), (r5,A4,b99), (r5,A4,b100), (r5,A4,b101), (r5,A4,b102), (r5,A4,b103), (r5,A4,b104), (r5,A4,b105), (r5,A4,b106), (r5,A4,b107), (r5,A4,b108), (r5,A4,b109), (r5,A4,b110), (r5,A4,b111), (r5,A4, b112), (r5,A4,b113), (r5,A4,b114), (r5,A4,b115), (r5,A4,b116), (r5,A4,b117), (r5,A4,b118), (r5,A4,b119), (r5,A4,b120), (r5,A4,b121), (r5,A4,b122), (r5,A4,b123), (r5,A4,b124), (r5,A4,b125), (r5,A4,b126), (r5, A4,b127), (r5,A4,b128), (r5,A4,b129), (r5,A4,b130), (r5,A4,b131), (r5,A4,b132), (r5,A4,b133), (r5,A4,b134),
(r6,A1,b1), (r6,A1,b2), (r6,A1,b3), (r6,A1,b 4), (r6,A1,b5), (r6,A1,b6), (r6,A1,b7), (r6,A1,b8), (r6,A1,b9), (r6,A1,b10), (r6,A1,b11), (r6,A1,b12), (r6,A1,b13), (r6,A1,b14), (r6,A1,b15), (r6,A1,b16), (r6,A1,b17), (r6, A1,b18), (r6,A1,b19), (r6,A1,b20), (r6,A1,b21), (r6,A1,b22), (r6,A1,b23), (r6,A1,b24), (r6,A1,b25), (r6,A 1,b26), (r6,A1,b27), (r6,A1,b28), (r6,A1,b29), (r6,A1,b 30), (r6,A1,b31), (r6,A1,b32), (r6,A1,b33), (r6,A1, b34), (r6,A1,b35), (r6,A1,b36), (r6,A1,b37), (r6,A1,b38), (r6,A1,b39), (r6,A1,b40), (r6,A1,b41), (r6,A1,b 42), (r6,A1,b43), (r6,A1,b44), (r6,A1,b45), (r6,A1,b46), (r6,A1,b47), (r6,A1,b48), (r6,A1,b49), (r6,A1,b 5 0), (r6,A1,b51), (r6,A1,b52), (r6,A1,b53), (r6,A1,b54), (r6,A1,b55), (r6,A1,b56), (r6,A1,b57), (r6,A1,b58), (r6,A1,b59), (r6,A1,b60), (r6,A1,b61), (r6,A1,b62), (r6,A1,b63), (r6,A1,b64), (r6,A1,b65), (r6,A1,b66), (r6,A1,b67), (r6,A1,b68), (r6,A1,b69), (r6,A1,b70), (r6,A1,b71), (r6,A1,b72), (r6,A1,b73), (r6,A1,b74), (r6, A1,b75), (r6,A1,b76), (r6,A1,b77), (r6,A1,b78), (r6,A1,b79), (r6,A1,b80), (r6,A1,b81), (r6,A1,b82), (r6,A 1,b83), (r6,A1,b84), (r6,A1,b85), (r6,A1,b86), (r6,A1,b87), (r6,A1,b88), (r6,A1,b89), (r6,A1,b90), (r6,A1, b91), (r6,A1,b92), (r6,A1,b93), (r6,A1,b94), (r6,A1,b95), (r6,A1,b96), (r6,A1,b97), (r6,A1,b98), (r6,A1,b99), (r6,A1,b100), (r6,A1,b101), (r6,A1,b102), (r6,A1,b103), (r6,A1,b104), (r6,A1,b105), (r6,A1,b106), (r 6,A1,b107), (r6,A1,b108), (r6,A1,b109), (r6,A1,b110), (r6,A1,b111), (r6,A1,b112), (r6,A1,b113), (r6,A1, b114), (r6,A1,b115), (r6,A1,b116), (r6,A1,b117), (r6,A1,b118), (r6,A1,b119), (r6,A1,b120), (r6,A1,b121), (r6,A1,b122), (r6,A1,b123), (r6,A1,b124), (r6,A1,b125), (r6,A1,b126), (r6,A1,b127), (r6,A1,b128), (r6,A 1,b129), (r6,A1,b130), (r6,A1,b131), (r6,A1,b132), (r6,A1,b133), (r6,A1,b134), (r6,A2,b1), (r6,A2,b2), 6,A2,b3), (r6,A2,b 4), (r6,A2,b 5), (r6,A2,b6), (r6,A2,b7), (r6,A2,b8), (r6,A2,b9), (r6,A2,b10), (r6,A2,b11), (r6,A2,b12), (r6,A2,b13), (r6,A2,b14), (r6,A2,b15), (r6,A2,b16), (r6,A2,b17), (r6,A2,b18), (r6,A2,b19), (r 6,A2,b20), (r6,A2,b21), (r6,A2,b22), (r6,A2,b23), (r6,A2,b24), (r6,A2, b 25), (r6,A2,b26), (r6,A2,b27), (r6, A2,b28), (r6,A2,b29), (r6,A2,b 30), (r6,A2,b31), (r6,A2,b 32), (r6,A2,b33), (r6,A2,b34), (r6,A2,b35), (r6,A 2,b36), (r6,A2,b37), (r6,A2,b 38), (r6,A2,b39), (r6,A2,b 40), (r6,A2,b 41), (r6,A2,b 42), (r6,A2,b43), (r6,A2, b44), (r6,A2,b 45), (r6,A2,b 46), (r6,A2,b47), (r6,A2,b 48), (r6,A2,b 49), (r6,A2,b 50), (r6,A2,b 51), (r6,A2,b 52), (r6,A2,b53), (r6,A2,b 54), (r6,A2,b 55), (r6,A2,b56), (r6,A2,b 57), (r6,A2,b 58), (r6,A2,b 59), (r6,A2,b6 0), (r6,A2,b 61), (r6,A2,b62), (r6,A2,b63), (r6,A2,b64), (r6,A2,b65), (r6,A2,b66), (r6,A2,b67), (r6,A2,b68), (r6,A2,b69), (r6,A2,b 70), (r6,A2,b71), (r6,A2,b 72), (r6,A2,b 73), (r6,A2,b74), (r6,A2,b 75), (r6,A2,b 76), (r6,A2,b77), (r6,A2,b 78), (r6,A2,b79), (r6,A2,b80), (r6,A2,b81), (r6,A2,b82), (r6,A2,b 83), (r6,A2,b84), (r6, A2,b85), (r6,A2,b86), (r6,A2,b87), (r6,A2,b88), (r6,A2,b89), (r6,A2,b90), (r6,A2,b91), (r6,A2,b92), (r6,A 2,b93), (r6,A2,b94), (r6,A2,b95), (r6,A2,b96), (r6,A2,b97), (r6,A2,b98), (r6,A2,b99), (r6,A2,b100), (r6,A 2,b101), (r6,A2,b102), (r6,A2,b103), (r6,A2,b104), (r6,A2,b105), (r6,A2,b106), (r6,A2,b107), (r6,A2,b10 8), (r6,A2,b109), (r6,A2,b110), (r6,A2,b111), (r6,A2,b112), (r6,A2,b113), (r6,A2,b114), (r6,A2,b115), (r6, A2,b116), (r6,A2,b117), (r6,A2,b118), (r6,A2,b119), (r6,A2,b120), (r6,A2,b121), (r6,A2,b122), (r6,A2,b1 23), (r6,A2,b124), (r6,A2,b125), (r6,A2,b126), (r6,A2,b127), (r6,A2,b128), (r6,A2,b129), (r6,A2,b130), (r 6,A2,b131), (r6,A2,b132), (r6,A2,b133), (r6,A2,b134), (r6,A3,b1), (r6,A3,b2), (r6,A3,b 3), (r6,A3,b4), (r6, A3,b 5), (r6,A3,b6), (r6,A3,b7), (r6,A3,b8), (r6,A3,b9), (r6,A3,b10), (r6,A3,b11), (r6,A3,b12), (r6,A3,b13), (r6,A3,b14), (r6,A3,b15), (r6,A3,b16), (r6,A3,b17), (r6,A3,b18), (r6,A3,b19), (r6,A3,b20), (r6,A3,b21), 6,A3,b22), (r6,A3,b23), (r6,A3,b24), (r6,A3,b25), (r6,A3,b26), (r6,A3,b27), (r6,A3,b28), (r6,A3,b29), (r6, A3,b30), (r6,A3,b 31), (r6,A3,b 32), (r6,A3,b 33), (r6,A3,b34), (r6,A3,b35), (r6,A3,b 36), (r6,A3,b 37), (r6,A 3,b38), (r6,A3,b 39), (r6,A3,b40), (r6,A3,b41), (r6,A3,b 42), (r6,A3,b 43), (r6,A3,b44), (r6,A3,b45), (r6,A3, b46), (r6,A3,b 47), (r6,A3,b 48), (r6,A3,b 49), (r6,A3,b 50), (r6,A3,b 51), (r6,A3,b52), (r6,A3,b 53), (r6,A3,b 54), (r6,A3,b 55), (r6,A3,b 56), (r6,A3,b 57), (r6,A3,b 58), (r6,A3,b 59), (r6,A3,b60), (r6,A3,b61), (r6,A3,b6 2), (r6,A3,b 63), (r6,A3,b64), (r6,A3,b65), (r6,A3,b66), (r6,A3,b67), (r6,A3,b68), (r6,A3,b69), (r6,A3,b 70), (r6,A3,b 71), (r6,A3,b72), (r6,A3,b73), (r6,A3,b74), (r6,A3,b 75), (r6,A3,b 76), (r6,A3,b 77), (r6,A3,b 78), (r6,A3,b79), (r6,A3,b80), (r6,A3,b81), (r6,A3,b82), (r6,A3,b83), (r6,A3,b84), (r6,A3,b85), (r6,A3,b86), (r6, A3,b87), (r6,A3,b88), (r6,A3,b89), (r6,A3,b 90), (r6,A3,b91), (r6,A3,b 92), (r6,A3,b93), (r6,A3,b94), (r6,A 3,b95), (r6,A3,b96), (r6,A3,b97), (r6,A3,b98), (r6,A3,b99), (r6,A3,b100), (r6,A3,b101), (r6,A3,b102), (r6, A3,b103), (r6,A3,b104), (r6,A3,b105), (r6,A3,b106), (r6,A3,b107), (r6,A3,b108), (r6,A3,b109), (r6,A3,b110), (r6,A3,b111), (r6,A3,b112), (r6,A3,b113), (r6,A3,b114), (r6,A3,b115), (r6,A3,b116), (r6,A3,b117), (r6,A3,b118), (r6,A3,b119), (r6,A3,b120), (r6,A3,b121), (r6,A3,b122), (r6,A3,b123), (r6,A3,b124), (r6,A3, b125), (r6,A3,b126), (r6,A3,b127), (r6,A3,b128), (r6,A3,b129), (r6,A3,b130), (r6,A3,b131), (r6,A3,b132), (r6,A3,b133), (r6,A3,b134), (r6,A4,b (r6,A4,b2), (r6,A4,b3), (r6,A4,b4), (r6,A4,b 5), (r6,A4,b6), (r6,A 4,b 7), (r6,A4,b8), (r6,A4,b9), (r6,A4,b10), (r6,A4,b11), (r6,A4,b12), (r6,A4,b13), (r6,A4,b14), (r6,A4,b15), (r6,A4,b16), (r6,A4,b17), (r6,A4,b18), (r6,A4,b19), (r6,A4,b20), (r6,A4,b 21), (r6,A4,b22), (r6,A4,b23), (r6,A4,b24), (r6,A4,b25), (r6,A4,b26), (r6,A4,b27), (r6,A4,b28), (r6,A4,b29), (r6,A4,b 30), (r6,A4,b 31), (r6, A4,b 32), (r6,A4,b 33), (r6,A4,b 34), (r6,A4,b 35), (r6,A4,b 36), (r6,A4,b 37), (r6,A4,b 38), (r6,A4,b39), (r6,A 4,b40), (r6,A4,b 41), (r6,A4,b42), (r6,A4,b43), (r6,A4,b 44), (r6,A4,b 45), (r6,A4,b 46), (r6,A4,b 47), (r6,A4, b 48), (r6,A4,b 49), (r6,A4,b 50), (r6,A4,b 51), (r6,A4,b 52), (r6,A4,b 53), (r6,A4,b54), (r6,A4,b 55), (r6,A4,b 56), (r6,A4,b57), (r6,A4,b 58), (r6,A4,b 59), (r6,A4,b60), (r6,A4,b61), (r6,A4,b62), (r6,A4,b63), (r6,A4,b6 4), (r6,A4,b 65), (r6,A4,b66), (r6,A4,b 67), (r6,A4,b68), (r6,A4,b69), (r6,A4,b70), (r6,A4,b71), (r6,A4,b72), (r6,A4,b 73), (r6,A4,b74), (r6,A4,b75), (r6,A4,b76), (r6,A4,b 77), (r6,A4,b 78), (r6,A4,b 79), (r6,A4,b80), (r6,A4,b81), (r6,A4,b 82), (r6,A4,b83), (r6,A4,b84), (r6,A4,b 85), (r6,A4,b86), (r6,A4,b87), (r6,A4,b88), (r6, A4,b89), (r6,A4,b90), (r6,A4,b91), (r6,A4,b92), (r6,A4,b93), (r6,A4,b94), (r6,A4,b95), (r6,A4,b96), (r6,A 4,b97), (r6,A4,b98), (r6,A4,b99), (r6,A4,b100), (r6,A4,b101), (r6,A4,b102), (r6,A4,b103), (r6,A4,b104), (r6,A4,b105), (r6,A4,b106), (r6,A4,b107), (r6,A4,b108), (r6,A4,b109), (r6,A4,b110), (r6,A4,b111), (r6,A4, b112), (r6,A4,b113), (r6,A4,b114), (r6,A4,b115), (r6,A4,b116), (r6,A4,b117), (r6,A4,b118), (r6,A4,b119), (r6,A4,b120), (r6,A4,b121), (r6,A4,b122), (r6,A4,b123), (r6,A4,b124), (r6,A4,b125), (r6,A4,b126), (r6, A4,b127), (r6,A4,b128), (r6,A4,b129), (r6,A4,b130), (r6,A4,b131), (r6,A4,b132), (r6,A4,b133), (r6,A4,b134),
(r7,A1,b1), (r7,A1,b2), (r7,A1,b3), (r7,A1,b4), (r7,A1,b5), (r7,A1,b6), (r7,A1,b7), (r7,A1,b8), (r7,A1,b9), (r7,A1,b10), (r7,A1,b11), (r7,A1,b12), (r7,A1,b13), (r7,A1,b14), (r7,A1,b15), (r7,A1,b16), (r7,A1,b17), (r7, A1,b18), (r7,A1,b 19), (r7,A1,b20), (r7,A1,b21), (r7,A1,b22), (r7,A1,b23), (r7,A1,b24), (r7,A1,b25), (r7,A 1,b26), (r7,A1,b27), (r7,A1,b28), (r7,A1,b29), (r7,A1,b30), (r7,A1,b31), (r7,A1,b32), (r7,A1,b33), (r7,A1, b34), (r7,A1,b35), (r7,A1,b36), (r7,A1,b37), (r7,A1,b38), (r7,A1,b39), (r7,A1,b40), (r7,A1,b41), (r7,A1,b 42), (r7,A1,b43), (r7,A1,b44), (r7,A1,b45), (r7,A1,b46), (r7,A1,b47), (r7,A1,b48), (r7,A1,b49), (r7,A1,b5 0), (r7,A1,b51), (r7,A1,b52), (r7,A1,b53), (r7,A1,b54), (r7,A1,b55), (r7,A1,b56), (r7,A1,b57), (r7,A1,b58), (r7,A1,b59), (r7,A1,b60), (r7,A1,b61), (r7,A1,b62), (r7,A1,b63), (r7,A1,b64), (r7,A1,b65), (r7,A1,b66), (r7,A1,b67), (r7,A1,b68), (r7,A1,b69), (r7,A1,b70), (r7,A1,b71), (r7,A1,b72), (r7,A1,b73), (r7,A1,b74), (r7, A1,b75), (r7,A1,b76), (r7,A1,b77), (r7,A1,b78), (r7,A1,b79), (r7,A1,b80), (r7,A1,b81), (r7,A1,b82), (r7,A 1,b83), (r7,A1,b84), (r7,A1,b85), (r7,A1,b86), (r7,A1,b87), (r7,A1,b88), (r7,A1,b89), (r7,A1,b90), (r7,A1, b91), (r7,A1,b92), (r7,A1,b93), (r7,A1,b94), (r7,A1,b95), (r7,A1,b96), (r7,A1,b97), (r7,A1,b98), (r7,A1,b99), (r7,A1,b100), (r7,A1,b101), (r7,A1,b102), (r7,A1,b103), (r7,A1,b104), (r7,A1,b105), (r7,A1,b106), (r 7,A1,b107), (r7,A1,b108), (r7,A1,b109), (r7,A1,b110), (r7,A1,b111), (r7,A1,b112), (r7,A1,b113), (r7,A1, b114), (r7,A1,b115), (r7,A1,b116), (r7,A1,b117), (r7,A1,b118), (r7,A1,b119), (r7,A1,b120), (r7,A1,b121), (r7,A1,b122), (r7,A1,b123), (r7,A1,b124), (r7,A1,b125), (r7,A1,b126), (r7,A1,b127), (r7,A1,b128), (r7,A 1,b129), (r7,A1,b130), (r7,A1,b131), (r7,A1,b132), (r7,A1,b133), (r7,A1,b134), (r7,A2,b1), (r7,A2,b2), (r 7,A2,b3), (r7,A2,b 4), (r7,A2,b 5), (r7,A2,b6), (r7,A2,b7), (r7,A2,b8), (r7,A2,b9), (r7,A2,b10), (r7,A2,b11), (r7,A2,b12), (r7,A2,b13), (r7,A2,b14), (r7,A2,b15), (r7,A2,b16), (r7,A2,b17), (r7,A2,b18), (r7,A2,b19), (r 7,A2,b20), (r7,A2,b21), (r7,A2,b22), (r7,A2,b23), (r7,A2,b24), (r7,A2,b25), (r7,A2,b26), (r7,A2,b27), (r7, A2,b28), (r7,A2,b29), (r7,A2,b30), (r7,A2,b 31), (r7,A2,b32), (r7,A2,b33), (r7,A2,b 34), (r7,A2,b35), (r7,A 2,b36), (r7,A2,b37), (r7,A2,b 38), (r7,A2,b39), (r7,A2,b 40), (r7,A2,b 41), (r7,A2,b 42), (r7,A2,b43), (r7,A2, b44), (r7,A2, b45), (r7,A2,b 46), (r7,A2,b47), (r7,A2,b48), (r7,A2,b 49), (r7,A2,b50), (r7,A2,b 51), (r7,A2,b 52), (r7,A2,b53), (r7,A2,b 54), (r7,A2,b 55), (r7,A2,b56), (r7,A2,b 57), (r7,A2,b 58), (r7,A2,b 59), (r7,A2,b6 0), (r7,A2,b61), (r7,A2,b62), (r7,A2,b63), (r7,A2,b64), (r7,A2,b65), (r7,A2,b66), (r7,A2,b67), (r7,A2,b68), (r7,A2,b69), (r7,A2,b70), (r7,A2,b 71), (r7,A2,b 72), (r7,A2,b73), (r7,A2,b 74), (r7,A2,b 75), (r7,A2,b76), (r7,A2,b 77), (r7,A2,b 78), (r7,A2,b 79), (r7,A2,b80), (r7,A2,b81), (r7,A2,b82), (r7,A2,b83), (r7,A2,b84), (r7, A2,b85), (r7,A2,b86), (r7,A2,b87), (r7,A2,b88), (r7,A2,b89), (r7,A2,b90), (r7,A2,b91), (r7,A2,b92), (r7,A 2,b93), (r7,A2,b94), (r7,A2,b95), (r7,A2,b96), (r7,A2,b97), (r7,A2,b98), (r7,A2,b99), (r7,A2,b100), (r7,A 2,b101), (r7,A2,b102), (r7,A2,b103), (r7,A2,b104), (r7,A2,b105), (r7,A2,b106), (r7,A2,b107), (r7,A2,b10 8), (r7,A2,b109), (r7,A2,b110), (r7,A2,b111), (r7,A2,b112), (r7,A2,b113), (r7,A2,b114), (r7,A2,b115), (r7, A2,b116), (r7,A2,b117), (r7,A2,b118), (r7,A2,b119), (r7,A2,b120), (r7,A2,b121), (r7,A2,b122), (r7,A2,b1 23), (r7,A2,b124), (r7,A2,b125), (r7,A2,b126), (r7,A2,b127), (r7,A2,b128), (r7,A2,b129), (r7,A2,b130), (r 7,A2,b131), (r7,A2,b132), (r7,A2,b133), (r7,A2,b134), (r7,A3,b1), (r7,A3,b2), (r7,A3,b3), (r7,A3,b4), (r7, A3,b 5), (r7,A3,b6), (r7,A3,b7), (r7,A3,b8), (r7,A3,b9), (r7,A3,b10), (r7,A3,b11), (r7,A3,b12), (r7,A3,b13), (r7,A3,b14), (r7,A3,b15), (r7,A3,b16), (r7,A3,b17), (r7,A3,b18), (r7,A3,b19), (r7,A3,b20), (r7,A3,b21), (r 7,A3,b22), (r7,A3,b23), (r7,A3,b24), (r7,A3,b25), (r7,A3,b26), (r7,A3,b27), (r7,A3,b28), (r7,A3,b29), (r7, A3,b 30), (r7,A3,b 31), (r7,A3,b 32), (r7,A3,b33), (r7,A3,b 34), (r7,A3,b35), (r7,A3,b 36), (r7,A3,b37), (r7,A 3,b38), (r7,A3,b39), (r7,A3,b40), (r7,A3,b41), (r7,A3,b42), (r7,A3,b43), (r7,A3,b44), (r7,A3,b45), (r7,A3, b46), (r7,A3,b47), (r7,A3,b48), (r7,A3,b49), (r7,A3,b50), (r7,A3,b51), (r7,A3,b52), (r7,A3,b53), (r7,A3,b 54), (r7,A3,b55), (r7,A3,b56), (r7,A3,b57), (r7,A3,b58), (r7,A3,b59), (r7,A3,b60), (r7,A3,b61), (r7,A3,b6 2), (r7,A3,b63), (r7,A3,b64), (r7,A3,b65), (r7,A3,b66), (r7,A3,b67), (r7,A3,b68), (r7,A3,b69), (r7,A3,b70), (r7,A3,b71), (r7,A3,b72), (r7,A3,b73), (r7,A3,b74), (r7,A3,b75), (r7,A3,b76), (r7,A3,b77), (r7,A3,b78), (r7,A3,b79), (r7,A3,b 80), (r7,A3,b81), (r7,A3,b82), (r7,A3,b83), (r7,A3,b84), (r7,A3,b85), (r7,A3,b86), (r7, A3,b87), (r7,A3,b88), (r7,A3,b89), (r7,A3,b90), (r7,A3,b91), (r7,A3,b92), (r7,A3,b93), (r7,A3,b94), (r7,A 3,b95), (r7,A3,b96), (r7,A3,b97), (r7,A3,b98), (r7,A3,b99), (r7,A3,b100), (r7,A3,b101), (r7,A3,b102), (r7, A3,b103), (r7,A3,b104), (r7,A3,b105), (r7,A3,b106), (r7,A3,b107), (r7,A3,b108), (r7,A3,b109), (r7,A3,b 110), (r7,A3,b111), (r7,A3,b112), (r7,A3,b113), (r7,A3,b114), (r7,A3,b115), (r7,A3,b116), (r7,A3,b117), (r7,A3,b118), (r7,A3,b119), (r7,A3,b120), (r7,A3,b121), (r7,A3,b122), (r7,A3,b123), (r7,A3,b124), (r7,A3, b125), (r7,A3,b126), (r7,A3,b127), (r7,A3,b128), (r7,A3,b129), (r7,A3,b130), (r7,A3,b131), (r7,A3,b132), (r7,A3,b133), (r7,A3,b134), (r7,A4,b1), (r7,A4,b2), (r7,A4,b 3), (r7,A4,b4), (r7,A4,b 5), (r7,A4,b 6), (r7,A 4,b7), (r7,A4,b8), (r7,A4,b9), (r7,A4,b10), (r7,A4,b11), (r7,A4,b12), (r7,A4,b13), (r7,A4,b14), (r7,A4,b15), (r7,A4,b16), (r7,A4,b17), (r7,A4,b18), (r7,A4,b19), (r7,A4,b20), (r7,A4,b21), (r7,A4,b22), (r7,A4,b23), (r7,A4,b24), (r7,A4,b25), (r7,A4,b26), (r7,A4,b27), (r7,A4,b28), (r7,A4,b29), (r7,A4,b30), (r7,A4,b31), (r7, A4,b 32), (r7,A4,b33), (r7,A4,b34), (r7,A4,b35), (r7,A4, b36), (r7,A4,b 37), (r7,A4,b 38), (r7,A4,b39), (r7,A 4,b40), (r7,A4,b 41), (r7,A4,b42), (r7,A4,b 43), (r7,A4,b 44), (r7,A4,b 45), (r7,A4,b46), (r7,A4,b47), (r7,A4, b48), (r7,A4,b 49), (r7,A4,b50), (r7,A4,b 51), (r7,A4,b 52), (r7,A4,b 53), (r7,A4,b 54), (r7,A4,b 55), (r7,A4,b 56), (r7,A4,b57), (r7,A4,b 58), (r7,A4,b 59), (r7,A4,b60), (r7,A4,b61), (r7,A4,b62), (r7,A4,b63), (r7,A4,b6 4), (r7,A4,b 65), (r7,A4,b66), (r7,A4,b67), (r7,A4,b68), (r7,A4,b69), (r7,A4,b 70), (r7,A4,b71), (r7,A4,b 72), (r7,A4,b 73), (r7,A4,b74), (r7,A4,b75), (r7,A4,b 76), (r7,A4,b77), (r7,A4,b 78), (r7,A4,b79), (r7,A4,b80), (r7,A4,b81), (r7,A4,b82), (r7,A4,b83), (r7,A4,b84), (r7,A4,b85), (r7,A4,b86), (r7,A4,b87), (r7,A4,b88), (r7, A4,b89), (r7,A4,b90), (r7,A4,b91), (r7,A4,b92), (r7,A4,b93), (r7,A4,b94), (r7,A4,b95), (r7,A4,b96), (r7,A 4,b97), (r7,A4,b98), (r7,A4,b99), (r7,A4,b100), (r7,A4,b101), (r7,A4,b102), (r7,A4,b103), (r7,A4,b104), (r7,A4,b105), (r7,A4,b106), (r7,A4,b107), (r7,A4,b108), (r7,A4,b109), (r7,A4,b110), (r7,A4,b111), (r7,A4, b112), (r7,A4,b113), (r7,A4,b114), (r7,A4,b115), (r7,A4,b116), (r7,A4,b117), (r7,A4,b118), (r7,A4,b119), (r7,A4,b120), (r7,A4,b121), (r7,A4,b122), (r7,A4,b123), (r7,A4,b124), (r7,A4,b125), (r7,A4,b126), (r7, A4,b127), (r7,A4,b128), (r7,A4,b129), (r7,A4,b130), (r7,A4,b131), (r7,A4,b132), (r7,A4,b133), (r7,A4,b 134),
(r8,A1,b1), (r8,A1,b2), (r8,A1,b3), (r8,A1,b 4), (r8,A1,b 5), (r8,A1,b6), (r8,A1,b7), (r8,A1,b8), (r8,A1,b9), (r8,A1,b10), (r8,A1,b11), (r8,A1,b12), (r8,A1,b13), (r8,A1,b14), (r8,A1,b15), (r8,A1,b16), (r8,A1,b17), (r8, A1,b18), (r8,A1,b19), (r8,A1,b20), (r8,A1,b21), (r8,A1,b22), (r8,A1,b23), (r8,A1,b24), (r8,A1,b25), (r8,A 1,b26), (r8,A1,b 27), (r8,A1,b28), (r8,A1,b29), (r8,A1,b 30), (r8,A1,b 31), (r8,A1,b 32), (r8,A1,b33), (r8,A1, b 34), (r8,A1,b35), (r8,A1,b 36), (r8,A1,b 37), (r8,A1,b 38), (r8,A1,b 39), (r8,A1,b 40), (r8,A1,b 41), (r8,A1,b 42), (r8,A1,b 43), (r8,A1,b 44), (r8,A1,b45), (r8,A1,b46), (r8,A1,b 47), (r8,A1,b 48), (r8,A1,b 49), (r8,A1,b 5 0), (r8,A1,b51), (r8,A1,b52), (r8,A1,b53), (r8,A1,b54), (r8,A1,b55), (r8,A1,b56), (r8,A1,b57), (r8,A1,b58), (r8,A1,b59), (r8,A1,b60), (r8,A1,b61), (r8,A1,b62), (r8,A1,b63), (r8,A1,b64), (r8,A1,b65), (r8,A1,b66), (r8,A1,b67), (r8,A1,b68), (r8,A1,b69), (r8,A1,b 70), (r8,A1,b 71), (r8,A1,b72), (r8,A1,b 73), (r8,A1,b 74), (r8, A1,b 75), (r8,A1, b76), (r8,A1,b 77), (r8,A1,b 78), (r8,A1,b79), (r8,A1,b80), (r8,A1,b81), (r8,A1,b82), (r8,A 1,b83), (r8,A1,b84), (r8,A1,b85), (r8,A1,b86), (r8,A1,b87), (r8,A1,b88), (r8,A1,b89), (r8,A1,b90), (r8,A1, b91), (r8,A1,b92), (r8,A1,b93), (r8,A1,b94), (r8,A1,b95), (r8,A1,b96), (r8,A1,b97), (r8,A1,b98), (r8,A1,b 99), (r8,A1,b100), (r8,A1,b101), (r8,A1,b102), (r8,A1,b103), (r8,A1,b104), (r8,A1,b105), (r8,A1,b106), (r 8,A1,b107), (r8,A1,b108), (r8,A1,b109), (r8,A1,b110), (r8,A1,b111), (r8,A1,b112), (r8,A1,b113), (r8,A1, b114), (r8,A1,b115), (r8,A1,b116), (r8,A1,b117), (r8,A1,b118), (r8,A1,b119), (r8,A1,b120), (r8,A1,b121), (r8,A1,b122), (r8,A1,b123), (r8,A1,b124), (r8,A1,b125), (r8,A1,b126), (r8,A1,b127), (r8,A1,b128), (r8,A 1,b129), (r8,A1,b130), (r8,A1,b131), (r8,A1,b132), (r8,A1,b133), (r8,A1,b134), (r8,A2,b1), (r8,A2,b2), (r 8,A2,b3), (r8,A2,b 4), (r8,A2,b 5), (r8,A2,b6), (r8,A2,b7), (r8,A2,b8), (r8,A2,b9), (r8,A2,b10), (r8,A2,b11), (r8,A2,b12), (r8,A2,b13), (r8,A2,b14), (r8,A2,b15), (r8,A2,b16), (r8,A2,b17), (r8,A2,b18), (r8,A2,b19), (r 8,A2,b20), (r8,A2,b21), (r8,A2,b22), (r8,A2,b23), (r8,A2,b24), (r8,A2,b25), (r8,A2,b 26), (r8,A2,b 27), (r8, A2,b28), (r8,A2,b29), (r8,A2,b 30), (r8,A2,b 31), (r8,A2,b 32), (r8,A2,b 33), (r8,A2,b 34), (r8,A2,b 35), (r8,A 2,b 36), (r8,A2,b 37), (r8,A2,b 38), (r8,A2,b 39), (r8,A2,b 40), (r8,A2,b41), (r8,A2,b 42), (r8,A2,b 43), (r8,A2, b44), (r8,A2,b 45), (r8,A2,b 46), (r8,A2,b47), (r8,A2,b48), (r8,A2,b 49), (r8,A2,b50), (r8,A2,b 51), (r8,A2,b 52), (r8,A2,b53), (r8,A2,b 54), (r8,A2,b 55), (r8,A2,b56), (r8,A2,b 57), (r8,A2,b58), (r8,A2,b59), (r8,A2,b 6 0), (r8,A2,b 61), (r8,A2,b62), (r8,A2,b63), (r8,A2,b64), (r8,A2,b65), (r8,A2,b66), (r8,A2,b67), (r8,A2,b68), (r8,A2,b69), (r8,A2,b70), (r8,A2,b71), (r8,A2,b 72), (r8,A2,b 73), (r8,A2,b 74), (r8,A2,b 75), (r8,A2,b 76), (r8,A2,b77), (r8,A2,b 78), (r8,A2,b 79), (r8,A2,b80), (r8,A2,b81), (r8,A2,b82), (r8,A2,b83), (r8,A2,b84), (r8, A2,b85), (r8,A2,b86), (r8,A2,b87), (r8,A2,b88), (r8,A2,b89), (r8,A2,b 90), (r8,A2,b91), (r8,A2,b92), (r8,A 2,b93), (r8,A2,b94), (r8,A2,b95), (r8,A2,b96), (r8,A2,b97), (r8,A2,b98), (r8,A2,b99), (r8,A2,b100), (r8,A 2,b101), (r8,A2,b102), (r8,A2,b103), (r8,A2,b104), (r8,A2,b105), (r8,A2,b106), (r8,A2,b107), (r8,A2,b10 8), (r8,A2,b109), (r8,A2,b110), (r8,A2,b111), (r8,A2,b112), (r8,A2,b113), (r8,A2,b114), (r8,A2,b115), (r8, A2,b116), (r8,A2,b117), (r8,A2,b118), (r8,A2,b119), (r8,A2,b120), (r8,A2,b121), (r8,A2,b122), (r8,A2,b1 23), (r8,A2,b124), (r8,A2,b125), (r8,A2,b126), (r8,A2,b127), (r8,A2,b128), (r8,A2,b129), (r8,A2,b130), (r 8,A2,b131), (r8,A2,b132), (r8,A2,b133), (r8,A2,b134), (r8,A3,b1), (r8,A3,b2), (r8,A3,b 3), (r8,A3,b 4), (r8, A3,b 5), (r8,A3,b6), (r8,A3,b 7), (r8,A3,b8), (r8,A3,b9), (r8,A3,b10), (r8,A3,b11), (r8,A3,b12), (r8,A3,b13), (r8,A3,b14), (r8,A3,b15), (r8,A3,b16), (r8,A3,b17), (r8,A3,b18), (r8,A3,b19), (r8,A3,b20), (r8,A3,b21), (r 8,A3,b22), (r8,A3,b23), (r8,A3,b24), (r8,A3,b25), (r8,A3,b26), (r8,A3,b27), (r8,A3,b28), (r8,A3,b29), (r8, A3,b 30), (r8,A3,b 31), (r8,A3,b 32), (r8,A3,b 33), (r8,A3,b 34), (r8,A3,b35), (r8,A3,b 36), (r8,A3,b37), (r8,A 3,b 38), (r8,A3,b 39), (r8,A3,b 40), (r8,A3,b41), (r8,A3,b 42), (r8,A3,b 43), (r8,A3,b44), (r8,A3,b45), (r8,A3, b46), (r8,A3,b 47), (r8,A3,b 48), (r8,A3,b 49), (r8,A3,b 50), (r8,A3,b 51), (r8,A3,b52), (r8,A3,b 53), (r8,A3,b 54), (r8,A3,b55), (r8,A3,b56), (r8,A3,b57), (r8,A3,b58), (r8,A3,b 59), (r8,A3,b 60), (r8,A3,b61), (r8,A3,b6 2), (r8,A3,b63), (r8,A3,b64), (r8,A3,b65), (r8,A3,b66), (r8,A3,b67), (r8,A3,b68), (r8,A3,b69), (r8,A3,b 70), (r8,A3,b 71), (r8,A3,b72), (r8,A3,b73), (r8,A3,b 74), (r8,A3,b75), (r8,A3,b 76), (r8,A3,b 77), (r8,A3,b78), (r8,A3,b 79), (r8,A3,b80), (r8,A3,b81), (r8,A3,b82), (r8,A3,b83), (r8,A3,b84), (r8,A3,b85), (r8,A3,b86), (r8, A3,b87), (r8,A3,b88), (r8,A3,b89), (r8,A3,b 90), (r8,A3,b91), (r8,A3,b 92), (r8,A3,b93), (r8,A3,b94), (r8,A 3,b95), (r8,A3,b96), (r8,A3,b97), (r8,A3,b98), (r8,A3,b99), (r8,A3,b100), (r8,A3,b101), (r8,A3,b102), (r8, A3,b103), (r8,A3,b104), (r8,A3,b105), (r8,A3,b106), (r8,A3,b107), (r8,A3,b108), (r8,A3,b109), (r8,A3,b 110), (r8,A3,b111), (r8,A3,b112), (r8,A3,b113), (r8,A3,b114), (r8,A3,b115), (r8,A3,b116), (r8,A3,b117), (r8,A3,b118), (r8,A3,b119), (r8,A3,b120), (r8,A3,b121), (r8,A3,b122), (r8,A3,b123), (r8,A3,b124), (r8,A3, b125), (r8,A3,b126), (r8,A3,b127), (r8,A3,b128), (r8,A3,b129), (r8,A3,b130), (r8,A3,b131), (r8,A3,b132), (r8,A3,b133), (r8,A3,b134), (r8,A4,b1), (r8,A4,b2), (r8,A4,b3), (r8,A4,b4), (r8,A4,b 5), (r8,A4,b6), (r8,A 4,b7), (r8,A4,b8), (r8,A4,b9), (r8,A4,b10), (r8,A4,b11), (r8,A4,b12), (r8,A4,b13), (r8,A4,b14), (r8,A4,b15), (r8,A4,b16), (r8,A4,b17), (r8,A4,b18), (r8,A4,b19), (r8,A4,b20), (r8,A4,b21), (r8,A4,b22), (r8,A4,b23), (r8,A4,b24), (r8,A4,b25), (r8,A4,b26), (r8,A4,b27), (r8,A4,b 28), (r8,A4,b29), (r8,A4,b 30), (r8,A4,b 31), (r8, A4,b 32), (r8,A4,b33), (r8,A4,b34), (r8,A4,b 35), (r8,A4,b 36), (r8,A4,b 37), (r8,A4,b 38), (r8,A4,b39), (r8,A 4,b 40), (r8,A4,b 41), (r8,A4,b 42), (r8,A4,b43), (r8,A4,b 44), (r8,A4,b 45), (r8,A4,b 46), (r8,A4,b 47), (r8,A4, b48), (r8,A4,b 49), (r8,A4,b50), (r8,A4,b51), (r8,A4,b 52), (r8,A4,b 53), (r8,A4,b54), (r8,A4,b 55), (r8,A4,b 56), (r8,A4,b 57), (r8,A4,b 58), (r8,A4,b 59), (r8,A4,b60), (r8,A4,b61), (r8,A4,b62), (r8,A4,b63), (r8,A4,b6 4), (r8,A4,b65), (r8,A4,b66), (r8,A4,b67), (r8,A4,b68), (r8,A4,b69), (r8,A4,b70), (r8,A4,b 71), (r8,A4,b 72), (r8,A4,b 73), (r8,A4,b 74), (r8,A4,b75), (r8,A4,b76), (r8,A4,b77), (r8,A4,b 78), (r8,A4,b 79), (r8,A4,b80), (r8,A4,b81), (r8,A4,b82), (r8,A4,b83), (r8,A4,b84), (r8,A4,b85), (r8,A4,b86), (r8,A4,b87), (r8,A4,b 88), (r8, A4,b89), (r8,A4,b90), (r8,A4,b91), (r8,A4,b92), (r8,A4,b93), (r8,A4,b94), (r8,A4,b95), (r8,A4,b96), (r8,A 4,b97), (r8,A4,b98), (r8,A4,b99), (r8,A4,b100), (r8,A4,b101), (r8,A4,b102), (r8,A4,b103), (r8,A4,b104), (r8,A4,b105), (r8,A4,b106), (r8,A4,b107), (r8,A4,b108), (r8,A4,b109), (r8,A4,b110), (r8,A4,b111), (r8,A4, b112), (r8,A4,b113), (r8,A4,b114), (r8,A4,b115), (r8,A4,b116), (r8,A4,b117), (r8,A4,b118), (r8,A4,b119), (r8,A4,b120), (r8,A4,b121), (r8,A4,b122), (r8,A4,b123), (r8,A4,b124), (r8,A4,b125), (r8,A4,b126), (r8, A4,b127), (r8,A4,b128), (r8,A4,b129), (r8,A4,b130), (r8,A4,b131), (r8,A4,b132), (r8,A4,b133), (r8,A4,b 134),
(r9,A1,b1), (r9,A1,b2), (r9,A1,b3), (r9,A1,b4), (r9,A1,b 5), (r9,A1,b6), (r9,A1,b7), (r9,A1,b8), (r9,A1,b9), (r9,A1,b10), (r9,A1,b11), (r9,A1,b12), (r9,A1,b13), (r9,A1,b14), (r9,A1,b15), (r9,A1,b16), (r9,A1,b17), (r9, A1,b18), (r9,A1,b19), (r9,A1,b20), (r9,A1,b21), (r9,A1,b22), (r9,A1,b23), (r9,A1,b24), (r9,A1,b25), (r9,A 1,b26), (r9,A1,b27), (r9,A1,b28), (r9,A1,b29), (r9,A1,b30), (r9,A1,b31), (r9,A1,b32), (r9,A1,b33), (r9,A1, b34), (r9,A1,b35), (r9,A1,b36), (r9,A1,b37), (r9,A1,b 38), (r9,A1,b39), (r9,A1,b40), (r9,A1,b41), (r9,A1,b 42), (r9,A1,b43), (r9,A1,b44), (r9,A1,b 45), (r9,A1,b46), (r9,A1,b 47), (r9,A1,b 48), (r9,A1,b 49), (r9,A1,b 5 0), (r9,A1,b51), (r9,A1,b52), (r9,A1,b53), (r9,A1,b54), (r9,A1,b55), (r9,A1,b56), (r9,A1,b57), (r9,A1,b58), (r9,A1,b59), (r9,A1,b60), (r9,A1,b61), (r9,A1,b62), (r9,A1,b63), (r9,A1,b64), (r9,A1,b65), (r9,A1,b66), (r9,A1,b67), (r9,A1,b68), (r9,A1,b69), (r9,A1,b70), (r9,A1,b71), (r9,A1,b72), (r9,A1,b73), (r9,A1,b74), (r9, A1,b75), (r9,A1,b76), (r9,A1,b77), (r9,A1,b78), (r9,A1,b79), (r9,A1,b80), (r9,A1,b81), (r9,A1,b82), (r9,A 1,b83), (r9,A1,b84), (r9,A1,b85), (r9,A1,b86), (r9,A1,b87), (r9,A1,b88), (r9,A1,b89), (r9,A1,b90), (r9,A1, b91), (r9,A1,b92), (r9,A1,b93), (r9,A1,b94), (r9,A1,b95), (r9,A1,b96), (r9,A1,b97), (r9,A1,b98), (r9,A1,b 99), (r9,A1,b100), (r9,A1,b101), (r9,A1,b102), (r9,A1,b103), (r9,A1,b104), (r9,A1,b105), (r9,A1,b106), (r 9,A 1,b107), (r9,A1,b108), (r9,A1,b109), (r9,A1,b110), (r9,A1,b111), (r9,A1,b112), (r9,A1,b113), (r9,A1, b114), (r9,A1,b115), (r9,A1,b116), (r9,A1,b117), (r9,A1,b118), (r9,A1,b119), (r9,A1,b120), (r9,A1,b121), (r9,A1,b122), (r9,A1,b123), (r9,A1,b124), (r9,A1,b125), (r9,A1,b126), (r9,A1,b127), (r9,A1,b128), (r9,A 1,b129), (r9,A1,b130), (r9,A1,b131), (r9,A1,b132), (r9,A1,b133), (r9,A1,b134), (r9,A2,b1), (r9,A2,b2), (r 9,A2,b3), (r9,A2,b 4), (r9,A2,b 5), (r9,A2,b6), (r9,A2,b7), (r9,A2,b8), (r9,A2,b9), (r9,A2,b10), (r9,A2,b11), (r9,A2,b12), (r9,A2,b13), (r9,A2,b14), (r9,A2,b15), (r9,A2,b16), (r9,A2,b17), (r9,A2,b18), (r9,A2,b19), (r 9,A2,b20), (r9,A2,b21), (r9,A2,b22), (r9,A2,b23), (r9,A2,b24), (r9,A2,b25), (r9,A2,b26), (r9,A2,b27), (r9, A2,b28), (r9,A2,b29), (r9,A2,b 30), (r9,A2,b 31), (r9,A2,b 32), (r9,A2,b33), (r9,A2,b 34), (r9,A2,b35), (r9,A 2,b36), (r9,A2,b 37), (r9,A2,b 38), (r9,A2,b39), (r9,A2,b 40), (r9,A2,b41), (r9,A2,b 42), (r9,A2,b43), (r9,A2, b44), (r9,A2,b 45), (r9,A2,b46), (r9,A2,b 47), (r9,A2,b 48), (r9,A2,b 49), (r9,A2,b 50), (r9,A2,b 51), (r9,A2,b 52), (r9,A2,b53), (r9,A2,b 54), (r9,A2,b 55), (r9,A2,b56), (r9,A2,b 57), (r9,A2,b 58), (r9,A2,b59), (r9,A2,b6 0), (r9,A2,b61), (r9,A2,b62), (r9,A2,b63), (r9,A2,b64), (r9,A2,b65), (r9,A2,b 66), (r9,A2,b67), (r9,A2,b68), (r9,A2,b 69), (r9,A2,b 70), (r9,A2,b71), (r9,A2,b72), (r9,A2,b 73), (r9,A2,b 74), (r9,A2,b 75), (r9,A2,b 76), (r9,A2,b77), (r9,A2,b78), (r9,A2,b 79), (r9,A2,b80), (r9,A2,b81), (r9,A2,b82), (r9,A2,b83), (r9,A2,b84), (r9, A2,b85), (r9,A2,b86), (r9,A2,b 87), (r9,A2,b88), (r9,A2,b89), (r9,A2,b90), (r9,A2,b91), (r9,A2,b92), (r9,A 2,b93), (r9,A2,b94), (r9,A2,b 95), (r9,A2,b96), (r9,A2,b 97), (r9,A2,b98), (r9,A2,b99), (r9,A2,b100), (r9,A 2,b101), (r9,A2,b102), (r9,A2,b103), (r9,A2,b104), (r9,A2,b105), (r9,A2,b106), (r9,A2,b107), (r9,A2,b10 8), (r9,A2,b109), (r9,A2,b110), (r9,A2,b111), (r9,A2,b112), (r9,A2,b113), (r9,A2,b114), (r9,A2,b115), (r9, A2,b116), (r9,A2,b117), (r9,A2,b118), (r9,A2,b119), (r9,A2,b120), (r9,A2,b121), (r9,A2,b122), (r9,A2,b1 23), (r9,A2,b124), (r9,A2,b125), (r9,A2,b126), (r9,A2,b127), (r9,A2,b128), (r9,A2,b129), (r9,A2,b130), (r 9,A2,b131), (r9,A2,b132), (r9,A2,b133), (r9,A2,b134), (r9,A3,b1), (r9,A3,b2), (r9,A3,b 3), (r9,A3,b 4), (r9, A3,b 5), (r9,A3,b6), (r9,A3,b 7), (r9,A3,b8), (r9,A3,b9), (r9,A3,b10), (r9,A3,b11), (r9,A3,b12), (r9,A3,b13), (r9,A3,b14), (r9,A3,b15), (r9,A3,b16), (r9,A3,b17), (r9,A3,b18), (r9,A3,b19), (r9,A3,b20), (r9,A3,b21), (r 9,A3,b22), (r9,A3,b23), (r9,A3,b24), (r9,A3,b25), (r9,A3,b26), (r9,A3,b27), (r9,A3,b28), (r9,A3,b29), (r9, A3,b30), (r9,A3,b 31), (r9,A3,b 32), (r9,A3,b 33), (r9,A3,b 34), (r9,A3,b35), (r9,A3,b 36), (r9,A3, b37), (r9,A 3,b 38), (r9,A3,b 39), (r9,A3,b 40), (r9,A3,b41), (r9,A3,b 42), (r9,A3,b43), (r9,A3,b 44), (r9,A3,b 45), (r9,A3, b46), (r9,A3,b47), (r9,A3,b48), (r9,A3,b49), (r9,A3,b 50), (r9,A3,b 51), (r9,A3,b 52), (r9,A3,b 53), (r9,A3,b 54), (r9,A3,b55), (r9,A3,b56), (r9,A3,b57), (r9,A3,b58), (r9,A3,b 59), (r9,A3,b60), (r9,A3,b61), (r9,A3,b6 2), (r9,A3,b 63), (r9,A3,b64), (r9,A3,b65), (r9,A3,b66), (r9,A3,b67), (r9,A3,b68), (r9,A3,b69), (r9,A3,b 70), (r9,A3,b 71), (r9,A3,b72), (r9,A3,b73), (r9,A3,b 74), (r9,A3,b75), (r9,A3,b 76), (r9,A3,b 77), (r9,A3,b78), (r9,A3,b 79), (r9,A3,b80), (r9,A3,b81), (r9,A3,b82), (r9,A3,b83), (r9,A3,b84), (r9,A3,b85), (r9,A3,b86), (r9, A3,b87), (r9,A3,b88), (r9,A3,b89), (r9,A3,b90), (r9,A3,b91), (r9,A3,b92), (r9,A3,b93), (r9,A3,b94), (r9,A 3,b95), (r9,A3,b96), (r9,A3,b97), (r9,A3,b98), (r9,A3,b99), (r9,A3,b100), (r9,A3,b101), (r9,A3,b102), (r9, A3,b103), (r9,A3,b104), (r9,A3,b105), (r9,A3,b106), (r9,A3,b107), (r9,A3,b108), (r9,A3,b109), (r9,A3,b 110), (r9,A3,b111), (r9,A3,b112), (r9,A3,b113), (r9,A3,b114), (r9,A3,b115), (r9,A3,b116), (r9,A3,b117), (r9,A3,b118), (r9,A3,b119), (r9,A3,b120), (r9,A3,b121), (r9,A3,b122), (r9,A3,b123), (r9,A3,b124), (r9,A3, b125), (r9,A3,b126), (r9,A3,b127), (r9,A3,b128), (r9,A3,b129), (r9,A3,b130), (r9,A3,b131), (r9,A3,b132), (r9,A3,b133), (r9,A3,b134), (r9,A4,b1), (r9,A4,b2), (r9,A4,b3), (r9,A4,b4), (r9,A4,b5), (r9,A4,b 6), (r9,A 4,b7), (r9,A4,b8), (r9,A4,b9), (r9,A4,b10), (r9,A4,b11), (r9,A4,b12), (r9,A4,b13), (r9,A4,b14), (r9,A4,b15), (r9,A4,b16), (r9,A4,b17), (r9,A4,b18), (r9,A4,b19), (r9,A4,b20), (r9,A4,b21), (r9,A4,b22), (r9,A4,b23), (r9,A4,b24), (r9,A4,b25), (r9,A4,b26), (r9,A4,b27), (r9,A4,b28), (r9,A4,b29), (r9,A4,b 30), (r9,A4,b 31), (r9, A4,b 32), (r9,A4,b 33), (r9,A4,b 34), (r9,A4,b 35), (r9,A4,b 36), (r9,A4,b 37), (r9,A4,b 38), (r9,A4,b39), (r9,A 4,b40), (r9,A4,b 41), (r9,A4,b 42), (r9,A4,b43), (r9,A4,b44), (r9,A4,b 45), (r9,A4,b 46), (r9,A4,b 47), (r9,A4, b48), (r9,A4,b49), (r9,A4,b50), (r9,A4,b 51), (r9,A4,b 52), (r9,A4,b 53), (r9,A4,b54), (r9,A4,b55), (r9,A4,b 56), (r9,A4,b57), (r9,A4,b58), (r9,A4,b 59), (r9,A4,b60), (r9,A4,b 61), (r9,A4,b62), (r9,A4,b63), (r9,A4,b6 4), (r9,A4,b 65), (r9,A4,b66), (r9,A4,b67), (r9,A4,b 68), (r9,A4,b69), (r9,A4,b70), (r9,A4,b71), (r9,A4,b 72), (r9,A4,b 73), (r9,A4,b74), (r9,A4,b75), (r9,A4,b 76), (r9,A4,b77), (r9,A4,b 78), (r9,A4,b 79), (r9,A4,b80), (r9,A4,b81), (r9,A4,b82), (r9,A4,b83), (r9,A4,b84), (r9,A4,b85), (r9,A4,b86), (r9,A4,b87), (r9,A4,b88), (r9, A4,b89), (r9,A4,b90), (r9,A4,b 91), (r9,A4,b92), (r9,A4,b93), (r9,A4,b94), (r9,A4,b95), (r9,A4,b96), (r9,A 4,b97), (r9,A4,b98), (r9,A4,b99), (r9,A4,b100), (r9,A4,b101), (r9,A4,b102), (r9,A4,b103), (r9,A4,b104), (r9,A4,b105), (r9,A4,b106), (r9,A4,b107), (r9,A4,b108), (r9,A4,b109), (r9,A4,b110), (r9,A4,b111), (r9,A4, b112), (r9,A4,b113), (r9,A4,b114), (r9,A4,b115), (r9,A4,b116), (r9,A4,b117), (r9,A4,b118), (r9,A4,b119), (r9,A4,b120), (r9,A4,b121), (r9,A4,b122), (r9,A4,b123), (r9,A4,b124), (r9,A4,b125), (r9,A4,b126), (r9, A4,b127), (r9,A4,b128), (r9,A4,b129), (r9,A4,b130), (r9,A4,b131), (r9,A4,b132), (r9,A4,b133), (r9,A4,b 134),
(r10,A1,b1), (r10,A1,b2), (r10,A1,b3), (r10,A1,b4), (r10,A1,b5), (r10,A1,b6), (r10,A1,b7), (r10,A1,b8), (r 10,A1,b9), (r10,A1,b10), (r10,A1,b11), (r10,A1,b12), (r10,A1,b13), (r10,A1,b14), (r10,A1,b15), (r10,A1, b16), (r10,A1,b17), (r10,A1,b18), (r10,A1,b19), (r10,A1,b20), (r10,A1,b21), (r10,A1,b22), (r10,A1,b23), (r10,A1,b24), (r10,A1,b25), (r10,A1,b26), (r10,A1,b27), (r10,A1,b28), (r10,A1,b29), (r10,A1,b30), (r10, A1,b31), (r10,A1,b32), (r10,A1,b33), (r10,A1,b34), (r10,A1,b35), (r10,A1,b36), (r10,A1,b37), (r10,A1,b 38), (r10,A1,b39), (r10,A1,b40), (r10,A1,b41), (r10,A1,b42), (r10,A1,b43), (r10,A1,b44), (r10,A1,b45), (r 10,A1,b46), (r10,A1,b47), (r10,A1,b48), (r10,A1,b49), (r10,A1,b50), (r10,A1,b51), (r10,A1,b52), (r10,A 1,b53), (r10,A1,b54), (r10,A1,b55), (r10,A1,b56), (r10,A1,b57), (r10,A1,b58), (r10,A1,b59), (r10,A1,b60), (r10,A1,b61), (r10,A1,b62), (r10,A1,b63), (r10,A1,b64), (r10,A1,b65), (r10,A1,b66), (r10,A1,b67), (r10, A1,b68), (r10,A1,b69), (r10,A1,b70), (r10,A1,b71), (r10,A1,b72), (r10,A1,b73), (r10,A1,b74), (r10,A1,b 75), (r10,A1,b76), (r10,A1,b77), (r10,A1,b78), (r10,A1,b79), (r10,A1,b80), (r10,A1,b81), (r10,A1,b82), (r 10,A1,b83), (r10,A1,b84), (r10,A1,b85), (r10,A1,b86), (r10,A1,b87), (r10,A1,b88), (r10,A1,b89), (r10,A 1,b90), (r10,A1,b91), (r10,A1,b92), (r10,A1,b93), (r10,A1,b94), (r10,A1,b95), (r10,A1,b96), (r10,A1,b97), (r10,A1,b98), (r10,A1,b99), (r10,A1,b 100), (r10,A1,b101), (r10,A1,b102), (r10,A1,b 103), (r10,A1,b10 4), (r10,A1,b105), (r10,A1,b106), (r10,A1,b107), (r10,A1,b108), (r10,A1,b109), (r10,A1,b110), (r10,A1, b111), (r10,A1,b112), (r10,A1,b113), (r10,A1,b114), (r10,A1,b115), (r10,A1,b116), (r10,A1,b117), (r10, A1,b118), (r10,A1,b119), (r10,A1,b120), (r10,A1,b121), (r10,A1,b122), (r10,A1,b123), (r10,A1,b124), (r 10,A1,b125), (r10,A1,b126), (r10,A1,b127), (r10,A1,b128), (r10,A1,b129), (r10,A1,b130), (r10,A1,b131), (r10,A1,b132), (r10,A1,b133), (r10,A1,b134), (r10,A2,b1), (r10,A2,b2), (r10,A2,b3), (r10,A2,b4), (r10, A2,b5), (r10,A2,b6), (r10,A2,b7), (r10,A2,b8), (r10,A2,b9), (r10,A2,b10), (r10,A2,b11), (r10,A2,b12), (r1 0,A2,b13), (r10,A2,b14), (r10,A2,b15), (r10,A2,b16), (r10,A2,b17), (r10,A2,b18), (r10,A2,b19), (r10,A2, b20), (r10,A2,b21), (r10,A2,b22), (r10,A2,b23), (r10,A2,b24), (r10,A2,b25), (r10,A2,b26), (r10,A2,b27), (r10,A2,b28), (r10,A2,b29), (r10,A2,b30), (r10,A2,b31), (r10,A2,b32), (r10,A2,b33), (r10,A2,b34), (r10, A2,b35), (r10,A2,b36), (r10,A2,b37), (r10,A2,b 38), (r10,A2,b39), 10,A2,b40), (r10,A2,b41), (r10,A2,b 42), (r10,A2,b43), (r10,A2,b44), (r10,A2,b45), (r10,A2,b46), (r10,A2,b47), 10,A2,b48), (r10,A2,b 49), (r 10,A2,b50), (r10,A2,b51), (r10,A2,b52), (r10,A2,b53), (r10,A2,b54), (r10,A2,b55), (r10,A2,b56), (r10,A 2,b57), (r10,A2,b58), (r10,A2,b59), (r10,A2,b60), (r10,A2,b61), (r10,A2,b62), (r10,A2,b63), (r10,A2,b64), (r10,A2,b65), (r10,A2,b66), (r10,A2,b67), (r10,A2,b68), (r10,A2,b69), (r10,A2,b70), (r10,A2,b71), (r10, A2,b72), (r10,A2,b73), (r10,A2,b74), (r10,A2,b75), (r10,A2,b76), (r10,A2,b77), (r10,A2,b78), (r10,A2,b 79), (r10,A2,b80), (r10,A2,b81), (r10,A2,b82), (r10,A2,b83), (r10,A2,b84), (r10,A2,b85), (r10,A2,b86), 10,A2,b87), (r10,A2,b88), (r10,A2,b89), (r10,A2,b90), (r10,A2,b91), (r10,A2,b92), (r10,A2,b93), (r10,A 2,b94), (r10,A2,b95), (r10,A2,b96), (r10,A2,b97), (r10,A2,b98), (r10,A2,b99), (r10,A2,b100), (r10,A2,b1 01), (r10,A2,b102), (r10,A2,b103), (r10,A2,b104), (r10,A2,b105), (r10,A2,b106), (r10,A2,b107), (r10,A2, b108), (r10,A2,b109), (r10,A2,b110), (r10,A2,b111), (r10,A2,b112), (r10,A2,b113), (r10,A2,b114), (r10, A2,b115), (r10,A2,b116), (r10,A2,b117), (r10,A2,b118), (r10,A2,b119), (r10,A2,b120), (r10,A2,b121), (r 10,A2,b122), (r10,A2,b123), (r10,A2,b124), (r10,A2,b125), (r10,A2,b126), (r10,A2,b127), (r10,A2,b128), (r10,A2,b129), (r10,A2,b130), (r10,A2,b131), (r10,A2,b132), (r10,A2,b133), (r10,A2,b134), (r10,A3,b 1), (r10,A3,b2), 10,A3,b3), (r10,A3,b4), (r10,A3,b5), (r10,A3,b6), (r10,A3,b7), (r10,A3,b8), (r10,A3,b9), (r10,A3,b10), (r10,A3,b11), (r10,A3,b12), (r10,A3,b13), (r10,A3,b14), (r10,A3,b15), (r10,A3,b16), (r10, A3,b17), (r10,A3,b18), (r10,A3,b19), (r10,A3,b20), (r10,A3,b21), (r10,A3,b22), (r10,A3,b23), (r10,A3,b 24), (r10,A3,b25), (r10,A3,b26), (r10,A3,b27), (r10,A3,b28), (r10,A3,b29), (r10,A3,b30), (r10,A3,b31), (r 10,A3,b32), (r10,A3,b33), (r10,A3,b34), (r10,A3,b35), (r10,A3,b36), (r10,A3,b37), (r10,A3,b38), (r10,A 3,b39), (r10,A3,b40), (r10,A3,b41), (r10,A3,b42), (r10,A3,b43), (r10,A3,b44), (r10,A3,b45), (r10,A3,b46), (r10,A3,b47), (r10,A3,b48), (r10,A3,b49), (r10,A3,b50), (r10,A3,b51), (r10,A3,b52), (r10,A3,b53), (r10, A3,b54), (r10,A3,b55), (r10,A3,b56), (r10,A3,b57), (r10,A3,b58), (r10,A3,b59), (r10,A3,b60), 10,A3,b 61), (r10,A3,b62), (r10,A3,b63), (r10,A3,b64), (r10,A3,b65), 10,A3,b66), (r10,A3,b67), (r10,A3,b68), 10,A3,b69), (r10,A3,b70), (r10,A3,b71), (r10,A3,b72), (r10,A3,b73), (r10,A3,b74), (r10,A3,b75), (r10,A 3,b76), (r10,A3,b77), (r10,A3,b78), (r10,A3,b79), (r10,A3,b80), (r10,A3,b81), (r10,A3,b82), (r10,A3,b83), (r10,A3,b84), (r10,A3,b85), (r10,A3,b86), (r10,A3,b87), (r10,A3,b88), (r10,A3,b89), (r10,A3,b90), (r10, A3,b91), (r10,A3,b92), (r10,A3,b93), (r10,A3,b94), (r10,A3,b95), (r10,A3,b96), (r10,A3,b97), (r10,A3,b 98), (r10,A3,b99), (r10,A3,b100), (r10,A3,b101), (r10,A3,b102), (r10,A3,b103), (r10,A3,b104), (r10,A3, b105), (r10,A3,b106), (r10,A3,b107), (r10,A3,b108), (r10,A3,b109), (r10,A3,b110), (r10,A3,b111), (r10, A3,b112), (r10,A3,b113), (r10,A3,b114), (r10,A3,b115), (r10,A3,b116), (r10,A3,b117), (r10,A3,b118), (r 10,A3,b119), (r10,A3,b120), (r10,A3,b121), (r10,A3,b122), (r10,A3,b123), (r10,A3,b124), (r10,A3,b125), (r10,A3,b126), (r10,A3,b127), (r10,A3,b128), (r10,A3,b129), (r10,A3,b130), (r10,A3,b131), (r10,A3,b 132), (r10,A3,b133), (r10,A3,b134), (r10,A4,b1), (r10,A4,b2), (r10,A4,b3), (r10,A4,b4), (r10,A4,b5), (r10, A4,b6), (r10,A4,b7), (r10,A4,b8), (r10,A4,b9), (r10,A4,b10), (r10,A4,b11), (r10,A4,b12), (r10,A4,b13), (r10,A4,b14), (r10,A4,b15), (r10,A4,b16), (r10,A4,b17), (r10,A4,b18), (r10,A4,b19), (r10,A4,b20), (r10, A4,b21), (r10,A4,b22), (r10,A4,b23), (r10,A4,b24), (r10,A4,b25), (r10,A4,b26), (r10,A4,b27), (r10,A4,b 28), (r10,A4,b29), (r10,A4,b30), (r10,A4,b31), (r10,A4,b32), (r10,A4,b33), (r10,A4,b34), (r10,A4,b35), (r 10,A4,b36), (r10,A4,b37), (r10,A4,b38), (r10,A4,b39), (r10,A4,b40), (r10,A4,b41), (r10,A4,b42), (r10,A 4,b43), (r10,A4,b44), (r10,A4,b45), (r10,A4,b46), 10,A4,b47), (r10,A4,b48), (r10,A4,b49), (r10,A4,b50), (r10,A4,b51), (r10,A4,b52), (r10,A4,b53), (r10,A4,b54), (r10,A4,b55), (r10,A4,b56), (r10,A4,b57), (r10, A4,b58), (r10,A4,b59), (r10,A4,b60), (r10,A4,b61), (r10,A4,b62), (r10,A4,b63), (r10,A4,b64), (r10,A4,b 65), (r10,A4,b66), (r10,A4,b67), (r10,A4,b68), (r10,A4,b69), (r10,A4,b70), (r10,A4,b71), (r10,A4,b72), 10,A4,b73), (r10,A4,b74), (r10,A4,b75), (r10,A4,b76), (r10,A4,b77), (r10,A4,b78), (r10,A4,b79), (r10,A 4,b80), (r10,A4,b81), (r10,A4,b82), (r10,A4,b83), (r10,A4,b84), (r10,A4,b85), (r10,A4,b86), (r10,A4,b87), (r10,A4,b88), (r10,A4,b89), (r10,A4,b90), (r10,A4,b91), (r10,A4,b92), (r10,A4,b93), (r10,A4,b94), (r10, A4,b95), (r10,A4,b96), (r10,A4,b97), (r10,A4,b98), (r10,A4,b99), (r10,A4,b100), (r10,A4,b101), (r10,A 4,b102), (r10,A4,b103), (r10,A4,b104), (r10,A4,b105), (r10,A4,b106), (r10,A4,b107), (r10,A4,b108), (r1 0,A4,b109), (r10,A4,b110), (r10,A4,b111), (r10,A4,b112), (r10,A4,b113), (r10,A4,b114), (r10,A4,b115), (r10,A4,b116), (r10,A4,b117), (r10,A4,b118), (r10,A4,b119), (r10,A4,b120), (r10,A4,b121), (r10,A4,b12 2), (r10,A4,b123), (r10,A4,b124), (r10,A4,b125), (r10,A4,b126), (r10,A4,b127), (r10,A4,b128), (r10,A4, b129), (r10,A4,b130), (r10,A4,b131), (r10,A4,b132), (r10,A4,b133), (r10,A4,b134),
(r11,A1,b1), (r11,A1,b2), (r11,A1,b3), (r11,A1,b4), (r11,A1,b5), (r11,A1,b6), (r11,A1,b7), (r11,A1,b8), (r1 1,A1,b9), (r11,A1,b10), (r11,A1,b11), (r11,A1,b12), (r11,A1,b13), (r11,A1,b14), (r11,A1,b15), (r11,A1,b1 6), (r11,A1,b17), (r11,A1,b18), (r11,A1,b19), (r11,A1,b20), (r11,A1,b21), (r11,A1,b22), (r11,A1,b23), (r1 1,A1,b24), (r11,A1,b25), (r11,A1,b26), (r11,A1,b27), (r11,A1,b28), (r11,A1,b29), (r11,A1,b30), (r11,A1, b31), (r11,A1,b32), (r11,A1,b33), (r11,A1,b34), (r11,A1,b35), (r11,A1,b36), (r11,A1,b37), (r11,A1,b38), (r11,A1,b39), (r11,A1,b40), (r11,A1,b41), (r11,A1,b42), (r11,A1,b43), (r11,A1,b44), (r11,A1,b45), (r11,A 1,b46), (r11,A1,b47), (r11,A1,b48), (r11,A1,b49), (r11,A1,b50), (r11,A1,b51), (r11,A1,b52), (r11,A1,b53) (r11,A1,b54), (r11,A1,b55), (r11,A1,b56), (r11,A1,b57), (r11,A1,b58), (r11,A1,b59), (r11,A1,b60), (r11, A1,b61), (r11,A1,b62), (r11,A1,b63), (r11,A1,b64), (r11,A1,b65), (r11,A1,b66), (r11,A1,b67), (r11,A1,b6 8), (r11,A1,b69), (r11,A1,b70), (r11,A1,b71), (r11,A1,b72), (r11,A1,b73), (r11,A1,b74), (r11,A1,b75), (r1 1,A1,b76), (r11,A1,b77), (r11,A1,b78), (r11,A1,b79), (r11,A1,b80), (r11,A1,b81), (r11,A1,b82), (r11,A1, b83), (r11,A1,b84), (r11,A1,b85), (r11,A1,b86), (r11,A1,b87), (r11,A1,b88), (r11,A1,b89), (r11,A1,b90), (r11,A1,b91), (r11,A1,b92), (r11,A1,b93), (r11,A1,b94), (r11,A1,b95), (r11,A1,b96), (r11,A1,b97), (r11,A 1,b98), (r11,A1,b99), (r11,A1,b100), (r11,A1,b101), (r11,A1,b102), (r11,A1,b103), (r11,A1,b104), (r11,A 1,b105), (r11,A1,b106), (r11,A1,b107), (r11,A1,b108), (r11,A1,b109), (r11,A1,b110), (r11,A1,b111), (r11, A1,b112), (r11,A1,b113), (r11,A1,b114), (r11,A1,b115), (r11,A1,b116), (r11,A1,b117), (r11,A1,b118), (r 11,A1,b119), (r11,A1,b120), (r11,A1,b121), (r11,A1,b122), (r11,A1,b123), (r11,A1,b124), (r11,A1,b125) (r11,A1,b126), (r11,A1,b127), (r11,A1,b128), (r11,A1,b129), (r11,A1,b130), (r11,A1,b131), (r11,A1,b1 32), (r11,A1,b133), (r11,A1,b134), (r11,A2,b1), (r11,A2,b2), (r11,A2,b3), (r11,A2,b4), (r11,A2,b5), (r11,A 2,b6), (r11,A2,b7), (r11,A2,b8), (r11,A2,b9), (r11,A2,b10), (r11,A2,b11), (r11,A2,b12), (r11,A2,b13), (r11, A2,b14), (r11,A2,b15), (r11,A2,b16), (r11,A2,b17), (r11,A2,b18), (r11,A2,b19), (r11,A2,b20), (r11,A2,b 21), (r11,A2,b22), (r11,A2,b23), (r11,A2,b24), (r11,A2,b25), (r11,A2,b26), 11,A2,b27), (r11,A2,b28), 11,A2,b29), (r11,A2,b30), (r11,A2,b31), (r11,A2,b32), (r11,A2,b33), (r11,A2,b34), (r11,A2,b35), (r11,A2, b36), 11,A2,b 37), (r11,A2,b 38), (r11,A2,b39), (r11,A2,b40), (r11,A2,b41), 11,A2,b42), 11,A2,b43), (r11,A2,b44), (r11,A2,b45), (r11,A2,b46), (r11,A2,b47), (r11,A2,b48), (r11,A2,b49), (r11,A2,b50), (r11,A 2,b51), (r11,A2,b52), (r11,A2,b53), (r11,A2,b54), (r11,A2,b55), (r11,A2,b56), (r11,A2,b57), (r11,A2,b58) (r11,A2,b59), (r11,A2,b60), (r11,A2,b61), (r11,A2,b62), (r11,A2,b63), (r11,A2,b64), (r11,A2,b65), (r11, A2,b66), 11,A2,b67), (r11,A2,b68), (r11,A2,b69), (r11,A2,b70), (r11,A2,b71), (r11,A2,b72), (r11,A2,b7 3), (c11,A2,b74), 11,A2,b75), (r11,A2,b76), (r11,A2,b77), (r11,A2,b78), 11,A2,b79), (r11,A2,b80), (r1 1,A2,b81), (r11,A2,b82), (r11,A2,b83), (r11,A2,b84), (r11,A2,b85), 11,A2,b86), 11,A2,b87), 11,A2, b88), (r11,A2,b89), (r11,A2,b90), (r11,A2,b91), (r11,A2,b92), (r11,A2,b93), (r11,A2,b94), (r11,A2,b95), (r11,A2,b96), (r11,A2,b97), (r11,A2,b98), (r11,A2,b99), (r11,A2,b100), (r11,A2,b101), (r11,A2,b102), (r1 1,A2,b103), (r11,A2,b104), (r11,A2,b105), (r11,A2,b106), (r11,A2,b107), (r11,A2,b108), (r11,A2,b109), (r11,A2,b110), (r11,A2,b111), (r11,A2,b112), (r11,A2,b113), (r11,A2,b114), (r11,A2,b115), (r11,A2,b116), (r11,A2,b117), (r11,A2,b118), (r11,A2,b119), (r11,A2,b120), (r11,A2,b121), (r11,A2,b122), (r11,A2,b1 23), (r11,A2,b124), (r11,A2,b125), (r11,A2,b126), (r11,A2,b127), (r11,A2,b128), (r11,A2,b129), (r11,A2, b130), (r11,A2,b131), (r11,A2,b132), (r11,A2,b133), (r11,A2,b134), (r11,A3,b1), (r11,A3,b2), (r11,A3,b3), (r11,A3,b 4), (r11,A3,b5), (r11,A3,b6), (r11,A3,b7), (r11,A3,b8), (r11,A3,b9), (r11,A3,b10), (r11,A3,b11) (r11,A3,b12), (r11,A3,b13), (r11,A3,b14), (r 11,A3,b15), (r11,A3,b16), (r11,A3,b17), (r11,A3,b18), (r11, A3,b19), (r11,A3,b20), (r11,A3,b21), (r11,A3,b22), (r11,A3,b23), (r11,A3,b24), (r11,A3,b25), (r11,A3,b2 6), (r11,A3,b27), 11,A3,b28), 11,A3,b29), (r11,A3,b 30), 11,A3,b31), (r11,A3,b32), (r11,A3,b33), (r1 1,A3,b34), (r11,A3,b35), (r11,A3,b36), (r11,A3,b37), (r11,A3,b38), (r11,A3,b39), (r11,A3,b40), (r11,A3, b41), (r11,A3,b42), (r11,A3,b43), (r11,A3,b44), (r11,A3,b45), (r11,A3,b46), (r11,A3,b47), (r11,A3,b48), (r11,A3,b49), (r11,A3,b50), (r11,A3,b51), (r11,A3,b52), (r11,A3,b53), (r11,A3,b54), (r11,A3,b55), (r11,A 3,b56), (r11,A3,b57), (r11,A3,b58), (r11,A3,b59), (r11,A3,b60), (r11,A3,b61), (r11,A3,b62), (r11,A3,b63), (r11,A3,b64), (r11,A3,b65), (r11,A3,b66), (r11,A3,b67), (r11,A3,b68), (r11,A3,b69), (r11,A3,b70), (r11, A3,b71), (r11,A3,b72), (r11,A3,b73), (r11,A3,b74), (r11,A3,b75), (r11,A3,b76), (r11,A3,b77), (r11,A3,b7 8), (r11,A3,b79), (r11,A3,b80), (r11,A3,b81), (r11,A3,b82), (r11,A3,b83), (r11,A3,b84), (r11,A3,b85), (r1 1,A3,b86), (r11,A3,b87), (r11,A3,b88), (r11,A3,b89), (r11,A3,b90), (r11,A3,b91), (r11,A3,b92), (r11,A3, b93), (r11,A3,b94), (r11,A3,b95), (r11,A3,b96), (r11,A3,b97), (r11,A3,b98), (r11,A3,b99), (r11,A3,b100), (r11,A3,b101), (r11,A3,b102), (r11,A3,b103), (r11,A3,b104), (r11,A3,b105), (r11,A3,b106), (r11,A3,b10 7), (r11,A3,b108), (r11,A3,b109), (r11,A3,b110), (r11,A3,b111), (r11,A3,b112), (r11,A3,b113), (r11,A3,b 114), (r11,A3,b115), (r11,A3,b116), (r11,A3,b117), (r11,A3,b118), (r11,A3,b119), (r11,A3,b120), (r11,A3, b121), (r11,A3,b122), (r11,A3,b123), (r11,A3,b124), (r11,A3,b125), (r11,A3,b126), (r11,A3,b127), (r11, A3,b128), (r11,A3,b129), (r11,A3,b130), (r11,A3,b131), (r11,A3,b132), (r11,A3,b133), (r11,A3,b134), (r 11,A4,b1), (r11,A4,b2), (r11,A4,b3), (r11,A4,b4), 11,A4,b5), (r11,A4,b6), (r11,A4,b7), (r11,A4,b8), (r11, A4,b9), (r11,A4,b10), (r11,A4,b11), (r11,A4,b12), (r11,A4,b13), (r11,A4,b14), (r11,A4,b15), (r11,A4,b16), (r11,A4,b17), (r11,A4,b18), (r11,A4,b19), (r11,A4,b20), (r11,A4,b21), (r11,A4,b22), (r11,A4,b23), (r11, A4,b24), (r11,A4,b25), (r11,A4,b26), (r11,A4,b27), (r11,A4,b28), (r11,A4,b29), (r11,A4,b30), (r11,A4,b3 1), (r11,A4,b32), (r11,A4,b33), (r11,A4,b34), (r11,A4,b35), (r11,A4,b36), (r11,A4,b37), (r11,A4,b38), (r1 1,A4,b39), (r11,A4,b40), (r11,A4,b41), (r11,A4,b42), (r11,A4,b43), (r11,A4,b44), (r11,A4,b45), (r11,A4, b46), (r11,A4,b47), (r11,A4,b48), (r11,A4,b49), (r11,A4,b50), (r11,A4,b51), (r11,A4,b52), (r11,A4,b53), (r11,A4,b54), (r11,A4,b55), (r11,A4,b56), (r11,A4,b 57), (r11,A4,b58), (r11,A4,b59), 11,A4,b 60), (r11,A 4,b61), (r11,A4,b62), (r11,A4,b63), (r11,A4,b64), (r11,A4,b65), (r11,A4,b66), (r11,A4,b67), (r11,A4,b68) (r11,A4,b69), (r11,A4,b70), (r11,A4,b71), (r11,A4,b72), (r11,A4,b73), (r11,A4,b74), (r11,A4,b75), (r11, A4,b76), (r11,A4,b77), (r11,A4,b78), (r11,A4,b79), (r11,A4,b80), (r11,A4,b81), (r11,A4,b82), (r11,A4,b8 3), (r11,A4,b84), (r11,A4,b85), (r11,A4,b86), (r11,A4,b87), (r11,A4,b88), (r11,A4,b89), (r11,A4,b90), (r1 1,A4,b91), (r11,A4,b92), (r11,A4,b93), (r11,A4,b94), (r11,A4,b95), (r11,A4,b96), (r11,A4,b97), (r11,A4, b98), (r11,A4,b99), (r11,A4,b100), (r11,A4,b101), (r11,A4,b102), (r11,A4,b103), (r11,A4,b104), (r11,A4, b105), (r11,A4,b106), (r11,A4,b107), (r11,A4,b108), (r11,A4,b109), (r11,A4,b110), (r11,A4,b111), (r11,A 4,b112), (r11,A4,b113), (r11,A4,b114), (r11,A4,b115), (r11,A4,b116), (r11,A4,b117), (r11,A4,b118), (r11, A4,b119), (r11,A4,b120), (r11,A4,b121), (r11,A4,b122), (r11,A4,b123), (r11,A4,b124), (r11,A4,b125), (r 11,A4,b126), (r11,A4,b127), (r11,A4,b128), (r11,A4,b129), (r11,A4,b130), (r11,A4,b131), (r11,A4,b132), (r11,A4,b133), (r11,A4,b134),
(r12,A1,b1), (r12,A1,b2), (r12,A1,b3), (r12,A1,b4), (r12,A1,b5), (r12,A1,b6), (r12,A1,b7), (r12,A1,b8), (r 12,A1,b9), (r12,A1,b10), (r12,A1,b11), (r12,A1,b12), (r12,A1,b13), (r12,A1,b14), (r12,A1,b15), (r12,A1, b16), (r12,A1,b17), (r12,A1,b18), (r12,A1,b19), (r12,A1,b20), (r12,A1,b21), (r12,A1,b22), (r12,A1,b23), (r12,A1,b24), (r12,A1,b25), (r12,A1,b26), (r12,A1,b27), (r12,A1,b28), (r12,A1,b29), (r12,A1,b30), (r12, A1,b31), (r12,A1,b32), (r12,A1,b33), (r12,A1,b34), (r12,A1,b35), (r12,A1,b36), (r12,A1,b37), (r12,A1,b 38), (r12,A1,b39), (r12,A1,b40), (r12,A1,b41), (r12,A1,b42), (r12,A1,b43), (r12,A1,b44), (r12,A1,b45), (r 12,A1,b46), (r12,A1,b47), (r12,A1,b48), (r12,A1,b49), (r12,A1,b50), (r12,A1,b51), (r12,A1,b52), (r12,A 1,b53), (r12,A1,b54), (r12,A1,b55), (r12,A1,b56), (r12,A1,b57), (r12,A1,b58), (r12,A1,b59), (r12,A1,b60), (r12,A1,b61), (r12,A1,b62), (r12,A1,b63), (r12,A1,b64), (r12,A1,b65), (r12,A1,b66), (r12,A1,b67), (r12, A1,b68), (r12,A1,b69), (r12,A1,b70), (r12,A1,b71), (r12,A1,b72), (r12,A1,b73), (r12,A1,b74), (r12,A1,b 75), (r12,A1,b76), (r12,A1,b77), (r12,A1,b78), (r12,A1,b79), (r12,A1,b80), (r12,A1,b81), (r12,A1,b82), (r 12,A1,b83), (r12,A1,b84), (r12,A1,b85), (r12,A1,b86), (r12,A1,b87), (r12,A1,b88), (r12,A1,b89), (r12,A 1,b90), (r12,A1,b91), (r12,A1,b92), (r12,A1,b93), (r12,A1,b94), (r12,A1,b95), (r12,A1,b96), (r12,A1,b97), (r12,A1,b98), (r12,A1,b99), (r12,A1,b100), (r12,A1,b101), (r12,A1,b102), (r12,A1,b103), (r12,A1,b10 4), (r12,A1,b105), (r12,A1,b106), (r12,A1,b107), (r12,A1,b108), (r12,A1,b109), (r12,A1,b110), (r12,A1, b111), (r12,A1,b112), (r12,A1,b113), (r12,A1,b114), (r12,A1,b115), (r12,A1,b116), (r12,A1,b117), (r12, A1,b118), (r12,A1,b119), (r12,A1,b120), (r12,A1,b121), (r12,A1,b122), (r12,A1,b123), (r12,A1,b124), (r 12,A1,b125), (r12,A1,b126), (r12,A1,b127), (r12,A1,b128), (r12,A1,b129), (r12,A1,b130), (r12,A1,b131), (r12,A1,b132), (r12,A1,b133), (r12,A1,b134), (r12,A2,b1), (r12,A2,b2), (r12,A2,b3), (r12,A2,b4), (r12, A2,b5), (r12,A2,b6), (r12,A2,b7), (r12,A2,b8), (r12,A2,b9), (r12,A2,b10), (r12,A2,b11), (r12,A2,b12), (r1 2,A2,b13), (r12,A2,b14), (r12,A2,b15), (r12,A2,b16), (r12,A2,b17), (r12,A2,b18), (r12,A2,b19), (r12,A2, b20), (r12,A2,b21), (r12,A2,b22), (r12,A2,b23), (r12,A2,b24), (r12,A2,b25), (r12,A2,b26), (r12,A2,b27), (r12,A2,b28), (r12,A2,b29), (r12,A2,b30), (r12,A2,b31), (r12,A2,b32), (r12,A2,b33), (r12,A2,b34), (r12, A2,b35), (r12,A2,b36), (r12,A2,b37), (r12,A2,b38), (r12,A2,b39), (r12,A2,b40), (r12,A2,b41), (r12,A2,b 42), (r12,A2, b43), (r12,A2,b44), (r12,A2,b45), (r12,A2,b46), (r12,A2,b47), (r12,A2,b48), (r12,A2,b49), (r 12,A2,b50), (r12,A2,b51), (r12,A2,b52), (r12,A2,b53), (r12,A2,b54), (r12,A2,b55), (r12,A2,b56), (r12,A 2,b57), (r12,A2,b58), (r12,A2,b59), (r12,A2,b60), (r12,A2,b61), (r12,A2,b62), (r12,A2,b63), (r12,A2,b64), (r12,A2,b65), (r12,A2,b66), (r12,A2,b67), (r12,A2,b68), (r12,A2,b69), (r12,A2,b70), (r12,A2,b71), (r12, A2,b72), (r12,A2,b73), (r12,A2,b74), (r12,A2,b75), (r12,A2,b76), (r12,A2,b77), (r12,A2,b78), (r12,A2,b 79), (r12,A2,b80), 12,A2,b81), (r12,A2,b82), (r12,A2,b83), (r12,A2,b84), (r12,A2,b85), (r12,A2,b86), (r 12,A2,b87), (r12,A2,b88), (r12,A2,b89), (r12,A2,b90), (r12,A2,b91), (r12,A2,b92), (r12,A2,b93), (r12,A 2,b94), (r12,A2,b95), (r12,A2,b96), (r12,A2,b97), (r12,A2,b98), (r12,A2,b99), (r12,A2,b100), (r12,A2,b1 01), (r12,A2,b102), (r12,A2,b103), (r12,A2,b104), (r12,A2,b105), (r12,A2,b106), (r12,A2,b107), (r12,A2, b108), (r12,A2,b109), (r12,A2,b110), (r12,A2,b111), (r12,A2,b112), (r12,A2,b113), (r12,A2,b114), (r12, A2,b115), (r12,A2,b116), (r12,A2,b117), (r12,A2,b118), (r12,A2,b119), (r12,A2,b120), (r12,A2,b121), (r12,A2,b122), (r12,A2,b123), (r12,A2,b124), (r12,A2,b125), (r12,A2,b126), (r12,A2,b127), (r12,A2,b128), (r12,A2,b129), (r12,A2,b130), (r12,A2,b131), (r12,A2,b132), (r12,A2,b133), (r12,A2,b134), (r12,A3,b 1), (r12,A3,b2), (r12,A3,b3), (r12,A3,b4), (r12,A3,b5), (r12,A3,b6), (r12,A3,b7), (r12,A3,b8), (r12,A3,b9), (r12,A3,b10), (r12,A3,b11), (r12,A3,b12), (r12,A3,b13), (r12,A3,b14), (r12,A3,b15), (r12,A3,b16), (r12, A3,b17), (r12,A3,b18), (r12,A3,b19), (r12,A3,b20), (r12,A3,b21), (r12,A3,b22), (r12,A3,b23), (r12,A3,b 24), (r12,A3,b25), (r12,A3,b26), (r12,A3,b27), (r12,A3,b28), (r12,A3,b29), (r12,A3,b30), (r12,A3,b31), (r 12,A3,b32), (r12,A3,b33), (r12,A3,b34), (r12,A3,b35), (r12,A3,b36), (r12,A3,b37), (r12,A3,b38), (r12,A 3,b39), (r12,A3,b40), (r12,A3,b41), (r12,A3,b42), (r12,A3,b43), (r12,A3,b44), (r12,A3,b45), (r12,A3,b46), (r12,A3,b47), (r12,A3,b48), (r12,A3,b49), (r12,A3,b50), (r12,A3,b51), (r12,A3,b52), (r12,A3,b53), (r12, A3,b54), (r12,A3,b55), (r12,A3,b56), (r12,A3,b57), (r12,A3,b58), (r12,A3,b59), (r12,A3,b60), (r12,A3,b 61), (r12,A3,b62), (r12,A3,b63), (r12,A3,b64), (r12,A3,b65), (r12,A3,b66), (r12,A3,b67), (r12,A3,b68), (r 12,A3,b69), (r12,A3,b70), (r12,A3,b71), (r12,A3,b72), (r12,A3,b73), (r12,A3,b74), (r12,A3,b75), (r12,A 3,b76), (r12,A3,b77), (r12,A3,b78), (r12,A3,b79), (r12,A3,b80), (r12,A3,b81), (r12,A3,b82), (r12,A3,b83), (r12,A3,b84), (r12,A3,b85), (r12,A3,b86), (r12,A3,b87), (r12,A3,b88), (r12,A3,b89), (r12,A3,b90), (r12, A3,b91), (r12,A3,b92), (r12,A3,b93), (r12,A3,b94), (r12,A3,b95), (r12,A3,b96), (r12,A3,b97), (r12,A3,b 98), (r12,A3,b99), (r12,A3,b100), (r12,A3,b101), (r12,A3,b102), (r12,A3,b103), (r12,A3,b104), (r12,A3, b105), (r12,A3,b106), (r12,A3,b107), (r12,A3,b108), (r12,A3,b109), (r12,A3,b110), (r12,A3,b111), (r12, A3,b112), (r12,A3,b113), (r12,A3,b114), (r12,A3,b115), (r12,A3,b116), (r12,A3,b117), (r12,A3,b118), (r 12,A3,b119), (r12,A3,b120), (r12,A3,b121), (r12,A3,b122), (r12,A3,b123), (r12,A3,b124), (r12,A3,b125), (r12,A3,b126), (r12,A3,b127), (r12,A3,b128), (r12,A3,b129), (r12,A3,b130), (r12,A3,b131), (r12,A3,b 132), (r12,A3,b133), (r12,A3,b134), (r12,A4,b1), (r12,A4,b2), (r12,A4,b3), (r12,A4,b4), (r12,A4,b5), (r12, A4,b6), (r12,A4,b7), (r12,A4,b8), (r12,A4,b9), (r12,A4,b10), (r12,A4,b11), (r12,A4,b12), (r12,A4,b13), (r12,A4,b14), (r12,A4,b15), (r12,A4,b16), (r12,A4,b17), (r12,A4,b18), (r12,A4,b19), (r12,A4,b20), (r12, A4,b21), (r12,A4,b22), (r12,A4,b23), (r12,A4,b24), (r12,A4,b25), (r12,A4,b26), (r12,A4,b27), (r12,A4,b 28), (r12,A4,b29), (r12,A4,b30), (r12,A4,b31), (r12,A4,b32), (r12,A4,b33), (r12,A4,b34), (r12,A4,b35), (r 12,A4,b36), (r12,A4,b37), (r12,A4,b38), (r12,A4,b39), (r12,A4,b40), (r12,A4,b41), (r12,A4,b42), (r12,A 4,b43), (r12,A4,b44), (r12,A4,b45), (r12,A4,b46), (r12,A4,b47), (r12,A4,b48), (r12,A4,b49), (r12,A4,b50), (r12,A4,b51), (r12,A4,b52), (r12,A4,b53), (r12,A4,b54), (r12,A4,b55), (r12,A4,b56), (r12,A4,b57), (r12, A4,b58), (r12,A4,b59), (r12,A4,b60), (r12,A4,b61), (r12,A4,b62), (r12,A4,b63), (r12,A4,b64), (r12,A4,b 65), (r12,A4,b66), (r12,A4,b67), 12,A4,b68), (r12,A4,b69), (r12,A4,b70), 12,A4,b71), (r12,A4,b72), 12,A4,b73), (r12,A4,b74), (r12,A4,b75), (r12,A4,b76), (r12,A4,b77), (r12,A4,b78), (r12,A4,b79), (r12,A 4,b80), (r12,A4,b81), (r12,A4,b82), (r12,A4,b83), (r12,A4,b84), (r12,A4,b85), (r12,A4,b86), (r12,A4,b87), (r12,A4,b88), (r12,A4,b89), (r12,A4,b90), (r12,A4,b91), (r12,A4,b92), (r12,A4,b93), (r12,A4,b94), (r12, A4,b95), (r12,A4,b96), (r12,A4,b97), (r12,A4,b98), (r12,A4,b99), (r12,A4,b100), (r12,A4,b101), (r12,A 4,b102), (r12,A4,b103), (r12,A4,b104), (r12,A4,b105), (r12,A4,b106), (r12,A4,b107), (r12,A4,b108), (r1 2,A4,b109), (r12,A4,b110), (r12,A4,b111), (r12,A4,b112), (r12,A4,b113), (r12,A4,b114), (r12,A4,b115), (r12,A4,b116), (r12,A4,b117), (r12,A4,b118), (r12,A4,b119), (r12,A4,b120), (r12,A4,b121), (r12,A4,b12 2), (r12,A4,b123), (r12,A4,b124), (r12,A4,b125), (r12,A4,b126), (r12,A4,b127), (r12,A4,b128), (r12,A4, b129), (r12,A4,b130), (r12,A4,b131), (r12,A4,b132), (r12,A4,b133), (r12,A4,b134),
(r13,A1,b1), (r13,A1,b2), (r13,A1,b3), (r13,A1,b4), (r13,A1,b5), (r13,A1,b6), (r13,A1,b7), (r13,A1,b8), (r 13,A1,b9), (r13,A1,b10), (r13,A1,b11), (r13,A1,b12), (r13,A1,b13), (r13,A1,b14), (r13,A1,b15), (r13,A1, b16), (r13,A1,b17), (r13,A1,b18), (r13,A1,b19), (r13,A1,b20), (r13,A1,b21), (r13,A1,b22), (r13,A1,b23), (r13,A1,b24), (r13,A1,b25), (r13,A1,b26), (r13,A1,b27), (r13,A1,b28), (r13,A1,b29), (r13,A1,b30), (r13, A 1,b31), (r13,A1,b32), (r13,A1,b33), (r13,A1,b34), (r13,A1,b35), (r13,A1,b36), (r13,A1,b37), (r13,A1,b 38), (r13,A1,b39), (r13,A1,b40), (r13,A1,b41), (r13,A1,b42), (r13,A1,b43), (r13,A1,b44), (r13,A1,b45), (r 13,A1,b46), (r13,A1,b47), (r13,A1,b48), (r13,A1,b49), (r13,A1,b50), (r13,A1,b51), (r13,A1,b52), (r13,A 1,b53), (r13,A1,b54), (r13,A1,b55), (r13,A1,b56), (r13,A1,b57), (r13,A1,b58), (r13,A1,b59), (r13,A1,b60), (r13,A1,b61), (r13,A1,b62), (r13,A1,b63), (r13,A1,b64), (r13,A1,b65), (r13,A1,b66), (r13,A1,b67), (r13, A1,b68), (r13,A1,b69), (r13,A1,b70), (r13,A1,b71), (r13,A1,b72), (r13,A1,b73), (r13,A1,b74), (r13,A1,b 75), (r13,A1,b76), (r13,A1,b77), (r13,A1,b78), (r13,A1,b79), (r13,A1,b80), (r13,A1,b81), (r13,A1,b82), (r 13,A1,b83), (r13,A1,b84), (r13,A1,b85), (r13,A1,b86), (r13,A1,b87), (r13,A1,b88), (r13,A1,b89), (r13,A 1,b90), (r13,A1,b91), (r13,A1,b92), (r13,A1,b93), (r13,A1,b94), (r13,A1,b95), (r13,A1,b96), (r13,A1,b97), (r13,A1,b98), (r13,A1,b99), (r13,A1,b100), (r13,A1,b101), (r13,A1,b102), (r13,A1,b103), (r13,A1,b10 4), (r13,A1,b105), (r13,A1,b106), (r13,A1,b107), (r13,A1,b108), (r13,A1,b109), (r13,A1,b110), (r13,A1, b111), (r13,A1,b112), (r13,A1,b113), (r13,A1,b114), (r13,A1,b115), (r13,A1,b116), (r13,A1,b117), (r13, A1,b118), (r13,A1,b119), (r13,A1,b120), (r13,A1,b121), (r13,A1,b122), (r13,A1,b123), (r13,A1,b124), (r 13,A1,b125), (r13,A1,b126), (r13,A1,b127), (r13,A1,b128), (r13,A1,b129), (r13,A1,b130), (r13,A1,b131), (r13,A1,b132), (r13,A1,b133), (r13,A1,b134), (r13,A2,b1), (r13,A2,b2), (r13,A2,b 3), (r13,A2,b 4), (r13, A2,b5), (r13,A2,b6), (r13,A2,b7), (r13,A2,b8), (r13,A2,b9), (r13,A2,b10), (r13,A2,b11), (r13,A2,b12), (r1 3,A2,b13), (r13,A2,b14), (r13,A2,b15), (r13,A2,b16), (r13,A2,b17), (r13,A2,b18), (r13,A2,b19), (r13,A2, b20), (r13,A2,b21), (r13,A2,b22), (r13,A2,b23), (r13,A2,b24), (r13,A2,b25), (r13,A2,b26), (r13,A2,b27), (r13,A2,b28), (r13,A2,b29), (r13,A2,b30), (r13,A2,b31), (r13,A2,b32), (r13,A2,b33), (r13,A2,b34), (r13, A2,b35), (r13,A2,b36), (r13,A2,b37), (r13,A2,b38), (r13,A2,b39), (r13,A2,b40), (r13,A2,b41), 13,A2,b 42), (r13,A2,b 43), (r13,A2,b 44), (r13,A2,b 45), (r13,A2,b 46), (r13,A2,b47), (r13,A2,b 48), (r13,A2,b 49), (r 13,A2,b50), (r13,A2,b51), (r13,A2,b52), (r13,A2,b53), (r13,A2,b54), (r13,A2,b55), (r13,A2,b56), (r13,A 2,b57), (r13,A2,b 58), (r13,A2,b59), (r13,A2,b60), (r13,A2,b61), (r13,A2,b62), (r13,A2,b63), (r13,A2,b64), (r13,A2,b65), (r13,A2,b66), (r13,A2,b67), (r13,A2,b68), (r13,A2,b69), (r13,A2,b70), (r13,A2,b71), (r13, A2,b72), (r13,A2,b73), (r13,A2,b74), (r13,A2,b75), (r13,A2,b76), (r13,A2,b77), (r13,A2,b78), (r13,A2,b 79), (r13,A2,b80), (r13,A2,b81), (r13,A2,b82), (r13,A2,b83), (r13,A2,b84), (r13,A2,b85), (r13,A2,b86), (r 13,A2,b87), (r13,A2,b88), (r13,A2,b89), (r13,A2,b90), (r13,A2,b91), (r13,A2,b92), (r13,A2,b93), (r13,A 2,b94), (r13,A2,b95), (r13,A2,b96), (r13,A2,b97), (r13,A2,b98), (r13,A2,b99), (r13,A2,b100), (r13,A2,b1 01), (r13,A2,b102), (r13,A2,b103), (r13,A2,b104), (r13,A2,b105), (r13,A2,b106), (r13,A2,b107), (r13,A2, b108), (r13,A2,b109), (r13,A2,b110), (r13,A2,b111), (r13,A2,b112), (r13,A2,b113), (r13,A2,b114), (r13, A2,b115), (r13,A2,b116), (r13,A2,b117), (r13,A2,b118), (r13,A2,b119), (r13,A2,b120), (r13,A2,b121), (r 13,A2,b122), (r13,A2,b123), (r13,A2,b124), (r13,A2,b125), (r13,A2,b126), (r13,A2,b127), (r13,A2,b128), (r13,A2,b129), (r13,A2,b130), (r13,A2,b131), (r13,A2,b132), (r13,A2,b133), (r13,A2,b134), (r13,A3,b 1), (r13,A3,b2), (r13,A3,b3), (r13,A3,b4), (r13,A3,b5), (r13,A3,b6), (r13,A3,b7), (r13,A3,b8), (r13,A3,b9), (r13,A3,b10), (r13,A3,b11), (r13,A3,b12), (r13,A3,b13), (r13,A3,b14), (r13,A3,b15), (r13,A3,b16), (r13, A3,b17), (r13,A3,b18), (r13,A3,b19), (r13,A3,b20), (r13,A3,b21), (r13,A3,b22), (r13,A3,b23), (r13,A3,b 24), (r13,A3,b25), (r13,A3,b26), (r13,A3,b27), (r13,A3,b28), (r13,A3,b29), (r13,A3,b30), (r13,A3,b31), (r 13,A3,b32), (r13,A3,b33), (r13,A3,b34), (r13,A3,b35), (r13,A3,b36), (r13,A3,b37), (r13,A3,b38), (r13,A 3,b39), (r13,A3,b40), (r13,A3,b41), (r13,A3,b42), (r13,A3,b43), (r13,A3,b44), (r13,A3,b45), (r13,A3,b46), (r13,A3,b47), (r13,A3,b48), (r13,A3,b49), (r13,A3,b50), (r13,A3,b51), (r13,A3,b52), (r13,A3,b53), (r13, A3,b54), (r13,A3,b55), (r13,A3,b56), (r13,A3,b57), (r13,A3,b58), (r13,A3,b59), (r13,A3,b60), (r13,A3,b 61), (r13,A3,b62), (r13,A3,b63), (r13,A3,b64), (r13,A3,b65), (r13,A3,b66), (r13,A3,b67), (r13,A3,b68), (r 13,A3,b69), (r13,A3,b70), (r13,A3,b71), (r13,A3,b72), (r13,A3,b73), (r13,A3,b74), (r13,A3,b75), (r13,A 3,b76), (r13,A3,b77), (r13,A3,b78), (r13,A3,b79), (r13,A3,b80), (r13,A3,b81), (r13,A3,b82), (r13,A3,b83), (r13,A3,b84), (r13,A3,b85), (r13,A3,b86), (r13,A3,b87), (r13,A3,b88), (r13,A3,b89), (r13,A3,b90), (r13, A3,b91), (r13,A3,b92), (r13,A3,b93), (r13,A3,b94), (r13,A3,b95), (r13,A3,b96), (r13,A3,b97), (r13,A3,b 98), (r13,A3,b99), (r13,A3,b100), (r13,A3,b101), (r13,A3,b102), (r13,A3,b103), (r13,A3,b104), (r13,A3, b105), (r13,A3,b106), (r13,A3,b107), (r13,A3,b108), (r13,A3,b109), (r13,A3,b110), (r13,A3,b111), (r13, A3,b112), (r13,A3,b113), (r13,A3,b114), (r13,A3,b115), (r13,A3,b116), (r13,A3,b117), (r13,A3,b118), (r 13,A3,b119), (r13,A3,b120), (r13,A3,b121), (r13,A3,b122), (r13,A3,b123), (r13,A3,b124), (r13,A3,b125), (r13,A3,b126), (r13,A3,b127), (r13,A3,b128), (r13,A3,b129), (r13,A3,b130), (r13,A3,b131), (r13,A3,b 132), (r13,A3,b133), (r13,A3,b134), (r13,A4,b1), (r13,A4,b2), (r13,A4,b3), (r13,A4,b4), (r13,A4,b5), (r13, A4,b6), (r13,A4,b7), (r13,A4,b8), (r13,A4,b9), (r13,A4,b10), (r13,A4,b11), (r13,A4,b12), (r13,A4,b13), (r13,A4,b14), (r13,A4,b15), (r13,A4,b16), (r13,A4,b17), (r13,A4,b18), (r13,A4,b19), (r13,A4,b20), (r13, A4,b21), (r13,A4,b22), (r13,A4,b23), (r13,A4,b24), (r13,A4,b25), (r13,A4,b26), (r13,A4,b27), (r13,A4,b 28), (r13,A4,b29), (r13,A4,b30), (r13,A4,b31), (r13,A4,b32), (r13,A4,b33), (r13,A4,b34), (r13,A4,b35), (r 13,A4,b36), (r13,A4,b37), (r13,A4,b38), (r13,A4,b39), (r13,A4,b40), (r13,A4,b41), (r13,A4,b42), (r13,A 4,b43), (r13,A4,b44), (r13,A4,b45), (r13,A4,b46), (r13,A4,b47), (r13,A4,b48), (r13,A4,b49), (r13,A4,b50), (r13,A4,b51), (r13,A4,b52), (r13,A4,b53), (r13,A4,b54), (r13,A4,b55), (r13,A4,b56), (r13,A4,b57), (r13, A4,b58), (r13,A4,b59), (r13,A4,b60), (r13,A4,b61), (r13,A4,b62), (r13,A4,b63), (r13,A4,b64), (r13,A4,b 65), (r13,A4,b66), (r13,A4,b67), (r13,A4,b68), (r13,A4,b69), (r13,A4,b70), (r13,A4,b71), (r13,A4,b72), (r 13,A4,b73), (r13,A4,b74), (r13,A4,b75), (r13,A4,b76), (r13,A4,b77), (r13,A4,b78), (r13,A4,b79), (r13,A 4,b80), (r13,A4,b81), (r13,A4,b82), (r13,A4,b83), (r13,A4,b84), (r13,A4,b85), (r13,A4,b86), (r13,A4,b87), (r13,A4,b88), (r13,A4,b89), (r13,A4,b90), (r13,A4,b91), (r13,A4,b92), (r13,A4,b93), (r13,A4,b94), (r13, A4,b95), (r13,A4,b96), (r13,A4,b97), (r13,A4,b98), (r13,A4,b99), (r13,A4,b100), (r13,A4,b101), (r13,A 4,b102), (r13,A4,b103), (r13,A4,b104), (r105), (r13,A4,b106), (r13,A4,b107), (r13,A4,b108), (r1 3,A4,b109), (r13,A4,b110), (r13,A4,b111), (r13,A4,b112), (r13,A4,b113), (r13,A4,b114), (r13,A4,b115), (r13,A4,b116), (r13,A4,b117), (r13,A4,b118), (r13,A4,b119), (r13,A4,b120), (r13,A4,b121), (r13,A4,b12 2), (r13,A4,b123), (r13,A4,b124), (r13,A4,b125), (r13,A4,b126), (r13,A4,b127), (r13,A4,b128), (c13,A4, b129), (r13,A4,b130), (r13,A4,b131), (r13,A4,b132), (r13,A4,b133), (r13,A4,b134),
(r14,A1,b1), (r14,A1,b2), (r14,A1,b3), (r14,A1,b4), (r14,A1,b5), (r14,A1,b6), (r14,A1,b7), (r14,A1,b8), (r 14,A1,b9), (r14,A1,b10), (r14,A1,b11), (r14,A1,b12), (r14,A1,b13), (r14,A1,b14), (r14,A1,b15), (r14,A1, b16), (r14,A1,b17), (r14,A1,b18), (r14,A1,b19), (r14,A1,b20), (r14,A1,b21), (r14,A1,b22), (r14,A1,b23), (r14,A1,b24), (r14,A1,b25), (r14,A1,b26), (r14,A1,b27), (r14,A1,b28), (r14,A1,b29), (r14,A1,b30), (r14, A1,b31), (r14,A1,b32), (r14,A1,b33), (r14,A1,b34), (r14,A1,b35), (r14,A1,b36), (r14,A1,b37), (r14,A1,b 38), (r14,A1,b39), (r14,A1,b40), (r14,A1,b41), (r14,A1,b42), (r14,A1,b43), (r14,A1,b44), (r14,A1,b45), (r 14,A1,b46), (r14,A1,b47), (r14,A1,b48), (r14,A1,b49), (r14,A1,b50), (r14,A1,b51), (r14,A1,b52), (r14,A 1,b53), (r14,A1,b54), (r14,A1,b55), (r14,A1,b56), (r14,A1,b57), (r14,A1,b58), (r14,A1,b59), (r14,A1,b60), (r14,A1,b61), (r14,A1,b62), (r14,A1,b63), (r14,A1,b64), (r14,A1,b65), (r14,A1,b66), (r14,A1,b67), (r14, A1,b68), (r14,A1,b69), (r14,A1,b70), (r14,A1,b71), (r14,A1,b72), (r14,A1,b73), (r14,A1,b74), (r14,A1,b 75), (r14,A1,b76), (r14,A1,b77), (r14,A1,b78), (r14,A1,b79), (r14,A1,b80), (r14,A1,b81), (r14,A1,b82), (r 14,A1,b83), (r14,A1,b84), (r14,A1,b85), (r14,A1,b86), (r14,A1,b87), (r14,A1,b88), (r14,A1,b89), (r14,A 1,b90), (r14,A1,b91), (r14,A1,b92), (r14,A1,b93), (r14,A1,b94), (r14,A1,b95), (r14,A1,b96), (r14,A1,b97), (r14,A1,b98), (r14,A1,b99), (r14,A1,b100), (r14,A1,b101), (r14,A1,b102), (r14,A1,b103), (r14,A1,b10 4), (r14,A1,b105), (r14,A1,b106), (r14,A1,b107), (r14,A1,b108), (r14,A1,b109), (r14,A1,b110), (r14,A1, b111), (r14,A1,b112), (r14,A1,b113), (r14,A1,b114), (r14,A1,b115), (r14,A1,b116), (r14,A1,b117), (r14, A1,b118), (r14,A1,b119), (r14,A1,b120), (r14,A1,b121), (r14,A1,b122), (r14,A1,b123), (r14,A1,b124), (r 14,A1,b125), (r14,A1,b126), (r14,A1,b127), (r14,A1,b128), (r14,A1,b129), (r14,A1,b130), (r14,A1,b131), (r14,A1,b132), (r14,A1,b133), (r14,A1,b134), (r14,A2,b1), (r14,A2,b2), (r14,A2,b3), (r14,A2,b4), (r14, A2,b5), (r14,A2,b6), (r14,A2,b7), (r14,A2,b8), (r14,A2,b9), (r14,A2,b10), (r14,A2,b11), (r14,A2,b12), (r1 4,A2,b13), (r14,A2,b14), (r14,A2,b15), (r14,A2,b16), (r14,A2,b17), (r14,A2,b18), (r14,A2,b19), (r14,A2, b20), (r14,A2,b21), (r14,A2,b22), (r14,A2,b23), (r14,A2,b24), (r14,A2,b25), (r14,A2,b26), (r14,A2,b27), (r14,A2,b28), (r14,A2,b29), (r14,A2,b30), (r14,A2,b31), (r14,A2,b32), (r14,A2,b33), (r14,A2,b34), (r14, A2,b35), (r14,A2,b36), (r14,A2,b37), (r14,A2,b38), (r14,A2,b39), (r14,A2,b40), (r14,A2,b41), (r14,A2,b 42), (r14,A2,b43), (r14,A2,b44), (r14,A2,b 45), (r14,A2,b 46), (r14,A2,b 47), (r14,A2,b48), (r14,A2,b 49), (r 14,A2,b50), (r14,A2,b51), (r14,A2,b52), (r14,A2,b53), (r14,A2,b54), (r14,A2,b55), (r14,A2,b56), (r14,A 2,b57), (r14,A2,b58), (r14,A2,b59), (r14,A2,b60), (r14,A2,b61), (r14,A2,b62), (r14,A2,b63), (r14,A2,b64), (r14,A2,b65), (r14,A2,b66), (r14,A2,b67), (r14,A2,b68), (r14,A2,b69), (r14,A2,b70), (r14,A2,b71), (r14, A2,b72), (r14,A2,b73), (r14,A2,b74), (r14,A2,b75), (r14,A2,b76), (r14,A2,b77), (r14,A2,b78), (r14,A2,b 79), (r14,A2,b80), (r14,A2,b81), (r14,A2,b82), (r14,A2,b83), (r14,A2,b84), (r14,A2,b85), (r14,A2,b86), (r 14,A2,b87), (r14,A2,b88), (r14,A2,b89), (r14,A2,b90), (r14,A2,b91), (r14,A2,b92), (r14,A2,b93), (r14,A 2,b94), (r14,A2,b95), (r14,A2,b96), (r14,A2,b97), (r14,A2,b98), (r14,A2,b99), (r14,A2,b100), (r14,A2,b1 01), (r14,A2,b102), (r14,A2,b103), (r14,A2,b104), (r14,A2,b105), (r14,A2,b106), (r14,A2,b107), (r14,A2, b108), (r14,A2,b109), (r14,A2,b110), (r14,A2,b111), (r14,A2,b112), (r14,A2,b113), (r14,A2,b114), (r14, A2,b115), (r14,A2,b116), (r14,A2,b117), (r14,A2,b118), (r14,A2,b119), (r14,A2,b120), (r14,A2,b121), (r 14,A2,b122), (r14,A2,b123), (r14,A2,b124), (r14,A2,b125), (r14,A2,b126), (r14,A2,b127), (r14,A2,b128), (r14,A2,b129), (r14,A2,b130), (r14,A2,b131), (r14,A2,b132), (r14,A2,b133), (r14,A2,b134), (r14,A3,b 1), (r14,A3,b2), (r14,A3,b3), (r14,A3,b4), (r14,A3,b5), (r14,A3,b6), (r14,A3,b7), (r14,A3,b8), (r14,A3,b9), (r14,A3,b10), (r14,A3,b11), (r14,A3,b12), (r14,A3,b13), (r14,A3,b14), (r14,A3,b15), (r14,A3,b16), (r14, A3,b17), (r14,A3,b18), (r14,A3,b19), (r14,A3,b20), (r14,A3,b21), (r14,A3,b22), (r14,A3,b23), (r14,A3,b 24), (r14,A3,b25), (r14,A3,b26), (r14,A3,b27), (r14,A3,b28), (r14,A3,b29), (r14,A3,b30), (r14,A3,b 31), (r 14,A3,b32), (r14,A3,b33), (r14,A3,b34), (r14,A3,b35), (r14,A3,b36), (r14,A3,b37), (r14,A3,b38), (r14,A 3,b39), (r14,A3,b40), (r14,A3,b41), (r14,A3,b42), (r14,A3,b43), (r14,A3,b44), (r14,A3,b45), (r14,A3,b46), (r14,A3,b47), (r14,A3,b48), (r14,A3,b49), (r14,A3,b50), (r14,A3,b51), (r14,A3,b52), (r14,A3,b53), (r14, A3,b54), (r14,A3,b 55), (r14,A3,b56), (r14,A3,b57), (r14,A3,b58), (r14,A3,b59), (r14,A3,b60), 14,A3,b 61), (r14,A3,b62), (r14,A3,b63), (r14,A3,b64), (r14,A3,b65), (r14,A3,b66), (r14,A3,b67), (r14,A3,b68), (r 14,A3,b69), (r14,A3,b70), (r14,A3,b71), (r14,A3,b72), (r14,A3,b73), (r14,A3,b74), (r14,A3,b75), (r14,A 3,b76), (r14,A3,b77), (r14,A3,b78), (r14,A3,b79), (r14,A3,b80), (r14,A3,b81), (r14,A3,b82), (r14,A3,b83), (r14,A3,b84), (r14,A3,b85), (r14,A3,b86), (r14,A3,b87), (r14,A3,b88), (r14,A3,b89), (r14,A3,b90), (r14, A3,b91), (r14,A3,b92), (r14,A3,b93), (r14,A3,b94), (r14,A3,b95), (r14,A3,b96), (r14,A3,b97), (r14,A3,b 98), (r14,A3,b99), (r14,A3,b100), (r14,A3,b101), (r14,A3,b102), (r14,A3,b103), (r14,A3,b104), (r14,A3, b105), (r14,A3,b106), (r14,A3,b107), (r14,A3,b108), (r14,A3,b109), (r14,A3,b110), (r14,A3,b111), (r14, A3,b112), (r14,A3,b113), (r14,A3,b114), (r14,A3,b115), (r14,A3,b116), (r14,A3,b117), (r14,A3,b118), (r 14,A3,b119), (r14,A3,b120), (r14,A3,b121), (r14,A3,b122), (r14,A3,b123), (r14,A3,b124), (r14,A3,b125), (r14,A3,b126), (r14,A3,b127), (r14,A3,b128), (r14,A3,b129), (r14,A3,b130), (r14,A3,b131), (r14,A3,b 132), (r14,A3,b133), (r14,A3,b134), (r14,A4,b1), (r14,A4,b2), (r14,A4,b3), (r14,A4,b4), (r14,A4,b5), (r14, A4,b6), (r14,A4,b7), (r14,A4,b8), (r14,A4,b9), (r14,A4,b10), (r14,A4,b11), (r14,A4,b12), (r14,A4,b13), (r14,A4,b14), (r14,A4,b15), (r14,A4,b16), (r14,A4,b17), (r14,A4,b18), (r14,A4,b19), (r14,A4,b20), (r14, A4,b21), (r14,A4,b22), (r14,A4,b23), (r14,A4,b24), (r14,A4,b25), (r14,A4,b26), (r14,A4,b27), (r14,A4,b 28), (r14,A4,b29), (r14,A4,b30), (r14,A4,b31), (r14,A4,b32), (r14,A4,b33), (r14,A4,b34), (r14,A4,b35), 14,A4,b36), (r14,A4,b37), (r14,A4,b 38), (r14,A4,b39), (r14,A4,b40), (r14,A4,b41), (r14,A4,b42), (r14,A 4,b43), (r14,A4,b44), (r14,A4,b45), (r14,A4,b46), (r14,A4,b47), (r14,A4,b48), (r14,A4,b49), (r14,A4,b50), (r14,A4,b51), (r14,A4,b52), (r14,A4,b53), (r14,A4,b54), (r14,A4,b55), (r14,A4,b56), (r14,A4,b57), (r14, A4,b58), (r14,A4,b59), (r14,A4,b60), (r14,A4,b61), (r14,A4,b62), (r14,A4,b63), (r14,A4,b64), (r14,A4,b 65), (r14,A4,b66), (r14,A4,b67), (r14,A4,b68), (r14,A4,b69), (r14,A4,b70), (r14,A4,b71), (r14,A4,b72), 14,A4,b73), (r14,A4,b74), (r14,A4,b75), (r14,A4,b76), (r14,A4,b77), (r14,A4,b78), (r14,A4,b79), (r14,A 4,b80), (r14,A4,b81), (r14,A4,b82), (r14,A4,b83), (r14,A4,b84), (r14,A4,b85), (r14,A4,b86), (r14,A4,b87), (r14,A4,b88), (r14,A4,b89), (r14,A4,b90), (r14,A4,b91), (r14,A4,b92), (r14,A4,b93), (r14,A4,b94), (r14, A4,b95), (r14,A4,b96), (r14,A4,b97), (r14,A4,b98), (r14,A4,b99), (r14,A4,b100), (r14,A4,b101), (r14,A 4,b102), (r14,A4,b103), (r14,A4,b104), (r14,A4,b105), (r14,A4,b106), (r14,A4,b107), (r14,A4,b108), (r1 4,A4,b109), (r14,A4,b110), (r14,A4,b111), (r14,A4,b112), (r14,A4,b113), (r14,A4,b114), (r115), (r14,A4,b116), (r14,A4,b117), (r14,A4,b118), (r119), (r14,A4,b120), (r14,A4,b121), (r14,A4,b12 2), (r14,A4,b123), (r14,A4,b124), (r14,A4,b125), (r14,A4,b126), (r14,A4,b127), (r14,A4,b128), (r14,A4, b129), (r14,A4,b130), (r14,A4,b131), (r14,A4,b132), (r14,A4,b133), (r14,A4,b134),
(r15,A1,b1), (r15,A1,b2), (r15,A1,b3), (r15,A1,b4), (r15,A1,b5), (r15,A1,b6), (r15,A1,b7), (r15,A1,b8), (r 15,A1,b9), (r15,A1,b10), (r15,A1,b11), (r15,A1,b12), (r15,A1,b13), (r15,A1,b14), (r15,A1,b15), (r15,A1, b16), (r15,A1,b17), (r15,A1,b18), (r15,A1,b19), (r15,A1,b20), (r15,A1,b21), (r15,A1,b22), (r15,A1,b23), (r15,A1,b24), (r15,A1,b25), (r15,A1,b26), (r15,A1,b27), (r15,A1,b28), (r15,A1,b29), (r15,A1,b30), (r15, A 1,b31), (r15,A1,b32), (r15,A1,b33), (r15,A1,b34), (r15,A1,b35), (r15,A1,b36), (r15,A1,b37), (r15,A1,b 38), (r15,A1,b39), (r15,A1,b40), (r15,A1,b41), (r15,A1,b42), (r15,A1,b43), (r15,A1,b44), (r15,A1,b45), (r 15,A1,b46), (r15,A1,b47), (r15,A1,b48), (r15,A1,b49), (r15,A1,b50), (r15,A1,b51), (r15,A1,b52), (r15,A 1,b53), (r15,A1,b54), (r15,A1,b55), (r15,A1,b56), (r15,A1,b57), (r15,A1,b58), (r15,A1,b59), (r15,A1,b60), (r15,A1,b61), (r15,A1,b62), (r15,A1,b63), (r15,A1,b64), (r15,A1,b65), (r15,A1,b66), (r15,A1,b67), (r15, A1,b68), (r15,A1,b69), (r15,A1,b70), (r15,A1,b71), (r15,A1,b72), (r15,A1,b73), (r15,A1,b74), (r15,A1,b 75), (r15,A1,b76), (r15,A1,b77), (r15,A1,b78), (r15,A1,b79), (r15,A1,b80), (r15,A1,b81), (r15,A1,b82), (r 15,A1,b83), (r15,A1,b84), (r15,A1,b85), (r15,A1,b86), (r15,A1,b87), (r15,A1,b88), (r15,A1,b89), (r15,A 1,b90), (r15,A1,b91), (r15,A1,b92), (r15,A1,b93), (r15,A1,b94), (r15,A1,b95), (r15,A1,b96), (r15,A1,b97), (r15,A1,b98), (r15,A1,b99), (r15,A1,b100), (r15,A1,b101), (r15,A1,b102), (r15,A1,b103), (r15,A1,b10 4), (r15,A1,b105), (r15,A1,b106), (r15,A1,b107), (r15,A1,b108), (r15,A1,b109), (r15,A1,b110), (r15,A1, b111), (r15,A1,b112), (r15,A1,b113), (r15,A1,b114), (r15,A1,b115), (r15,A1,b116), (r15,A1,b117), (r15, A1,b118), (r15,A1,b119), (r15,A1,b120), (r15,A1,b121), (r15,A1,b122), (r15,A1,b123), (r15,A1,b124), (r 15,A1,b125), (r15,A1,b126), (r15,A1,b127), (r15,A1,b128), (r15,A1,b129), (r15,A1,b130), (r15,A1,b131), (r15,A1,b132), (r15,A1,b133), (r15,A1,b134), (r15,A2,b1), (r15,A2,b2), (r15,A2,b3), (r15,A2,b4), (r15, A2,b5), (r15,A2,b6), (r15,A2,b7), (r15,A2,b8), (r15,A2,b9), (r15,A2,b10), (r15,A2,b11), (r15,A2,b12), (r1 5,A2,b13), (r15,A2,b14), (r15,A2,b15), (r15,A2,b16), (r15,A2,b17), (r15,A2,b18), (r15,A2,b19), (r15,A2, b20), (r15,A2,b21), (r15,A2,b22), (r15,A2,b23), (r15,A2,b24), (r15,A2,b25), (r15,A2,b26), (r15,A2,b27), (r15,A2,b28), (r15,A2,b29), (r15,A2,b30), (r15,A2,b31), (r15,A2,b32), (r15,A2,b33), (r15,A2,b34), (r15, A2,b35), (r15,A2,b36), (r15,A2,b37), (r15,A2,b38), (r15,A2,b39), (r15,A2,b40), (r15,A2,b41), (r15,A2,b 42), (r15,A2,b 43), (r15,A2,b 44), (r15,A2,b 45), (r15,A2,b 46), (r15,A2,b 47), (r15,A2,b 48), (r15,A2,b 49), (r 15,A2,b50), (r15,A2,b51), (r15,A2,b52), (r15,A2,b53), (r15,A2,b54), (r15,A2,b55), (r15,A2,b56), (r15,A 2,b 57), (r15,A2,b58), (r15,A2,b59), (r15,A2,b60), (r15,A2,b61), (r15,A2,b62), (r15,A2,b63), (r15,A2,b64), (r15,A2,b65), (r15,A2,b66), (r15,A2,b67), (r15,A2,b68), (r15,A2,b69), (r15,A2,b70), (r15,A2,b71), (r15, A2,b72), (r15,A2,b73), (r15,A2,b74), (r15,A2,b75), (r15,A2,b76), (r15,A2,b77), (r15,A2,b78), (r15,A2,b 79), (r15,A2,b80), (r15,A2,b81), 15,A2,b82), (r15,A2,b83), (r15,A2,b84), (r15,A2,b85), (r15,A2,b86), (r 15,A2,b87), (r15,A2,b88), (r15,A2,b89), (r15,A2,b90), (r15,A2,b91), (r15,A2,b92), (r15,A2,b93), (r15,A 2,b94), (r15,A2,b95), (r15,A2,b96), (r15,A2,b97), (r15,A2,b98), (r15,A2,b99), (r15,A2,b100), (r15,A2,b1 01), (r15,A2,b102), (r15,A2,b103), (r15,A2,b104), (r15,A2,b105), (r15,A2,b106), (r15,A2,b107), (r15,A2, b108), (r15,A2,b109), (r15,A2,b110), (r15,A2,b111), (r15,A2,b112), (r15,A2,b113), (r15,A2,b114), (r15, A2,b115), (r15,A2,b116), (r15,A2,b117), (r15,A2,b118), (r15,A2,b119), (r15,A2,b120), (r15,A2,b121), (r 15,A2,b122), (r15,A2,b123), (r15,A2,b124), (r15,A2,b125), (r15,A2,b126), (r15,A2,b127), (r15,A2,b128), (r15,A2,b129), (r15,A2,b130), (r15,A2,b131), (r15,A2,b132), (r15,A2,b133), (r15,A2,b134), (r15,A3,b 1), (r15,A3,b2), (r15,A3,b3), (r15,A3,b4), (r15,A3,b5), (r15,A3,b6), (r15,A3,b7), (r15,A3,b8), (r15,A3,b9), (r15,A3,b10), (r15,A3,b11), (r15,A3,b12), (r15,A3,b13), (r15,A3,b14), (r15,A3,b15), (r15,A3,b16), (r15, A3,b17), (r15,A3,b18), (r15,A3,b19), (r15,A3,b20), (r15,A3,b21), (r15,A3,b22), (r15,A3,b23), (r15,A3,b 24), (r15,A3,b25), (r15,A3,b26), (r15,A3,b27), (r15,A3,b28), (r15,A3,b29), (r15,A3,b30), (r15,A3,b31), (r 15,A3,b32), (r15,A3,b33), (r15,A3,b34), (r15,A3,b35), (r15,A3,b36), (r15,A3,b37), (r15,A3,b38), (r15,A 3,b39), (r15,A3,b40), (r15,A3,b41), (r15,A3,b42), (r15,A3,b43), (r15,A3,b 44), (r15,A3,b45), (r15,A3,b46), (r15,A3,b47), (r15,A3,b48), (r15,A3,b49), (r15,A3,b50), (r15,A3,b51), (r15,A3,b52), (r15,A3,b53), (r15, A3,b54), (r15,A3,b55), (r15,A3,b56), (r15,A3,b57), (r15,A3,b58), (r15,A3,b59), (r15,A3,b60), (r15,A3,b 61), (r15,A3,b62), (r15,A3,b63), (r15,A3,b64), (r15,A3,b65), (r15,A3,b66), (r15,A3,b67), (r15,A3,b68), (r 15,A3,b69), (r15,A3,b70), (r15,A3,b71), (r15,A3,b72), (r15,A3,b73), (r15,A3,b74), (r15,A3,b75), (r15,A 3,b76), (r15,A3,b77), (r15,A3,b78), (r15,A3,b79), (r15,A3,b80), (r15,A3,b81), (r15,A3,b82), (r15,A3,b83), (r15,A3,b84), (r15,A3,b85), (r15,A3,b86), (r15,A3,b87), (r15,A3,b88), (r15,A3,b89), (r15,A3,b90), (r15, A3,b91), (r15,A3,b92), (r15,A3,b93), (r15,A3,b94), (r15,A3,b95), (r15,A3,b96), (r15,A3,b97), (r15,A3,b 98), (r15,A3,b99), (r15,A3,b100), (r15,A3,b101), (r15,A3,b102), (r15,A3,b103), (r15,A3,b104), (r15,A3, b105), (r15,A3,b106), (r15,A3,b107), (r15,A3,b108), (r15,A3,b109), (r15,A3,b110), (r15,A3,b111), (r15, A3,b112), (r15,A3,b113), (r15,A3,b114), (r15,A3,b115), (r15,A3,b116), (r15,A3,b117), (r15,A3,b118), (r 15,A3,b119), (r15,A3,b120), (r15,A3,b121), (r15,A3,b122), (r15,A3,b123), (r15,A3,b124), (r15,A3,b125), (r15,A3,b126), (r15,A3,b127), (r15,A3,b128), (r15,A3,b129), (r15,A3,b130), (r15,A3,b131), (r15,A3,b 132), (r15,A3,b133), (r15,A3,b134), (r15,A4,b1), (r15,A4,b2), (r15,A4,b3), (r15,A4,b4), (r15,A4,b5), (r15, A4,b6), (r15,A4,b7), (r15,A4,b8), (r15,A4,b9), (r15,A4,b10), (r15,A4,b11), (r15,A4,b12), (r15,A4,b13), (r15,A4,b14), (r15,A4,b15), (r15,A4,b16), (r15,A4,b17), (r15,A4,b18), (r15,A4,b19), (r15,A4,b20), (r15, A4,b21), (r15,A4,b22), (r15,A4,b23), (r15,A4,b24), (r15,A4,b25), (r15,A4,b26), (r15,A4,b27), (r15,A4,b 28), (r15,A4,b29), (r15,A4,b30), (r15,A4,b 31), (r15,A4,b32), (r15,A4,b33), (r15,A4,b34), (r15,A4,b 35), (r 15,A4,b36), (r15,A4,b37), (r15,A4,b38), (r15,A4,b39), (r15,A4,b40), (r15,A4,b41), (r15,A4,b42), (r15,A 4,b43), (r15,A4,b44), (r15,A4,b45), (r15,A4,b46), (r15,A4,b47), (r15,A4,b48), (r15,A4,b49), (r15,A4,b50), (r15,A4,b51), (r15,A4,b52), (r15,A4,b53), (r15,A4,b54), (r15,A4,b 55), (r15,A4,b56), (r15,A4,b 57), (r15, A4,b58), (r15,A4,b59), 15,A4,b60), (r15,A4,b61), 15,A4,b62), (r15,A4,b63), (r15,A4,b64), (r15,A4,b 65), (r15,A4,b66), (r15,A4,b67), (r15,A4,b68), (r15,A4,b69), (r15,A4,b70), (r15,A4,b71), (r15,A4,b 72), (r 15,A4,b73), (r15,A4,b74), (r15,A4,b75), (r15,A4,b76), (r15,A4,b77), (r15,A4,b78), (r15,A4,b79), (r15,A 4,b80), (r15,A4,b81), (r15,A4,b82), (r15,A4,b83), (r15,A4,b84), (r15,A4,b 85), (r15,A4,b86), (r15,A4,b87), (r15,A4,b88), (r15,A4,b89), (r15,A4,b90), (r15,A4,b91), (r15,A4,b92), (r15,A4,b93), (r15,A4,b94), (r15, A4,b95), (r15,A4,b96), (r15,A4,b97), (r15,A4,b98), (r15,A4,b99), (r15,A4,b100), (r15,A4,b101), (r15,A 4,b102), (r15,A4,b103), (r15,A4,b104), (r15,A4,b105), (r15,A4,b106), (r15,A4,b107), (r15,A4,b108), (r1 5,A4,b109), (r15,A4,b110), (r15,A4,b111), (r15,A4,b112), (r15,A4,b113), (r15,A4,b114), (r15,A4,b115), (r15,A4,b116), (r15,A4,b117), (r15,A4,b118), (r15,A4,b119), (r15,A4,b120), (r15,A4,b121), (r15,A4,b12 2), (r15,A4,b123), (r15,A4,b124), (r15,A4,b125), (r15,A4,b126), (r15,A4,b127), (r15,A4,b128), (r15,A4, b129), (r15,A4,b130), (r15,A4,b131), (r15,A4,b132), (r15,A4,b133), or (r15,A4,b134). - The present compounds are useful in disease induced by the production, secretion or deposition of amyloid 6 protein, and are effective in treatment and/or prevention, and symptom improvement of such as dementia of the Alzheimer's type (Alzheimer's disease, senile dementia of Alzheimer type), Down's syndrome, memory impairment, prion disease (Creutzfeldt-Jakob disease), mild cognitive impairment (MCI), Dutch type of hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, other type of degenerative dementia, mixed dementia with Alzheimer's and vascular type, dementia with Parkinson's Disease, dementia with progressive supranuclear palsy, dementia with Cortico-basal degeneration, Alzheimer's disease with diffuse Lewy body disease, age-related macular degeneration, Parkinson's Disease, amyloid angiopathy and so on.
- In the present invention, “treating Alzheimer's disease” includes prevention of advancing in severity of MCI and prevention of onset of familial Alzheimer's disease. In the present invention, “a pharmaceutical composition for treating Alzheimer's disease” includes a pharmaceutical composition for prevention of advancing in severity of MCI and prevention of onset of familial Alzheimer's disease.
- Since the present compound has high inhibitory activity on BACE1, and/or has high selectivity on other enzymes, it can be a medicament with reduced side effect. Further, since the compound has high effect of reducing amyloid p production in a cell system, particularly, has high effect of reducing amyloid 6 production in brain, it can be an excellent medicament. In addition, by converting the compound into an optically active compound having suitable stereochemistry, the compound can be a medicament having a larger safety margin on the side effect. In addition, the present compound also has advantages that metabolism stability is high, solubility is high, oral absorbability is high, good bioavailability is exhibited, clearance is good, brain transference is high, a half life is high, non-protein binding rate is high, hERG channel inhibition is low, CYP inhibition is low, CYP MBI (irreversible inhibition (mechanism-based inhibition)) is low and/or an Ames test is negative.
- The present compounds can be administrated in combination with other pharmaceutical agents such as other therapeutic drugs for Alzheimer's disease, e.g., acetylcholinesterase and the like. The present compounds can be treated with concomitantly with the anti-dementia agents such as Donepezil Hydrochloride, Tacrine, Galantamine, Rivastigmine, Zanapezil, Memantine, and Vinpocetine.
- When the present compound is administered to a human, it can be administered orally as powders, granules, tablets, capsules, pills, solutions, or the like, or parenterally as injectables, suppositories, transdermal absorbable agents, inhalations, or the like. In addition, the present compound can be formulated into pharmaceutical preparations by adding pharmaceutical additives such as excipients, binders, wetting agents, disintegrating agents, lubricants and the like, which are suitable for formulations and an effective amount of the present compound.
- A dose is different depending on state of disease, an administration route, and an age and a weight of a patient, and is usually 0.1 μg to 1 g/day, preferably 0.01 to 200 mg/day when orally administered to an adult, and is usually 1 μg to 10 g/day, preferably 0.1 to 2 g/day when parenterally administered.
- Following examples and test examples illustrate the present invention in more detail, but the present invention is not limited by these examples.
- 1H-NMR was measured in deuterium chloroform (CDCl3) using tetramethylsilane as an internal standard. δ values were shown as ppm. Binding constants (J) were shown as Hz. In the data, s, d, t, m, br, and brs means singlet, doublet, triplet, multiplet, broad-line and broad-singlet, respectively.
- Dashed bond shows relative configuration and all compounds are racemates.
- In example, the meaning of each abbreviation is as follows:
- Me methyl
Et ethyl
Bz benzoyl
Boc t-butoxycarbonyl
Fmoc 9-fluorenylmethoxycarbonyl
Ns nitrobenzenesulfonyl
THF tetrahydrofuran
DMF dimethylformamide
DMSO dimethyl sulfoxide
TFA trifluoroacetyl
DBU 1,8-diazabicyclo[5.4.0]undeca-7-ene - LC/MS data of the present compounds were measured under the following conditions, and a retention time and [M+H]+ are shown.
- Column: Xbridge (registered trade name) C18 (5 μm, i.d. 4.6×50 mm)(Waters)
Flow rate: 3 mL/min.
UV detection wavelength: 254 nm
Mobile phase: [A] 0.1% formic acid-containing aqueous solution; [B] 0.1% formic acid-containing acetonitrile solution
Gradient: performing linear gradient of 10% to 100% solvent [B] for 3 minutes, and keeping 100% solvent [B] for 1 minute - Flow rate: 3 mL/min.
UV detection wavelength: 254 nm
Mobile phase: [A]0.1% formic acid-containing aqueous solution; [B]0.1% formic acid containing methanol solution
Gradient: performing linear gradient of 5% to 100% solvent [B] for 3.5 minutes, and keeping 100% solvent [B] for 5 minutes. - Column: ACQUITY HPLC (registered trade name) BEH C18 (1.7 μm i.d.2.1×50 mm) (Waters)
Flow rate: 1.0 mL/min.
UV detection wavelength: 254 nm
Mobile phase:[A] 0.1% formic acid-containing aqueous solution, [B] 0.1% formic acid-containing acetonitrile solution
Gradient: performing linear gradient of 10% to 100% solvent [B] for 3.5 minutes, and keeping 100% solvent [B] for 0.5 minutes. - Column: ACQUITY HPLC (registered trade name) BEH C18 (1.7 μm i.d.2.1×50 mm) (Waters)
Flow rate: 0.9 mL/min
UV detection wavelength: 254 nm
Mobile phase: [A] 0.1% formic acid-containing aqueous solution, [B] 0.1% formic acid-containing acetonitrile solution
Gradient: performing linear gradient 10% to 100% solvent [B] for 3.5 minutes, and keeping 100% solvent [B] for 0.5 minute. -
- A mixed solution of a known compound (1) (3.13 g) which can be prepared according to the method described in Patent Literature 4 and 5% Rh/C (924 mg) in ethanol (40 ml) was stirred under hydrogen atmosphere at room temperature for 22 hours. The insoluble material was removed by filtration and the filtrate was concentrated. The residue was dissolved in THF (50 mL) and di-tert-butyldicarbonate (3.92 g) was added. The mixed solution was stirred at 55° C. for 15 hours. The reaction solution was evaporated under reduced pressure. The crude product was purified by silica gel chromatography to give Compound (3)(4.08 g). 1H-NMR (CDCl3) δ:1.37 (s, 9H), 3.27 (m, 1H), 3.55-3.70 (m, 2H), 3.70-3.85 (m, 2H), 3.95-4.15 (m, 2H), 4.20-4.30 (m, 2H), 5.79 (brs, 1H), 7.02 (dd, J=12.2, 8.1 Hz, 1H), 7.14 (t, J=7.5 Hz, 1H), 7.22-7.31 (m, 1H), 7.80 (m, 1H)
- To a solution of Compound (3) (4.06 g) in ethyl acetate (50 mL) was added 2-iodoxybenzoic acid at room temperature. The reaction mixture was stirred at 80° C. for 4.5 hours. The insoluble material was removed by filtration and the filtrate was evaporated under the reduced pressure. The crude product was purified by silica gel chromatography to give Compound (4) (3.36 g).
- 1H-NMR (CDCl3) δ:1.30 (s, 9H), 3.78 (m, 1H), 4.10 (t, J=8.6 Hz, 1H), 4.29 (dd, J=9.6, 2.1 Hz, 1H), 4.39 (dd, J=9.0, 7.0 Hz, 1H), 5.49 (brs, 1H), 7.08 (ddd, J=12.2, 8.1, 1.3 Hz, 1H), 7.17 (td, J=7.6, 1.3 Hz, 1H), 7.27-7.35 (m, 1H), 7.50 (td, J=8.0, 1.7, 1H), 9.86 (d, J=2.6, 1H)
- To a solution of methyltriphenylphosphonium iodide (3.02 g) in THF (15 mL) was dropwisely added 1.57 M n-butyllithium hexane solution (4.76 mL) under nitrogen atmosphere under ice-cooling. The mixture solution was stirred at the same temperature for 30 minutes. To the mixture solution was dropwisely added a solution of Compound 4 (771 mg) in THF (10 mL) under nitrogen atmosphere under ice-cooling. The reaction mixture was stirred at the same temperature for 30 minutes. To the reaction mixture was added an aqueous solution of ammonium chloride and the mixture was allowed to warm to room temperature. To the reaction mixture was added ethyl acetate and the organic layer was partitioned. The organic layer was washed with brine. The organic layer was dried over anhydrous magnesium sulfate and the insoluble material was removed by filtration. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (5) (62 mg).
- 1H-NMR (CDCl3) δ:1.37 (s, 9H), 3.21 (m, 1H), 3.82 (dd, J=8.5, 6.7 Hz, 1H), 4.06 (t, J=7.8 Hz, 1H), 4.21 (m, 1 H), 4.78 (m, 1H), 5.20-5.35 (m, 3H), 5.75-5.87 (m, 1H), 7.01-7.14 (m, 2H), 7.11 (td, J=7.7, 1.4 Hz, 1H), 7.26 (mm, 1H), 7.40 (td, J=8.1, 1.7 Hz, 1H)
- To a solution of Compound 5 (61 mg) in methylene chloride (1 mL) was added trifluoroacetic acid (0.5 mL) under ice-cooling. The reaction mixture was warmed to room temperature and stirred for 40 minutes. To the reaction mixture was added a saturated aqueous sodium bicarbonate solution (10 mL) under ice-cooling and the mixture was extracted with ethyl acetate. The organic layer was washed with brine. The organic layer was dried over anhydrous magnesium sulfate and the insoluble material was removed by filtration. The filtrate was evaporated under reduced pressure.
- The residue was dissolved in acetone (1 mL) and Fmoc-isothiocyanate (61 mg) was added under ice-cooling. The reaction mixture was warmed to room temperature and stirred at room temperature for 1.5 hours. The solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (7) (95 mg).
- 1H-NMR (CDCl3) δ:3.26 (m, 1H), 3.87 (dd, J=9.0, 5.6 Hz, 1H), 4.09 (dd, J=8.9, 6.5 Hz, 1H), 4.28 (t, J=6.7, 1H), 4.38 (d, J=10.7, 1H), 4.55 (d, J=6.9, 2H), 5.31 (d, J=10.1, 1H), 5.39 (d, J=17.1, 1H), 5.48 (d, J=10.4, 1H), 5.9 6 (m, 1H), 7.09 (ddd, J=12.3, 8.1, 1.3 Hz, 1H), 7.18 (td, J=7.6, 1.3 Hz, 1H), 7.32 (m, 1H), 7.38 (td, J=7.4, 1.2Hz, 1H), 7.48-7.52 (m, 3H), 7.60 (d, J=7.6, 2H), 7.83 (d, J=7.6, 2H), 7.95 (brs, 1H), 10.46 (brs, 1H)
- To a solution of Compound (7) (21 mg) in methylene chloride (1 mL) was added iodine (22 mg) under ice-cooling. The reaction solution was warmed to room temperature and stirred at room temperature for 30 minutes. To the reaction mixture were added 10% Na2S2O3 5H2O (1 mL), and a saturated aqueous NaHCO3 solution (2 mL), and the mixture was extracted with ethyl acetate. The organic layer was washed with brine. The organic layer was dried over anhydrous magnesium sulfate and the insoluble material was removed by filtration. The filtrate was evaporated under reduced pressure.
- The residue was dissolved in THF (1 mL) and DBU (20 mg) was added under ice-cooling. After the mixture was stirred at the same temperature for 15 minutes, it was warmed to room temperature and stirred at room temperature for 1.5 hours. Water and ethyl avetate were added to the reaction mixture and the organic layer was partitioned. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (I-1) (10 mg).
-
- To a solution of a known compound (1) (550 mg) which can be prepared according to the method described in Patent Literature 4 in concentrated sulfuric acid (3.3 mL) was dropwisely added fuming nitric acid (0.12 mL) under ice-cooling and the mixture was stirred at the same temperature for 1 hour. After the reaction mixture was poured into ice water and a saturated aqueous sodium bicarbonate solution, the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (9) (610 mg).
- 1H-NMR (CDCl3) δ:3.41 (1H, q, J=7.4 Hz), 3.55-3.61 (1H, m), 3.87 (2H, ddd, J=21.0, 10.4, 3.2Hz), 4.03 (1H, d, J=9.6 Hz), 4.13-4.19 (1H, m), 4.57 (1H, t, J=8.4 Hz), 5.17 (1H, s), 7.21 (1H, dd, J=10.3, 8.9 Hz), 8.19 (1H, d dd, J=8.9, 4.3, 3.0 Hz), 8.88 (1H, dd, J=6.7, 3.0 Hz)
- To a solution of Compound (9) (30 mg) in ethanol (0.75 mL) were added reduced iron (53 mg) and a saturated aqueous ammonium chloride solution (0.19 mL). The mixed solution was stirred at 50° C. for 1 hour and cooled to room temperature. The solution was filtered and the filtrate was extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (10) (610 mg).
- 1H-NMR (CDCl3) δ:3.39 (1H, dd, J=14.2, 7.5 Hz), 3.43-3.76 (3H, m), 3.79-3.88 (2H, m), 3.95 (1H, d, J=9.5H z), 4.10-4.17 (1H, m), 4.51 (1H, t, J=7.9 Hz), 5.06 (1H, s), 6.53 (1H, ddd, J=8.6, 3.9, 3.1 Hz), 6.84 (1H, dd, J=11. 2, 8.6 Hz), 7.22 (1H,brs)
- To a solution of Compound (10) (490 mg) in methanol (5 mL) were added ethyl trifluoroacetate (652 mg) and triethylamine (0.30 mL) at room temperature. The mixture was stirred at the same temperature for 4 hours. After being diluted with water, the aqueous layer was extracted with ethyl acetate and the organic layer was washed with brine. The organic layer was dried over anhydrous magnesium sulfate. The insoluble material removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (11) (610 mg).
- 1H-NMR (CDCl3) δ:3.40 (1H, dd, J=14.4, 7.7 Hz), 3.57 (1H, t, J=8.1 Hz), 3.86 (2H, d, J=2.7 Hz), 4.00 (1H, d, J=9.3 Hz), 4.16 (1H, ddd, J=9.3, 5.8, 2.3 Hz), 4.55 (1H, t, J=8.5 Hz), 5.14 (1H, s), 7.11 (1H, dd, J=10.8, 8.8 Hz), 7.78 (1H, dd, J=6.6, 2.9 Hz), 7.89 (1H, ddd, J=8.8, 4.3, 2.9Hz), 7.95 (1H, s).
- To a solution of Compound (11) (627 mg) in ethanol (12 mL) was added 5% Rh/C (121 mg) at room temperature. The mixed solution was stirred at the same temperature for 29 hours under hydrogen atmosphere. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure.
- The residue containing Compound (12) was dissolved in THF (3 mL). To the solution was added di-tert-butyldicarbonate (855 mg) at room temperature and the mixture was refluxed for 1 hour. The reaction mixture was cooled to room temperature and evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (13) (695 mg).
- 1H-NMR (CDCl3) δ:1.37 (9H, s), 3.16-3.31 (1H, m), 3.55 (1H, t, J=8.5 Hz), 3.77 (2H, t, J=6.4 Hz), 3.87-4.11 (3H, m), 4.23 (1H, d, J=8.4 Hz), 5.76 (1H, s), 7.07 (1H, dd, J=11.3, 8.8 Hz), 7.68-7.75 (1H, m), 7.85-7.92 (1H, m), 8.57 (1H, s)
- To a solution of Compound (13) (690 mg) in ethyl acetate (7 mL) was added 2-iodoxybenzoic acid (549 mg) at room temperature. The reaction mixture was stirred at 80° C. for 5 hours. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The crude product was purified by silica gel chromatography to give Compound (14) (386 mg).
- 1H-NMR (CDCl3) δ:1.33 (s, 9H), 3.76 (m, 1H), 4.07-4.17 (m, 2H), 4.29 (dd, J=9.5, 2.1 Hz, 1H), 4.40 (dd, J=9. 2, 6.9 Hz, 1H), 5.60 (brs, 1H), 7.12 (m, 1H), 7.63-7.70 (m, 2H), 8.17 (brs, 1H), 9.85 (d, J=2.9, 1H)
- To a solution of methyltriphenylphosphonium iodide (2.74 g) in THF (10 mL) was added n-butyl lithium hexane solution (2.61 mL, 2.6 M) was dropwisely added under nitrogen atmosphere under ice-cooling. The reaction mixture was stirred at the same temperature for 30 minutes. After the mixture was stirred at room temperature for 1 hour, a solution of Compound (14) (285 mg) in THF (1 mL) was dropwisely added to the reaction mixture under nitrogen atmosphere. After the mixture was stirred at the same temperature for 30 minutes, it was poured into an ice water containing ammonium chloride and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (15) (38 mg).
- 1H-NMR (CDCl3) δ:1.36 (9H, s), 3.15-3.22 (1H, m), 3.81 (1H, dd, J=8.8, 6.1 Hz), 4.04-4.15 (2H, m), 4.76-4.8 0 (1H, m), 5.24-5.37 (3H, m), 5.81 (1H, ddd, J=17.9, 9.5, 7.8H_), 7.09 (1H, dd, J=11.4, 8.9 Hz), 7.45-7.46 (1H, m), 7.64-7.69 (1H, m), 7.90 (1H, s)
- To a solution of Compound (15) (52 mg) in methylene chloride (2 mL) was added trifluoroacetic acid (0.2 mL) under ice-cooling and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added a saturated aqueous sodium bicarbonate solution under ice cooling and the aqueous layer was extracted with methylene chloride. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (16) (37 mg).
- 1H-NMR (CDCl3) δ:3.45 (1H, dd, J=17.1, 8.2 Hz), 3.93-3.99 (2H, m), 4.13-4.20 (2H, m), 5.17-5.29 (2H, m), 5.76-5.87 (1H, m), 7.09 (1H, dd, J=11.4, 8.8 Hz), 7.53 (1H, ddd, J=8.8, 4.0, 2.8 Hz), 7.80 (1H, dd, J=6.9, 2.7 Hz), 7.84 (1H, s)
- To a solution of Compound (16) (37 mg) in acetone (2 mL) was added benzoyl isothiocyanate (22 mg) under ice-cooling and the mixture was stirred at room temperature for 150 minutes. The solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (17) (56 mg).
- 1H-NMR (CDCl3) δ:3.26 (1H, dd, J=14.7, 6.3 Hz), 3.89 (1H, dd, J=9.0, 5.8 Hz), 4.08-4.15 (1H, m), 4.36 (1H, d, J=10.2 Hz), 5.26 (1H, d, J=10.2 Hz), 5.43 (1H, d, J=16.9 Hz), 5.54 (1H, d, J=10.2 Hz), 5.91-6.03 (1H, m), 7.1 1 (1H, dd, J=11.2, 8.9 Hz), 7.40 (1H, dd, J=6.9, 2.7 Hz), 7.48-7.53 (2H, m), 7.59-7.65 (1H, m), 7.75-7.85 (3H, m), 7.96 (1H, s), 8.86 (1H, s), 11.48 (1H, s)
- To a solution of Compound (17) (56 mg) in methylene chloride (2 mL) was added iodine (62 mg) under ice-cooling. The reaction mixture was warmed to room temperature and stirred at room temperature for 50 minutes. An aqueous sodium thiosulfate solution and a saturated aqueous sodium bicarbonate solution were added to the reaction mixture and the aqueous layer was extracted with methylene chloride. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure.
- The residue containing Compound (18) was dissolved in THF (2 mL) and was added DBU (44 mg) under ice-cooling. The mixture was stirred at room temperature for 50 minutes. Water and ethyl acetate were added to the mixture and the mixture was partitioned. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (19) (36 mg).
- 1H-NMR (CDCl3) δ:3.97 (1H, t, J=9.0 Hz), 4.09 (1H, t, J=9.0 Hz), 4.25 (1H, t, J=9.0 Hz), 4.31-4.32 (2H, m), 5.38 (1H, d, J=0.8 Hz), 5.46 (1H, s), 7.15 (1H, dd, J=11.1, 8.8 Hz), 7.40-7.46 (2H, m), 7.50-7.68 (3H, m), 8.05-8. 08 (3H, m)
- To a solution of Compound (19) (36 mg) in THF (1.5 mL) were added di-tert-butyldicarbonate (45 mg) and DMAP (11 mg) at room temperature. The mixture was stirred at room temperature for 1 hour and the evaporated at 40° C. under reduced pressure. The residue was roughly purified by silica gel chromatography.
- After the obtained crude purified product (43 mg) containing Compound (20) was dissolved in THF (0.75 mL), methanol (0.75 mL) and water (0.45 mL) were added thereto. Potassium carbonate (61 mg) was addedto the mixture at room temperature, and the mixture was stirred at the same temperature for 2 hours. After the reaction mixture was warmed to 45° C. and stirred for 150 minutes, it was cooled to room temperature. To the reaction mixture was added potassium carbonate (61 mg), and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure.
- The obtained residue containing Compound (21) (35 mg) was dissolved in methylene chloride (1.5 mL). To the mixture was added trifluoroacetic acid (0.15 mL) under ice-cooling and the mixture was stirred at room temperature for 150 minutes. 2N Aqueous solution of sodium hydroxide (1 mL) and water were added to the reaction mixture. The aqueous layer was extracted with chloroform-methanol (9:1). The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give Compound (I-2) (18 mg).
- 1H-NMR (CDCl3) δ:3.52 (2H, s), 3.74-3.89 (2H, m), 4.08 (1H, d, J=8.1 Hz), 4.14 (1H, dd, J=8.1, 3.3 Hz), 4.37 (1H, dd, J=8.1, 1.1 Hz), 5.16 (1H, s), 5.28 (1H, s), 6.51 (1H, ddd, J=8.7, 3.6, 3.0 Hz), 6.61 (1H, dd, J=6.6, 3.0 Hz), 6.83 (1H, dd, J=11.7, 8.7 Hz).
- To a solution of Compound (I-2) (18 mg) in methanol (0.75 mL) was added 2M hydrochloric acid (0.032 mL) and the mixture was stirred at room temperature for 10 minutes. To the mixture were added 5-cyanopicolinic acid hydrate (11 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (13 mg) under ice-cooling. The mixture was stirred at the same temperature for 10 minutes, warmed to room temperature and stirred for 50 minutes. To the reaction mixture were added 5-cyanopicolinic acid hydrate (11 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (13 mg) under ice-cooling. The mixture was warmed to room temperature and stirred for 50 minutes. 2N Aqueous solution of sodium hydroxide (0.032 mL) and 50% aqueous solution of potassium carbonate were added to the reaction mixture under ice-cooling. To the mixture were added water and ethyl acetate and the organic layer was partitioned. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The insoluble material was removed by filtration and the filtrate was evaporated under reduced pressure. Diethyl ether was added to the residue and the precipitated solid was collected by filtration. The obtained solid was washed with diethyl ether and ethyl acetate to give Compound (I-3) (13 mg).
-
- To a solution of Compound (22) (1.50 g) in ethyl acetate (15 ml) was added 2-iodoxy benzoic acid (4.78 g) at room temperature. The mixture was heated under reflux for 3 hours. After the reaction mixture was cooled to room temperature and filtered, the filtrate was evaporated under reduced pressure at room temperature. To a solution of the residue in a 50% aqueous ethanol solution (40 ml) were added hydroxylamine hydrochloride (1.37 g) and sodium acetate (1.94 g) at room temperature and the mixture was stirred for 90 minutes. The solvent was evaporated under reduced pressure and ethyl acetate was added to the residue. The organic layer was successively washed with water and brine, and dried over anhydrous magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure to give Compound (23) (1.27 g).
- MS; m/z 128 [M++H]
- 1H-NMR (CDCl3) δ: 1.40-1.55 (4H, m), 2.04-2.12 (2H, m), 2.17-2.24 (1H, m), 2.35-2.42 (1H, m), 4.92-5.04 (2H, m), 5.72-5.86 (1H, m), 6.71 and 7.41 (1H, each t, J=5.5 Hz and J=6.1 Hz), 7.19 and 7.52 (1H, each br s).
- To a solution of Compound (23) (1.26 g) in methylene chloride (44 ml) was added a 5% aqueous solution of sodium hypochlorite (14.7 ml) at room temperature. The mixture was stirred at the same temperature for 30 minutes and the partitioned organic layer was dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was purified by chromatography to give Compound (24) (1.07 g).
- MS; m/z 126 [M++H]
- 1H-NMR (CDCl3) δ: 1.26-1.50 (3H, m), 1.81-1.92 (1H, m), 1.94-2.19 (3H, m), 2.76-2.82 (1H, m), 3.11-3.18 (1H, m), 3.77 (1H, dd, J=10.2, 8.0 Hz), 4.49 (1H, dd, J=10.2, 8.0 Hz).
- To a solution of 2-bromofluorobenzene (2.98 g) in toluene/tetrahydrofuran (36 ml/9 ml) was dropwisely added n-butyllithium hexane solution (1.65 mol/L, 10.3 ml) at −70° C. under nitrogen atmosphere. The mixture was stirred at the same temperature for 30 minutes. Boron trifluoride-diethyl ether complex (1.08 ml) was dropwisely added the mixture and the mixture stirred for 25 minutes. A solution of Compound (24) (1.07 g) in toluene (54 ml) was dropwisely added to the mixture at the same temperature and the mixture was stirred for 75 minutes. To the mixture was added an aqueous solution of ammonium chloride and the aqueous layer was extracted with ethyl acetate. The obtained organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure. The obtained residue was roughly purified by column chromatography and a solid was precipitated from diethyl ether-hexane solution to give Compound (25) (1.17 g).
- MS; m/z 222 [M++H]
- 1H-NMR (CDCl3) δ: 1.31-1.60 (3H, m), 1.63-1.91 (4H, m), 2.19-2.29 (1H, m), 2.87-2.94 (1H, m), 3.55 (1H, br s), 3.66 (1H, d, J=6.7 Hz), 5.96 (1H, s), 7.01 (1H, ddd, J=12.3, 8.0, 1.3 Hz), 7.12 (1H, td, J=7.5, 1.3 Hz), 7.19-7.26 (1H, m), 7.83 (1H, t, J=7.8 Hz).
- To a solution of Compound (25) (1.17 g) in concentrated sulfuric acid (7 ml) was dropwisely added fuming nitric acid (0.24 ml) under ice-cooling. The mixture was stirred at the same temperature for 1 hour. After an aqueous solution of sodium carbonate was added to the mixture and quenched, the mixture was extracted with chloroform. The obtained organic layer was dried over magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure and ethyl acetate-diethyl ether-hexane solution was added to the residue. The precipitated solid was collected by filtration to give Compound (26) (1.29 g).
- MS; m/z 267 [M++H]
- 1H-NMR (CDCl3) δ: 1.31-1.59 (3H, m), 1.70-1.96 (4H, m), 2.11-2.22 (1H, m), 2.85-2.92 (1H, m), 3.51 (1H, dd, J=7.0, 5.6 Hz), 3.68 (1H, d, J=7.0 Hz), 6.00 (1H, s), 7.16 (1H, dd, J=10.8, 8.9 Hz), 8.14 (1H, ddd, J=8.9, 4.1, 3.0 Hz), 8.81 (1H, dd, J=6.9, 3.0 Hz).
- To a solution of Compound (26) (1.29 g) in ethanol (32 ml) were added iron (2.15 g) and an aqueous solution of ammonium chloride (8 mol/L, 7.84 ml) at room temperature. The mixture was stirred at 45° C. for 2 hours. The reaction mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried over magnesium sulfate and the extract was filtered. The filtrate was evaporated under reduced pressure and diethyl ether-hexane solution was added to the residue. The precipitated solid was collected by filtration to give Compound (27) (989 mg).
- MS; m/z 237 [M++H]
- 1H-NMR (CDCl3) δ: 1.24-1.53 (3H, m), 1.67-1.90 (4H, m), 2.21 (1H, td, J=13.8, 4.9 Hz), 2.84-2.91 (1H, m), 3.56-3.66 (4H, m), 5.93 (1H, br s), 6.50 (1H, ddd, J=8.4, 3.4, 3.0 Hz), 6.80 (1H, dd, J=11.7, 8.4 Hz), 7.16 (1H, dd, J=6.8, 3.0 Hz).
- To a solution of Compound (27) (1.08 g) in methanol (10 ml) were added ethyl trifluoroacetate (1.14 ml) and triethylamine (0.63 ml) at room temperature. The mixture was stirred at the same temperature for 4 hours and the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water and brine, and dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was purified by column chromatography to give Compound (28) (1.41 g).
- MS; m/z 333 [M++H]
- 1H-NMR (CDCl3) δ: 1.30-1.56 (3H, m), 1.73-1.94 (4H, m), 2.21 (1H, td, J=13.9, 4.8 Hz), 2.85-2.93 (1H, m), 3.52 (1H, t, J=6.1 Hz), 3.67 (1H, d, J=7.0 Hz), 5.99 (1H, s), 7.07 (1H, dd, J=11.3, 8.8 Hz), 7.64 (1H, dd, J=6.9, 2.9 Hz), 7.90-7.95 (2H, m).
- To a solution of Compound (28) (1.41 g) in ethanol (14 ml) was added 5% Rh/C at room temperature. The mixture was stirred at the same temperature for 23 hours under hydrogen atmosphere. The reaction mixture was filtered through Celite and the obtained filtrate was evaporated under reduced pressure. The obtained residue was dissolved in tetrahydrofuran (10 ml) and was added di-tert-butyl dicarbonate at room temperature. The mixture was stirred at 70° C. for 14 hours and the solvent was evaporated under reduced pressure. The obtained residue was purified by column chromatography to give Compound (29) (1.23 g).
- MS; m/z 435 [M++H]
- 1H-NMR (CDCl3) δ: 1.35-1.64 (13H, m), 1.83-2.02 (3H, m), 2.14-2.19 (1H, m), 2.79-2.89 (1H, m), 3.42-3.54 (2H, m), 6.34 (1H, br s), 7.03 (1H, dd, J=12.0, 8.8 Hz), 7.44-7.47 (1H, m), 7.54-7.60 (1H, m), 8.04 (1H, br s).
- To a solution of Compound (29) (1.23 g) in tetrahydrofuran/methanol/water (6 ml/8 ml/8 ml) was added potassium carbonate (938 mg) at room temperature. The mixture was stirred at 50° C. for 5.5 hours and ethyl acetate and water were added to the mixture. The organic layer was partitioned, washed with brine and dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was purified by column chromatography to give Compound (30) (791 mg).
- MS; m/z 339 [M++H]
- 1H-NMR (CDCl3) δ: 1.36-2.13 (19H, m), 2.90 (1H, d, J=13.4 Hz), 3.43-3.53 (2H, m), 6.35 (1H, br s), 6.50 (1H, dt, J=8.5, 3.0 Hz), 6.68 (1H, dd, J=6.8, 3.0 Hz), 6.78 (1H, dd, J=12.4, 8.5 Hz).
- To a solution of Compound (30) (789 mg) in tetrahydrofuran/water (12 ml/2.4 ml) were added 2-nitrobenzenesulfonyl chloride (1.03 g) and triethyl amine (0.97 ml) under ice-cooling. The mixture was stirred at room temperature for 4.5 hours. To the reaction mixture were added a saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was partitioned, washed with brine and dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. To the residue was added methylene chloride and the precipitated solid was collected by filtration to give Compound (31) (1.02 g).
- MS; m/z 524 [M++H]
- 1H-NMR (CDCl3) δ: 1.23-1.55 (13H, m), 1.84-2.06 (4H, m), 2.80 (1H, d, J=12.7 Hz), 3.18-3.24 (1H, m), 3.39 (1H, td, J=7.4, 3.7 Hz), 6.27 (1H, br s), 6.89 (1H, dd, J=11.9, 8.5 Hz), 7.05 (1H, dt, J=8.5, 3.0 Hz), 7.17 (1H, s), 7.28 (1H, dd, J=7.0, 2.7 Hz), 7.58 (1H, td, J=7.7, 1.2 Hz), 7.67 (1H, td, J=7.7, 1.2 Hz), 7.83 (2H, t, J=7.8 Hz).
- To a solution of Compound (31) (1.02 g) in ethyl acetate (10 ml) was added 2-iodoxybenzoic acid (761 mg) at room temperature. The mixture was heated under reflux for 6 hours. After the reaction mixture was cooled to room temperature and filtered, the filtrate was evaporated under reduced pressure at room temperature. To the residue was added 2 mol/L hydrochloric acid-methanol solution at room temperature and the mixture was stirred at the same temperature for 2 hours. After standing overnight, an aqueous solution of sodium carbonate and ethyl acetate were added to the reaction solution. The organic layer was partitioned, washed with brine and dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was purified by column chromatography to give Compound (32) (875 mg).
- MS; m/z 468 [M++H]
- 1H-NMR (CDCl3) δ: 1.27-1.41 (2H, m), 1.49-1.64 (3H, m), 1.70-1.85 (2H, m), 2.03-2.13 (1H, m), 2.47 (1H, dt, J=12.0, 3.2 Hz), 3.05 (3H, s), 3.14 (3H, s), 3.62 (1H, d, J=2.7 Hz), 6.91 (1H, dd, J=11.9, 8.6 Hz), 7.12 (1H, ddd, J=8.6, 3.9, 2.9 Hz), 7.57 (1H, td, J=7.6, 1.2 Hz), 7.65-7.72 (2H, m), 7.84 (2H, ddd, J=11.7, 7.9, 1.2 Hz).
- To a solution of Compound (32) (872 g) in acetone (8.7 ml) was added benzoyl isothiocyanate (342 mg) under ice-cooling. The mixture was stirred at room temperature for 50 minutes. The solvent was evaporated under reduced pressure and the obtained residue was roughly purified by column chromatography. Diethyl ether-hexane solution was added to the oil and the precipitated solid was collected by filtration to give Compound (33) (1.06 g).
- MS; m/z 629 [M+-H]
- Compound (33) (500 mg) was dissolved in concentrated sulfuric acid (6.34 ml) at room temperature and the solution was stirred at the same temperature for 15.5 hours. To the mixture was added an aqueous solution of sodium carbonate under ice-cooling and extracted with ethyl acetate. The organic layer was partitioned, washed with brine and dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was purified by column chromatography to give Compound (34) (170 mg).
- MS; m/z 463 [M+-H]
- 1H-NMR (CDCl3) δ: 1.19-1.48 (2H, m), 1.61-1.69 (2H, m), 1.81-1.90 (1H, m), 2.06-2.18 (1H, m), 2.32-2.39 (1H, m), 2.56-2.64 (1H, m), 6.04 (1H, d, J=1.7 Hz), 6.89-6.98 (1H, m), 7.01-7.08 (2H, m), 7.55 (1H, td, J=7.7, 1.3 Hz), 7.65-7.75 (2H, m), 7.83 (1H, dd, J=7.9, 1.3 Hz).
- To a solution of Compound (34) (365 mg) in N,N-dimethylacetamide were added triethylamine (1.09 ml) and 4-chlorobenzenethiol (571 mg) at room temperature. The mixture was stirred at 60° C. for 2 hours. After the mixture was acidified with 1 mol/L aqueous hydrochloric acid, it was washed with ethyl acetate. The aqueous layer was alkalinized with an aqueous solution of sodium carbonate and extracted with chloroform-methanol (9:1) solution.
- The partitioned organic layer was dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was purified by column chromatography to give Compound (35) (146 mg).
- MS; m/z 278 [M++H]
- 1H-NMR (CDCl3) δ: 1.37-1.61 (2H, m), 1.69-1.76 (2H, m), 1.87-1.96 (1H, m), 2.27-2.42 (2H, m), 2.71-2.78 (1H, m), 3.52 (2H, br s), 6.00 (1H, d, J=1.2 Hz), 6.52 (1H, ddd, J=8.5, 3.3, 2.9 Hz), 6.61 (1H, dd, J=6.6, 2.9 Hz), 6.83 (1H, dd, J=11.9, 8.5 Hz).
- To a solution of Compound (35) (42 mg) in methanol (1 ml) was added an aqueous hydrochloric acid (2 mol/1.76 μl) at room temperature. The mixture was stirred at the same temperature for 10 minutes. To the mixture were added 5-methoxypyrazine-2-carboxylic acid (27.7 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (31.9 mg) under ice-cooling and the mixture was stirred at room temperature for 50 minutes. The mixture was alkalinized with an aqueous solution of sodium hydroxide (2 mol/L, 76 μL) and 50% aqueous solution of potassium carbonate, and extracted with ethyl acetate. The organic layer was washed with water and brine and dried over magnesium sulfate. The extract was filtered and the filtrate was evaporated under reduced pressure. The obtained residue was roughly purified by chromatography and diethyl ether was added to the oil. The precipitated solid was collected by filtration to give Compound (I-17) (34 mg).
-
- To a solution of Compound (36) (4.03 g) in acetone (30 ml) was added benzoyl isothiocyanate (1.85 ml) with stirring in an ice bath. The mixture was warmed to room temperature and stirred for 3 hours. The solvent was evaporated under reduced pressure and the obtained residue was roughly purified by chromatography to give Compound (37) (6.07 g).
- MS; m/z 486 [M++H]
- To a solution of Compound (37) (6.07 g) in dichloromethane (60 ml) was gradually added meta-chloroperoxybenzoic acid (7.09 g) with stirring in an ice bath. The mixture was warmed to room temperature and stirred for 3 hours. To the reaction mixture was added a saturated aqueous sodium bicarbonate solution and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution and brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the obtained residue was purified by chromatography to give Compound (38) (3.61 g).
- MS; m/z 452 [M++H]
- 1H-NMR (CDCl3) δ: 3.91-4.27 (7H, m), 7.12 (1H, t, J=10.0 Hz), 7.33 (2H, t, J=7.2 Hz), 7.44 (1H, t, J=6.4 Hz), 7.72 (1H, d, J=5.2 Hz), 7.95 (2H, s), 8.06 (3H, d, J=7.2 Hz), 10.04 (1H, s).
- To a solution of Comopund (38) (2.6 g) in tetrahydrofuran (10 ml)-methanol (10 ml)-water (10 ml) was added potassium carbonate (2.37 g) at room temperature. The mixture was stirred at 40° C. for 23 hours. Water was added to the mixture and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure to give Compound (39) (1.77 g).
- MS; m/z 356 [M++H]
- 1H-NMR (DMSO-d6) δ: 3.86-4.17 (5H, m), 4.32 (1H, d, J=11.1 Hz), 4.46 (1H, d, J=11.1 Hz), 5.16 (2H, s), 6.58 (1H, s), 6.75 (1H, s), 6.98 (1H, t, J=10.4 Hz), 7.45 (2H, t, J=7.2 Hz), 7.53 (1H, t, J=7.2 Hz), 8.09 (2H, d, J=8.0 Hz), 11.46 (1H, s).
- To a solution of Compound (39) (1.77 g) in concentrated hydrochloric acid (17 ml) was dropwisely added an aqueous solution (7.5 ml) of sodium nitrite (687 mg) with stirring in an ice bath. The mixture was warmed to room temperature and stirred at the same temperature for 1 hour. The reaction mixture was gradually added to a solution of potassium iodide (4.1 g) in water (10 ml) in an ice bath. The mixture was warmed to room temperature and stirred for 2 hours. Water was added to the mixture and extracted with ethyl acetate. The organic layer was washed with 10% sodium thiosulfate and brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by chromatography to give Compound (40) (1.28 g).
- MS; m/z 465 [M++H]
- 1H-NMR (CDCl3) δ: 3.25 (1H, s), 4.08-4.14 (3H, m), 4.23-4.32 (3H, m), 6.92 (1H, t, J=10.0 Hz), 7.39-7.50 (3H, m), 7.69 (1H, s), 7.80 (1H, d, J=6.4 Hz), 8.21 (2H, d, J=6.8 Hz), 11.81 (1H, s).
- To a solution of Compound (40) (1.28 g) in tetrahydrofuran (15 ml) were added di-tert-butyl dicarbonate (0.89 ml) and dimethylamino pyridine (402 mg). The mixture was stirred at room temperature for 5 hours. Water was added to the mixture and extracted with ethyl acetate. The organic layer was washed with water and brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure to give Comopund (41) (1.74 g) as a crude product.
- MS; m/z 567 [M++H]
- To a solution of Compound (41) (1.55 g) in tetrahydrofuran (5 ml), methanol (5 ml) and water (1 ml) was added potassium carbonate (1.14 g). The mixture was stirred at room temperature for 17 hours. To the mixture was added a saturated aqueous sodium bicarbonate solution and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure and ethyl acetate was added to the residue. The precipitated solid was collected to give Compound (42) (972 mg).
- MS; m/z 463 [M++H]
- Compound (42) (80 mg), aryl boronic acid (1.5 equivalent) and dichlorobis(triphenylphosphine)palladium (14 mg) were dissolved in dimethylformamide (0.5 ml).
- To a solution was added a 2 mol/L aqueous solution of sodium carbonate (260 ml) and stirred at 100° C. for 6 hours under nitrogen atmosphere. Water was added to the mixture and extracted with ethyl acetate. The organic layer was washed with water and brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the obtained residue was purified by reversed phase chromatography to give Compound (I-40) (27 mg).
-
- A solution of Compound (43) (1.80 g) in concentrated sulfuric acid (1 ml) was stirred at 60° C. for 1.5 hours. The reaction mixture was poured into ice water and neutralized with a 2 mol/L aqueous solution of sodium hydroxide. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution and brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure to give Compound (44) (1.39 g).
- MS; m/z 364 [M++H]
- 1H-NMR (CDCl3) δ: 1.26 (1H, t, J=7.2 Hz), 3.01-3.07 (2H, m), 3.79 (1H, dd, J=2.3, 8.2 Hz), 4.10-4.15 (2H, m), 4.41 (1H, dd, J=1.8, 8.7 Hz), 7.10 (1H, dd, J=11.7, 9.0 Hz), 7.44-7.48 (1H, m), 7.74-7.77 (1H, m).
- To a solution of Compound (44) (1.39 g) in methanol (15 tetrahydrofuran (5 ml) and water (5 ml) was added potassium carbonate (1.57 g) and the mixture was stirred at 40° C. for 17 hours. To the mixture was added a saturated aqueous sodium bicarbonate solution and the mixture was extracted with chloroform-methanol (9:1) solution. The organic layer was washed with brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure to give Compound (45) (923 g).
- MS; m/z 268 [M++H]
- 1H-NMR (CDCl3) δ: 2.79 (1H, dd, J=14.2, 6.0 Hz), 3.04-3.11 (2H, m), 3.59 (2H, s), 3.77 (1H, dd, J=8.5, 2.2 Hz), 4.10 (2H, dt, J=17.0, 6.8 Hz), 4.44 (1H, dd, J=8.4, 1.4 Hz), 6.50-6.55 (1H, m), 6.75-6.87 (2H, m).
- To a solution of Compound (45) (50 mg) in methanol (1 ml) was added 2 mol/L hydrochloric acid (0.099 ml) and the mixture was stirred at room temperature for 15 minutes. Carboxylic acid (34 mg) and WSCD hydrochloride were added to the reaction mixture and the mixture was stirred at the same temperature for 1.5 hours. A 10% aqueous sodium bicarbonate solution was added to the mixture and the precipitated solid was collected by filtration. The solid was washed with water and heat-dried to give Compound (I-35) (34 mg).
- The following compounds are prepared according to the above examples. In the tables, RT represents a retention time (minutes).
-
TABLE 1-1 Compound NMR MS LC/MS LC/MS No. Structure (solvent: shift value ascending order) [M + 1] RT Method I-1 1H-NMR (CDCl3) δ: 3.76 (m, 1H), 3.86 (dd, J = 9.6, 7.8 Hz, 1H), 4.11 (t, J = 8.2 Hz, 1H), 4.25 (dd, J = 8.2, 3.6 1H), 4.38 (dd, J = 8.2, 1.1, 1H), 5.18 (s, 1H), 5.30 (m, 1H), 7.00-7.11 (m, 2H), 7.25 (m, 1H), 7.33 (td, J = 7.9, 1.8, 1H). 265 1.13 B I-2 1H-NMR (CDCl3) δ: 3.52 (2H, s), 3.74-3.89 (2H, m), 4.08 (1H, d, J = 8.1 Hz), 4.14 (1H, dd, J = 8.1, 3.3 Hz), 4.37 (1H, dd, J = 8.1, 1.1 Hz), 5.16 (1H, s), 5.28 (1H, s), 6.51 (1H, ddd, J = 8.7, 3.6, 3.0 Hz), 6.61 (1H, dd, J = 6.6, 3.0 Hz), 6.83 (1H, dd, J = 11.7, 8.7 Hz). I-3 1H-NMR (CDCl3) δ: 3.86 (2H, td, J = 17.0, 8.9 Hz), 4.12 (1H, d, J = 8.2 Hz), 4.18 (1H, dd, J = 8.0, 3.3 Hz), 4.40 (1H, dd, J = 8.1, 1.2 Hz), 4.56 (2H, br s), 5.20 (1H, s), 5.33 (1H, s), 7.09 (1H, dd, J = 11.5, 8.8 Hz), 7.55 (1H, dd, J = 6.9, 2.7 Hz), 7.83 (1H, ddd, J = 8.8, 4.0, 2.8 Hz), 8.19 (1H, dd, J = 8.2, 2.0 Hz), 8.41 (1H, dd, J = 8.2, 0.8 Hz), 8.88 (1H, dd, J = 2.0, 0.9 Hz), 9.79 (1H, s). 410 1.06 A -
TABLE 1-5 Com- NMR pound (solvent: shift value MS LC/MS LC/MS No. Structure ascending order) [M + 1] RT Method I-33 1H-NHR (DMSO-d6) δ: 3.21 (1H, dd, J = 5.2, 2.0 Hz), 3.88-4.25 (5H, m), 4.35-4.60 (2H, m), 7.38 (1H, t, J = 10.3 Hz), 8.08-8.20 (2H, m), 8.35 (1H, d, J = 8.2 Hz), 8.65 (1H, dt, J = 8.2, 2.1, Hz), 9.26 (1H, s), 11.04 (1H, s). 382 1.36 B I-34 1H-NHR (CDCl3) δ: 0.85 (2H, s), 2.69 (3H, s), 3.07 (1H, s), 3.78 (1H, d, J = 7.2 Hz), 3.95-4.05 (4H, m), 4.22-4.32 (3H, m), 7.09 (1H, t, J = 9.6 Hz), 7.75 (1H, d, J = 6.4 Hz), 8.01 (1H, s), 8.43 (1H, s), 9.35 (1H, s), 9.68 (1H, s). 372 0.84 C I-35 1H-NHR (DMSO-d6) δ: 2.88 (1H, s), 3.66 (1H, d, J = 6.4 Hz), 3.79-3.87 (2H, m), 4.02-4.06 (6H, m), 5.53 (2H, s), 7.15 (1H, t, J = 10.4 Hz), 7.79 (1H, s), 8.06 (1H, d, J = 6.0 Hz), 8.40 (1H, s), 8.88 (1H, s), 10.52 (1H, s). 388 0.91 A I-36 1H-NHR (DMSO-d6) δ: 2.88 (1H, s), 3.66 (1H, d, J = 6.0 Hz), 3.79-3.88 (2H, m), 4.00-4.06 (3H, m), 5.56 (2H, s), 7.15 (1H, t, J = 10.4 Hz), 7.82 (1H, s), 8.06 (1H, d, J = 4.4 Hz), 8.17 (2H, dd, J = 8.4, 14.0 Hz), 8.77 (1H, s), 10.68 (1H, s). 391 1.05 A I-37 1H-NHR (DMSO-d6) δ: 1.85 (3H, s), 2.88 (1H, s), 3.66 (1H, d, J = 5.8 Hz), 3.79-3.88 (2H, m), 3.99-4.08 (3H, m), 5.08 (2H, s), 5.53 (2H, s), 7.15 (1H, t, J = 10.2 Hz), 7.78 (1H, s), 8.07 (1H, d, J = 5.4 Hz), 8.43 (1H, s), 8.88 (1H, s), 10.54 (1H, s). 426 1.16 A I-38 1H-NHR (DMSO-d6) δ: 1.70 (5H, s), 1.94-1.99 (1H, m), 2.31 (1H, s), 3.69 (1H, d, J = 10.4 Hz), 3.89 (1H, d, J = 8.8 Hz), 5.40 (2H, s), 7.13 (1H, s), 7.77 (1H, s), 7.97 (1H, s), 8.28 (1H, d, J = 7.2 Hz), 8.59 (1H, d, J = 7.2 Hz), 9.20 (1H, s), 10.79 (1H, s). 380 1.1 A -
TABLE 1-6 Compound NMR MS LC/MS LC/MS No. Structure (solvent: shift value ascending order) [M + 1] RT Method I-39 1H-NMR (DMSO-d6) δ: 1.72-1.88 (5H, m), 2.05 (1H, br s), 2.32-2.39 (1H, m), 2.73 (1H, s), 3.91 (1H, d, J = 10.4 Hz), 4.06 (1H, d, J = 10.4 Hz), 7.36 (1H, t, J = 10.4 Hz), 7.75 (1H, s), 7.87 (1H, d, J = 6.8 Hz), 9.07 (2H, s), 9.19 (1H, s). 313 0.84 D I-40 1H-NMR (DMSO-d6) δ: 1.69-1.79 (2H, m), 1.91 (1H, s), 2.14 (2H, br s), 2.99 (1H, s), 4.27 (1H, d, J = 12.8 Hz), 4.41 (1H, d, J = 12.0 Hz), 7.41-7.51 (2H, m), 7.68 (2H, s), 8.28-8.20 (2H, m). 330 1.12 D I-41 1H-NMR (DMSO-d6) δ: 1.72 (4H, s), 1.98 (1H, d, J = 7.6 Hz), 2.33 (1H, d, J = 7.6 Hz), 2.59 (1H, s), 3.70 (1H, d, J = 10.8 Hz), 3.90 (4H, s), 5.58 (2H, s), 7.26 (1H, t, J = 10.0 Hz), 7.50 (1H, s), 7.63 (1H, br s), 7.87 (1H, d, J = 8.0 Hz), 8.28 (1H, s), 8.38 (1H, s). 342 0.9 D I-42 1H-NMR (DMSO-d6) δ: 2.96 (1H, s), 3.67 (1H, d, J = 7.2 Hz), 3.84 (2H, d, J = 9.2 Hz), 4.01 (1H, d, J = 11.2 Hz), 4.11 (2H, s), 5.70 (2H, s), 7.33 (1H, t, J = 10.2 Hz), 7.48 (1H, t, J = 5.2 Hz), 7.57 (1H, s), 7.89 (1H, d, J = 7.2 Hz), 8.07 (1H, t, J = 8.4 Hz), 8.26 (1H, d, J = 4.4 Hz). 332 0.82 A I-43 1H-NMR (DMSO-d6) δ: 2.85 (3H, d, J = 3.6 Hz), 2.97 (1H, s), 3.66 (1H, d, J = 6.8 Hz), 3.86 (2H, d, J = 10.4 Hz), 4.00 (1H, d, J = 10.4 Hz), 4.10 (2H, s), 5.67 (2H, s), 7.34 (1H, t, J = 9.6 Hz), 7.74 (1H, s), 7.99 (1H, d, J = 5.6 Hz), 8.10 (1H, d, J = 7.8 Hz), 8.18 (1H, d, J = 8.4 Hz), 8.79 (1H, s), 8.85 (1H, s). 371 0.76 A I-44 1H-NMR (DMSO-d6) δ: 2.97 (1H, s), 3.67 (1H, d, J = 7.6 Hz), 3.82-3.91 (5H, m), 4.00 (1H, d, J = 11.2 Hz), 4.10 (2H, s), 5.69 (2H, s), 7.31 (1H, t, J = 10.0 Hz), 7.53 (1H, s), 7.69 (1H, s), 7.94 (1H, d, J = 6.8 Hz), 8.30 (1H, s), 8.41 (1H, s). 344 0.59 A -
TABLE 1-7 Compound NMR MS LC/MS LC/MS No. Structure (solvent: shift value ascending order) [M + 1] RT Method I-45 1H-NMR (DMSO-d6) δ: 2.97 (1H, s), 3.67 (1H, d, J = 6.4 Hz), 3.82-3.90 (2H, m), 4.00 (1H, d, J = 10.0 Hz), 4.09 (2H, d, J = 6.4 Hz), 5.66 (2H, s), 7.33 (1H, t, J = 10.0 Hz), 7.71 (1H, s), 7.95 (1H, d, J = 6.8 Hz), 8.16 (1H, s), 8.62 (1H, s), 8.79 (1H, s). 348 0.96 A I-46 1H-NMR (DMSO-d6) δ: 1.70 (4H, s), 1.96 (1H, s), 2.30 (1H, s), 3.70 (1H, d, J = 10.0 Hz), 3.89 (1H, d, J = 10.8 Hz), 5.45 (2H, s), 7.11 (1H, t, J = 10.0 Hz), 7.48 (1H, t, J = 73.0 Hz), 7.76 (1H, s), 7.92 (2H, dd, J = 22.2, 7.8 Hz), 8.22 (1H, d, J = 8.6 Hz), 8.61 (1H, s), 10.57 (1H, s). 441 1.93 D I-47 1H-NMR (CDCl3) δ: 1.40-1.61 (2H, m), 1.71-1.80 (2H, br m), 1.91-2.00 (1H, m), 2.33-2.51 (2H, m), 2.75-2.83 (1H, m), 6.14 (1H, d, J = 1.2 Hz), 7.07 (1H, dd, J = 11.4, 9.6 Hz), 7.65 (2H, dd, J = 6.3, 2.9 Hz), 8.19 (1H, dd, J = 8.1, 2.1 Hz), 8.42 (1H, d, J = 8.1 Hz), 8.89 (1H, d, J = 1.4 Hz), 9.78 (1H, s). 408 1.3 D - The effect of the present compound is confirmed by the following test Examples.
- 48.5 μL of substrate peptide solution (Biotin-XSEVNLDAEFRHDSGC-Eu: X═ε-amino-n-capronic acid, Eu=Europium cryptate) was added to each well of 96-hole half-area plate (a black plate: Costar), and after addition of 0.5 μl of the test compound (dissolved in N,N′-dimethylformaldehyde) and 1 μl of Recombinant human BACE1 (R&D Systems), the reaction mixture was incubated at 30° C. for 3 hours. The substrate peptide was synthesized by reacting Cryptate TBPCOOH mono SMP (CIS bio international) with Biotin-XSEVNLDAEFRHDSGC (Peptide Institute, Inc.). The final concentrations of the substrate peptide and Recombinant human BACE1 were adjusted to 18 nmol/L and 7.4 nmol/L, respectively, and the reaction was performed in sodium acetate buffer (50 mmol/L sodium acetate, pH 5.0, 0.008% Triton X-100).
- After the incubation for reaction, 50 μl of 8.0 μg/ml Streptavidin-XL665 (CIS bio international) dissolved in phosphate buffer (150 mmol/L K2 HPO4—KH2PO4, pH 7.0, 0.008% Triton X-100, 0.8 mol/L KF) was added to each well and left stand at 30° C. for an hour. After then, fluorescence intensity was measured (excitation wavelength: 320 nm, measuring wavelength: 620 nm and 665 nm) using Wallac 1420 multilabel counter (Perkin Elmer life sciences). Enzymatic activity was determined from counting ratio of each wavelength (10,000× Count 665/Count 620) and 50% inhibitory concentration against the enzymatic activity was calculated.
- In addition, Compounds I-33, 35, 36 and 38 showed its IC50 value of 1 μM or less.
- Neuroblastoma SH—SY5Y cells (SH/APPwt) with human wild-type p-APP excessively expressed therein were prepared at 8×105 cells/mL, and 150 μl portions thereof were inoculated into each well of a 96-well culture plate (Falcon). The cells were cultured for 2 hours at 37° C. in a 5% gaseous carbon dioxide incubator. Then, a solution which had been preliminarily prepared by adding and suspending the test compound (DMSO (dimethyl sulfoxide) solution) so as to be 2 μl/50 μl medium was added to the cell sap. Namely, the final DMSO concentration was 1%, and the amount of the cell culture was 200 μl. After the incubation was performed for 24 hours from the addition of the test compound, 100 μl of the culture supernatant was collected from each fraction. The amount of the Aβ in each fraction was measured.
- The Aβ amount was measured as follows. 10 μl of a homogeneous time resolved fluorescence (HTRF) measurement reagent (Amyloid β 1-40 peptide; IBA Molecular Holding, S. A.) and 10 μl of the culture supernatant were put into a 384-well half area microplate (black microplate, Costar) and mixed with each other, and then left standing overnight at 4° C. while the light was shielded. Then, the fluorescence intensity (excitation wavelength: 337 nm, measurement wavelength: 620 nm and 665 nm) was measured with a Wallac 1420 multilabel counter (Perkin Elmer life sciences). The Aβ amount was determined from the count rate at each measurement wavelength (10000× Count 665/Count 620), and the amount needed to inhibit Aβ production by 50% (IC50) was calculated from at least six different dosages.
- In addition, Compounds I-3, 33 to 36, and 38 to 46 showed its IC50 value of 1 μM or less.
- A test compound is suspended in 0.5% methylcellulose, the final concentration is adjusted to 2 mg/mL, and this is orally administered to male Crj: SD rat (7 to 9 weeks old) at 10 mg/kg. In a vehicle control group, only 0.5% methylcellulose is administered, and an administration test is performed at 3 to 8 animals per group. A brain is isolated 3 hours after administration, a cerebral hemisphere is isolated, a weight thereof is measured, the hemisphere is rapidly frozen in liquid nitrogen, and stored at −80° C. until extraction date. The frozen cerebral hemisphere is transferred to a homogenizer manufactured by Teflon (registered trade name) under ice cooling, a 5-fold volume of a weight of an extraction buffer (containing 1% CHAPS ({3-[(3-chloroamidopropyl)dimethylammonio]-1-propanesulfonate}), 20 mmol/L M Tris-HCl (pH 8.0), 150 mmol/L NaCl, Complete (Roche) protease inhibitor) is added, up and down movement is repeated, and this is homogenized to solubilize for 2 minutes. The suspension is transferred to a centrifugation tube, allowed to stand on an ice for 3 hours or more and, thereafter centrifuged at 100,000×g, 4° C. for 20 minutes. After centrifugation, the supernatant is transferred to an ELISA plate (product No. 294-62501, Wako Junyaku Kogyo) for measuring β amyloid 40. ELISA measurement is performed according to the attached instruction. The lowering effect is calculated as a ratio compared to the brain β amyloid 40 level of vehicle control group of each test.
- The CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction, and the test was performed using, as CYP3A4 enzyme expressed in Escherichia coli and employing, as an index, a reaction in which 7-benzyloxytrifluoromethylchmarin (7-BFC) is debenzylated by the CYP3A4 enzyme to produce a metabolite, 7-hydroxytrifluoromethylchmarin (HFC) emitting fluorescent light.
- The reaction conditions were as follows: substrate, 5.6 μmol/L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25° C. (room temperature); CYP3A4 content (expressed in Escherichia coli), at pre-reaction 62.5 μmol/mL, at reaction 6.25 μmol/mL (at 10-fold dilution); test drug concentration, 0.625, 1.25, 2.5, 5, 10, 20 μmol/L (six points).
- An enzyme in a K-Pi buffer (pH 7.4) and a test drug solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction, a part of it was transferred to another 96-well plate so that it was 1/10 diluted by a substrate in a K-Pi buffer, NADPH as a co-factor was added to initiate a reaction as an index (without preincubation) and, after a predetermined time of a reaction, acetonitrile/0.5 mol/L Tris(trishydroxyaminomethane)=4/1 was added to stop the reaction. In addition, NADPH was added to a remaining preincubation solution to initiate a preincubation (with preincubation) and, after a predetermined time of a preincubation, a part was transferred to another plate so that it was 1/10 diluted with a substrate and a K-Pi buffer to initiate a reaction as an index. After a predetermined time of a reaction, acetonitrile/0.5 mol/L Tris(trishydroxyaminomethane)=4/1 was added to stop the reaction. For the plate on which each index reaction had been performed, a fluorescent value of 7-HFC which is a metabolite was measured with a fluorescent plate reader. (Ex=420 nm, Em=535 nm).
- Addition of only DMSO which is a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution, and IC50 was calculated by reverse-presumption by a logistic model using a concentration and an inhibition rate. When a difference of IC50 value was 5 μM or more, the result was defined as (+). When the difference was 3 μM or less, the result was defined as (−).
- Using commercially available pooled human hepatic microsome, and employing, as markers, 7-ethoxyresorufin O-deethylation (CYP1A2), tolbutamide methyl-hydroxylation (CYP2C9), mephenyloin 4′-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), and terfenadine hydroxylation (CYP3A4) as typical substrate metabolism reactions of human main five CYP enzyme forms (CYP1A2, 2C9, 2C19, 2D6, 3A4), an inhibitory degree of each metabolite production amount by a test compound was assessed.
- The reaction conditions were as follows: substrate, 0.5 μmol/L ethoxyresorufin (CYP1A2), 100 μmol/L tolbutamide (CYP2C9), 50 μmol/L S-mephenyloin (CYP2C19), 5 μmol/L dextromethorphan (CYP2D6), 1 μmol/L terfenadine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37° C.; enzyme, pooled human hepatic microsome 0.2 mg protein/mL; test drug concentration, 1, 5, 10, 20 μmol/L (four points).
- Each five kinds of substrates, human hepatic microsome, and a test drug in 50 mmol/L Hepes buffer as a reaction solution was added to a 96-well plate at the composition as described above, NADPH, as a cofactor was added to initiate metabolism reactions as markers and, after the incubation at 37° C. for 15 minutes, a methanol/acetonitrile=1/1 (v/v) solution was added to stop the reaction. After the centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant was quantified by a fluorescent multilabel counter and tolbutamide hydroxide (CYP2C9 metabolite), mephenyloin 4′ hydroxide (CYP2C19 metabolite), dextrorphan (CYP2D6 metabolite), and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC/MS/MS.
- Addition of only DMSO being a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution and IC50 was calculated by reverse presumption by a logistic model using a concentration and an inhibition rate.
- Compound I-33: IC50>20 (five kinds)
- Each 20 μL of freeze-stored Salmonella typhimurium (TA98 and TA100 strain) is inoculated in 10 mL of liquid nutrient medium (2.5% Oxoid nutrient broth No. 2), and the cultures are incubated at 37° C. under shaking for 10 hours. 9 mL of TA98 culture is centrifuged (2000×g, 10 minutes) to remove medium, and the bacteria is suspended in 9 mL of Micro F buffer (K2HPO4: 3.5 g/L, KH2PO4: 1 g/L, (NH4)2SO4: 1 g/L, trisodium citrate dihydrate: 0.25 g/L, MgSO4.7H2O: 0.1 g/L), and the suspension is added to 110 mL of Exposure medium (Micro F buffer containing Biotin: 8 μg/mL, histidine 0.2 μg/mL, glucose: 8 mg/mL) 3.16 mL of TA100 culture is added to 120 mL of Exposure medium to prepare the test bacterial solution. 588 μL of the test bacterial solution (or mixed solution of 498 μl of the test bacterial solution and 90 μL of the S9 mix in the case with metabolic activation system) are mixed with each 12 μL of the following solution: DMSO solution of the test substance (eight dose levels from maximum dose 50 mg/mL at 2-fold ratio); DMSO as negative control; 50 μg/mL of 4-nitroquinoline-1-oxide DMSO solution as positive control for TA98 without metabolic activation system; 0.25 μg/mL of 2-(2-furyl)-3-(5-nitro-2-furypacrylamide DMSO solution as positive control for TA100 without metabolic activation system; 40 μg/mL of 2-aminoanthracene DMSO solution as positive control for TA98 with metabolic activation system; or 20 μg/mL of 2-aminoanthracene DMSO solution as positive control for TA100 with metabolic activation system. 124 of the solution and 588 μL of the test bacterial solution (a mixed solution of 498 μl of the test bacterial solution and 90 μL of S9 mix with metabolic activation condition) were mixed and incubated at 37° C. under shaking for 90 minutes. 460 μL of the bacterial solution exposed to the test substance is mixed with 2300 μL of Indicator medium (Micro F buffer containing biotin: 8 μg/mL, histidine: 0.2 μg/mL, glucose: 8 mg/mL, Bromo Cresol Purple: 37.5 μg/mL), each 50 μL is dispensed into 48 wells per dose in the microwell plates, and is subjected to stationary cultivation at 37° C. for 3 days. A well containing the bacteria, which has obtained the ability of proliferation by mutation in the gene coding amino acid (histidine) synthetase, turns the color from purple to yellow due to pH change. The mutagenicity is evaluated by counting the number of the yellow wells among the 48 total wells per dose and comparing with the negative control group. (−) means that mutagenicity is negative and (+) means positive.
- A 2-fold dilution series (12 points) of a 10 mM solution of a test compound in DMSO was added to a medium (JP-I, JP-II) (2%), and solubility was assessed by 3 stages (High; >40 μM, Medium; 3-40 μM, Low; <3 μM) from a turbidity after 4 hours (crystallization information).
- Using commercially available pooled human hepatic microsomes, a test compound is reacted for a constant time, a remaining rate is calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver is assessed.
- A reaction is performed (oxidative reaction) at 37° C. for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes. After the reaction, 50 μL of the reaction solution is added to 100 μL of a methanol/acetonitrile=1/1 (v/v), mixed and centrifuged at 3000 rpm for 15 minutes. The test compound in the supernatant is quantified by LC/MS/MS, and a remaining amount of the test compound after the reaction is calculated, letting a compound amount at 0 minute reaction time to be 100%.
- For the purpose of assessing risk of an electrocardiogram QT interval prolongation, effects on delayed rectifier K+ current (IKr), which plays an important role in the ventricular repolarization process of the compound of the present invention, is studied using HEK293 cells expressing human ether-a-go-go related gene (hERG) channel.
- After a cell was retained at a membrane potential of −80 mV by whole cell patch clamp method using an automated patch clamp system (PatchXpress 7000A, Axon Instruments Inc.), IKr induced by depolarization pulse stimulation at +40 mV for 2 seconds and, further, repolarization pulse stimulation at −50 mV for 2 seconds was recorded. After the generated current was stabilized, extracellular solution (NaCl: 135 mmol/L, KCl: 5.4 mmol/L, NaH2PO4: 0.3 mmol/L, CaCl2.2H2O: 1.8 mmol/L, MgCl2.6H2O: 1 mmol/L, glucose: 10 mmol/L, HEPES (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid): 10 mmol/L, pH=7.4) in which the test compound had been dissolved at an objective concentration was applied to the cell under the room temperature condition for 10 minutes. From the recording IKr, an absolute value of the tail peak current was measured based on the current value at the resting membrane potential using analysis software (DataXpress ver. 1, Molecular Devices Corporation). Further, the % inhibition relative to the tail peak current before application of the test compound was calculated, and compared with the vehicle-applied group (0.1% dimethyl sulfoxide solution) to assess influence of the test compound on IKr.
- Appropriate amounts of the test substances are put into appropriate containers. To the respective containers are added 200 μL of JP-1 fluid (sodium chloride 2.0 g, hydrochloric acid 7.0 mL and water to reach 1000 mL), 200 μL of JP-2 fluid (phosphate buffer (pH 6.8) 500 mL and water 500 mL), and 2004 of 20 mmol/L TCA (sodium taurocholate)/JP-2 fluid (TCA 1.08 g and water to reach 100 mL). In the case that the test compound is dissolved after the addition of the test fluid, the bulk powder is added as appropriate. The containers are sealed, and shaken for 1 hour at 37° C. The mixtures are filtered, and 100 μL of methanol is added to each of the filtrate (100 μL) so that the filtrates are two-fold diluted. The dilution ratio may be changed if necessary. The dilutions are observed for bubbles and precipitates, and then the containers are sealed and shaken. Quantification is performed by HPLC with an absolute calibration method.
- Materials and methods for studies on oral absorption
- (1) Animal: mice or rats
- (2) Breeding conditions: mice or rats are allowed to freely take solid feed and sterilized tap water
- (3) Dose and grouping: orally or intravenously administered at a predetermined dose; grouping is as follows (Dose depends on the compound)
- Oral administration: 1 to 30 mg/kg (n=2 to 3)
- Intravenous administration: 0.5 to 10 mg/kg (n=2 to 3)
- (4) Preparation of dosing solution: for oral administration, in a solution or a suspension state; for intravenous administration, in a solubilized state
- (5) Administration method: in oral administration, forcedly administer into ventriculus with oral probe; in intravenous administration, administer from caudal vein with a needle-equipped syringe
- (6) Evaluation items: blood is collected over time, and the plasma concentration of drug is measured by LC/MS/MS
- (7) Statistical analysis: regarding the transition of the plasma concentration, the area under the plasma concentration-time curve (AUC) is calculated by non-linear least squares program WinNonlin (Registered trade name), and the bioavailability (BA) is calculated from the AUCs of the oral administration group and intravenous administration group
- Intravenous administration is carried out to a rat by 0.5 mg/mL/kg dosage of the compound. 30 minutes later, all blood is drawn from vena cava inferior under isoflurane anesthesia for death from exsanguination. Then, the brain is extracted and 20-25% of homogenate thereof is prepared with distilled water. On the other hand, the obtained blood is used as plasma after centrifuging. Then, to the brain sample is added the control plasma at 1:1. To the plasma samples is added the control brains at 1:1. Each sample is measured using LC/MS/MS. The obtained area ratio (a brain/plasma) is used for the brain Kp value.
- A granule containing the following ingredients is produced.
- Ingredient
-
Compound of the formula (I) 10 mg Lactose 700 mg Corn starch 274 mg HPC-L 16 mg 1000 mg - The compound of the formula (I), and lactose are passed through a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve. These are mixed with a V-type mixer. To the mixed powder is added a HPC-L (low viscosity hydroxypropyl cellulose) aqueous solution, this is kneaded, granulated (extrusion granulation, pore diameter 0.5 to 1 mm), and dried. The resulting dry granule is passed through a vibration sieve (12/60 mesh) to give a granule.
- A granule for filling a capsule containing the following ingredients is produced.
- Ingredient
-
Compound of the formula (I) 15 mg Lactose 90 mg Corn starch 42 mg HPC-L 3 mg 150 mg - The compound of the formula (I), and lactose are passed through a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve. These are mixed, a HPC-L solution is added to the mixed powder, this is kneaded, granulated, and dried. The resulting dry granule is adjusted in a size, and 150 mg of it is filled into a No. 4 hard gelatin capsule.
- A tablet containing the following ingredients is produced.
- Ingredient
-
Compound of the formula (I) 10 mg Lactose 90 mg Microcrystalline cellulose 30 mg CMC-Na 15 mg Magnesium stearate 5 mg 150 mg - The compound of the formula (I), lactose, microcrystalline cellulose, and CMC-Na (carboxymethyl cellulose sodium salt) are passed through a 60 mesh sieve, and mixed. Magnesium stearate is mixed into the mixed powder to give a mixed powder for tabletting. The present mixed powder is directly compressed to give a 150 mg of a tablet.
- The following ingredients are warmed, mixed, and sterilized to give an injectable.
- Ingredient
-
Compound of the formula (I) 3 mg Nonionic surfactant 15 mg Purified water for injection 1 ml - The present compound can be a medicament useful as an agent for treating or preventing diseases induced by production, secretion and/or deposition of amyloid β protein.
Claims (17)
1. A compound of formula (I):
wherein —X— is —O—, —S— or —N(R1)—,
R1 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl,
R2a and R2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl or substituted or unsubstituted carbamoyl,
ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle,
wherein —Y— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)—, —O—, —S—, —SO— or —SO2—,
—Z— is a bond, substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, —N(R7)Ak—, —OAk—, —SAk—, —SOAk- or —SO2 Ak—,
Ak is a bond, substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C2-C3 alkenylene,
provided that when —Y— is —N(R7)—, —O—, —S—, —SO— or —SO2—, then Ak is not a bond,
R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenyl sulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl,
Rza and Rzb are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy or substituted or unsubstituted heterocyclyloxycarbonyl, or Rza and Rzb together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle,
R3a and R3b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, or R3a and R3b together with the carbon atom to which they are attached may form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle,
R4a and R4b are each independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy or substituted or unsubstituted heterocyclyloxycarbonyl,
provided that when —X— is —S—, then R4b is not hydrogen, and
R5a, R5b, R6a and R6b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, or
R5a and R5b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R6a and R6b together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, its pharmaceutically acceptable salt or a solvate thereof.
2. The compound according to claim 1 wherein —X— is —O— or —S—, its pharmaceutically acceptable salt or a solvate thereof.
4. The compound according toclaim 1 wherein —Y— is substituted or unsubstituted C1-C3 alkylene or —O—, and —Z— is a bond, its pharmaceutically acceptable salt or a solvate thereof.
5. The compound according to any claim 1 wherein ring A is
wherein ring A′ and ring B are each independently a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle,
—W— is a bond, -L1-C(═O)N(R8)-L2-, -L1-N(R8)C(═O)-L2 or -L1-N(R8)-L2-, L1 and L2 are each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene,
R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl,
its pharmaceutically acceptable salt or a solvate thereof.
6. The compound according to claim 5 wherein —W— is —C(═O)N(R8)—, its pharmaceutically acceptable salt or a solvate thereof.
7. The compound according to claim 5 wherein ring A′ is substituted or unsubstituted benzene, ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine, its pharmaceutically acceptable salt or a solvate thereof.
8. A pharmaceutical composition comprising the compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof as an active ingredient.
9. A pharmaceutical composition having BACE1 inhibitory activity comprising the compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof as an active ingredient.
10. The pharmaceutical composition according to claim 8 , which is a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins.
11. The pharmaceutical composition according to claim 8 , which is a medicament for treating or preventing Alzheimer's disease.
12. A method for inhibiting BACE1 activity comprising administering the compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof.
13. The compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof for use in a method for inhibiting BACE1 activity.
14. A method for treating or preventing diseases induced by production, secretion or deposition of amyloid-β proteins comprising administering the compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof.
15. The compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof for use in a method for treating or preventing diseases induced by production, secretion or deposition of amyloid-β proteins.
16. A method for treating or preventing Alzheimer's disease comprising administering the compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof.
17. The compound according to claim 1 , its pharmaceutically acceptable salt or a solvate thereof for use in a method for treating or preventing Alzheimer's disease.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009282193 | 2009-12-11 | ||
| JP2009-282193 | 2009-12-11 | ||
| PCT/JP2010/072121 WO2011071109A1 (en) | 2009-12-11 | 2010-12-09 | Fused heterocyclic compound having amino group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20120245155A1 true US20120245155A1 (en) | 2012-09-27 |
Family
ID=44145654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/514,907 Abandoned US20120245155A1 (en) | 2009-12-11 | 2010-12-09 | Fused heterocyclic compound having amino group |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120245155A1 (en) |
| EP (1) | EP2511269A4 (en) |
| JP (1) | JPWO2011071109A1 (en) |
| WO (1) | WO2011071109A1 (en) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160290A1 (en) * | 2007-04-24 | 2010-06-24 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
| US20110190279A1 (en) * | 2008-06-13 | 2011-08-04 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| US8546380B2 (en) | 2005-10-25 | 2013-10-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
| US8629270B2 (en) | 2012-04-03 | 2014-01-14 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US8822456B2 (en) | 2012-12-11 | 2014-09-02 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8841293B1 (en) | 2013-03-12 | 2014-09-23 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US8865706B2 (en) | 2013-02-13 | 2014-10-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| US8884062B2 (en) | 2007-04-24 | 2014-11-11 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| WO2014204730A1 (en) | 2013-06-18 | 2014-12-24 | Eli Lilly And Company | Bace inhibitors |
| US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US8933221B2 (en) | 2011-08-31 | 2015-01-13 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8962616B2 (en) | 2012-05-04 | 2015-02-24 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9290466B2 (en) | 2009-12-11 | 2016-03-22 | Shionogi & Co., Ltd. | Oxazine derivatives |
| US9315520B2 (en) | 2014-04-10 | 2016-04-19 | Pfizer Inc. | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
| US9328124B2 (en) | 2012-10-26 | 2016-05-03 | Eli Lilly And Company | BACE inhibitors |
| US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9522923B2 (en) | 2015-02-23 | 2016-12-20 | Eli Lilly And Company | Selective BACE1 inhibitors |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| WO2017051276A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| WO2018162443A1 (en) * | 2017-03-07 | 2018-09-13 | Janssen Pharmaceutica Nv | Inhibitors of beta secretase |
| CN110382507A (en) * | 2017-03-07 | 2019-10-25 | 詹森药业有限公司 | The inhibitor of beta-secretase |
| CN110418793A (en) * | 2017-03-07 | 2019-11-05 | 詹森药业有限公司 | The inhibitor of beta-secretase |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2010047372A1 (en) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
| EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
| US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (en) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS$ 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR INHIBITORS OR BACE2 |
| US8877744B2 (en) * | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| CN103874496A (en) | 2011-08-22 | 2014-06-18 | 默沙东公司 | 2-spiro-substituted iminothiazines as BACE inhibitors and their mono- and dioxide-oxides, compositions and uses thereof |
| EA027059B1 (en) * | 2012-01-26 | 2017-06-30 | Ф.Хоффманн-Ля Рош Аг | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| GB201212871D0 (en) * | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EP2964644B1 (en) | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| TW201623295A (en) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | Dihydrothiazine and dihydrooxazine derivatives having BACE1 inhibitory activity |
| US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
| TWI675034B (en) * | 2016-05-20 | 2019-10-21 | 美商美國禮來大藥廠 | Tetrahydrofurooxazine compounds and their use as selective bace1 inhibitors |
| CN107892697B (en) * | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | [1,3] thiazine-2-amine compound and application and pharmaceutical composition thereof |
| KR20250103804A (en) | 2018-03-08 | 2025-07-07 | 인사이트 코포레이션 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| EP3784674B1 (en) | 2018-04-27 | 2023-02-22 | Shionogi & Co., Ltd | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2548388A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| KR20080029965A (en) * | 2005-06-14 | 2008-04-03 | 쉐링 코포레이션 | Aspartyl Protease Inhibitor |
| AU2006307314C1 (en) | 2005-10-25 | 2011-08-25 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| US20100016341A1 (en) * | 2006-12-12 | 2010-01-21 | Zhaoning Zhu | Aspartyl protease inhibitors containing a tricyclic ring system |
| MX2009006228A (en) | 2006-12-12 | 2009-06-22 | Schering Corp | Aspartyl protease inhibitors. |
| US8168630B2 (en) | 2007-04-24 | 2012-05-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| JP5383483B2 (en) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | Pharmaceutical composition for the treatment of Alzheimer's disease |
| JP4520533B2 (en) | 2008-01-18 | 2010-08-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Condensed aminodihydrothiazine derivatives |
| AU2009239536C1 (en) | 2008-04-22 | 2012-12-13 | Merck Sharp & Dohme Corp. | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| WO2010013302A1 (en) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Spiroaminodihydrothiazine derivative |
| ES2433223T3 (en) | 2008-07-28 | 2013-12-10 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrotiazine derivatives |
| NZ591878A (en) | 2008-09-30 | 2012-06-29 | Eisai R&D Man Co Ltd | Novel fused aminodihydrothiazine derivative |
| AR077277A1 (en) * | 2009-07-09 | 2011-08-17 | Lilly Co Eli | BICYCLE COMPOUNDS (1,3) TIAZIN-2-AMINA PHARMACEUTICAL FORMULATION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| GB0912778D0 (en) * | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
-
2010
- 2010-12-09 JP JP2011545241A patent/JPWO2011071109A1/en active Pending
- 2010-12-09 WO PCT/JP2010/072121 patent/WO2011071109A1/en active Application Filing
- 2010-12-09 US US13/514,907 patent/US20120245155A1/en not_active Abandoned
- 2010-12-09 EP EP10836029.8A patent/EP2511269A4/en not_active Withdrawn
Cited By (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815851B2 (en) | 2005-10-25 | 2014-08-26 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
| US8633188B2 (en) | 2005-10-25 | 2014-01-21 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
| US8546380B2 (en) | 2005-10-25 | 2013-10-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
| US9029358B2 (en) | 2005-10-25 | 2015-05-12 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
| US8884062B2 (en) | 2007-04-24 | 2014-11-11 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| US8895548B2 (en) | 2007-04-24 | 2014-11-25 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| US20100160290A1 (en) * | 2007-04-24 | 2010-06-24 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
| US9273053B2 (en) | 2008-06-13 | 2016-03-01 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity |
| US20110190279A1 (en) * | 2008-06-13 | 2011-08-04 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| US9650371B2 (en) | 2008-06-13 | 2017-05-16 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| US9656974B2 (en) | 2009-12-11 | 2017-05-23 | Shionogi & Co., Ltd. | Oxazine derivatives |
| US9290466B2 (en) | 2009-12-11 | 2016-03-22 | Shionogi & Co., Ltd. | Oxazine derivatives |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| US9550795B2 (en) | 2011-08-31 | 2017-01-24 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8933221B2 (en) | 2011-08-31 | 2015-01-13 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8772282B2 (en) | 2012-04-03 | 2014-07-08 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US8889856B2 (en) | 2012-04-03 | 2014-11-18 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US8629270B2 (en) | 2012-04-03 | 2014-01-14 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US8962616B2 (en) | 2012-05-04 | 2015-02-24 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9758513B2 (en) | 2012-10-24 | 2017-09-12 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| US9328124B2 (en) | 2012-10-26 | 2016-05-03 | Eli Lilly And Company | BACE inhibitors |
| US9045498B2 (en) | 2012-12-11 | 2015-06-02 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8822456B2 (en) | 2012-12-11 | 2014-09-02 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9198917B2 (en) | 2012-12-11 | 2015-12-01 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9192612B2 (en) | 2013-02-13 | 2015-11-24 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8865706B2 (en) | 2013-02-13 | 2014-10-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9045499B2 (en) | 2013-02-13 | 2015-06-02 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US8841293B1 (en) | 2013-03-12 | 2014-09-23 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US8987254B2 (en) | 2013-03-12 | 2015-03-24 | Eli Lilly And Company | Tetrahydropyrrolothiazine compounds |
| US9029367B2 (en) | 2013-06-18 | 2015-05-12 | Eli Lilly And Company | BACE inhibitors |
| US9169271B2 (en) | 2013-06-18 | 2015-10-27 | Eli Lilly And Company | BACE inhibitors |
| WO2014204730A1 (en) | 2013-06-18 | 2014-12-24 | Eli Lilly And Company | Bace inhibitors |
| US9428523B2 (en) | 2014-04-10 | 2016-08-30 | Pfizer Inc. | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
| US9605007B2 (en) | 2014-04-10 | 2017-03-28 | Pfizer Inc. | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
| US10028962B2 (en) | 2014-04-10 | 2018-07-24 | Pfizer Inc. | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
| US9744173B2 (en) | 2014-04-10 | 2017-08-29 | Pfizer Inc. | 2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
| US9315520B2 (en) | 2014-04-10 | 2016-04-19 | Pfizer Inc. | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
| US9522923B2 (en) | 2015-02-23 | 2016-12-20 | Eli Lilly And Company | Selective BACE1 inhibitors |
| US9611264B1 (en) | 2015-09-24 | 2017-04-04 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| US9751895B2 (en) | 2015-09-24 | 2017-09-05 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| US9771379B2 (en) | 2015-09-24 | 2017-09-26 | Pfizer Inc. | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides |
| WO2017051276A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
| US10112958B2 (en) | 2015-09-24 | 2018-10-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides |
| US10253042B2 (en) * | 2015-09-24 | 2019-04-09 | Pfizer Inc. | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides |
| WO2018162443A1 (en) * | 2017-03-07 | 2018-09-13 | Janssen Pharmaceutica Nv | Inhibitors of beta secretase |
| CN110382507A (en) * | 2017-03-07 | 2019-10-25 | 詹森药业有限公司 | The inhibitor of beta-secretase |
| CN110418793A (en) * | 2017-03-07 | 2019-11-05 | 詹森药业有限公司 | The inhibitor of beta-secretase |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011071109A1 (en) | 2011-06-16 |
| JPWO2011071109A1 (en) | 2013-04-22 |
| EP2511269A4 (en) | 2013-04-24 |
| EP2511269A1 (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120245155A1 (en) | Fused heterocyclic compound having amino group | |
| US9656974B2 (en) | Oxazine derivatives | |
| US20120245154A1 (en) | Substituted aminothiazine derivative | |
| US20120238557A1 (en) | Aminothiazine or aminooxazine derivative having amino linker | |
| US20120258961A1 (en) | 4-amino-1,3-thiazine or oxazine derivative | |
| US8883779B2 (en) | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them | |
| US8927721B2 (en) | Naphthyridine derivative | |
| US9018219B2 (en) | Fused aminodihydropyrimidine derivative | |
| JP2012250933A (en) | Pharmaceutical composition containing oxazine derivative for treating or preventing alzheimer's disease | |
| CN103649082A (en) | Pyridine derivatives and BACE1 inhibitors containing the same | |
| JP2014101353A (en) | Pharmaceutical composition for alzheimer's disease medical treatment or prevention including oxazin derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SHIONOGI & CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOSHIDA, SYUHEI;KATO, ISSEI;FUCHINO, KOUKI;AND OTHERS;SIGNING DATES FROM 20120515 TO 20120521;REEL/FRAME:028388/0107 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |






















































































































